,id,ticker,title,category,content,date,provider,url,article_id
29794,251309,CSII,Cardiovascular Systems  CSII  Stock Hits New 52 Week High,opinion,"Shares of Cardiovascular Systems  Inc    NASDAQ CSII   reached a new 52 week high of  53 71 on Jan 17  closing the session marginally lower at  53 61  The stock has rallied 2 7  since its first quarter fiscal 2020 earnings announcement on Oct 29 The company witnessed mixed fiscal first quarter results  backed by strong performance in the domestic and international markets  Notably  it is concentrating on product innovation through R D investments Let us delve deeper  
 Q3 PerformanceCardiovascular Systems ended first quarter fiscal 2020 on a mixed note  with wider than expected loss and a revenue beat  It witnessed year over year revenue improvements in Coronary and Peripheral device segments within the domestic market  Treatment of the first patient in the Middle East with a peripheral orbital atherectomy system is another highlight of the quarter  The FDA approval of Viperwire Advance Coronary Guide Wire with Flex Tip instills optimism Over and above  the company s reaffirmed guidance for fiscal 2020 indicates that it will be able to maintain its ongoing momentum in the second quarter as well Other Key DriversPortfolio Expansion  Investors are optimistic about the impressive customer adoption of Cardiovascular Systems  1 millimeter Sapphire balloon  the Teleport Microcatheter and radio support  The company is increasingly focusing on improving its R D  thus leading to product launches like that of the Nitinol Coronary ViperWire Advance wire with Flex Tip in the United States The launch of Nitino is a crucial addition to Cardiovascular Systems  complex coronary portfolio  consisting of Diamondback 360 Coronary Orbital Atherectomy System with GlideAssist  the Sapphire balloon  including the only 1 0mm coronary angioplasty balloon in the U S  market  and the Teleport microcatheter Notably  the company introduced Peripheral Orbital Atherectomy System With GlideAssist in Europe in December 2019 International Business  The concerted efforts of Cardiovascular Systems to increase its global footprint buoy optimism within the investors  The company is making progress in introducing orbital atherectomy system  OAS  globally  In this respect  Cardiovascular Systems is performing robustly on its partnership with OrbusNeich  which allows OrbusNeich to distribute Cardiovascular Systems  coronary and peripheral orbital atherectomy systems in multiple countries outside the United States and Japan Zacks Rank   Key PicksCurrently  Cardiovascular Systems carries a Zacks Rank  3  Hold  Some better ranked stocks from the broader medical space are Haemonetics Corporation   NYSE HAE    Hill Rom Holdings  Inc    NYSE HRC   and Medtronic plc   NYSE MDT   Haemonetics currently sports a Zacks Rank  1  Strong Buy  and has a projected long term earnings growth rate of 13 5   You can see Hill Rom s long term earnings growth rate is estimated at 11 7   The company currently carries a Zacks Rank of 2  Buy  Medtronic s long term earnings growth rate is expected at 7 4   It currently has a Zacks Rank  2 Biggest Tech Breakthrough in a GenerationBe among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity  Current technology will soon be outdated and replaced by these new devices  In the process  it s expected to create 22 million jobs and generate  12 3 trillion in activity A select few stocks could skyrocket the most as rollout accelerates for this new tech  Early investors could see gains similar to buying Microsoft  NASDAQ MSFT  in the 1990s  Zacks  just released special report reveals 8 stocks to watch  The report is only available for a limited time ",2020-01-19,Zacks Investment Research,https://www.investing.com/analysis/cardiovascular-systems-csii-stock-hits-new-52week-high-200500046,200500046
29801,251316,CSII,HealthEquity  HQY  Set To Acquire WageWorks For  2 Billion,opinion,HealthEquity  Inc    NASDAQ HQY    which is known for being largest independent health savings account  HSA  non bank custodian in the United States  has recently announced its decision to acquire WageWorks  Inc  in an all cash deal of approximately  2 billion  The acquisition is expected to aid HealthEquity to expedite the market wide transition to HSAs For investors  notice  WageWorks   NYSE WAGE   is known for being a leader in administering HSAs and complementary consumer directed benefits  CDBs  Following the announcement  shares of HealthEquity rose nearly 5  to  65 27 at close on Jun 27 Financial TermsPer the terms of the deal  HealthEquity will acquire all of the issued and outstanding shares of common stock of WageWorks for  51 35 per share in cash  which reflects the total enterprise value of about  2 billion In order to finance the buyout  HealthEquity received a debt commitment from Wells Fargo  NYSE WFC  Bank  The acquirer anticipates deleveraging quickly through solid  predictable future cash flow and growth Financial Impact of the AcquisitionWith this buyout  HealthEquity might realize substantial synergy opportunities and projects around  50 million in annualized  on going synergies that will be realized within 24 to 36 months of deal completion  This will be realized mainly through custodial and interchange revenue and operating efficiencies Further  HealthEquity expects to generate substantial incremental revenue synergies over time as the combined client base takes advantage of the complete offering How is HealthEquity Poised to Benefit The buyout is set to provide access to more of the thriving HSA market through expansion of its direct distribution to employers and benefits advisors as a single source  premium provider of HSAs and complementary CDBs The deal will help in developing a large provider of health savings accounts and additional CDBs that will include flexible spending  health reimbursement plans and commuter accounts Interestingly  the transaction will help in building an end to end proprietary platform  which will persuade members to spend prudently while saving for healthcare in retirement Bright Prospects in HSA MarketAccording to a recent report by   based on the projections of    healthcare account investment expert   the HSA market is anticipated to grow in value from just below  54 billion in 2018 to nearly  75 billion in 2020 Zacks Rank and Share Price PerformanceCurrently  HealthEquity carries a Zacks Rank  2  Buy   Shares of the company have gained 9 4  year to date  outperforming the  s rally of 6 6   However  the stock fell short of the S P 500 index s growth of 14 9  Other Key PicksInvestors interested in other top ranked stocks from the broader medical space are Cardiovascular Systems  Inc    NASDAQ CSII   and Haemonetics Corporation   NYSE HAE    each sporting a Zacks Rank  1  Strong Buy   You can see  Cardiovascular Systems has earnings growth rate for fiscal fourth quarter of 2019 of 33 3  Haemonetics has a long term earnings growth rate 13 5  Will you retire a millionaire  One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-06-28,Zacks Investment Research,https://www.investing.com/analysis/healthequity-hqy-set-to-acquire-wageworks-for-2-billion-200435595,200435595
29802,251317,CSII,Here s Why You Should Retain Cardinal Health  CAH  Stock,opinion,Cardinal Health  Inc    NYSE CAH   is well poised for growth backed by diversified product portfolio  acquisition driven strategy and robust pharmaceutical segment  However  integration risks remain a concern The stock currently carries a Zacks Rank  3  Hold  Price PerformanceShares of Cardinal Health have gained 5 6   underperforming the  s growth of 18 2  on a year to date basis  Further  the stock fell short of the S P 500 Index s rally of 16  What s Weighing on the Stock Given the acquisition driven strategy followed by the company  integration risks tend to follow Moreover  intense competition in each of the business segments poses a concern for Cardinal Health Factors to Bolster Cardinal HealthCardinal Health s Medical and Pharmaceutical offerings provide the company a competitive edge in the niche space  It offers industry expertise and an expanding portfolio of safe products The company follows an acquisition driven strategy and continues to remain committed toward investment in key growth businesses to gain market traction and bolster profits The company s Pharmaceutical segment boasts of being the second largest pharmaceutical distributor in the United States  The segment s products and services consist of pharmaceutical distribution  manufacturer and specialty services  and nuclear and pharmacy services  These in turn are anticipated to drive the company s performance in the quarters ahead Which Way Are Estimates Headed For 2019  the Zacks Consensus Estimate for revenues is pegged at  144 82 billion  indicating an improvement of 5 9  from the year ago period  For adjusted earnings per share  the same stands at  5 10  suggesting growth of 2  from the year ago reported figure Key PicksSome better ranked stocks from the broader medical space are Cardiovascular Systems  Inc    NASDAQ CSII    Oxford Immunotec Global PLC   NASDAQ OXFD   and Haemonetics Corporation   NYSE HAE    each sporting a Zacks Rank  1  Strong Buy   You can see  Cardiovascular Systems has earnings growth rate for fiscal fourth quarter of 2019 of 33 3  Oxford Immunotec has a long term earnings growth rate of 25  Haemonetics has a long term earnings growth rate 13 5  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-07-01,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-retain-cardinal-health-cah-stock-200436047,200436047
29803,251318,CSII,Cardiovascular Systems  CSII  Earnings Match Estimates In Q4,opinion,"Cardiovascular Systems  Inc    NASDAQ CSII   delivered earnings per share  EPS  of 4 cents in fourth quarter fiscal 2019  down 63 6  year over year  The reported figure was in line with the Zacks Consensus Estimate For the full year  loss per share came in at a cent  reflecting a sharp decline from the year ago earnings of 5 cents Net SalesCardiovascular Systems  revenues of  68 2 million in the fourth quarter mark a 15 4  year over year increase  Meanwhile  the top line beat the Zacks Consensus Estimate by 3 33  For the full year  revenues totaled  248 million  up 14 3  from a year ago Segment DetailsIn the quarter under review  global Coronary device revenues jumped 24  year over year to  20 million  Total U S  revenues increased 13  to  65 7 million  Domestic coronary revenues grew 16   primarily driven by expanded unit volumes  Domestic peripheral revenue registered growth of 12  to  48 2 million  International revenues totaled  2 5 million Cardiovascular Systems  Inc  Price  Consensus and EPS Surprise
    MarginGross margin in the reported quarter was 80 3   down 145 basis points  bps  year over year Meanwhile  selling  general and administrative  SG A  expenses rose 16 2  to  43 9 million plus research and development  R D  expenses escalated 41 8  to  9 5 million  As a result  operating expenses increased 20 1  to  53 5 million  Operating margin in the reported quarter contracted 454 bps to 1 8  Financial PositionThe company exited fiscal 2019 with cash and cash equivalents of  74 2 million compared with  116 3 million at the end of fiscal 2018 2020 OutlookCardiovascular Systems initiated its fiscal 2020 guidance  The company projects revenues within  278  283 million for fiscal 2020  The Zacks Consensus Estimate for fiscal 2020 revenues is pegged at  277 2 million  just below the company s view Moreover  the company anticipates gross profit margin within 79 80  Our TakeCardiovascular Systems exited fiscal 2019 with in line earnings and revenue beat  We are upbeat about the year over year uptick in both Coronary and peripheral device revenues within the company s domestic market  It is making concerted efforts in product innovation through R D investments  The acquisition of WIRION Embolic Protection System during the quarter buoys optimism  The enrollment of the first patient inREACH PVI Clinical Study is encouraging as well On the flip side  contraction in both margins is disappointing  Also  Cardiovascular Systems faces cut throat competition in the niche space Zacks Rank and Key PicksCardiovascular Systems currently carries a Zacks Rank  5  Strong Sell  A few better ranked companies  which posted solid results this earnings season  are Stryker Corporation   NYSE SYK    Baxter International Inc    NYSE BAX   and Intuitive Surgical  Inc    NASDAQ ISRG   Baxter delivered second quarter 2019 adjusted EPS of 89 cents  which surpassed the Zacks Consensus Estimate of 81 cents by 9 9   Revenues of  2 84 billion beat the Zacks Consensus Estimate of  2 79 billion by 1 9   The company holds a Zacks Rank  2  Buy   You can see  Stryker delivered second quarter 2019 adjusted EPS of  1 98  beating the Zacks Consensus Estimate by 2 6   Revenues of  3 65 billion surpassed the Zacks Consensus Estimate by 1 4   The company carries a Zacks Rank of 2 Intuitive Surgical reported second quarter 2019 adjusted EPS of  3 25  which beat the Zacks Consensus Estimate of  2 85  Revenues were  1 1 billion  surpassing the Zacks Consensus Estimate of  1 03 billion  The company has a Zacks Rank  1 Biggest Tech Breakthrough in a Generation Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity  Current technology will soon be outdated and replaced by these new devices  In the process  it s expected to create 22 million jobs and generate  12 3 trillion in activity  A select few stocks could skyrocket the most as rollout accelerates for this new tech  Early investors could see gains similar to buying Microsoft  NASDAQ MSFT  in the 1990s  Zacks  just released special report reveals 7 stocks to watch  The report is only available for a limited time ",2019-08-08,Zacks Investment Research,https://www.investing.com/analysis/cardiovascular-systems-csii-earnings-match-estimates-in-q4-200452888,200452888
29804,251319,CSII,Cardiovascular Systems Set To Present LIBERTY 360 Outcome,opinion,Cardiovascular Systems  Inc    NASDAQ CSII   recently announced that the three year results from its LIBERTY 360 clinical study will be demonstrated in a late breaking presentation at the 2019 Amputation Prevention Symposium  AMP  in Chicago on Aug 16  Alongside that  the two year endovascular peripheral artery disease  PAD  related health care costs in LIBERTY 360 and an orbital atherectomy economic sub analysis will also be presented on Aug 15 This study outcome is expected to be a major stride in the company s endeavor to offer treatment to patients with multi level PAD More About the Study OutcomeLIBERTY 360 is a real world  unique study designed with the aim of evaluating the acute and long term clinical and economic outcomes of peripheral vascular interventions  PVI  in patients suffering from PAD  It is among the first PAD studies to examine patients across the spectrum of symptomatic PAD  including a record 100 Rutherford Class 6 patients  LIBERTY 360 s trial design included any endovascular device which has been cleared by the FDA for the treatment of PAD  The trial study has around 1 204 patients enrolled at 51 sites across the United States Post this presentation  the company plans to commercially launch its Diamondback Exchangeable Series   the most sophisticated orbital atherectomy system designed for optimal  complete leg revascularization of PAD patients who have lesions above and below the knee Market ProspectsPer   the global peripheral artery disease market was valued at  3 13 billion in 2016  and is anticipated to reach  4 98 million by 2023  at a CAGR of 6 8  from 2017 to 2023  Hence  the study results are being presented at an ideal time Recent DevelopmentsLately  the company has been focusing on offering treatment to PAD patients In June 2019  Cardiovascular Systems announced the enrolment of the first patient under its REACH PVI clinical study  The aim of this study is to assess acute clinical outcomes of orbital atherectomy via transradial access for the treatment of PAD in lower extremity lesions Key CompetitorsMajor companies posing competitive threat to Cardiovascular Systems in the PAD treatment space are Medtronic   NYSE MDT   Boston Scientific   NYSE BSX   and Becton  Dickinson and Company   NYSE BDX    among others Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases  Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-08-14,Zacks Investment Research,https://www.investing.com/analysis/cardiovascular-systems-set-to-present-liberty-360-outcome-200455444,200455444
29805,251320,CSII,Cardiovascular Systems  CSII  Loss Wider Than Estimates In Q1,opinion,"Cardiovascular Systems  Inc    NASDAQ CSII   reported a loss per share of 17 cents in first quarter fiscal 2020  wider than the loss per share of 9 cents in the prior year period  The reported figure was also wider than the Zacks Consensus Estimate of a loss of 9 cents Net SalesCardiovascular Systems  revenues of  64 5 million in the first quarter marked a 14 6  year over year increase  Meanwhile  the top line beat the Zacks Consensus Estimate by 0 7  Segment DetailsIn the quarter under review  global Coronary device revenues jumped 26  year over year to  19 million  Domestic coronary revenues rose 17  to  16 3 million   Global peripheral revenue increased 10  to  45 5 million led by the launch of new peripheral orbital atherectomy devices  Domestic peripheral revenue increased 10  to  45 2 million Cardiovascular Systems  Inc  Price  Consensus and EPS Surprise
    Total U S  revenues increased 12  to  61 5 million while International revenue totaled just under  3 million MarginGross margin in the reported quarter was 80 3   down 85 basis points  bps  year over year on a 19 8  rise in cost of goods sold Meanwhile  selling  general and administrative  SG A  expenses rose 13 4  to  46 8 million plus research and development  R D  expenses escalated 46 2  to  10 8 million  As a result  operating expenses increased 18 3  to  57 5 million  Operating loss in the reported quarter came in at  5 7 million  wider than the operating loss of  2 9 million in the year ago period Financial PositionThe company exited first quarter fiscal 2020 with cash and cash equivalents of  58 9 million compared with  74 2 million at the end of fiscal 2019 2020 OutlookCardiovascular Systems reaffirmed its fiscal 2020 guidance  The company projects revenues within  278  283 million for fiscal 2020 indicating 12  to 14  growth over fiscal 2019  The Zacks Consensus Estimate for fiscal 2020 revenues is pegged at  280 4 million  below the company s view Moreover  the company reiterates gross profit margin at the band of 79 80  Our TakeCardiovascular Systems exited the first quarter of fiscal 2020 on a mixed note with wider than estimated loss and a revenue beat  We are upbeat about the year over year uptick in both Coronary and peripheral device revenues within the company s domestic market  The company is making concerted efforts in product innovation through R D investments  Treatment of the first patient in the Middle East with peripheral orbital atherectomy system is another crucial highlight of the quarter  The FDA approval of Viperwire Advance Coronary Guide Wire with Flex Tip instills optimism On the flip side  operating loss and contraction of margins during the quarter are disappointing  Also  Cardiovascular Systems faces cut throat competition in the niche space Earnings of Other MedTech Majors at a GlanceCardiovascular Systems carries a Zacks Rank  3  Hold  Some better ranked companies  which posted solid results this earnings season  are Edwards Lifesciences   NYSE EW    Thermo Fisher Scientific Inc    NYSE TMO   and ResMed Inc    NYSE RMD    each carrying a Zacks Rank  2  Buy   You can see  Edwards Lifesciences delivered third quarter 2019 adjusted earnings per share  EPS  of  1 41  outpacing the Zacks Consensus Estimate by 15 6   Third quarter net sales of  1 09 billion surpassed the Zacks Consensus Estimate by 5 5  Thermo Fisher delivered third quarter 2019 adjusted EPS of  2 94  which surpassed the Zacks Consensus Estimate by 2 1   Revenues of  6 27 billion outpaced the Zacks Consensus Estimate by 1 3  ResMed reported first quarter fiscal 2020 adjusted EPS of 93 cents  which beat the Zacks Consensus Estimate of 87 cents by 6 9   Revenues were  681 1 million  surpassing the Zacks Consensus Estimate by 3 6  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-10-30,Zacks Investment Research,https://www.investing.com/analysis/cardiovascular-systems-csii-loss-wider-than-estimates-in-q1-200480030,200480030
29806,251321,CSII,Cardiovascular Systems Sees Peripheral OAS Micro Crown Success,opinion,Cardiovascular Systems  Inc    NASDAQ CSII   has successfully treated the first patient in Europe with its Stealth 360 Peripheral Orbital Atherectomy System  OAS  1 25 mm Micro Crown with GlideAssist  1 25 Micro Crown   The company has launched the 1 25 Micro Crown in Germany  in partnership with OrbusNeich  a leading provider of cardiovascular solutions This is a major achievement for the company toward strengthening its portfolio for the treatment of critical limb ischemia or CLI More About the 1 25 Micro CrownThe 1 25 Micro Crown is a minimally invasive option to efficiently treat CLI by modifying calcified lesions below the knee and resuming blood flow to the foot The GlideAssist feature aids the 1 25 Micro Crown to rotate at a tedious speed of 5K rpm  thereby ensuring easier tracking and movement needed to access diffuse  calcified lesions located below the knee  The device s dual mechanism of action of differential sanding and pulsatile forces will be critical in treating the challenging calcified lesions found below the knee  Market ProspectsPer   the global CLI treatment market reached a worth of  3 12 billion in 2018 and is anticipated to reach  5 39 billion by 2025  at a CAGR of 8 1   Hence  this development comes at an ideal time for the company Recent DevelopmentsLately  Cardiovascular Systems has been witnessing significant progress with its OAS technology  In 2018  the company had launched OAS in Asia  Europe and the Middle East  in collaboration with its distribution partner  OrbusNeich In January 2019  the company treated the first patient in the UAE with its Diamondback 360 Coronary OAS In October 2019  the company announced its first successful patient treatment case with the Stealth 360 Peripheral OAS in the UAE Price PerformanceIn the past one year  the company s shares have outperformed the   The stock has rallied 58 9  compared with the industry s 13 5  rise Zacks Rank   Stocks Worth a LookCardiovascular Systems carries a Zacks Rank  5  Strong Sell  A few better ranked stocks from the broader medical space are Haemonetics Corporation   NYSE HAE    NuVasive  Inc   NASDAQ NUVA   and ResMed   NYSE RMD    While ResMed sports a Zacks Rank  1  Strong Buy   the other two carry a Zacks Rank  2  Buy   You can see Haemonetics has a projected long term earnings growth rate of 13 5  NuVasive has an expected long term earnings growth rate of 10 9  ResMed has a long term earnings growth rate of 12 9  Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2019-12-16,Zacks Investment Research,https://www.investing.com/analysis/cardiovascular-systems-sees-peripheral-oas-micro-crown-success-200493096,200493096
29811,251326,CSII,Here s Why You Should Hold On To McKesson  MCK  Stock Now,opinion,"McKesson Corporation   NYSE MCK   is well poised for growth backed by strong segmental performances and solid prospects in the pharmaceutical and medical supplies distribution market  However  increasing pricing pressure remains a concern The stock currently carries a Zacks Rank  3  Hold  Price PerformanceShares of McKesson have gained 18 7   outperforming the  s growth of 17 1  on a year to date basis  Moreover  the stock outpaced the S P 500 Index s rally of 16 5  

What s Weighing on the Stock The company has been witnessing escalating pricing pressure and entered fiscal 2020 with an assumption of branded inflation in the mid single digits Fluctuations in generic pharmaceuticals  negative currency movements and intense competition in the niche space are hindering the company s prospects Factors to Bolster McKessonBeing a major player in the pharmaceutical and medical supplies distribution market  McKesson continues to benefit from its position over a considerable period of time  The Distribution Solutions segment caters to a wide range of customers and businesses and stands to benefit from increased generic utilization  inflation in generics driven by several patent expirations in the next few years  and an aging population Notably  the company announced a multi year strategic growth initiative update that is currently expected to generate approximately  400  500  up from the previously guided range of  300  400 million  million in annual pre tax gross savings  This will be substantially realized by the end of fiscal 2021 McKesson continues to benefit from acquisitions and strategic collaborations  which in turn will drive the company s growth while contributing substantially to the top line Management aims to increase efficiency  accelerate execution and improve long term performance through its initiatives that consist of multiple growth pillars  Late 2018  management at McKesson announced that the company has made solid progress in its operating model and other cost out initiatives  Based on strong business strategies  the company is anticipated to drive increased efficiency and productivity Which Way Are Estimates Headed For 2020  the Zacks Consensus Estimate for revenues is pegged at  221 77 billion  indicating an improvement of 3 5  from the year ago period  For adjusted earnings per share  the same stands at  14 14  suggesting growth of 4 2  from the year ago reported figure Key PicksSome better ranked stocks from the broader medical space are Cardiovascular Systems  Inc    NASDAQ CSII    Oxford Immunotec Global PLC   NASDAQ OXFD   and Haemonetics Corp    NYSE HAE    each sporting a Zacks Rank  1  Strong Buy   You can see  
Cardiovascular Systems has earnings growth rate for fiscal fourth quarter of 2019 of 33 3  Oxford Immunotec has a long term earnings growth rate of 25  Haemonetics has a long term earnings growth rate 13 5  
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-06-25,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-hold-on-to-mckesson-mck-stock-now-200434610,200434610
29812,251327,CSII,Here s Why You Should Hold On To Surmodics  SRDX  Stock Now,opinion,Surmodics  Inc    NASDAQ SRDX   is well poised for growth backed by consistent growth In Vitro Diagnostics  IVD  unit and persistent efforts to bolster research and development  R D  functionalities  However  the company s drug coated balloons continue to face intense competition in the nice space and remains a concern The stock currently carries a Zacks Rank  3  Hold  Price PerformanceShares of Surmodics have lost 16 4   against the  s growth of 15 9  on a year to date basis  Further  the stock compared unfavorably with the S P 500 Index s rally of 16 2  What s Weighing on the Stock Given the highly fragmented diagnostics market  the company s SurVeil Drug Coated Balloons continues to face stiff competition with Medtronic s admiral IN PACT platform Moreover  surface modification and device drug delivery are competitive markets and carry the risk of technological obsolescence  Meanwhile  the IVD segment faces increased competition Factors to Bolster SurmodicsSurmodics  IVD unit continues to drive the company s performance as traditionally the segment has been a leader in developing an ELISA EIA  immunoblot western blot  line assay or microarray Further  the company continues to gain from core Medical Devices unit which witnessed significant contribution from its SurVeil agreement with Abbott  Management anticipates this segment to witness double digit revenue growth in fiscal 2019 Surmodics  continued efforts to boost its R D stature have been a key growth driver  The company s whole product solutions pipeline and sirolimus based below the knee DCB program deserve a mention here Moreover  acquisitions made by the company in the last few years have not only diversified its revenue base but also expanded customer base Which Way Are Estimates Headed For 2019  the Zacks Consensus Estimate for revenues is pegged at  91 2 million  indicating an improvement of 12 1  from the year ago period  For adjusted earnings per share  the same stands at 38 cents  suggesting a decline of 38 8  from the year ago reported figure Key PicksSome better ranked stocks from the broader medical space are Cardiovascular Systems  Inc    NASDAQ CSII    Oxford Immunotec Global PLC   NASDAQ OXFD   and Haemonetics Corporation   NYSE HAE    each sporting a Zacks Rank  1  Strong Buy   You can see  Cardiovascular Systems has earnings growth rate for fiscal fourth quarter of 2019 of 33 3  Oxford Immunotec has a long term earnings growth rate of 25  Haemonetics has a long term earnings growth rate 13 5  More Stock News  This Is Bigger than the iPhone It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 ,2019-06-25,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-hold-on-to-surmodics-srdx-stock-now-200434902,200434902
29860,251375,CSII,Here s Why You Should Retain Allscripts  MDRX  Stock Now,opinion,Allscripts Healthcare Solutions  Inc    NASDAQ MDRX   is well poised for growth on the back of strategic acquisitions and divestments  and strong prospects in Sunrise EHR platform  However  integration risks remain a concern The stock currently carries a Zacks Rank  3  Hold  Price PerformanceShares of Allscripts have gained 17 4   underperforming the  s growth of 32 5  on a year to date basis  However  the stock outpaced the S P 500 Index s rally of 16 4  What s Weighing on the Stock Given the dependence on acquisitions and mergers  the company is exposed to considerable integration risks Moreover  stiff competition in the niche space is an added concern Factors to Boost AllscriptsAllscripts continues to benefit from acquisitions and mergers  which in turn will accelerate the company s overall performance and contribute substantially to the top line Moreover  the company continues to gain traction from the prospective Sunrise and Paragon EHR platform   an important growth driver of Allscripts  Notably  the company s EHR diagnostic tools  including dbMotion  EPSi  FollowMyHealth and 2bPrecise  have been witnessing a growing list of clients outside the company s EHR base Allscripts continues to gain from its Software  Delivery  Support and Maintenance units  which delivered solid growth in the last couple of quarters  Significant growth in bookings also buoys optimism Which Way Are Estimates Headed For 2019  the Zacks Consensus Estimate for revenues is pegged at  1 79 billion  indicating a decline of 15 9  from the year ago period  For adjusted earnings per share  the same stands at 68 cents  suggesting a fall of 5 6  from the year ago reported figure Key PicksSome better ranked stocks from the broader medical space are Cardiovascular Systems  Inc    NASDAQ CSII    Oxford Immunotec Global PLC   NASDAQ OXFD   and Haemonetics Corporation   NYSE HAE    each sporting a Zacks Rank  1  Strong Buy   You can see  Cardiovascular Systems has earnings growth rate for fiscal fourth quarter of 2019 of 33 3  Oxford Immunotec has a long term earnings growth rate of 25  Haemonetics has a long term earnings growth rate 13 5  More Stock News  This Is Bigger than the iPhone It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 ,2019-06-23,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-retain-allscripts-mdrx-stock-now-200434173,200434173
29861,251376,CSII,Masimo s O3 Oximetry Gets FDA Nod  Boosts Patient Monitoring,opinion,Masimo Corporation   NASDAQ MASI   recently announced that it has received FDA clearance for its O3 Regional Oximetry for utilization on neonatal and infant patients weighing less than 10 kg  This FDA nod will prove beneficial for the company as O3 Regional Oximetry uses near infrared spectroscopy  NIRS  to enable monitoring of cerebral tissue oxygen saturation  rSO2  and will help in delivering accurate measurement pertaining to neonatal patients Notably  the FDA clearance will expand the O3 platform and the benefits of monitoring with O3 will now be accessible to patients of all ages   from neonates to adults Few Words About O3 Regional OximetryO3 Regional Oximetry   one of Masimo s monitoring solutions   helps in monitoring cerebral oxygenation in cases wherein peripheral pulse oximetry alone might not be enough to fully indicate oxygen in the brain  The solution seamlessly integrates with the Root platform along with SedLine brain function monitoring  thereby delivering a more comprehensive brain monitoring solution With the usage of NIRS  the clinicians will be able to monitor rSO2 on both sides of the brain and this will be specifically helpful in offering an insight into neonatal patient status primarily because neonatal pathology is mostly brain related Masimo s Root Platform at a GlanceNotably  Masimo s Root platform is a very powerful  expandable patient monitoring and connectivity hub that brings together a range of technologies  devices  and systems to offer multimodal monitoring and connectivity solutions in a single  clinician centric platform O3 is available as a Masimo Open Connect  MOC 9  module for the Root Patient Monitoring and Connectivity Platform Root s plug and play expansion capabilities help in simultaneous monitoring of O3 and other measurements like SET Measure through Motion and Low Perfusion pulse oximetry Masimo  A Leading Player in Pulse OximetryMasimo is a global pioneer in the field of highly advanced non invasive monitoring technologies  The company s flagship Signal Extraction Technology  SET  pulse oximetry or SET pulse oximeter solution successfully eliminates the limitations of conventional mediums  Masimo s rainbow SET technology has been gaining traction driven by rapid product development Together with the proven benefits of Masimo SET Measure through Motion and Low Perfusion pulse oximetry  O3 can help clinicians get a far more expanded visibility of neonatal oxygenation status Patient Monitoring in FocusMasimo is touted to be the most innovative company in the patient monitoring space  According to report by   the global market for patient monitoring devices will witness a CAGR of 8 2  to nearly  30 7 billion by 2022  Growing economy  rise in the prevalence of chronic diseases and increasing adoption of cost effective remote patient monitoring devices will drive growth in this market The company remains committed toward enhancing patient monitoring and its efforts reflect the same  In non invasive patient monitoring  the company s Patient SafetyNet  Rainbow acoustic monitoring  SedLine brain function monitoring  Capnography and gas monitoring deserve mention Additionally  Masimo s program to improve opioid safety via innovative monitoring technology for both post surgical wards and home use deserves mention in this regard Zacks Rank and Price PerformanceCurrently Masimo carries a Zacks Rank  2  Buy   Shares of Masimo have gained 40  in a year s time  against the  s decline of 2 7   The stock has also outpaced the S P 500 index s rally of 2 7  Other Key PicksSome other top ranked stocks from the broader medical space are Cardiovascular Systems  Inc    NASDAQ CSII    Quidel Corporation   NASDAQ QDEL   and Heamonetics Corporation   NYSE HAE    each currently sporting a Zacks Rank  1  Strong Buy   You can see  Cardiovascular Systems has an earnings growth rate of 33 3  for the fourth quarter of fiscal 2019 Quidel Corporation has a long term earnings growth rate of 25  Heamonetics has a long term earnings growth rate of 13 5  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-06-11,Zacks Investment Research,https://www.investing.com/analysis/masimos-o3-oximetry-gets-fda-nod-boosts-patient-monitoring-200431020,200431020
29862,251377,CSII,Here s Why You Should Retain HMS Holdings  HMSY  Stock,opinion,HMS Holdings Corp    NASDAQ HMSY   is well poised for growth on the back of growing Payment Integrity Solutions and Total Population Management  and strong margins  However  intense competition in the U S  medical cost containment industry remains a concern The stock carries a Zacks Rank  3  Hold  Price PerformanceShares of HMS Holdings have gained 34 2   outperforming the  s growth of 6 4  in a year s time  The stock also outpaced the S P 500 Index s rally of 1 9  What s Favoring the Stock HMS Holdings continues to benefit from its promising and growing Payment Integrity Solutions  Payment Integrity  PI  has been benefiting from greater throughput in the implementation process  expedited customer approvals for new PI edits  applied technology to simplify processes  increased coder productivity and accelerated revenue generation Per management  PI is anticipated to be a significant contributor to the Analytical Services wing in 2019 Apart from PI solutions  Total Population Management  TPM  comes under HMS Holdings  unique suite of Analytical Services  The company has been gaining traction from TPM for a signioficant period of time that has been contributing significantly to the company s top line Product yield enhancements and process improvements are consistently bolstering HMS Holdings  margins and profitability  The company has been diligently managing operating expenses and broadening the use of technology tools such as robotic process automation and machine learning On the basis of these initiatives  the company has been exhibiting strong margins in the last few years and the momentum is expected to continue in the near term What s Deterring the Stock The company faces intense competition in the U S  medical cost containment space  which is a dynamic industry as customers have a lot of alternatives available to them Which Way Are Estimates Headed For 2019  the Zacks Consensus Estimate for revenues is pegged at  649 4 million  indicating an improvement of 8 5  from the year ago period  The same for earnings stands at  1 20 per share  suggesting growth of 15 4  from the year ago reported figure Key PicksSome better ranked stocks from the broader medical space are Cardiovascular Systems  Inc    NASDAQ CSII    Quidel Corporation   NASDAQ QDEL   and Heamonetics Corporation   NYSE HAE    each sporting a Zacks Rank  1  Strong Buy   You can see  Cardiovascular Systems has earnings growth rate for fiscal fourth quarter of 2019 of 33 3  Quidel Corporation has a long term earnings growth rate of 25  Heamonetics has a long term earnings growth rate 13 5  Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119 and  164 in as little as 1 month  The stocks in this report could perform even better ,2019-06-09,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-retain-hms-holdings-hmsy-stock-200430221,200430221
29863,251378,CSII,Ecolab Unveils Innovative Tested Tool To Improve Food Safety,opinion,Ecolab Inc    NYSE ECL   has recently launched an innovative and tested tool   Food Safety Culture Assessment   that will help in measurement and advancement of food safety behaviors and enhance the overall food safety culture associated with food retail organizations  With this new tool  the Ecolab expects to efficiently improve food safety and provide a boost to its Global Industrial segment Notably  this tool has been introduced as part of World Food Safety Day on Jun 7  2019 Few Words About Food Safety Culture AssessmentGiven the constant need for fresh food and varied eating options from restaurants and the foodservice industry  food safety risks increase rapidly  Apart from improving food safety  it is imperative to ensure customer safety  Consequently  the requirement to add new risk reduction techniques to the portfolio becomes a pressing need The Food Safety Culture Assessment is a series of easy to read and comprehensible questions on the key elements of an effective food safety culture  The assessment will take only minutes to complete  and the results can help to detect trends based on unique attributes important to a company Moreover  Ecolab can conduct the assessment across all levels of an organization  The assessment results are then reported with an overview by question and category  a Food Safety Culture Index  an industry benchmark score  and recommendations created to help prioritize an organization s action planning efforts The assessment can be taken annually or at any desired frequency that will help in checking the progress when it comes to maintaining and strengthening a robust food safety culture The tool has been created to offer better visibility into attitudes and actions of frontline employees  managers and corporate officers and detect the areas that require improvement Importance of Food SafetyFood safety is very critical in today s world as the continued success of a business depends on it According to World Health Organization  WHO  access to sufficient amount of safe and nutritious food is the key to sustained lives and promotion of good health Unsafe food carries harmful bacteria  viruses  parasites or chemical substances that leads to more than 200 diseases ranging from diarrhea to cancers An estimated 600 million   almost 1 in 10 people in the world   fall ill after eating contaminated food and 420 000 die every year  resulting in the loss of 33 million healthy life years  DALYs  Market Prospects  Per a report by  the food safety testing market is anticipated to grow from  17 billion in 2018  24 6 billion by 2023 at a CAGR of 7 7  during the forecast period  This can primarily be attributable to increase in global outbreaks of foodborne illnesses Additionally  strict food safety regulations  availability of advanced rapid technology  rise in demand for convenience and packaged food products  upsurge in outbreaks of chemical contamination in food processing industries  and increase in consumer awareness about food safety is projected to bolster the market Global Industrial Segment at a GlanceWith this new tool Ecolab expects to enhance its Global Industrial Segment and it is important to note that Food   Beverage falls under the aforementioned segment In the first quarter of 2019  sales in the segment grew 4 5  year over year fueled by major gains in the Water  Food   Beverage and Life Sciences units Zacks Rank and Price PerformanceCurrently Ecolab carries a Zacks Rank  3  Hold   Shares of Ecolab have gained 37 7  in a year s time  outperforming the  s growth of 5   The stock has also outpaced the S P 500 index s rally of 1 7  Key PicksSome other top ranked stocks from the broader medical space are Cardiovascular Systems  Inc    NASDAQ CSII    Quidel Corporation   NASDAQ QDEL   and Heamonetics Corporation   NYSE HAE    each currently sporting a Zacks Rank  1  You can see  Cardiovascular Systems has an earnings growth rate of 33 3  for the fourth quarter of fiscal 2019 Quidel Corporation has a long term earnings growth rate of 25  Heamonetics has a long term earnings growth rate of 13 5  Will you retire a millionaire  One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-06-10,Zacks Investment Research,https://www.investing.com/analysis/ecolab-unveils-innovative-tested-tool-to-improve-food-safety-200430457,200430457
29869,251384,CSII,Novo Nordisk says FDA approves new indication for Ozempic,news,"Novo Nordisk  NYSE NVO  says the Food and Drug  Administration approved a new indication for Ozempic  semaglutide  to  reduce the risk of major adverse cardiovascular events such as heart attack  stroke or death in adults with type 2 diabetes and known heart disease  
Novo says the FDA decision was based on results from the SUSTAIN 6 trial  which examined  the cardiovascular safety of adding Ozempic or placebo to standard of care in adults with type 2 diabetes and established cardiovascular disease  
Ozempic already is indicated for use to improve blood sugar in adults with type 2 diabetes mellitus and to reduce the risk of major cardiovascular events in adults with type 2 diabetes mellitus with known heart disease ",2020-01-16,Seeking Alpha,https://invst.ly/pj0jf,2061587
29916,251431,CSII,Here s Why You Should Add Cardiovascular Systems  CSII  Stock,opinion,"Cardiovascular Systems  Inc    NASDAQ CSII   is gaining investors  confidence  owing to impressive portfolio expansion 
The company has outperformed its  in the past year  The stock has surged 26 2  compared with the industry s 5 4  rise and the S P 500 s 2 7  increase in the said period 
This leading medical device manufacturer has a market cap of  1 36 billion  The company develops and commercializes innovative solutions to treat patients suffering from peripheral and coronary arterial diseases  including those with arterial calcium 
Banking on solid prospects  this Zacks Rank  1  Strong Buy  stock is an attractive pick for investors at the moment 
Market Dynamics  Currently  Cardiovascular Systems firmly stands to gain from several favorable trends existing in the PAD as well CAD market spaces  According to estimates delivered by the American Heart Association  AHA   as many as 8 12 million Americans suffer from peripheral artery disease  PAD   Moreover  an aging population coupled with increasing incidence of diabetes and obesity is likely to propel the prevalence of PAD 

 
Focus on International Business  Internationally  Cardiovascular Systems is progressing well with its partnership with OrbusNeich  Per the terms  OrbusNeich is distributing the company s coronary and peripheral orbital atherectomy systems in multiple countries in Europe and Southeast Asia  outside the United States and Japan 
Impressive Portfolio Expansion  The company has long been expanding product portfolio to enhance market reach and versatility  Currently  the company plans to launch more than 20 new products to expand the portfolio in the next five years  Recently  the company has increased R D expenses by 27   which is associated with investments in new product development and enrollment in the ECLIPSE clinical trial 
Which Way Are Estimates Treading 
For the fourth quarter of fiscal 2019  the Zacks Consensus Estimate for earnings is pegged at 4 cents  which indicates 63 6  fall from the year ago quarter s figure  The same for revenues is pegged at  66 million  calling for year over year growth of 11 7  from the prior year quarter s number 
For 2019  the Zacks Consensus Estimate for loss is pegged at 1 cent  suggesting 120  year over year fall  The same for revenues is pegged at  245 8 million  suggesting 13 3  rise from the prior year quarter s level 
Other Key Picks
Some other top ranked stocks in the broader medical space are Cerner Corp    NASDAQ CERN    Penumbra   NYSE PEN   and Bruker Corp    NASDAQ BRKR    While Cerner sports a Zacks Rank  1  Penumbra and Bruker carry a Zacks Rank  2  Buy   You can see  
Cerner s long term earnings growth rate is expected to be 13 5  
Penumbra s long term earnings growth rate is projected at 21 5  
Bruker s long term earnings growth rate is estimated at 11 7  
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-06-12,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-add-cardiovascular-systems-csii-stock-200431062,200431062
29917,251432,CSII,Here s Why You Should Hold On To PRA Health  PRAH  Stock Now,opinion,PRA Health Sciences  Inc    NASDAQ PRAH   is well poised for growth on the back of strong international expansion  growing Contact Research Organization  CRO  industry and favorable biopharmaceutical industry dynamics  However  the tough capital spending environment remains a concern The stock currently carries a Zacks Rank  3  Hold  Price PerformanceShares of PRA Health Sciences have gained 4 4   compared with the  s growth of 2 3  on a year to date basis  However  the stock fell short of the S P 500 Index s rally of 14  What s Deterring the Stock The general capital spending environment remains a woe for PRA Health  The company s cautious view comes on the back of few factors like the international trade dispute that has been affecting the financial markets in recent times  This in turn can put pressure on capital equipment expenditure  consequently lengthen the decision process leading to purchases Factors to Boost PRA HealthOn the back of worldwide increase in demand for outsourced clinical development solutions  the CRO industry has been gaining traction that has put it under the limelight  Going by a CRO Market Size Projections report by Industry Standard Research  ISR   the size of the worldwide CRO market was approximately  32 billion in 2016 and will witness a 7  CAGR to  44 billion in 2021 International expansion has been and continues to be a major growth driver  This is because PRA Health is one of the largest CROs in the world by revenues  focusing on executing clinical trials on a global basis We note that  PRA Health s revenues from international operations is growing fast  currently Europe  Africa  and Asia Pacific region contributes more than 30  of the company s total revenue  The company continues to gain from large pharmaceutical companies  which contributed to the top line in recent times Moreover  a solid 2019 outlook instills optimism in the stock  For 2019  PRA Health anticipates to achieve total revenues between  3 09 billion and  3 20 billion  representing reported and constant currency growth of 8  to 11   respectively Adjusted EPS for 2019 is expected between  4 93 and  5 08  representing growth of 15  to 19  from 2018 Which Way Are Estimates Headed For 2019  the Zacks Consensus Estimate for revenues is pegged at  3 10 billion  indicating an improvement of 11 1  from the year ago period  For adjusted earnings per share  the same is pinned at  5 03  suggesting growth of 17 5  year ago reported figure Key PicksSome better ranked stocks from the broader medical space are Cardiovascular Systems  Inc    NASDAQ CSII    Oxford Immunotec Global PLC   NASDAQ OXFD   and Haemonetics Corporation   NYSE HAE    each sporting a Zacks Rank  1  Strong Buy   You can see  Cardiovascular Systems has earnings growth rate for fiscal fourth quarter of 2019 of 33 3  Oxford Immunotec has a long term earnings growth rate of 25  Haemonetics has a long term earnings growth rate 13 5  Radical New Technology Creates  12 3 Trillion Opportunity Imagine buying Microsoft  NASDAQ MSFT  stock in the early days of personal computers  or Motorola  NYSE MSI  after it released the world s first cell phone  These technologies changed our lives and created massive profits for investors Today  we re on the brink of the next quantum leap in technology  7 innovative companies are leading this  4th Industrial Revolution    and early investors stand to earn the biggest profits ,2019-06-16,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-hold-on-to-pra-health-prah-stock-now-200432208,200432208
29918,251433,CSII,AMN Healthcare  AMN  Closes Advanced Medical Acquisition,opinion,AMN Healthcare Services  Inc    NYSE AMN   recently concluded the Advanced Medical Personnel Services  Inc  buyout  announced previously on Apr 30  2019   Advanced Medical has garnered a reputation of being an allied and nurse staffing firm  catering to hospitals  schools  clinics  skilled nursing facilities  and home health settings Financial TermsThe deal was completed for the previously announced purchase price of  200 million  with up to an additional amount of  20 million that will be paid upon Advanced Medical s achievement of certain financial results as of Dec 31  2019 In order to finance the buyout  AMN Healthcare utilized  51 million in capacity available under its existing secured revolving credit facility  Further  the company amended its credit facility to obtain a new  150 million term loan maturing in June 2024 Financial Impact of the AcquisitionThe buyout will be accretive to AMN Healthcare s second quarter 2019 results with estimated revenues of about  5 million Advanced Medical is expected to contribute revenues in the range of  70 75 million and around  10 million adjusted EBITDA in the second half of 2019  with fourth quarter revenues about 15  more than in the third quarter  This is because of the seasonality of Advanced Medical s school staffing business On a combined basis  AMN Healthcare s income tax rate for the second half of the year is projected to be 30  due to a higher tax rate for Advanced Medical  It will add approximately  0 3 million to depreciation expense in each of the third and fourth quarters How is AMN Healthcare Poised to Benefit With this buyout  AMN Healthcare will get an opportunity to boost its offerings in some of the rapidly growing and significant care settings  The buyout will help in expanding talent network of healthcare professionals  consequently increasing placement capabilities in the areas where there is most significant imbalances of talent supply and demand As part of AMN Healthcare  the combined teams will provide the healthcare industry s most creative and comprehensive services to a broad range of facilities  including schools  where there is a solid requirement for clinicians The acquisition has been structured to help the acquirer realize tax benefits with an estimated net present value of  8 million and is projected to be immediately accretive to AMN Healthcare s adjusted earnings per share Bright Prospects in Healthcare Staffing MarketPer a report by   the global healthcare staffing market is expected to reach  44 65 billion by 2025 at a CAGR of 6  during the forecast period  Increase in geriatric population can be attributed to demand for healthcare services worldwide  However  it is important to note that there is a shortage of efficient nurses and other healthcare professionals Zacks Rank and Share Price PerformanceCurrently  AMN Healthcare carries a Zacks Rank  3  Hold   Shares of the company have gained 10 4  in the past three months  against the  s decline of 11 9   Moreover  the stock has outpaced the S P 500 index s growth of 0 7  Key PicksSome better ranked stocks from the broader medical space are Cardiovascular Systems  Inc    NASDAQ CSII    Oxford Immunotec Global PLC   NASDAQ OXFD   and Haemonetics Corporation   NYSE HAE    each sporting a Zacks Rank  1  Strong Buy   You can see  Cardiovascular Systems has earnings growth rate for fiscal fourth quarter of 2019 of 33 3  Oxford Immunotec has a long term earnings growth rate of 25  Haemonetics has a long term earnings growth rate 13 5  Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119 and  164 in as little as 1 month  The stocks in this report could perform even better ,2019-06-17,Zacks Investment Research,https://www.investing.com/analysis/amn-healthcare-amn-closes-advanced-medical-acquisition-200432545,200432545
29919,251434,CSII,Here s Why You Should Hold On To Stryker  SYK  Stock Now,opinion,Stryker Corporation   NYSE SYK   is well poised for growth on the back of solid international improvement  diversified product portfolio and acquisition driven strategy  However  pricing pressure remains a concern The stock currently carries a Zacks Rank  3  Hold  Price PerformanceShares of Stryker have gained 26 5   outperforming the  s growth of 14 4  on a year to date basis  Moreover  the stock outpaced the S P 500 Index s rally of 15 2  What s Deterring the Stock An unfavorable pricing environment continues to weigh on Stryker s core businesses  The company s top line has also been adversely affected by such pressure and we expect this to continue in the near term as well Factors to Boost StrykerA robust and diversified product portfolio with the exposure to robotics  AI for health care and Medical Mechatronics has helped Stryker to gain a competitive edge in the MedTech space  In fact  a wide range of products makes the company immune to any significant sales shortfall during economic downturns Moreover  focus on international growth has proven to be beneficial for the company  A substantial turnaround in the company s European business owing to its effective restructuring measures reflects a potential upside On the back of an acquisition driven strategy  the company has been bolstering growth profile over a considerable period of time  Moreover  its K2M acquisition drove the core Neurotechnology   Spine unit in the last reported quarter Expansion in operating margin is a positive while strong outlook for 2019 is indicative of bright prospects Which Way Are Estimates Headed For 2019  the Zacks Consensus Estimate for revenues is pegged at  14 80 billion  indicating an improvement of 8 8  from the year ago period  For adjusted earnings per share  the same is pinned at  8 15  suggesting growth of 11 5  year ago reported figure Key PicksSome better ranked stocks from the broader medical space are Cardiovascular Systems  Inc    NASDAQ CSII    Oxford Immunotec Global PLC   NASDAQ OXFD   and Haemonetics Corporation   NYSE HAE    each sporting a Zacks Rank  1  Strong Buy   You can see  Cardiovascular Systems has earnings growth rate for fiscal fourth quarter of 2019 of 33 3  Oxford Immunotec has a long term earnings growth rate of 25  Haemonetics has a long term earnings growth rate 13 5  This Could Be the Fastest Way to Grow Wealth in 2019 Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119 and  164 gains in as little as 1 month ,2019-06-18,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-hold-on-to-stryker-syk-stock-now-200433005,200433005
29920,251435,CSII,Wall Street Foresees A Fed Rate Cut  Winners   Losers,opinion,Expectations that the Fed will start trimming interest rates have grown recently  Earlier  the Fed funds futures market was suggesting a 50 50 chance that the central bank will announce a rate cut in the July meeting  But now  the Fed funds futures market is showing an 85  chance of a July rate cut  which is up more than 25  from a month ago  according to the CME Group  NASDAQ CME  Some may argue that against the backdrop of a record low unemployment rate  steady rise in wages and uptick in consumer outlays  a rate cut as early as this month seems impossible  But  the view from Wall Street is quite different After all  the stock market has been able to enjoy a decade long bull market  as rates mostly remained low  which eventually infused life into stocks  And how can we forget that prolonged trade issues with the United States and its trading partners have raised concerns about global economic growth and corporate profit margins  Stocks  in fact  have fell nearly 7  from their recent highs By the way  the long term interest rates are currently lower than short term interest rates  which is a tell tale sign that recession is knocking at the door  James Bianco  president of Bianco Research  an economic consulting firm in Chicago added that  the yield curve inversion is a market signal that the Fed is too tight  and that the Fed has raised rates too much   The Goldman Sachs Group  Inc    NYSE GS   also acknowledged that a few analysts have started to price in  insurance cuts   which means it is expecting the Fed to cut rates right before a downturn in order to save the economy If not in July  the Fed will certainly cut rates this year  And that s exactly what Bank of America Corporation   NYSE BAC   believes  The banking behemoth may not be expecting a rate cut in July  but is pinning hopes on a 0 25 percentage point rate cut in September  and then again in December There is also a lot of pressure from President Trump to cut interest rates  Trump is now challenging the Fed to do exactly what the ECB has decided  That is taking steps to ease monetary policy Healthcare Stocks Outperform After a Rate CutBarclays  LON BARC  has compiled data that shows that healthcare stocks generally rise nearly 7  in the nine months following a rate cut  And what makes this set of stocks stand out is that they tend to rise consistently We all know that rate cuts mainly take place when the economy goes through a rough patch or is in recession  And healthcare stocks have time and again thrived in such scenarios  This is because they are mostly defensive in nature as their products are not directly related to the developments in the stock market Moreover  healthcare stocks are known for paying hefty dividends  which makes them more alluring when rates decline in uneasy economic conditions  Needless to say  lower interest rates mostly tend to raise prices of high yielding stocks   Image Source  Barclays Research Some of the top healthcare stocks one may now consider include Molina Healthcare  Inc    NYSE MOH    Cardiovascular Systems  Inc    NASDAQ CSII    Magellan Health  Inc    NASDAQ MGLN   and Repligen Corporation   NASDAQ RGEN    All of them flaunt a Zacks Rank  1  Strong Buy  and have consistently provided solid dividend yield over the past five year period  You can see  Rate Cut Loser   The Durables SectorThe durables sector tends to underperform after the Fed lowers rates and that too consistently  Traditionally  the sector has gained a meager 3  or slightly more after the central bank begins to lower interest rates  Barclays observed  Durable goods  by the by  includes autos  machinery and homes  which are very sensitive to the economic cycle Maneesh Deshpande  head of U S  equity strategy at Barclays  noted that Fed will lower rates in the wake of soft economic conditions  if not a recession  During late 2018  utilities and nondurables  better known as recession outperformers  had rallied but tech shares  known as soft patch outperformers  had taken a hit  But now  techs have bounced back while utilities and nondurables are weighed down   Image Source  Barclays Research This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ,2019-06-19,Zacks Investment Research,https://www.investing.com/analysis/wall-street-foresees-a-fed-rate-cut-winners--losers-200433029,200433029
29921,251436,CSII,Here s Why You Should Invest In Cooper Companies Stock Now,opinion,The Cooper Companies  Inc    NYSE COO   is well poised for growth on the back of strong segmental performances  increasing penetration in international markets and solid gains from core CooperVision  CVI  unit The stock carries a Zacks Rank  2  Buy  Price PerformanceShares of Cooper Companies have gained 30 3   outperforming the  s growth of 16 9  on a year to date basis  Moreover  the stock outpaced the S P 500 Index s rally of 15 6  What s Favoring the Stock Driven by a highly exclusive product portfolio featuring the likes of Biofinity and Clariti  Cooper Companies has been able to maintain its leading position in specialty lenses markets  Notably  the company s flagship silicone hydrogel lenses are anticipated to generate strong sales in the near term  We expect the company s MyDay and Clariti lenses to strengthen and bolster growth prospects further Moreover  the company s CooperVision segment has been garnering success globally and fortifying presence through developments such as Eye care professional  ECP  programs in Australia and New Zealand This apart  the aforementioned segment remains focused on multiple initiatives that will increase the adoption of its innovative MiSight 1 day product across major world markets For fiscal 2019  management expects revenues at CSI to grow 3 6  at pro forma With respect to CooperSurgical  CSI   its expanding product portfolio has been benefiting the segment consistently  Recently  the company inked a deal to purchase the flagship contraception platform of Israel based Teva Pharmaceutical Industries  NYSE TEVA    PARAGARD Intrauterine Device  The transaction is anticipated to bolster Cooper Companies  CooperSurgical  CSI  business in the global contraceptive device market Notably  revenues from CSI are anticipated within the range of  663 million to  681 million  up from the previous guidance of  660  680 million Strategic acquisitions play an important role with respect to company s long term growth prospects  CSI s acquisition of Incisive Surgical and CVI s buyout of Blanchard contact lenses are expected to prove beneficial for the respective segments  which in turn will fuel growth Which Way Are Estimates Headed For 2019  the Zacks Consensus Estimate for revenues is pegged at  2 65 billion  indicating an improvement of 4 9  from the year ago period  The same for earnings stands at  12 24  suggesting growth of 6 4  from the year reported figure Other Stocks to ConsiderSome other top ranked stocks from the broader medical space are Cardiovascular Systems  Inc    NASDAQ CSII    Oxford Immunotec Global PLC   NASDAQ OXFD   and Haemonetics Corporation   NYSE HAE    each sporting a Zacks Rank  1  Strong Buy   You can see  Cardiovascular Systems has earnings growth rate for fiscal fourth quarter of 2019 of 33 3  Oxford Immunotec has a long term earnings growth rate of 25  Haemonetics has a long term earnings growth rate 13 5  Will you retire a millionaire  One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-06-19,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-invest-in-cooper-companies-stock-now-200433274,200433274
29938,251453,CSII,Here s Why You Should Retain NextGen Healthcare  NXGN  Stock,opinion,NextGen Healthcare  Inc    NASDAQ NXGN   is well poised for growth on the back of growing RCM  Revenue Cycle Management  and electronic health record  EHR  markets  and solid demand for other NextGen solutions  However  intense competition in the healthcare information technology market remains a concern The stock carries a Zacks Rank  3  Hold  Price PerformanceShares of NextGen Healthcare have gained 6 7   outperforming the  s growth of 6 2  in a year s time  The stock also outpaced the S P 500 Index s rally of 0 9  What s Favoring the Stock Being a major player in the U S  RCM space  the company continues to benefit from this market  The global RCM market is anticipated to reach  73 2 billion by 2026  It is expected to witness a CAGR of 12 0  during the period Given the popularity of the RCM solution  the company intends to expand into dental and hospital markets that will boost top line growth On the basis of the latest trend of EHR services in the U S  MedTech space gaining prominence  the company is expected to benefit from the growing global EHR market According to Transparency Market Research  the global EHR market is estimated to reach  38 29 billion by 2025  with a CAGR of 5 7   Further  reports indicate that MedTech companies with solid exposure to big data automated EHRs will excel with respect to operations and margins Apart from RCM  NextGen will continue to benefit from strong demand for its other NextGen solutions that include Hospitals  EHR and practice management  NextGen s Inpatient Clinicals  Lab and Patient Portal EHR solutions have also been gaining significant traction Strength in the company s NextGen division is significantly bolstering the company s revenue growth  Moreover  recurring revenue stream and growing base of physicians  dentists and hospitals are other major tailwinds What s Deterring the Stock The company faces intense competition owing to the highly competitive healthcare information technology  HCIT  market it operates in  This in turn will aggravate pricing pressure Further  the company has been witnessing margin pressure for a considerable period of time and it might persist in the near term as well Which Way Are Estimates Headed For fiscal 2019  the Zacks Consensus Estimate for revenues is pegged at  552 7 million  indicating an improvement of 4 5  from the year ago period  The same for earnings stands at 90 cents per share  suggesting growth of 4 7  from the year ago reported figure Key PicksSome better ranked stocks from the broader medical space are Cardiovascular Systems  Inc    NASDAQ CSII    Quidel Corporation   NASDAQ QDEL   and Heamonetics Corporation   NYSE HAE    each sporting a Zacks Rank  1  Strong Buy   You can see  Cardiovascular Systems has earnings growth rate for fiscal fourth quarter of 2019 of 33 3  Quidel Corporation has a long term earnings growth rate of 25  Heamonetics has a long term earnings growth rate 13 5  More Stock News  This Is Bigger than the iPhone It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 ,2019-06-07,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-retain-nextgen-healthcare-nxgn-stock-200429535,200429535
29944,251459,CSII,Here s Why You Should Retain Cooper Companies  COO  Stock,opinion,The Cooper Companies  Inc    NYSE COO   is well poised for growth on the back of strong segmental performances  increasing penetration in international markets and solid gains from its core CooperVision  CVI  unit The stock carries a Zacks Rank  3  Hold  Price PerformanceShares of Cooper Companies have gained 15 1   outperforming the  s growth of 12  on a year to date basis  The stock also outpaced the S P 500 Index s rally of 13 4  What s Favoring the Stock Driven by highly exclusive product portfolio featuring the likes of Biofinity and Clariti  Cooper Companies has been able to maintain its leading position in specialty lenses markets  Notably  the company s flagship silicone hydrogel lenses are anticipated to generate strong sales in the near term  We expect its MyDay and Clariti lenses to further strengthen and bolster growth prospects Moreover  the company s CooperVision segment has been successful globally and is fortifying foothold through developments such as Eye care professional  ECP  programs in Australia and New Zealand This apart  the aforementioned segment remains focused on multiple initiatives that will increase the adoption of its innovative MiSight 1 day product across major world markets For fiscal 2019  management expects revenues at CooperSurgical  CSI  to grow 3 6  at pro forma With respect to CSI  its expanding product portfolio has been benefiting the segment consistently  Recently  the company inked a deal to purchase the flagship contraception platform of Israel based Teva Pharmaceutical Industries  NYSE TEVA    PARAGARD Intrauterine Device  The transaction is expected to bolster Cooper Companies  CSI business in the global contraceptive device market Notably  revenues from CSI are anticipated within the range of  663 million to  681 million  up from the previous guidance of  660  680 million Strategic acquisitions play an important role with respect to company s long term growth prospects  CSI s acquisition of Incisive Surgical and CVI s buyout of Blanchard contact lenses are expected to prove beneficial for the respective segments  which in turn will fuel growth What s Deterring the Stock The company faces intense competition due to the highly competitive contact lens industry it operates in  This in turn will continue to increase pricing pressure Further  Cooper Companies generates a substantial portion of revenues in foreign currencies and consequently  fluctuations in the same can adversely affect its overseas revenues  In fact  the company anticipates foreign exchange headwinds of 47 cents per share in 2019 Which Way Are Estimates Headed For fiscal 2019  the Zacks Consensus Estimate for revenues is pegged at  2 66 billion  indicating an improvement of 4 9  from the year ago quarter  The same for earnings stands at  12 01  suggesting growth of 4 4  from the year ago reported figure Key PicksSome better ranked stocks from the broader medical space are Cardiovascular Systems  Inc    NASDAQ CSII    Quidel Corporation   NASDAQ QDEL   and Heamonetics Corporation   NYSE HAE    each sporting a Zacks Rank  1  Strong Buy   You can see  Cardiovascular Systems has earnings growth rate for fiscal fourth quarter of 2019 of 33 3  Quidel Corporation has a long term earnings growth rate of 25  Heamonetics has a long term earnings growth rate 13 5  This Could Be the Fastest Way to Grow Wealth in 2019 Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119 and  164 gains in as little as 1 month ,2019-05-19,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-retain-cooper-companies-coo-stock-200423133,200423133
29945,251460,CSII,Masimo Gets FDA Nod For Radius PPG  Boosts Patient Monitoring,opinion,Masimo Corporation   NASDAQ MASI   recently announced that it has received a 510 k  clearance from the FDA for Radius PPG  This FDA nod will prove beneficial for the company as Radius PPG utilizes the power of clinically proven Masimo SET technology that will deliver accurate measurement while the patients are on the move  This in itself is expected to be a significant breakthrough in patient monitoring More Details on Radius PPGRadius PPG has been created to eliminate the need for a cabled connection to a pulse oximetry monitor  consequently providing patients the freedom and comfort to move while being continuously monitored in a reliable and correct way  Given the wireless connection  the measurements get displayed on Masimo host devices or third party multi parameter monitors integrated with Masimo technology  This in turn makes Radius PPG instantly available to around two million monitors globally Masimo  A Leading Player in Pulse OximetryMasimo is a global pioneer in the field of highly advanced non invasive monitoring technologies  The company s flagship Signal Extraction Technology  SET  pulse oximetry or SET pulse oximeter solution successfully eliminates the limitations of conventional mediums  Masimo s rainbow SET technology has been gaining traction driven by rapid product development Together with the proven benefits of Masimo SET Measure through Motion and Low Perfusion pulse oximetry  Radius PPG can be used anywhere providing patients with advantage of mobility Patient Monitoring in FocusMasimo is touted to be the most innovative company in the patient monitoring space  According to report by   the global market for patient monitoring devices will witness a CAGR of 8 2  to nearly  30 7 billion by 2022  Growing economy  rise in the prevalence of chronic diseases and increasing adoption of cost effective remote patient monitoring devices will drive growth in this market Masimo remains committed toward enhancing patient monitoring and its efforts reflect the same  In non invasive patient monitoring  the company s Patient SafetyNet  Rainbow acoustic monitoring  SedLine brain function monitoring  Capnography and gas monitoring deserve mention Additionally  Masimo s program to improve opioid safety via innovative monitoring technology for both post surgical wards and home use deserves mention in this regard Zacks Rank and Price PerformanceCurrently  Masimo carries a Zacks Rank  2  Buy   On a year to date basis  Masimo has outperformed the  it belongs to  The stock has rallied 29  compared with the industry s rise of 6 4  Other Stocks that Warrant a LookSome other top ranked stocks from the broader medical space are Cardiovascular Systems  Inc    NASDAQ CSII    Quidel Corporation   NASDAQ QDEL   and Heamonetics Corporation   NYSE HAE    each sporting a Zacks Rank  1  Strong Buy   You can see  Cardiovascular Systems has earnings growth rate for fiscal fourth quarter of 2019 of 33 3  Quidel Corporation has a long term earnings growth rate of 25  Heamonetics has a long term earnings growth rate 13 5  Will you retire a millionaire  One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-05-20,Zacks Investment Research,https://www.investing.com/analysis/masimo-gets-fda-nod-for-radius-ppg-boosts-patient-monitoring-200423517,200423517
29946,251461,CSII,ABIOMED Gets FDA Confirmation Of The Safety Of Impella RP,opinion,ABIOMED  Inc    NASDAQ ABMD   recently announced that the FDA has validated the company s Impella RP heart pump to be safe and effective for treatment of right heart failure  The FDA has emphasized on the utilization of early identification protocol  which will result in higher survival and native heart recovery ABIOMED s foothold in the cardiovascular devices market is likely to be strengthened following the confirmation Additionally  the company recently released the new data from the National Cardiogenic Shock Initiative Study  NCSI  that shows that the protocol based approach is capable of boosting survival rates in case of cardiogenic shock and is reproducible in academic and community hospitals across the United States  Here  NCSI protocol was utilized for treating patients  including placing of the Impella heart pump before revascularization Further Details on Impella RPNotably  the Impella RP heart pump delivers blood from the inlet area  which sits in the inferior vena cava  through the cannula to the outlet opening near the tip of the catheter in the pulmonary artery The aforementioned validation followed after the FDA examined the results from Abiomed s 18 month post approval study  PAS  of 42 Impella RP patients  According to the data  64  survival rate and 90  heart recovery has been witnessed for the subgroup of PAS patients who fulfilled the enrollment criteria of Impella RP s premarket clinical studies Impella RP is the most studied right sided device and the only percutaneous technology with FDA approval  hence the validation of being safe and effective for right heart support Impella Product Line at a GlanceBeing ABIOMED s flagship product line  Impella has been a consistent growth driver and is expected to boost results in the future as well Notably  worldwide Impella heart pump revenues in the reported quarter totaled  199 5 million  indicating an improvement of 19  from the year ago quarter ABIOMED has been steadily investing to expand the platforms of Impella CP  Impella Connect  Impella 5 5 and Impella RP  The company has also announced a new technology  Impella Connect  This new platform has received CE Mark approval in Europe Recently  the company announced that its Impella CP with SmartAssist will be commercially available at the 2019 Society for Cardiovascular Angiography   Interventions  SCAI  Scientific Sessions  Additionally  majority of the Impella CP heart pumps will be transitioned to SmartAssist in fiscal 2020   Read more    Additionally  the company also announced the FDA approval for the expansion of its flagship Impella 5 0 and Impella LD for treating cardiogenic shock  Notably  this approval means that the duration of support for each Impella pump can be expanded from six to 14 days   Read more    Market ProspectsAccording to a report by   the cardiovascular devices market is expected to reach a value of nearly  80 68 billion by 2022  at a CAGR of 5 7   New health reforms  growing economy and rising awareness of healthcare fuel growth Zacks Rank and Price PerformanceCurrently  ABIOMED carries a Zacks Rank  4  Sell   Shares of the company have lost 34 2   compared with the  s decline of 3 3   The current level also compares unfavorably with the S P 500 Index s growth of 4 1  Stocks that Warrant a LookSome better ranked stocks from the broader medical space are Cardiovascular Systems  Inc    NASDAQ CSII    Quidel Corporation   NASDAQ QDEL   and Heamonetics Corporation   NYSE HAE    each sporting a Zacks Rank  1  Strong Buy   You can see  Cardiovascular Systems has earnings growth rate for fiscal fourth quarter of 2019 of 33 3  Quidel Corporation has a long term earnings growth rate of 25  Heamonetics has a long term earnings growth rate 13 5  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-05-21,Zacks Investment Research,https://www.investing.com/analysis/abiomed-gets-fda-confirmation-of-the-safety-of-impella-rp-200423954,200423954
29947,251462,CSII,Here s Why You Should Bet On Merit Medical  MMSI  Stock Now,opinion,Merit Medical Systems  Inc    NASDAQ MMSI   is well poised for growth on the back of solid segmental performances  robust product pipeline  strategic expansion and strong prospects in the HeRO product line The stock currently carries a Zacks Rank  2  Buy  What s Favoring the Stock Merit Medical remains focused on bolstering its product pipeline which aids it in expanding customer base and enhance overall performance  The company remains optimistic about several new products that are in the pipeline and slated for introduction in the second quarter of 2019  These are expected to aid the company s growth and margins Further  the company continues to reap benefits from its HeRO product line  which has been a key catalyst  Given the strong global prospects of hemodialysis solutions  the HeRO product line is likely to provide Merit Medical with a competitive edge in the MedTech markets  Per a report by MarketWatch  the global hemodialysis and peritoneal dialysis market is estimated to reach a worth of  84 billion by 2024 at a CAGR of 6  The company continues to leverage from bolt on buyouts to drive inorganic growth  The company remains optimistic about Merit Medical s Becton Dickinson deal  acquisitions of Cianna Medical and Vascular Insights  and execution of the global growth and profitability plan Additionally  the company s continued focus on Research and Development  R D  helps in instilling investor confidence  The company s strong commitment to innovation led to the introduction of several new products  improvements in the existing products and expansion of product lines  and enhancements and new equipment in the R D facilities Notably  solid 2019 outlook buoys optimism for the stock  The company expects 2019 revenues in the band of  1 01  1 03 billion  Adjusted EPS are expected between  1 97 and  2 08  The company anticipates adjusted gross margins within 50 6 51 3  Merit Medical expects core revenue growth of 8 10   The company also expects an addition of 100 150 basis points to gross margin  and net income improvement of approximately 14 19  Price PerformanceShares of Merit Medical have declined 5 5   against the  s growth of 13 3  on a year to date basis  The stock also compares unfavorably with the S P 500 Index s rally of 12   We expect the aforementioned factors might aid the stock in rebounding in the near term  Which Way are Estimates Headed For 2019  the Zacks Consensus Estimate for revenues is pegged at  1 02 billion  indicating an improvement of 15 8  from the year ago period  The same for earnings stands at  2 02  suggesting growth of 19 5  from the year ago reported figure Other Key PicksSome other top ranked stocks from the broader medical space are Cardiovascular Systems  Inc    NASDAQ CSII    Quidel Corporation   NASDAQ QDEL   and Heamonetics Corporation   NYSE HAE    each currently sporting a Zacks Rank  1  Strong Buy   You can see  Cardiovascular Systems has an earnings growth rate of 33 3  for the fourth quarter of fiscal 2019 Quidel Corporation has a long term earnings growth rate of 25  Heamonetics has a long term earnings growth rate of 13 5  Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119 and  164 in as little as 1 month  The stocks in this report could perform even better ,2019-05-27,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-bet-on-merit-medical-mmsi-stock-now-200425637,200425637
29948,251463,CSII,Here s Why You Should Hold On To Medidata  MDSO  Stock Now,opinion,Medidata Solutions  Inc    NASDAQ MDSO   is well poised for growth on the back of strong focus on cloud based services  strategic buyouts and Rave Genomics platform  However  the market for clinical trial solutions is highly competitive  which in turn  might hurt the company s prospects over the long haul The stock currently carries a Zacks Rank  3  Hold  Price PerformanceShares of Medidata Solutions have gained 36   compared with the  s growth of 24 3  on a year to date basis  The stock also compares favorably with the S P 500 Index s rally of 8 9  What s Favoring the Stock Medidata Solutions remains focused on cloud based services that have been aiding the company s overall performance over a considerable period of time  Notably  Medidata Clinical Cloud helps in connecting patients  physicians  and life sciences professionals Moreover  the company entered into an alliance with Cognizant  NASDAQ CTSH  to offer healthcare clients a comprehensive solution that leverage the market s leading cloud platform with world class business and technology services Additionally  the company s continued focus on Research and Development  R D  helps in instilling investor confidence  Per management  the current focus on drug pricing can turn out to be a positive  Lesser reliance on price is likely to drive focus on innovation  consequently bringing new therapies to the market The company continues to benefit from strategic buyouts to drive inorganic growth  Last month  the company entered into a definitive agreement to acquire SHYFT Analytics in a bid to integrate the leading platform for clinical development with the top platform for commercial and real world data analytics Medidata Rave is a cloud based clinical data management system used to electronically capture  manage  and report clinical research data  The company continues to gain market share on the back of RAVE What s Deterring the Stock The market for clinical trial solutions is highly competitive  Consequently  intense competition in the niche space adds to concerns Moreover  Medidata faces substantial consolidation risks owing to the slew of acquisitions Which Way are Estimates Headed For 2019  the Zacks Consensus Estimate for revenues is pegged at  740 1 million  indicating an improvement of 16 4  from the year ago period  The same for earnings stands at  1 83  suggesting growth of 7  from the year ago reported figure Key PicksSome better ranked stocks from the broader medical space are Cardiovascular Systems  Inc    NASDAQ CSII    Quidel Corporation   NASDAQ QDEL   and Heamonetics Corporation   NYSE HAE    each currently sporting a Zacks Rank  1  Strong Buy   You can see  Cardiovascular Systems has an earnings growth rate of 33 3  for the fourth quarter of fiscal 2019 Quidel Corporation has a long term earnings growth rate of 25  Heamonetics has a long term earnings growth rate of 13 5  Will you retire a millionaire  One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-06-02,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-hold-on-to-medidata-mdso-stock-now-200427834,200427834
29949,251464,CSII,Here s Why You Should Hold On To PerkinElmer  PKI  Stock Now,opinion,PerkinElmer  Inc    NYSE PKI   continues to benefit from core Diagnostics unit  robust international growth and continued margin expansion  The company has a market capitalization of approximately  9 77 billion The stock currently carries a Zacks Rank  3  Hold  Price PerformanceShares of PerkinElmer have gained 12 2   underperforming the  s growth of 17 1  on a year to date basis  However  the stock compares favorably with the S P 500 Index s 11 5  rally What s Deterring the Stock With respect to potential headwinds  in the first quarter of 2019  management at PerkinElmer confirmed that it expects foreign exchange headwind of approximately  18 million in the second quarter of 2019 and  42 million for full year Meanwhile  on the tariff side  the company confirmed that it anticipates facing a headwind of  1 million or less in the coming quarters from China Growing exposure to international markets increases the risk of foreign exchange volatility that can negatively impact the company s international sales Factors to Boost PerkinElmerPerkinElmer continues to benefit from strong performance by Diagnostics segment  In the first quarter  revenues improved both on a reported and organic basis  while operating income increased significantly on a year over year basis  Per management  the upside can be attributed to strength across reproductive health  applied genomics and immunodiagnostics business In the first quarter  in line with management s expectations  the major geographies witnessed mixed results  High single and mid single digit organic revenue growth was witnessed in the United States and Asia Pacific  APAC   respectively  However  this improvement was partially offset by a low single digit organic revenue decrease in Europe  Nonetheless  organic revenue growth in China came in high single digits  excluding the impact of lost revenues owing to the U S  Government shutdown  Acquisitions and partnerships have been key catalysts for PerkinElmer over the years  In the first quarter  the company announced the buyout of Cisbio Bioassays   a leading custom assay service provider  The addition of Cisbio strengthens PerkinElmer s position in life sciences and diagnostics markets Further  continued expansion in gross and operating margins buoys optimism  It is encouraging to note that management anticipates operating margin in 2019 to expand by 120 150 bps Which Way Are Estimates Headed For 2019  the Zacks Consensus Estimate for revenues is pegged at  2 92 billion  up 5 1  year over year  For adjusted earnings  the same is pinned at  4 05  up 12 2  year over year Key PicksSome better ranked stocks from the broader medical space are Cardiovascular Systems  Inc    NASDAQ CSII    Quidel Corporation   NASDAQ QDEL   and Heamonetics Corporation   NYSE HAE    each carrying a Zacks Rank  1  Strong Buy   You can see  Cardiovascular Systems has fourth quarter fiscal 2019 earnings growth rate of 33 3  Quidel Corporation has a long term earnings growth rate of 25  Heamonetics has a long term earnings growth rate 13 5  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-05-13,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-hold-on-to-perkinelmer-pki-stock-now-200421172,200421172
29950,251465,CSII,Here s Why You Should Retain DaVita  DVA  In Your Portfolio,opinion,DaVita Inc    NYSE DVA   is gaining prominence in the MedTech space  courtesy of its incessant efforts to upgrade services  global expansion initiatives and acquisitions  The company has a market capitalization of approximately  8 36 billion The stock currently carries a Zacks Rank  3  Hold  Price PerformanceShares of DaVita have lost 2 4   against the  s growth of 5 4  on a year to date basis  Further  the stock compares unfavorably with the S P 500 Index s rally of 12 3  What s Deterring the Stock With respect to business strategy  DaVita has been growing through acquisitions of dialysis centers and other businesses  The company is also gaining from entry into joint ventures and expansion into new business models  This in turn can adversely affect operational performance  debt to capital ratio  capital expenditures and other aspects of business This apart  the company s decision to divest DMG segment is anticipated to lower cash flows  Management has not given any assurance with regard to generation of sufficient cash flows in the near term required to finance debts or to fund other liquidity needs Factors to Boost DaVitaDaVita has remained committed toward expansion related to international markets  In the last few years  the company has strengthened position in the emerging and developing markets of Brazil  China  Colombia  Germany  India  Malaysia  the Netherlands  Poland  Portugal and Saudi Arabia through strategic alliances and acquisitions of dialysis centers These strategic efforts are anticipated to help DaVita deliver more efficient patient care  Currently  the company is pursuing expansion in major European and Asian countries via acquisitions and partnerships In the United States  DaVita has witnessed strong demand of dialysis services in recent times  Prudent acquisitions of dialysis centers and businesses  which own and operate dialysis centers as well as other ancillary services  is the company s key business strategy  These initiatives have aided the company s top line to improve significantly over a considerable period of time In the first quarter of 2019  the company provided dialysis services at 2 932 outpatient dialysis centers  of which 2 689 centers were located in the United States and 243 in nine countries outside the United States  Although  2018 U S  dialysis and related lab services  revenues grossed  2 55 billion  which declined 3 3  from the year ago quarter  international dialysis patient service and other revenues totaled  120 million  up 3 2  year over year Which Way Are Estimates Headed For 2019  the Zacks Consensus Estimate for revenues is pegged at  11 39 billion  down 0 1  year over year  For adjusted earnings  the same is pinned at  4 26  up 19 3  year over year Key PicksSome better ranked stocks from the broader medical space are Cardiovascular Systems  Inc    NASDAQ CSII    Quidel Corporation   NASDAQ QDEL   and Heamonetics Corporation   NYSE HAE    each sporting a Zacks Rank  1  Strong Buy   You can see  Cardiovascular Systems has earnings growth rate for fiscal fourth quarter of 2019 of 33 3  Quidel Corporation has a long term earnings growth rate of 25  Heamonetics has a long term earnings growth rate 13 5  Radical New Technology Creates  12 3 Trillion Opportunity Imagine buying Microsoft  NASDAQ MSFT  stock in the early days of personal computers  or Motorola  NYSE MSI  after it released the world s first cell phone  These technologies changed our lives and created massive profits for investors Today  we re on the brink of the next quantum leap in technology  7 innovative companies are leading this  4th Industrial Revolution    and early investors stand to earn the biggest profits ,2019-05-15,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-retain-davita-dva-in-your-portfolio-200422145,200422145
29951,251466,CSII,Here s Why You Should Invest In DexCom  DXCM  Stock Now,opinion,DexCom  Inc    NASDAQ DXCM   is well poised for growth on the back of lucrative glucose monitoring market  solid international market presence and robust product portfolio The stock carries a Zacks Rank  2  Buy  Price PerformanceShares of DexCom have gained 37 9   against the  s decline of 3 8  in a year s time  The stock also outpaced the S P 500 Index s increase of 1 1  What s Favoring the Stock DexCom continues to gain from the lucrative and growing glucose monitoring market that presents substantial commercial opportunity  Per an article of Research and Markets  the blood glucose monitoring devices market is expected to witness a CAGR of over 9  between 2018 and 2024 Moreover  the company boasts of a robust product portfolio  which in turn has been bolstering its overall performance  Per management  the company is well poised to achieve long term target on the back of the expansion of the rollout of G6 and improve access to CGM  With this growing demand in mind  the company is on track to meet its goal of doubling G6 capacity by the end of 2019 DexCom continues to benefit from strong international presence and is eyeing the sizeable markets of Korea  India  China and Japan  If we go by statistics then more than half of the diabetic population in developing nations remain undiagnosed  Consequently  the company can boost sales by expanding into overseas territory  where the momentum is anticipated to continue in the future Additionally  the company s strategic collaborations and buyouts continue to bolster growth  DexCom has collaborative agreements with several companies  which should not only bring in cash in the form of milestone payments and royalties but should also help expand product use Which Way Are Estimates Headed For 2019  the Zacks Consensus Estimate for revenues is pegged at  1 29 billion  indicating an improvement of 24 7  from the year ago period  The same for earnings stands at 80 cents per share  suggesting growth of 166 7  from the year ago reported figure Key PicksSome better ranked stocks from the broader medical space are Cardiovascular Systems  Inc    NASDAQ CSII    Quidel Corporation   NASDAQ QDEL   and Heamonetics Corporation   NYSE HAE    each sporting a Zacks Rank  1  Strong Buy   You can see  Cardiovascular Systems has earnings growth rate for fiscal fourth quarter of 2019 of 33 3  Quidel Corporation has a long term earnings growth rate of 25  Heamonetics has a long term earnings growth rate 13 5  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-06-05,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-invest-in-dexcom-dxcm-stock-now-200429210,200429210
29980,251495,CSII,Here s Why Investors Should Hold DaVita  DVA  Stock Now,opinion,DaVita Inc    NYSE DVA   is gaining prominence in the MedTech space  courtesy of its incessant efforts to upgrade services  global expansion initiatives and acquisitions  The company has a market capitalization of approximately  9 80 billion However  DaVita incurred additional expenses in fourth quarter 2018  These expenses include  30 million of advocacy costs in countering union policy efforts including ballot initiatives  Additionally  it incurred an additional charge of  252 million on the DMG business and a  42 million goodwill impairment charge In a year s time  this Zacks Rank  3  Hold  stock has lost 19 1   significantly wider than the  s 11 5  decline Here we take a quick look at the factors that ensure near term recovery of DaVita s dull price performance Factors to Boost DaVitaDaVita has been steadily expanding in international markets  In the last few years  the company has strengthened its position in the emerging and developing markets of Brazil  China  Colombia  Germany  India  Malaysia  the Netherlands  Poland  Portugal and Saudi Arabia through strategic alliances as well as acquisitions of dialysis centers These strategic efforts are expected to help DaVita deliver more efficient patient care  Currently  DaVita is seeking to expand in major European and Asian countries via acquisitions and partnerships  In the fourth quarter  international dialysis patient service and other revenues totaled  124 million  up 30 5  year over year In the United States  DaVita has witnessed strong demand of dialysis services in recent times  In the fourth quarter of 2018  the company provided dialysis services at 2 905 outpatient dialysis centers  of which 2 664 centers were located in the United States and 241 in nine countries outside the country  Notably  fourth quarter U S  dialysis and related lab services  revenues grossed  2 63 billion  up 10  from the prior year quarter Which Way Are Estimates Headed For 2019  the Zacks Consensus Estimate for revenues is pegged at  11 60 billion  up 1 7  year over year  For adjusted earnings  the same is pinned at  4 42  up 23 8  year over year DaVita Inc  Price and Consensus    Key PicksA few better ranked stocks in the MedTech space are Surmodics  Inc   NASDAQ SRDX    Abbott Laboratories   NYSE ABT   and Cardiovascular Systems  Inc    NASDAQ CSII   Surmodics has a long term expected earnings growth rate of 10   The stock sports a Zacks Rank  1  Strong Buy   You can see  Abbott s long term earnings growth rate is projected at 11 7   The stock carries a Zacks Rank  2  Buy  Cardiovascular Systems exceeded the Zacks Consensus Estimate in each of the trailing four quarters  the average being 77 1   The stock sports a Zacks Rank of 1 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2019-02-21,Zacks Investment Research,https://www.investing.com/analysis/heres-why-investors-should-hold-davita-dva-stock-now-200391559,200391559
29981,251496,CSII,CVS Health Rides On Aetna Synergy  PBM Selling Season Modest,opinion,On Feb 22  we issued an updated research report on CVS Health   NYSE CVS    An increasing demand for Pharmacy Benefit Management  PBM  and specialty pharmacy was a major growth driver for the stock  The company currently carries a Zacks Rank  3  Hold  CVS Health ended fourth quarter 2018 on a promising note with better than expected results  The year over year growth in the top line was driven by a strong Pharmacy Services segment  benefiting from the upside in specialty services In the last reported quarter  CVS Health completed the  70 billion consolidation of Aetna  NYSE AET   marking the creation of a new healthcare powerhouse  The consolidated entity combines CVS Health s pharmacy business with Aetna s insurance base  Following this  CVS Health introduced Health Care Benefits segment  which holds immense potential With regard to its 2019 PBM selling season  CVS Health notes that the net benefits from this selling season are expected to be modest on Anthem related headwinds  However  the retention rate is 98  currently  higher than the rates it has seen over the last few years We note that despite tough pricing competition  CVS Health is doing well on high levels of service and execution  competitive pricing along with unique integrated model that allows the company to provide differentiated products and services that generate savings  better health outcomes and convenience On the flip side  CVS Health expects to see fewer RFP  Requests for Proposals  opportunities in the market than what it has seen over the past few years  This might pose an obstacle to its PBM selling season performance in the coming quarters  Also  according to CVS Health  Omnicare business performance should continue to remain soft through 2019 Key PicksA few better ranked stocks in the MedTech space are Surmodics  Inc   NASDAQ SRDX    Abbott Laboratories   NYSE ABT   and Cardiovascular Systems  Inc    NASDAQ CSII   Surmodics has a long term expected earnings growth rate of 10   The stock sports a Zacks Rank  1  Strong Buy   You can see  Abbott s long term earnings growth rate is projected to be 11 7   The stock carries a Zacks Rank  2  Buy  Cardiovascular Systems exceeded the Zacks Consensus Estimate in each of the trailing four quarters  with the average beat being 77 1   The stock sports a Zacks Rank of 1 This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ,2019-02-24,Zacks Investment Research,https://www.investing.com/analysis/cvs-health-rides-on-aetna-synergy-pbm-selling-season-modest-200392108,200392108
29982,251497,CSII,Here s Why Investors Should Buy DexCom  DXCM  Stock Now,opinion,"DexCom  Inc    NASDAQ DXCM    is one of the top players in the MedTech space  It is likely to gain from a solid fourth quarter performance and robust growth at the Sensor  Transmitter and Receiver segments 
In the past three months  this Zacks Rank  2  Buy  stock has rallied 13 4  compared with the S P 500 s 6 2  increase 
What s Favoring the Stock 
DexCom exited the fourth quarter on a strong note  wherein earnings and revenues outpaced the Zacks Consensus Estimate  Revenues at the Sensor segment  75  of total revenues  surged 57  on a year over year basis to  252 8 million  Transmitter revenues  17   increased 39  year over year to  59 million  Receiver revenues  8   rallied 46  year over year to  26 3 million 
For 2019  the company expects revenues in the range of  1 18  1 23 billion  However  gross profit margin is projected to be 65  of net revenues  While adjusted operating margin is expected to be 5 5  of net revenues  adjusted EBITDA margin is expected to be 18  
DexCom recently announced that it has received Health Canada approval for the next generation Dexcom G6 CGM System for people with diabetes aged two years and older 
Earlier  Dexcom G6 was introduced in the United States  the United Kingdom  Ireland and several other European countries  and has witnessed solid sales  In 2019  DexCom plans the G6 commercial launch in Canada as the company continues to build capacity for supporting global launch plans 
These apart  DexCom announced an amendment to its previously announced collaboration with Verily  The revised terms are likely to expand DexCom s product development goals 
By the end of fourth quarter 2018  management at DexCom announced that the company has been witnessing significant increases in adoption in both the Medicare and international markets 
Also  the company advanced its interoperability and decision support initiatives including the acquisition of TypeZero and solidified its product pipeline by amending the agreement with Verily 
Which Way Are Estimates Trending 
The Zacks Consensus Estimate for 2019 revenues is pegged at  1 23 billion  reflecting an 18 8  growth  The same for adjusted earnings is pinned at 28 cents  indicating a year over year decline of 6 7  
Key Picks
Other top ranked stocks in the MedTech space are Surmodics  Inc    NASDAQ SRDX    Abbott Laboratories   NYSE ABT   and Cardiovascular Systems  Inc    NASDAQ CSII   
Surmodics has a long term expected earnings growth rate of 10   The stock sports a Zacks Rank  1  Strong Buy   You can see  
Abbott s long term earnings growth rate is projected at 11 7   The stock carries a Zacks Rank  2 
Cardiovascular Systems exceeded the Zacks Consensus Estimate in each of the trailing four quarters  the average being 77 1   The stock sports a Zacks Rank of 1 
Breakout Biotech Stocks with Triple Digit Profit Potential
The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases 
Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-02-26,Zacks Investment Research,https://www.investing.com/analysis/heres-why-investors-should-buy-dexcom-dxcm-stock-now-200392765,200392765
29983,251498,CSII,Bruker Rides On Robust NANO   CALID Groups  Recent Buyouts ,opinion,"On Feb 25  we issued an updated research report on Bruker Corporation   NASDAQ BRKR    The stock carries a Zacks Rank  2  Buy   The company s Scientific Instruments segment has been performing well  driven by strong results from NANO and CALID groups 
In 2018  the Bruker Nano Surfaces group  which includes Bruker s atomic force microscopy product  reported high single digit revenue growth  Growth was driven by solid academic markets and strong industrial research demand for advanced X ray and Nano Materials Analysis products 
This apart  acquisitions like Anasys and JPK  completed in April and July 2018  respectively  also contributed to the segment s top line  Nano Surfaces and Nano analysis revenues increased in 2018 with organic growth supplemented by these two acquisitions 
The year 2019 is expected to be no exception in terms of revenue growth 
In mid December 2018  NANO closed the acquisition of Alicona Imaging  a provider of optical metrology products for lab and production applications  which will start to contribute to the group s results from the beginning of 2019 
The CALID Group is also delivering well with impressive full year revenues in high single digits  Growth was driven by mass spectrometry and molecular spectroscopy businesses  The company eyes the benefits of its life science mass spec portfolio transformation and expects further growth in 2019 and beyond as recently launched products like timsTOF Pro and the new scimaX MRMS ramp up its product menu 
On the flip side  Bruker conducts 80  of its business in the international markets  As a result  adverse currency fluctuations may weigh on profits  Also  headwinds like unfavorable economic conditions and an intense competition pose threats to the stock 
Other Key Picks
Some other top ranked stocks in the broader medical space are Surmodics  Inc   NASDAQ SRDX    Abbott Laboratories   NYSE ABT   and Cardiovascular Systems  Inc    NASDAQ CSII   
Surmodics has a long term expected earnings growth rate of 10   The stock sports a Zacks Rank  1  Strong Buy   You can see  
Abbott s long term earnings growth rate is projected to be 11 7   The stock carries a Zacks Rank  2 
Cardiovascular Systems exceeded the Zacks Consensus Estimate in each of the trailing four quarters  with the average beat being 77 1   The stock sports a Zacks Rank of 1 
Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-02-26,Zacks Investment Research,https://www.investing.com/analysis/bruker-rides-on-robust-nano--calid-groups-recent-buyouts-200392779,200392779
29984,251499,CSII,Medidata s  MDSO  Margins Under Pressure  Competition Rife,opinion,On Feb 19  we issued an updated research report on Medidata Solutions  Inc    NASDAQ MDSO    In the fourth quarter of 2018  the company s growth margins remained under pressure mainly due to the SHYFT buyout and associated purchase accounting implications  Additionally  its earnings per share declined in the same time frame  Adjusted earnings came in at 45 cents per share  which dropped by a penny from the year ago quarter number Notably  expensive valuation  a complex cloud based platform and stiff competition in the MedTech space are the major deterrents The stock currently carries a Zacks Rank  4  Sell  Factors Hurting Medidata s PerformanceThe market for clinical trial solutions is impacted by stiff competition  and changing technology and customer needs  Also  changes in laws and regulations  and frequent introductions of new products and services are concerning Further  Medidata has strong contenders like BioClinica  Inc   IQVIA  formerly QuintilesIMS   Oracle  NYSE ORCL   Parexel Informatics  Veeva Systems  Inc  and other large scale technology providers  It also competes with a number of vendors offering applications and systems namely ERT  CRF Health  Bracket  DataTrak International  Inc   Medrio  Inc   Merge Healthcare  an IBM  NYSE IBM  Company   and OmniComm Systems  Inc In fact  Medidata stock looks a bit expensive at the moment  A comparative analysis of the company s forward P E  TTM basis  ratio paints a drab picture  which might be a cause of concern for investors  The ratio is currently pegged at 78 95  significantly stretched when compared with the markets at large  The P E  TTM  ratio of S P 500 is 17 52 and the median level 19 50 over the past year Medidata also looks overvalued when compared with the broader industry s ratio of 48 32 Price PerformanceShares of Medidata have gained 11 1  compared with the  s growth of 2 3  in a year s time  The current level is also higher than the S P 500 index s increase of 3  over the same time frame  Notably  a solid focus on cloud based services and lucrative acquisitions are aiding Medidata s performance  In this regard  it is imperative to mention that the company expanded the use of Medidata Clinical Cloud in 2018 to automate operations  increase efficiencies  and gain better data visibility for accelerating their 2125 oncology development program  The Medidata Implementation Team   MIT   will deploy the solution to seamlessly enhance and maximize value throughout the company Moreover  it had earlier added regulated content and document management capabilities to the Medidata Clinical Cloud  which is noteworthy Stocks to ConsiderA few better ranked stocks in the broader medical space are Surmodics  Inc   NASDAQ SRDX    Abbott Laboratories   NYSE ABT   and Cardiovascular Systems  Inc    NASDAQ CSII   Surmodics has a long term expected earnings growth rate of 10   The stock sports a Zacks Rank  1  Strong Buy   You can see  Abbott s long term earnings growth rate is projected at 11 7   The stock carries a Zacks Rank  2  Buy  Cardiovascular Systems exceeded the Zacks Consensus Estimate in each of the trailing four quarters  the average being 77 1   The stock sports a Zacks Rank of 1 Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-02-20,Zacks Investment Research,https://www.investing.com/analysis/medidatas-mdso-margins-under-pressure-competition-rife-200390776,200390776
29995,251510,CSII,Cardiovascular Systems signs OAS distribution deal with OrbusNeich,news,Cardiovascular  Systems  NASDAQ CSII  inks an agreement with Hong Kong based OrbusNeich for exclusive distribution rights to its coronary and peripheral Orbital Atherectomy Systems  OAS  outside of the U S  and Japan CSII says it will release more details about the agreement during its Analyst Day on July 31 Now read ,2018-07-16,Seeking Alpha,https://www.investing.com/news/stock-market-news/cardiovascular-systems-signs-oas-distribution-deal-with-orbusneich-1531856,1531856
29996,251511,CSII,Cardiovascular Systems  Classic Crown and FlexTip OK d in Japan,news,The Japanese Ministry of Health  Labor and Welfare approves  Cardiovascular  Systems   NASDAQ CSII  Diamondback 360 Coronary Orbital Atherectomy System  OAS  with Classic Crown and ViperWire Advance Coronary Guidewire FlexTip Classic Crown is a coronary atherectomy device  used to remove plaque from a blood vessel  FlexTip is a guidewire that the company says has increased flexibility and resists kinking The company s Diamondback 360 Coronary OAS Micro Crown was approved there almost two years ago Now read ,2019-01-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/cardiovascular-systems-classic-crown-and-flextip-okd-in-japan-1734820,1734820
29997,251512,CSII,Cardiovascular Systems reports preliminary Q2 2019 revenues of  60 2M,news,Cardiovascular  Systems  CSII  0 2   announces preliminary Q2 2019 revenues ofn  60 2M  Domestic sales increased 11 3  to  58 6M  Sales to       international distributors totaled  1 6M FY 2019 revenues are expected in the range of  243M to 247M  Full Q2 2019 financial results are expected on January 30 with conference call scheduled at 3 30 p m  CT  4 30       p m  ET   Now read ,2019-01-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/cardiovascular-systems-reports-preliminary-q2-2019-revenues-of-602m-1739440,1739440
29998,251513,CSII,Premarket analyst action   healthcare,news,Aimmune Therapeutics  NASDAQ AIMT  initiated with Outperform rating and  64  76  upside  price target by Robert Baird Bluebird bio  NASDAQ BLUE  initiated with Market Perform rating by Oppenheimer Kura Oncology  NASDAQ KURA  initiated with Outperform rating and  19  33  upside  price target by Wedbush La Jolla Pharmaceutical  NASDAQ LJPC  initiated with Buy rating and  62  130  upside  price target by H C  Wainwright  Mustang Bio   NASDAQ MBIO  initiated with Outperform rating and  18  64  upside  price target by Oppenheimer Mirati Therapeutics  NASDAQ MRTX  initiated with Outperform rating by Cowen and Company TrovaGene  NASDAQ TROV  initiated with Buy rating and  1  300  upside  price target by H C  Wainwright  Shares up 8  premarket on robust volume  Rigel Pharmaceuticals   NASDAQ RIGL  resumed with Overweight rating and  6  79  upside  price target by Piper Jaffray  Cardiovascular  Systems  NASDAQ CSII  resumed with Market Perform rating by William Blair Axovant Sciences  NASDAQ AXON  downgraded to Hold with a  6  15  upside  price target by Jefferies  Shares down 6  premarket on light volume Now read ,2017-12-21,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-1018466,1018466
30035,251550,CSII,Wright Medical  WMGI  Q4 Earnings   Revenues Beat Estimates,opinion,Wright Medical Group N V    NASDAQ WMGI   reported fourth quarter 2018 adjusted earnings of 11 cents per share  which surpassed the Zacks Consensus Estimate of 6 cents  Notably  the company s adjusted earnings came in at 10 cents per share in the year ago quarter Fourth quarter revenues totaled  238 1 million  which outpaced the Zacks Consensus Estimate of  237 4 million  The top line also improved 9 4  year over year 2018 at a GlanceFor 2018  Wright Medical delivered revenues of  836 2 million  reflecting a year over year increase of 12 2   The reported figure exceeded the Zacks Consensus Estimate of  834 7 million The Upper Extremities segment recorded sales of  395 8 million  47 3  of net revenues  The Lower Extremities segment registered revenues of  311 5 million  37 3  of net revenues  The Biologics segment s revenues totaled  108 8 million  13  of net revenues  The Sports Med   Other segment recorded revenues of  20 1 million  2 1  of net revenues  Segment DetailsLower ExtremitiesThis segment posted worldwide revenues of  93 1 million  up 12 3  year over year Revenues in the United States increased 15  to  76 8 million on a year over year basis  International revenues totaled  16 2 million  up 0 9  year over year Upper ExtremitiesRevenues at this segment totaled  108 2 million  up 8 4  from the prior year quarter s level In the United States  revenues increased 9  on a year over year basis to  78 2 million  Internationally  the segment raked in revenues worth  30 million  up 7  year over year BiologicsBiologics revenues amounted to  31 4 million in the quarter under review  up 9 8  on a year over year basis While international revenues at the segment rose 8 6  to  7 4 million  U S  revenues summed  24 million  up 10 1  year over year Sports Med   OtherAt this segment  net revenues came in at  5 5 million  down 13 3  on a year over year basis The segment s U S  revenues decreased 15 3  to  2 6 million  while international revenues decreased 29 1  to  2 9 million Margin AnalysisIn the quarter under review  gross profit totaled almost  189 million  up 11  year over year  Gross margin was 79 4  of net revenues  which expanded 110 basis points  bps  from the year ago quarter s level Selling  general and administrative expenses were  160 6 million  up 20 7  year over year Research and development expenses amounted to  16 7 million  up 27 4  year over year Adjusted operating income in the fourth quarter of 2018 was  11 6 million  4 9  of net revenues Guidance For 2019  Wright Medical issued its revenue guidance in the band of  954  966 million  The mid point of  960 million is above the Zacks Consensus Estimate of  957 7 million  This also represents 15 17  net revenue growth on a constant currency basis  11 13  increase on a pro forma constant currency basis and 10 12  improvement on an organic constant currency basis The company expects 2018 adjusted earnings per share of 17 25 cents  Notably  the mid point of 21 cents is below the Zacks Consensus Estimate of 23 cents ConclusionWright Medical exited the fourth quarter on a promising note  The company s adjusted earnings and revenues outpaced Zacks Consensus Estimate  It expects to deliver double digit  constant currency net sales growth each year and maintain adjusted gross margin in the high 70  range every year Solid performance at the Upper and the Lower Extremities segments buoys optimism  Also  consistent growth in PERFORM Reversed glenoid and robust contributions from the SIMPLICITI shoulder system are impressive   Wright Medical is likely to gain from the upcoming launch of REVIVE revision shoulder system as well  Furthermore  management is confident about the recent acquisition of BLUEPRINT On the flip side  the Zacks Rank  2  Buy  company s increasing operating expenses are worrisome  Additionally  the sports business performed disappointingly in the fourth quarter  Distribution issues in Europe and Asia as well as foreign currency volatility add to the woes  Increased costs related to product launch and re building infrastructure is expected to keep the margins under pressure Other Key PicksSome other top ranked stocks in the MedTech space are Surmodics  Inc   NASDAQ SRDX    Abbott Laboratories   NYSE ABT   and Cardiovascular Systems  Inc    NASDAQ CSII   Surmodics has a long term expected earnings growth rate of 10   The stock sports a Zacks Rank  1  Strong Buy   You can see  Abbott s long term earnings growth rate is projected at 11 7   The stock carries a Zacks Rank  2 Cardiovascular Systems exceeded the Zacks Consensus Estimate in each of the trailing four quarters  the average being 77 1   The stock sports a Zacks Rank of 1 Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-02-26,Zacks Investment Research,https://www.investing.com/analysis/wright-medical-wmgi-q4-earnings--revenues-beat-estimates-200392992,200392992
30036,251551,CSII,Veeva Systems  VEEV  Beats On Q4 Earnings And Revenues ,opinion,Veeva Systems Inc    NYSE VEEV   reported fourth quarter fiscal 2019 adjusted earnings of 45 cents per share  which surpassed the Zacks Consensus Estimate of 31 cents  The bottom line also increased a whopping 87 5  on a year over year basis Total revenues came in at  232 3 million  outpacing the Zacks Consensus Estimate of  228 million  On a year over year basis  the top line improved 25  The company has a Zacks Rank  3  Hold  Segmental DetailsSubscription ServiceFiscal fourth quarter subscription service revenues summed  190 7 million  up 25 5  year over year  Per management  solid momentum in bookings continued across all areas of Vault  which was 45  of subscription revenues compared with 39  a year ago Professional Service and OthersProfessional Service revenues rose almost 22 4  to  41 7 million from the figure registered in the year ago quarter According to Veeva Systems  this improvement in revenues can be attributed to continued strong demand within Veeva Vault R D  research and development   Management also remains optimistic about the segment s impressive performance in the first quarter of fiscal 2020 Margin DetailsIn the reported quarter  adjusted gross profit increased 31 2  to  171 9 million  Adjusted gross margin was 74   which expanded 360 basis points  bps  Adjusted operating income totaled  84 3 million  up 52 8  year over year  In the quarter under review  the adjusted operating margin was 36 3   which expanded 660 bps  Per management  the upside was driven by impressive top line performance However  adjusted operating expenses rose 15 7  year over year to  87 6 million GuidanceFor first quarter fiscal 2020  Veeva Systems expects total revenues to be between  238 million and  239 million  The Zacks Consensus Estimate for the same is pegged at  234 2 million  below the guided range Adjusted earnings are expected to be between 44 cents and 45 cents per share  The Zacks Consensus Estimate for the same stands at 40 cents  below the projected figure  Adjusted operating income is expected in the  85  86 million band Veeva Systems issued guidance for fiscal 2020 as well Revenues are expected to be between  1 02 billion and  1 03 billion in fiscal 2020  The Zacks Consensus Estimate for the same stands at  1 02 billion  in line with the lower end of the guided range For the fiscal year  adjusted earnings are anticipated in the range of  1 91  1 94 per share  The Zacks Consensus Estimate for earnings is pinned at  1 79  below the projected range Wrapping UpVeeva Systems ended the fiscal fourth quarter on a strong note  wherein earnings and revenues outpaced the Zacks Consensus Estimate  Also  the Subscription business segment performed impressively in the quarter These apart  the company continues benefiting from its flagship Vault platform  In fact  Veeva Vault s customers have increased manifold in recent times  Markedly  Veeva Systems  unique solutions include Veeva Vault  Veeva CRM  Veeva Network and Veeva OpenData  Veeva s new CRM Sunrise UI and Nitro look promising as well  In Commercial Cloud  Veeva Systems secured a number of deals  The company is confident about growth in new markets with products like EDC  Safety  Nitro and Vault On the flip side  high expenses on the operational side are worrisome  Also  intense competition and a saturating life sciences market remain potent threats  Volatility in the foreign currency exchange rate is an added concern Key PicksSome better ranked stocks in the MedTech space are Surmodics  Inc   NASDAQ SRDX    Abbott Laboratories   NYSE ABT   and Cardiovascular Systems  Inc    NASDAQ CSII   Surmodics has a long term expected earnings growth rate of 10   The stock sports a Zacks Rank  1  Strong Buy   You can see  Abbott s long term earnings growth rate is projected at 11 7   The stock carries a Zacks Rank  2  Buy  Cardiovascular Systems exceeded the Zacks Consensus Estimate in each of the trailing four quarters  the average being 77 1   The stock sports a Zacks Rank of 1 Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-02-26,Zacks Investment Research,https://www.investing.com/analysis/veeva-systems-veev-beats-on-q4-earnings-and-revenues-200393051,200393051
30037,251552,CSII,Merit Medical  MMSI  Q4 Earnings   Revenues Surpass Estimates,opinion,Merit Medical Systems  Inc    NASDAQ MMSI   reported fourth quarter 2018 adjusted earnings per share  EPS  of 48 cents  which exceeded the Zacks Consensus Estimate of 45 cents  The bottom line also improved 45 5  from the year ago quarter s tally This Utah based provider of peripheral and cardiac intervention products reported worldwide revenues of  233 2 million  up 22 2  from the year ago quarter s tally  On a comparable  constant currency basis  the metric increased 13 1  year over year  Revenues surpassed the Zacks Consensus Estimate of  230 1 million 2018 at a GlanceMerit Medical reported 2018 worldwide revenues of  882 8 million  up 21 3  on a year over year basis Notably  the company generates revenues through two segments   the Cardiovascular unit and the Endoscopy devices segment The Cardiovascular segment recorded revenues of  849 5 million  96 2  of net revenues  The Endoscopy devices segment s revenues amounted to  33 3 million  3 8  of net revenues  Segmental AnalysisCardiovascularThe Cardiovascular unit recorded fourth quarter revenues of  225 1 million  up 22 7  year over year  The upside can be attributed to a 40 5  year over year increase in the segment s Stand alone devices to  101 2 million  Also  revenues from Catheters increased 24 9  to  41 7 million  Inflation devices revenues grew 11  year over year to  22 8 million  The same at the CRM EP unit rose 27 5  to  12 7 million On the flip side  revenues from Custom kits and procedure trays unit  under the Cardiovascular segment  declined 1 7 to  34 4 million  Also  embolization devices  revenues decreased 2 1  to  12 3 million Endoscopy DevicesRevenues from the Endoscopy devices totaled  8 2 million  up 9 9  year over year MarginsIn the quarter under review  gross profit totaled  104 7 million  up 22 2  on a year over year basis  Gross margin came in at 44 9  of net revenues  almost flat year over year  Adjusted gross margins expanded 150 basis points  bps  on a year over year basis to 49 4  of net revenues Merit Medical registered selling  general and administrative expenses of  75 6 million  up 27 7  year over year Meanwhile  research and development expenses summed  15 4 million  up 20 8  year over year Adjusted operating income in the quarter totaled  13 7 million  Adjusted operating margin was 5 9  of net revenues  down 130 basis points  bps  year over year 2019 Guidance Merit Medical issued guidance for 2019 This Zacks Rank  2  Buy  company expects full year revenues in the band of  1 01  1 03 billion The Zacks Consensus Estimate for the same is pegged at  1 01 billion  in line with the lower end of the guided range Adjusted EPS are expected between  1 97 and  2 08  The Zacks Consensus Estimate for the same is pinned at  1 97  in line with the lower end of the projected range The company expects adjusted gross margins within 50 6 51 3  Wrapping UpMerit Medical exited the fourth quarter of 2018 on a solid note  with considerable expansion in adjusted gross margins  Furthermore  upbeat guidance for 2019 indicates at the company s bright prospects  A robust Cardiovascular segment is an added positive Management is optimistic about Merit Medical s Becton Dickinson deal  the acquisitions of Cianna Medical and Vascular Insights  and the execution of the global growth and profitability plan  New products like EmboCube Embolization Gelatin  the basixTAU Inflation Device  the Prelude Prestige Splittable Sheath Introducer  the Prelude Ideal Sheath Introducer  thePreludeSYNC Radial Hemostasis Device are likely to expand the company s customer base However  surging operating expenses is concerning  Headwinds like stiff competition and higher consolidation in the healthcare industry add to the woes  Sluggishness in the Custom kits and procedure trays and Embolization devices units is also worrisome Key PicksOther top ranked stocks in the MedTech space are Surmodics  Inc   NASDAQ SRDX    Abbott Laboratories   NYSE ABT   and Cardiovascular Systems  Inc    NASDAQ CSII   Surmodics has a long term expected earnings growth rate of 10   The stock sports a Zacks Rank  1  Strong Buy   You can see  Abbott s long term earnings growth rate is projected at 11 7   The stock carries a Zacks Rank  2 Cardiovascular Systems exceeded the Zacks Consensus Estimate in each of the trailing four quarters  the average being 77 1   The stock sports a Zacks Rank of 1 Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-02-27,Zacks Investment Research,https://www.investing.com/analysis/merit-medical-mmsi-q4-earnings--revenues-surpass-estimates-200393532,200393532
30042,251557,CSII,Cardiovascular Systems thumped in whistleblower case  plaintiff awarded  25 1M,news,The plaintiff in a whistleblower related lawsuit prevails over defendant  Cardiovascular  Systems  NASDAQ CSII   The former regional sales manager  who accused the company of a range retaliatory actions including wrongful termination  was awarded  2 7M in compensatory damages and  22 4M in punitive damages by the jury in a Los Angeles court The company says it will appeal the decision and will assess the impact of the verdict on its finances and will provide updates as necessary Now read  Mid stage study underway assessing Ra Pharma s RA101495 for PNH,2017-04-26,Seeking Alpha,"https://www.investing.com/news/stock-market-news/cardiovascular-systems-thumped-in-whistleblower-case,-plaintiff-awarded-$25.1m-477579",477579
30051,251566,CSII,Here s Why Investors Should Buy Surmodics  SRDX  Stock Now,opinion,Surmodics  Inc    NASDAQ SRDX   is one of the top players in the MedTech space  The company s impressive performance in first quarter fiscal 2019 and consistent focus on Research and Development  R D  are working in favor of the stock In a year s time  this Zacks Rank  1  Strong Buy  stock has skyrocketed 106 9  compared with the industry s 5 9  growth  The current level is also significantly higher than the S P 500 s 1 6  increase What s Favoring Surmodics Surmodics  solid efforts to improve its research and development stature have been a key growth driver  Also  the company s whole product solutions pipeline and sirolimus based below the knee DCB program deserve a mention here Meanwhile  Surmodics has been making progress using its internally developed  014 balloon platform  The company has also been working through the preclinical studies for the data package that will be used to determine the readiness for first in human clinical trial  It is expected to make continued progress throughout the remainder of fiscal 2019 Furthermore  the company has made dramatic progress in developing its AV fistula drug coated balloon  In the non drug delivery R D pipeline  Surmodics also got the FDA clearance for its Telemark support microcatheter In first quarter fiscal 2019  R D expenses shot up 46 7  year over year  Considering the company s strength in the R D prospects  Surmodics has long term goals of generating double digit top line growth by the end of calendar 2019 Markedly  Surmodics  performance continues to be driven by its In Vitro Diagnostics  IVD  unit  For over 35 years  the segment has been a leader in developing an ELISA EIA  immunoblot western blot  line assay or microarray  In the first quarter of fiscal 2019  sales at IVD increased 17 6   reflecting strong sales growth of clinical components used in diagnostic tests and microarray slides slide  Operating income at the segment registered a robust growth of 47  from the year ago quarter s level Which Way Are Estimates Treading The Zacks Consensus Estimate for fiscal 2019 revenues is pegged at  96 7 million  reflecting an 18 9  growth  The same for adjusted earnings is pinned at 15 cents  indicating a year over year decline of 69 4  Other Key PicksSome other top ranked stocks in the broader medical space are Wright Medical Group N V    NASDAQ WMGI    Abbott Laboratories   NYSE ABT   and Cardiovascular Systems  Inc    NASDAQ CSII   Wright Medical has a long term expected earnings growth rate of 11   The stock sports a Zacks Rank  2  Buy   You can see  Abbott s long term earnings growth rate is projected at 11 7   The stock carries a Zacks Rank  2 Cardiovascular Systems exceeded the Zacks Consensus Estimate in each of the trailing four quarters  the average being 77 1   The stock sports a Zacks Rank of 1 Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-02-18,Zacks Investment Research,https://www.investing.com/analysis/heres-why-investors-should-buy-surmodics-srdx-stock-now-200389623,200389623
30055,251570,CSII,Here s Why You Should Hold Intuitive Surgical  ISRG  Stock ,opinion,"Intuitive Surgical Inc    NASDAQ ISRG   has been gaining from the adoption of da Vinci system  increasing procedure volumes  continuous innovations and a solid recurring revenue base  Currently  it has a market capitalization of approximately  59 92 billion 
In a year s time  this Zacks Rank  3  Hold  stock has rallied 31 5  compared with the industry s 9 1  growth 
Why Should You Retain 
Intuitive Surgical s da Vinci surgical system enables minimally invasive surgery  which reduces the trauma associated with open surgery  Powered by robotic technology  this surgical system has provided the company with a solid exposure to medical mechatronics  robotics and Artificial Intelligence for healthcare  The platform bolstered Intuitive Surgical s foothold in the Cardiac Surgery  Colorectal Surgery  General Surgery  Gynecologic Surgery  Head   Neck Surgery  Thoracic Surgery and Urologic Surgerymarkets 
The company also launched an upgrade to its flagship Vinci Xi technology   da Vinci X  Notably  the Xi suite is designed to seamlessly integrate future innovationssuch as advanced instrumentation  surgical skills simulation  software upgrades  and other advancements into one dynamic platform 
Meanwhile  the da Vinci Surgical System has been observed to cure patients diagnosed with inguinal hernia 
In the fourth quarter of 2018  da Vinci procedures grew approximately 19  over the fourth quarter of last year  Mature procedure growth in the United States  including prostatectomy and hysterectomy  has been robust  In Japan  procedures grew above 40  in the second half of 2018  European procedure performance has been in line  with solid growth in the United Kingdom and France 
For 2018  the company has strong prospects in the U S  general surgery market  particularly driven by procedures for hernia repair and colorectal surgery  Internationally  the company has significant opportunities in Japan  South Korea and China 
What s Deterring the Stock 
Intuitive Surgical used to enjoy a monopoly stature in the market for robots used in abdominal surgery since the launch of its flagship device called da Vinci back in 2000  However  competition for the company intensified following the regulatory approval of Transenterix s surgical robot for abdominal surgery in 2017 
Which Way Are Estimates Trending 
The Zacks Consensus Estimate for first quarter 2019 earnings is pegged at  2 67  mirroring 9 4  growthon a year over year basis  The same for revenues stands at  971 9 million  reflecting growth of 14 7  year over year 
For 2019  the Zacks Consensus Estimate for revenues is pinned at  4 30billion  indicating 15 4  growth  The same for adjusted earnings for 2019 is pegged at  12 01  showcasing a 9 3  rise year over year 
Intuitive Surgical  Inc  Price and Consensus
   Key Picks
A few better ranked stocks in the broader medical space are Surmodics  Inc    NASDAQ SRDX    Abbott Laboratories   NYSE ABT  and Cardiovascular Systems  Inc    NASDAQ CSII   
Surmodics has a long term expected earnings growth rate of 10   The stock sports a Zacks Rank  1  Strong Buy   You can see  
Abbott s long term earnings growth rate is projected at 11 7   The stock carries a Zacks Rank  2  Buy  
Cardiovascular Systems topped the Zacks Consensus Estimate in each of the trailing four quarters  the average beat being77 1   The stock has a Zacks Rank of 1 
Today s Best Stocks from Zacks
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1  and  98 3  
This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-02-04,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-hold-intuitive-surgical-isrg-stock-200383401,200383401
30056,251571,CSII,Here s Why You Should Invest In McKesson  MCK  Stock Now,opinion,McKesson Corporation s   NYSE MCK   third quarter fiscal 2019 performance was commendable  The U S  Pharmaceutical and Specialty Solutions unit also performed encouragingly  Management is optimistic about the 10 year partnership signed with Rite Aid With solid prospects  this Zacks Rank  2  Buy  stock is an attractive pick for investors at the moment  In a month s time  McKesson has gained 14 2  compared with the industry s 13  growth Strong Player in Distribution MarketMcKesson is a key player in the pharmaceutical and medical supplies distribution market In fiscal 2018  the company s Distribution Solutions segment continued to deliver solid performance despite weak pricing trends and customer consolidation  Notably  this segment caters to a wide range of customers and businesses  and stands to benefit from increased generic utilization and an aging population It is encouraging to note that  Rite Aid renewed its distribution and sourcing relationship with McKesson for another 10 years in the fiscal third quarter  Additionally  McKesson launched its Opioid Foundation that will focus on helping advance solutions to the U S  opioid crisis in the same period McKesson Canada Picks Up PaceMcKesson Canada plays a pivotal role in providing solutions to manufacturers  pharmacies and hospitals that serve the needs of patients in Canada every day Markedly  the segment rebounded in the fiscal third quarter  Evidently  McKesson Canada  a sub unit of the Other business segment of the company  saw a year over year upside in the quarter driven by high organic growth Which Way Are Estimates Trending The Zacks Consensus Estimate for fourth quarter fiscal 2019 earnings is pegged at  3 68  mirroring 5 4  growth on a year over year basis  The same for revenues stands at  53 43 billion  reflecting a 3 5  improvement year over year For fiscal 2019  the Zacks Consensus Estimate for revenues is pinned at  215 02 billion  indicating 3 2  growth  The same for adjusted earnings is pegged at  13 51  showcasing a 7 1  rise year over year Want More from the MedTech Space A few other top ranked stocks in the MedTech space are Surmodics  Inc    NASDAQ SRDX    Abbott Laboratories   NYSE ABT   and Cardiovascular Systems  Inc    NASDAQ CSII   Surmodics has a long term expected earnings growth rate of 10   The stock sports a Zacks Rank  1  Strong Buy   You can see  Abbott s long term earnings growth rate is projected at 11 7   The stock carries a Zacks Rank  2 Cardiovascular Systems exceeded the Zacks Consensus Estimate in each of the trailing four quarters  the average being 77 1   The stock has a Zacks Rank of 1 Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2019-02-05,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-invest-in-mckesson-mck-stock-now-200384468,200384468
30057,251572,CSII,Here s Why You Should Buy Wright Medical  WMGI  Stock Now,opinion,Wright Medical Group N V    NASDAQ WMGI   has been enjoying a favorable place in the investors  book  courtesy of its continued developments  In a year s time  the stock has outperformed its industry  Shares of the company have surged 51 5  compared with the  and S P 500 s growth of 11 1  and 2 1   respectively Notably  a growing orthopedic market  launch of new products like PERFORM Reversed glenoid  ORTHOLOC 3Di and the SIMPLICITI shoulder system are likely to drive the company s top line in the quarters ahead With solid prospects  this Zacks Rank  2  Buy  stock is an attractive pick for investors at the moment International ExpansionWright Medical s international net sales are expected to grow in the high single digits on a constant currency basis driven by continued strong performance in biologics  Further  solid improvement at upper extremities growth unit instils optimism  Meanwhile  the company s shoulder portfolio is gaining momentum in international markets  particularly with the launch of PERFORM Reversed In 2019  it intends to put more PERFORM Reversed into international market  Earlier in 2018  management confirmed that the launch of AUGMENT Injectable in Australia and Canada has considerably driven growth In the third quarter of 2018  international sales grew 13  on a year over year basis Strong Foothold in the Foot   Ankle MarketWright Medical s solid foot and ankle products portfolio  and extensive training provided to extremities dedicated surgeons have enabled it to emerge as a leading player in the foot and ankle market Furthermore  ORTHOLOC ankle and small bone fracture product launches has been impressive  Management is also upbeat about the third quarter launch of the Minimally Invasive Surgery System and AUGMENT Injectable  which is likely to provide further momentum to the U S  lower extremity business In the third quarter of 2018  Wright Medical s Lower Extremities business posted worldwide revenues of  71 1 million  up 8 8  year over year  While revenues in the United States increased 12  to  57 6 million on a year over year basis  international sales totaled  13 5 million  down 3 3  year over year Which Way Are Estimates Trending The Zacks Consensus Estimate for fourth quarter earnings is pegged at 6 cents  reflecting year over year decline of 40   The same for revenues stands at  237 4 million  mirroring a 9 1  improvement year over year For 2018  the Zacks Consensus Estimate is pinned at a loss of 7 cents  The same for revenues is pegged at  836 million Wright Medical Group N V  Price and Consensus    Key PicksA few top ranked stocks in the broader medical space are Surmodics  Inc   NASDAQ SRDX    Abbott Laboratories   NYSE ABT   and Cardiovascular Systems  Inc    NASDAQ CSII   Surmodics has a long term expected earnings growth rate of 10   The stock sports a Zacks Rank  1  Strong Buy   You can see  Abbott s long term earnings growth rate is projected at 11 7   The stock carries a Zacks Rank  2 Cardiovascular Systems exceeded the Zacks Consensus Estimate in the trailing four quarters  the average beat being 77 1   The stock sports a Zacks Rank of 1 Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-02-10,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-buy-wright-medical-wmgi-stock-now-200386265,200386265
30058,251573,CSII,Here s Why Investors Should Retain Accuray  ARAY  Stock Now,opinion,Accuray Incorporated   NASDAQ ARAY   is gaining prominence in the MedTech space  courtesy of solid demand for Radixact   CyberKnife platforms  Moreover  the company has been fortifying its foothold worldwide In 2018  the company received regulatory approval from India to sell its flagship Radixact X9 system  Management is optimistic about this development as it will expand Accuray s precision treatment solutions in emerging markets  These apart  the company has a strong presence in India s leading hospitals However  Accuray faces cutthroat competition in the radiation oncology space  In a year s time  this Zacks Rank  3  Hold  stock has gained 3 1  compared with the  s 11 1  growth So here we take a quick look at Accuray s major headwinds and discuss the factors that ensure near term recovery Cutthroat Competition in the Niche MarketsAccuray is exposed to significant competition in the radiation oncology market  which is characterized by rapid technological changes The company competes head to head with Varian Medical  Elekta  ViewRay and BrainLAB AG in this market  While  the CyberKnife System faces challenges from Varian s Trilogy system  TomoTherapy systems are challenged by Varian s RapidArc technology and the TrueBeam systems Software UpgradesA series of software upgrades has been acting as a key catalyst for Accuray  These upgrades were primarily focused on improvised imaging  faster planning capabilities as well as system connectivity Further  software enhancements involved improvisation of CyberKnife treatment planning efficiency  In this regard  it is imperative to mention that Accuray had introduced CTrue iterative reconstruction   an enhanced CT imaging capability for Radixact In fiscal 2018  Accuray launched an imaging software for Radixact  Per management  this software offers significant improvement in soft tissue resolution with up to 50  lesser image noise than the previous version  Another important development program for Radixact System is the launch of intra fraction motion tracking and correction capability It is encouraging to note that in second quarter fiscal 2019  Accuray received the FDA approval for its 510 k  application motion synchronization on the Radixact treatment system  Notably  motion synchronization has been a unique functional feature of the CyberKnife platform  Meanwhile  the kVCT imaging on Radixact is under development Which Way Are Estimates Trending The Zacks Consensus Estimate for third quarter fiscal 2019 is pegged at a loss of 4 cents  The same for revenues stands at  104 million  mirroring a 4 2  improvement year over year For fiscal 2019  the Zacks Consensus Estimate is pinned at a loss of 16 cents  The same for revenues is pegged at  420 4 million  reflecting a 3 8  improvement year over year Accuray Incorporated Price and Consensus    Key PicksA few better ranked stocks in the broader medical space are Surmodics  Inc   NASDAQ SRDX    Abbott Laboratories   NYSE ABT   and Cardiovascular Systems  Inc    NASDAQ CSII   Surmodics has a long term expected earnings growth rate of 10   The stock sports a Zacks Rank  1  Strong Buy   You can see  Abbott s long term earnings growth rate is projected at 11 7   The stock carries a Zacks Rank  2  Buy  Cardiovascular Systems exceeded the Zacks Consensus Estimate in the trailing four quarters  the average being 77 1   The stock sports a Zacks Rank of 2 Zacks  Best Stock Picking StrategyIt s hard to believe  even for us at Zacks  But from 2000 2018  while the market gained  4 8  per year  our top stock picking strategy averaged  54 3  per year How has that screen done lately  From 2017 2018  it sextupled the market s  15 8  gain with a soaring  98 3  return ,2019-02-11,Zacks Investment Research,https://www.investing.com/analysis/heres-why-investors-should-retain-accuray-aray-stock-now-200386762,200386762
30059,251574,CSII,Here s Why Investors Should Retain AmerisourceBergen Stock,opinion,AmerisourceBergen Corporation   NYSE ABC   is expected to benefit from its first quarter fiscal 2019 results and a strong Pharmaceutical Distribution unit  However  sluggishness in the MWI unit might hurt prospects Price PerformanceIn a year s time  shares of this Zacks Rank  3  Hold  company have lost 11  compared with the  s 4 4  decline  The current level also compares unfavorably with the S P 500 index s 0 6  decrease  Sluggishness in the MWI unit and an intensely competitive industry negatively impacted the company s prospects Let s take a quick look at AmerisourceBergen s major headwinds and discuss the factors that ensure near term recovery Why Should You Retain the Stock AmerisourceBergen s Pharmaceutical Distribution segment serves healthcare providers in the pharmaceutical supply channel  At this unit  the company has been witnessing solid revenue growth for the last couple of quarters  Markedly  Pharmaceutical Distribution rides on increasing volume and an expanding customer base  Strong organic growth rates in the U S  pharmaceutical market  improving patient access to medical care  improved economic conditions and population demographics should benefit the segment in the quarters to come In the first quarter of fiscal 2019  revenues at this segment totaled  43 74 billion  which increased 12 3  on a year over year basis  However  segmental operating income of  373 2 million declined 3 9  year over year  Meanwhile  the company s Specialty Distribution franchise of oncology and physician administered products continues to perform exceptionally well We are also optimistic about the deals signed by AmerisourceBergen  which should boost its top line  By the end of first quarter fiscal 2019  management at AmerisourceBergen announced that it currently partners with Good Neighbor Pharmacy Network  Walgreens and others on safe drug disposal programs MWI Slows DownMWI unit s revenues remained flat in the first quarter of fiscal 2019  Per management  the metric was negatively impacted by certain issues  From an operating income standpoint  MWI s operating income of  99 million decreased about 1  year over year  MWI experienced pressure relating to rebates as well  Moving ahead  the company s operating income growth rate is expected to improve with consistently strong customer relationships and commercial partnerships These apart  AmerisourceBergen s Memphis facility  PharMEDium  is not likely reopen in this fiscal year For fiscal 2019  adjusted earnings per share are expected in the range of  6 65  6 85  lower than the previous guidance of  6 65  6 95  Also  adjusted operating income growth is expected in the low single digit percent range  Pharmaceutical Distribution segment s operating income growth is too projected to be the low single digit percent range Which Way are Estimates Trending The Zacks Consensus Estimate for second quarter earnings is pegged at  1 98  up 2 1  year over year  The same for revenues stands at  43 7 billion  mirroring a 6 4  improvement year over year For fiscal 2019  the Zacks Consensus Estimate for earnings is pinned at  6 75  up 4  year over year  The same for revenues is pegged at  180 2 billion  reflecting a 7 3  improvement year over year AmerisourceBergen Corporation Price and Consensus    Key PicksA few better ranked stocks in the broader medical space are Surmodics  Inc   NASDAQ SRDX    Abbott Laboratories   NYSE ABT   and Cardiovascular Systems  Inc    NASDAQ CSII   Surmodics has a long term expected earnings growth rate of 10   The stock sports a Zacks Rank  1  Strong Buy   You can see  Abbott s long term earnings growth rate is projected at 11 7   The stock carries a Zacks Rank  2  Buy  Cardiovascular Systems exceeded the Zacks Consensus Estimate in the trailing four quarters  the average being 77 1   The stock sports a Zacks Rank of 1 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2019-02-12,Zacks Investment Research,https://www.investing.com/analysis/heres-why-investors-should-retain-amerisourcebergen-stock-200387567,200387567
30060,251575,CSII, Company News For Jan 31  2019,opinion,Cardiovascular Systems Inc  s   NASDAQ CSII   shares surged 3 4  after reporting fourth quarter 2018 adjusted earnings per share of  0 01  surpassing the Zacks Consensus Estimate of loss of  0 04 per shareShares of AT T Inc    NYSE T   tanked 4 3  after posting fourth quarter 2018 revenues of  47 993 million  missing the Zacks Consensus Estimate of  48 427 millionHess Corp    NYSE HES   shares soared 4  after the company posted fourth quarter 2018 adjusted loss per share of  0 31  narrower than the Zacks Consensus Estimate of a loss of  0 41Shares of Automatic Data Processing Inc    NASDAQ ADP   climbed 4  after the company reported second quarter fiscal 2019 adjusted earnings per share of  1 34  beating the Zacks Consensus Estimate of  1 18,2019-01-30,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-jan-31-2019-200381854,200381854
30062,251577,CSII,Baxter s Acute Therapies Profile Strong  Competition Rife,opinion,On Feb 13  we issued an updated research report on Baxter International Inc    NYSE BAX    While solid Acute Therapies profile is a positive  generic competition for Cyclophosphamide and lackluster sales in a few sub segments are key concerns The stock currently carries a Zacks Rank  3  Hold  Solid Acute Therapies ProfileBaxter s performance in Acute Therapies has been consistently driven by improving utilization for CRRT globally and increased demand for multi organ support products  In Acute Therapies  Baxter launched the first 3 in 1 oXIRIS set for continuous renal replacement therapy and sepsis management protocols  This adds to Baxter s multi organ therapy offering  utilizing the Prismaflex system For the Acute Therapies business  Baxter expects approximately 7 8  growth on a year over year basis in 2019 In fourth quarter 2018  net revenues at the Acute Therapies business totaled  137 million  representing 12  growth on a constant currency basis  Increased global demand for Baxter s continuous renal replacement therapieshelped the business to perform exceedingly well This apart  management at Baxter expects an upward trend across most of its segments in 2019  Also  it expects acquisitions to be accretive  Renal Care is expected to witness 2 3  growth  In Medication Delivery  management at Baxter expects sales to increase approximately 6  Moving to Clinical Nutrition  Baxter expects sales growth of approximately 3   In the Advanced Surgery business  the company anticipates sales to increase 3 4  on a constant currency basis Generic Competition for CyclophosphamideCyclophosphamide is a part of Baxter s Hospital Products segment  Over the last five years  cyclophosphamide has been displaying disappointing performance for the most part  Lower cyclophosphamide sales pose threats to the Integrated Pharmacy Solutions franchise business Despite a promising portfolio  the company has failed to grab market share and substantially boost its top line due to generic competition for cyclophosphamide For 2019  Baxter expects U S cyclophosphamide sales of approximately  95 million compared with  166 million registered in 2018 Price PerformanceIn a year s time  shares of Baxter have gained 10 1  comparing favorably with the  s 6 5  growth  The current level also compares favorably with the S P 500 index s decline of 6 9  over the same time frame  Key PicksA few better ranked stocks in the broader medical space are Surmodics  Inc   NASDAQ SRDX    Abbott Laboratories   NYSE ABT   and Cardiovascular Systems  Inc    NASDAQ CSII   Surmodics has a long term expected earnings growth rate of 10   The stock sports a Zacks Rank  1  Strong Buy   You can see  Abbott s long term earnings growth rate is projected at 11 7   The stock carries a Zacks Rank  2  Buy  Cardiovascular Systems exceeded the Zacks Consensus Estimate in the trailing four quarters  the average being 77 1   The stock sports a Zacks Rank of 1 Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2019-02-13,Zacks Investment Research,https://www.investing.com/analysis/baxters-acute-therapies-profile-strong-competition-rife-200388312,200388312
30099,251614,CSII,U S  futures higher  eyes on Bernanke speech  Dow Jones up 0 09 ,news,Investing com   U S  stock futures pointed to a higher open on Monday  as investors awaited a speech by Federal Reserve Chairman Ben Bernanke in Jackson Hole  Wyoming later in the week  for indications on whether the U S  central bank will soon announce fresh easing measures Ahead of the open  the Dow Jones Industrial Average futures pointed to a 0 09  rise  S P 500 futures signaled a 0 26  increase  while the Nasdaq 100 futures indicated a 0 57  gain Investors were awaiting more information from the Fed  after the minutes of its August meeting indicated that many policymakers may be leaning towards additional easing measures Meanwhile  investors remained cautious as renewed concerns over the ongoing debt crisis in the euro zone sapped risk appetite Earlier Monday  data showed that German business sentiment declined for a fourth month in August  underlining concerns over the impact of the debt crisis on the region s largest economy Pharmaceuticals were expected to be active  as Eli Lilly s heart drug Effient failed to beat the older product Plavix in a head to head clinical study  dealing a blow to hopes for its expanded use in treating less critically sick heart patients who are managed solely with medicines  Separately  Merck   Co said on Sunday it plans to file regulatory applications for a new type of blood clot preventer next year  and will also file with regulators for approval of another cardiovascular drug in 2013 Auto stocks were also likely to be in focus  as Ford  Mazda and their Chinese partner Chongqing Changan Automotive were said to have received approval from China s central government to split their three way  manufacturing and sales joint venture into two In addition  car rental company Hertz Global Holdings said it intends to buy rival Dollar Thrifty Automotive Group for about USD2 3 billion  ending more than two years of a takeover battle In the media sector  Sirius XM Radio was slated to move as investors were reportedly buying up the stock ahead of a potential share buyback On Sunday  media mogul Barry Diller s IAC said that its Ask com unit acquired information website About com from the New York Times Company for USD300 million in cash Other stocks in focus included jeweler Tiffany   Co  due to report second quarter results before the market open  The company was also slated to update its full year forecast  which was expected to reflect how Tiffany expects sales to trend as it heads toward the holiday period Across the Atlantic  European stock markets were higher  The EURO STOXX 50 rose 0 24   France s CAC 40 added 0 19   Germany s DAX advanced 0 24   while Britain s FTSE 100 was closed for a bank holiday weekend During the Asian trading session  Hong Kong s Hang Seng Index dropped 0 41   while Japan s Nikkei 225 Index added 0 16  Investors were also anticipating a speech by senior European Central Bank policymaker Joerg Asmussen later in the day ,2012-08-27,Investing.com,"https://www.investing.com/news/stock-market-news/u.s.-futures-higher,-eyes-on-bernanke-speech;-dow-jones-up-0.09-237569",237569
30100,251615,CSII,U S  stocks mixed amid Fed uncertainty  Dow Jones down 0 23 ,news,Investing com   U S  stocks opened mixed on Monday  as investors eyed a speech by Federal Reserve Chairman Ben Bernanke in Jackson Hole  Wyoming later in the week  for indications on whether the U S  central bank will soon announce fresh easing measures During early U S  trade  the Dow Jones Industrial Average fell 0 23   the S P 500 index dipped 0 01   while the Nasdaq Composite index added 0 11  Investors were awaiting more information from the Fed  after the minutes of its August meeting indicated that many policymakers may be leaning towards additional easing measures Meanwhile  investors also remained hopeful that the European Central Bank will implement policy measures to help stabilize the euro zone s sovereign debt markets at its next policy meeting in early September  Apple shares climbed 2 35   boosted by the tech giant s victory in a patent lawsuit against rival Samsung Last week  a U S  court ruled the world s biggest handset maker infringed six of seven patents  A ban may undermine Samsung s grip on the smartphone market and set a precedent for rival handset makers that use Google s Android operating system In pharmaceutical stocks  Eli Lilly saw shares rise 0 30   even as its heart drug Effient failed to beat the older product Plavix in a head to head clinical study  dealing a blow to hopes for its expanded use in treating less critically sick heart patients who are managed solely with medicines  Merck   Co dropped 0 39  on the other hand  after saying on Sunday that it plans to file regulatory applications for a new type of blood clot preventer next year  and will also file with regulators for approval of another cardiovascular drug in 2013 In M A news  employment solutions company Kenexa skyrocketed 41 19  amid reports it will be bought by IBM for USD1 3 billion M T Bank also added to gains  with shares surging 4 65  after announcing its intention to acquire Hudson City Bancorp for about USD3 7 billion Elsewhere in the financial sector  stocks were mixed  Shares in Bank of America tumbled 1 10  and JP Morgan fell 0 16   while Goldman Sachs and Citigroup added 0 10  and 0 20  respectively Meanwhile  Best Buy rallied 5 60  after the consumer electronics retailer said it has reached an agreement with founder Richard Schulze  allowing him to conduct due diligence and form an investment group with private equity sponsors Among earnings  Tiffany   Co saw shares soar 6 10   even as the jeweler slashed its fiscal year earnings and revenue guidance for the second quarter Across the Atlantic  European stock markets were higher  The EURO STOXX 50 rose 0 48   France s CAC 40 added 0 18   Germany s DAX advanced 0 51   while Britain s FTSE 100 was closed for a bank holiday weekend During the Asian trading session  Hong Kong s Hang Seng Index dropped 0 41   while Japan s Nikkei 225 Index added 0 16  Trade looked likely to remain quiet on Monday  with no significant economic data releases on the calendar ,2012-08-27,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-stocks-mixed-amid-fed-uncertainty;-dow-jones-down-0.23-237577,237577
30104,251619,CSII,Cardiovascular Systems Expands Portfolio Amid Stiff Rivalry,opinion,On Jan 4  we issued an updated research report on Cardiovascular Systems  Inc    NASDAQ CSII    The company has been pursuing product improvements and evaluating new technologies to strengthen and broaden its portfolio of powerful micro invasive tools  However  the company facing cut throat competition is a concern  The stock currently carries a Zacks Rank  3  Hold  Over the past year  Cardiovascular Systems has outperformed its   The stock has gained 21 6  versus its industry s fall of 10 3  We are upbeat about Cardiovascular Systems continuing to expand its portfolio to widen the company s reach  The company recently announced receipt of approval from Japan s Ministry of Health  Labor and Welfare   MHLW   for its Diamondback 360 Coronary Orbital Atherectomy System  OAS  with Classic Crown and ViperWire AdvanceCoronary Guidewire FlexTip Now featuring GlideAssist  Classic Crown is a popular coronary atherectomy device in the United States  Per management  Japan will be the first market with a chance to utilize Classic Crown and FlexTip together Following the receipt of the FDA 510 k  clearance for the OrbusNeich Teleport Microcatheter  Teleport   Cardiovascular Systems has also announced the treatment of the first patient in the United States with the same In November 2018  the company announced the treatment of the first patient in Germany with its Stealth 360 Peripheral OAS  Cardiovascular Systems announced the treatment of the first patient with its Diamondback 360 Coronary OAS in Hong Kong in the same month Cardiovascular Systems firing on all cylinders  of late  to expand its geographical presence also encourages us  In this regard  the company continues to develop a scalable medical education infrastructure  By the end of the next quarter  the company expects to have completed training around 40 international physicians on the use of OAS  Cardiovascular Systems was also informed about renewal of its CE Mark certification for peripheral OAS for next three years by the European Notified Body The company also plans to get its coronary product line the CE mark approval in the latter half of fiscal 2019 Meanwhile  the medical device industry being highly competitive is subject to rapid change and significantly affected by product introductions and other activities of industry participants  Cardiovascular Systems  OAS products compete with a variety of other products or devices for the treatment of vascular disease  including stents  balloon angioplasty catheters and atherectomy catheters  as well as products used in vascular surgery  According to management  Cardiovascular Systems may have difficulty competing effectively with these competitors due to their well established positions in the marketplace  significant financial and human capital resources  established reputations and worldwide distribution channels On the profitability front  Cardiovascular Systems bears a long history of incurring net losses since its inception in 1989 and there is no hope for the company to revive from it  at least not in the near future  Although the company registered net income in the second half of fiscal 2018  it could not sustain it  In the first quarter of fiscal 2019  the company again incurred net loss of  2 89 million Key PicksSome better ranked stocks in the broader medical space are Veeva Systems   NYSE VEEV    Surmodics  Inc    NASDAQ SRDX   and athenahealth  Inc     NASDAQ ATHN   Veeva Systems  long term earnings growth rate is estimated at 19 5   The stock flaunts a Zacks Rank  1  Strong Buy   You can see  Surmodics  long term earnings growth rate is projected at 10   The stock carries a Zacks Rank of 2  Buy  athenahealth s long term earnings growth rate is projected at 17 7   The stock has a Zacks Rank of 2 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2019-01-06,Zacks Investment Research,https://www.investing.com/analysis/cardiovascular-systems-expands-portfolio-amid-stiff-rivalry-200373343,200373343
30107,251622,CSII,Cardiovascular Systems Portfolio Solid  Competition Rife,opinion,On Feb 12  we issued an updated research report on Cardiovascular Systems  Inc    NASDAQ CSII    The stock carries a Zacks Rank  3  Hold  This medical device manufacturer  developer and marketer of innovative solutions to treat patients with peripheral and coronary arterial diseases  including those with arterial calcium  saw a solid second quarter of fiscal 2018  The company witnessed year over year rise in revenues at both coronary arterial disease  CAD  and coronary arterial disease  PAD  businesses  Also  the expansion in gross margin was impressive Cardiovascular Systems has been expanding its product portfolio to enhance market reach  Currently  Cardiovascular Systems is pursuing product improvement and evaluating new technologies to strengthen and broaden its portfolio of powerful micro invasive tools  Earlier  the company had received FDA approval for the Diamondback 360 Coronary OAS Micro Crown system to facilitate stent delivery in patients with CAD  The company also won approval from Japan s Ministry of Health  Labor and Welfare  MHLW  for the Diamondback 360 Coronary OAS Micro Crown and launched it commercially in February  Also  the company received FDA approval for radial access Diamondback 360 Peripheral Orbital Atherectomy Device to treat PAD  We are upbeat about Cardiovascular Systems  two new partnerships  which have broadened its portfolio  The company is now the U S  distributor of OrbusNeich balloon products  OrbusNeich PCI balloons include the Sapphire II Pro  which is scheduled to get FDA approval this year for the 1 0 mm coronary balloon  Moreover  the company has signed an original equipment manufacturer  OEM  agreement with Integer Holdings Corporation for CSI branded ZILIENT guidewires We are also optimistic about the favorable trends in the PAD as well as CAD spaces  Per the American Heart Association  as many as 8 12 million Americans suffer from PAD  Moreover  an aging population coupled with rising incidence of diabetes and obesity is likely to increase the occurrence of PAD  This offers a huge scope for the unique PAD Orbital Atherectomy System  OAS  of Cardiovascular Systems Over the past three months  Cardiovascular Systems has been underperforming the    The stock has declined 7 8  against the industry s 1 9  rise   Furthermore  the company faces cutthroat competition in the niche space  Its OAS products compete with a variety of other products or devices for the treatment of vascular disease  including stents  balloon angioplasty catheters and atherectomy catheters  as well as products used in vascular surgery  Larger competitors in the stent and balloon angioplasty market segments include bigwigs like Abbott Laboratories   NYSE ABT    Moreover  on the profitability front  Cardiovascular Systems has a long history of net losses since its inception in 1989  with no immediate recovery in sight  Key PicksSome better ranked stocks in the broader medical sector are PerkinElmer   NYSE PKI   and Bio Rad Laboratories   NYSE BIO   Bio Rad Laboratories has a Zacks Rank  2  Buy   You can see  The company has a long term expected earnings growth rate of 25  PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-02-15,Zacks Investment Research,https://www.investing.com/analysis/cardiovascular-systems-portfolio-solid-competition-rife-200291490,200291490
30164,251679,CSII,Cardiovascular Systems Gains From 510K For OrbusNeich Device,opinion,Cardiovascular Systems  Inc    NASDAQ CSII   has recently announced that OrbusNeich s 1 0mm Sapphire II PRO coronary balloon has secured 510 k  clearance from the FDA  The company is the exclusive distributor of OrbusNeich s balloon products since January 2018  Accordingly  this 510 k  clearance is a major step toward the company gaining expansion to its scope of distribution Headquartered in Hong Kong with operations in Shenzhen  China  OrbusNeich is a balloon technologies company  particularly catering to the fields of percutaneous coronary intervention  PCI  and percutaneous transluminal angioplasty  PTA  The 1 0mm Sapphire II PRO coronary balloon by OrbusNeich is claimed to be the first and the only 1 0mm coronary balloon available in the United States  The product offers entry and crossing profiles and is precision engineered for crossing and treating extremely tight and complex lesions  Per Cardiovascular Systems  this 1 0mm balloon complements the company s orbital atherectomy system in treating complex and high risk indicated patients Post the launch  Cardiovascular Systems is going to distribute both the 1 0 4 0mm Sapphire II PRO as well as the 2 0 4 0mm Sapphire NC Plus non compliant coronary balloons on a limited basis  The company also expects OrbusNeich s full balloon product portfolio to be available in the United States throughout 2018 and 2019 Market ProspectsCardiovascular Systems firmly stands to gain as a distributor of coronary balloons from several favorable trends existing in the peripheral arterial disease  PAD  as well as coronary arterial disease market spaces  According to estimates delivered by American Heart Association  as many as 8 12 million Americans suffer from PAD  Moreover  an aging population coupled with the increasing incidence of diabetes and obesity  is likely to propel the prevalence of PAD further  This in turn also offers a huge scope to the unique PAD Orbital Atherectomy System system of Cardiovascular Systems  Per a report by Transparency Market Research  the global market for coronary heart diseases is expected to witness a surge in demand due to the rising instance of chronic diseases  Going by Technavio data  this market is likely to witness a CAGR of more than 5  by 2021 Price Comparison Over the past six months  Cardiovascular Systems has underperformed the broader   The stock has declined 25 2  against the 6 4  rise of the broader industry  Strategic developments like these are anticipated to help reviving the company s share price trend to some extent Zacks Ranks   Key PicksCardiovascular Systems carries a Zacks Rank  3  Hold   A few better ranked stocks in the broader medical space are athenahealth  Inc    NASDAQ ATHN    Centene Corporation   NYSE CNC   and Mednax  Inc    NYSE MD    each sporting a Zacks Rank  1  Strong Buy   You can see athenahealth has a projected long term growth rate of 20 7   The stock has returned 10  in the past three months Centene has a long term growth rate of 14 4   The stock has rallied 18 9  in the past six months Mednax has an expected long term growth rate of 10   In the past six months  the stock has jumped 26  Don t Even Think About Buying Bitcoin Until You Read This The most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks  has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ,2018-03-01,Zacks Investment Research,https://www.investing.com/analysis/cardiovascular-systems-gains-from-510k-for-orbusneich-device-200295650,200295650
30165,251680,CSII,Cardiovascular Systems  CSII  Up 2  Since Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Cardiovascular Systems  Inc    NASDAQ CSII    Shares have added about 2  in that time frame 
Will the recent positive trend continue leading up to its next earnings release  or is CSII due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts 
Recent EarningsCardiovascular Systems reported adjusted loss per share of a penny in second quarter fiscal 2018  against the year ago quarter s adjusted earnings of 3 cents The figure was narrower than the earlier guided range of loss per share of 6 3 cents  The figure also compared favorably with the Zacks Consensus Estimate of a loss of 4 cents Net SalesCardiovascular Systems recorded revenues of  52 6 million in the fiscal second quarter  marking a year over year increase of 5 1   Also  the figure was within the guided range of  52 5  54 million  However  revenues missed the Zacks Consensus Estimate of  53 3 million Segment DetailsCoronary device revenues increased 3 5  year over year to  13 4 million  To date  Cardiovascular Systems has sold over 3 56 000 devices to leading institutions in the United StatesMeanwhile  peripheral device revenues rose 5 8  to  39 2 million on a year over year basis  The company added 29 new peripheral accounts and 30 coronary accounts in the fiscal second quarter MarginGross margin in the reported quarter was 81 9   up 20 basis points  bps  year over year Meanwhile  selling and administrative  SG A  expenses contracted 8 9  to  37 million and research and development  R D  expenses were up 10 2  to  6 4 million  Resultantly  adjusted operating expenses were up 9 1  to  43 4 million Per management  operating expenses were lower than the earlier provided guidance due to reduced incentive compensation and payroll expenses  Operating loss was around  0 3 million  against operating income of  1 1 million in the year ago quarter Financial positionThe company exited the second quarter of fiscal 2018 with cash and cash equivalents of  107 3 million  compared with  104 7 million at the end of preceding quarter  The company has no long term debt OutlookCardiovascular Systems updated its fiscal 2018 revenue guidance to the range of  215  219 million  down from  226  233 million  The current Zacks Consensus Estimate for fiscal 2018 revenues is pegged at  225 3 million  below the company s guided range The company expects revenues in the range of  55  56 5 million for third quarter fiscal 2018  The current Zacks Consensus Estimate is pegged at  59 5 million  above the company s guided range Moreover  the company expects gross profit to account for 81  of revenues  while operating expenses are estimated at around  45 5 million for third quarter fiscal 2018 The company expects to incur net loss of  0 9 million to  0 0 million  Adjusted earnings per share is expected to be between negative 3 cents and breakeven  The current Zacks Consensus Estimate is pegged earnings at 3 cents  above the company s guided range 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  There have been three revisions lower for the current quarter Cardiovascular Systems  Inc  Price and Consensus    VGM Scores
At this time  CSII has a nice Growth Score of B  though it is lagging a lot on the momentum front with an F  The stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of D  If you aren t focused on one strategy  this score is the one you should be interested in 
Our style scores indicate that the stock is more suitable for growth investors than value investors 
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift  Notably  CSII has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-03-08,Zacks Investment Research,https://www.investing.com/analysis/cardiovascular-systems-csii-up-2-since-earnings-report-can-it-continue-200296881,200296881
30166,251681,CSII,Cardiovascular Systems  CSII  Q3 Earnings Top  Revenues Meet,opinion,Cardiovascular Systems  Inc    NASDAQ CSII   reported earnings per share of a penny in third quarter fiscal 2018 against the year ago quarterly loss of 5 cents The figure remained ahead of the earlier guided range of a loss of 3 cents to breakeven  Moreover  the bottom line compared favorably with the Zacks Consensus Estimate of a loss of 2 cents Net SalesCardiovascular Systems recorded revenues of  55 6 million in the fiscal third quarter  marking a 6 6  year over year increase  Also  the metric was within the guided range of  55  56 5 million  Moreover  the top line matched the Zacks Consensus Estimate Segment DetailsCoronary device revenues increased 8  year over year to  14 6 million  In the United States  coronary units sold increased 5   partially offset by a low single digit decline in ASP  average selling price  Cardiovascular Systems  Inc  Price  Consensus and EPS Surprise    Meanwhile  peripheral device revenues rose 6  to  41 million on a year over year basis  This improvement came on the back of continued strength in the hospital setting MarginGross margin in the reported quarter was 82 1   up 343 basis points  bps  year over year Meanwhile  selling and administrative  SG A  expenses inched up 1 2  to  37 8 million whereas research and development  R D  expenses were up 34 9  to  7 3 million  As a result  adjusted operating expenses increased 5 5  to  45 1 million Per management  operating expenses were about  400 000  lower than the previous projection  Operating income was around  489 million against operating loss of  1 8 million in the year ago quarter Financial PositionThe company exited the third quarter of fiscal 2018 with cash and cash equivalents of  109 3 million compared with  107 3 million at the end of the preceding quarter  On a positive note  it has no long term debt OutlookThe company expects revenues in the range of  57 5  59 million for fourth quarter fiscal 2018  The Zacks Consensus Estimate is pegged at  58 6 million  falling within the company s estimated range Moreover  the company is likely to earn a gross profit  accounting for 81  of revenues while operating expenses are anticipated at around  45 million for the fiscal fourth quarter The company projects net income of  1 7   2 6 million  Net earnings per share are predicted between 5 cents and 8 cents  The consensus mark is pegged at a couple of cents  lying below the company s expected range Our TakeCardiovascular Systems exited third quarter fiscal 2018 on a solid note with year over year increase in both Coronary device and peripheral device segment  Overall  revenues grew the back of strength in both the company segments year over year  Also  the expansion in gross margin buoys optimism  The company is putting efforts in product innovation through R D investments  On the flip side  Cardiovascular Systems faces a cut throat competition in the niche space Zacks Rank   Key ReleasesCardiovascular Systems has a Zacks Rank  3  Hold   A few better ranked stocks in the broader medical sector with solid results this reporting cycle are Intuitive Surgical   NASDAQ ISRG    Chemed Corp    NYSE CHE   and Baxter International Inc    NYSE BAX    While Intuitive Surgical sports a Zacks Rank  1  Strong Buy   Chemed and Baxter carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported first quarter 2018 adjusted earnings per share  EPS  of  2 44  which beat the Zacks Consensus Estimate by 22 6   Revenues of  848 million also surpassed the consensus estimate by 10 6  Chemed posted first quarter 2018 adjusted EPS of  2 72  outshining the Zacks Consensus Estimate of  2 37  Revenues came in at  439 2 million  surpassing the Zacks Consensus Estimate of  420 million Baxter released first quarter 2018 adjusted EPS of 70 cents  which crossed the consensus mark by 12 9   Revenues of  2 68 billion also exceeded the Zacks Consensus Estimate of  2 62 billion 5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2018-05-02,Zacks Investment Research,https://www.investing.com/analysis/cardiovascular-systems-csii-q3-earnings-top-revenues-meet-200312718,200312718
30167,251682,CSII,4 Handsome Stocks To Watch  CASI  COOL  HABT  TNDM,opinion,"Casi Pharmaceuticals  NASDAQ CASI  had a nice looking mini coil or flag on Tuesday  up 25 cents  or 3 1 2   to 7 30  on 177 134 shares  If we break out across the double top  which will be our next objective  to take out 8 33 35  and then head towards 11 
PolarityTE Inc  NASDAQ COOL  after a spike off the low and a pull back  it formed a little wedge  It broke out on Tuesday and went ahead and picked up a little bit  Up 1 48  or 7   to 22 79  on 547 000 shares  I want to see if there s more upside  Key resistance now 26 and 29 1 2  Those are my targets as well 
Habit Restaurants Inc  NASDAQ HABT  broke out  pulled back  and exploded recently  It s right at that major declining topsline  Up 30 cents  or 2   to 12 70  on 450 907 shares on Tuesday  Had an inside day as it backed off of it  but a positive day  If we break out  we should test the gap at 14 40 and then 15 60 
Tandem Diabetes Care Inc  NASDAQ TNDM  after pulling back for a few days  it exploded back up on Tuesday  Up 2 72  or 11   to 27 56  on 3 7 million shares  The buy in was the heaviest we ve seen in about a month  If it breaks out above 28 90  this stock will be in the mid 30 s  Keep an eye on this one 
Stocks on the long side included ADMA Biologics Inc  NASDAQ ADMA   Aerojet Rocketdyne Holdings  Inc   AJRD   Allison Transmission Holdings Inc  NYSE ALSN   Arconic Inc   ARNC   Attunity Ltd  NASDAQ ATTU   CASI Pharmaceuticals  Inc   CASI   CareDx  Inc   CDNA   Cognex Corporation  NASDAQ CGNX   Coherus BioSciences  Inc   CHRS   PolarityTE  Inc   COOL   Correvio Pharma Corp   CORV   Cardiovascular Systems Inc  NASDAQ CSII   Echo Global Logistics  Inc   ECHO   The Habit Restaurants  Inc   HABT   Libbey Inc   LBY   NII Holdings  Inc   NIHD   Northern Oil and Gas  Inc   NOG   Tandem Diabetes Care  Inc   TNDM   Veoneer  Inc   VNE   and Xenon Pharmaceuticals Inc  NASDAQ XENE  
Watch video here ",2018-08-01,Harry Boxer,https://www.investing.com/analysis/casi-cool-habt-tndm-200335119,200335119
30168,251683,CSII,Cardiovascular Systems   CSII  Q1 Loss Wider Than Expected ,opinion,"Cardiovascular Systems  Inc    NASDAQ CSII   reported loss per share of 9 cents in first quarter fiscal 2019 compared with the year ago loss of 6 cents The reported figure was wider than the Zacks Consensus Estimate of a loss of 6 cents Net SalesCardiovascular Systems recorded revenues of  56 3 million in the fiscal first quarter  marking a 13 3  year over year increase  The top line steered past the Zacks Consensus Estimate by 0 6  Segment DetailsCoronary device revenues increased over 30  year over year to  15 million  Meanwhile  peripheral device revenues rose 8  to  41 2 million on a year over year basis  The company continued to see strong adoption of its Orbital Atherectomy System  OAS   Also  Cardiovascular Systems is progressing well with its objective to introduce OAS globally MarginGross margin in the reported quarter was 81 2   down 30 basis points  bps  year over year due to the full market launch of coronary balloons and peripheral guidewires along with rising revenues from international distributors 
Cardiovascular Systems  Inc  Price  Consensus and EPS Surprise
    Meanwhile  selling and administrative  SG A  expenses rose 14 8  to  41 2 million and research and development  R D  expenses were up 17 6  to  7 4 million  As a result  adjusted operating expenses rose 15 4  to  48 7million Loss from operations came in at around  3 million  compared with a loss of  1 8 million in the year ago period Financial positionThe company exited first quarter fiscal 2019 with cash and cash equivalents of  113 4 million  compared with  116 3 million at the end of fiscal 2018 OutlookCardiovascular Systems reiterated its fiscal 2019 guidance  The company expects revenues in the range of  240  250 million for fiscal 2019  The current Zacks Consensus Estimate for fiscal 2019 revenues is pegged at  244 2 million  within the company s guidance Moreover  the company expects gross profit to account for 80  of revenues in fiscal 2019 The company expects to incur net loss of 1 2  of revenues in fiscal 2019  The current Zacks Consensus Estimate is pegged at a loss of 10 cents Our TakeCardiovascular Systems exited first quarter fiscal 2019 on a mixed note  However  the company witnessed year over year increase in both Coronary device and peripheral device segments  Overall  revenues grew year over year on segmental strength  The company is putting efforts in product innovation through R D investments   Cardiovascular Systems also announced the first global commercial use of its minimally invasive Stealth 360Peripheral OAS in Hong Kong in the quarter Further  management seems to be upbeat about the exclusive international distribution agreement with OrbusNeich to sell its coronary and peripheral OAS outside the United States and Japan  According to management  the company saw the strongest quarterly growth in the first quarter of fiscal 2019 in the last 18 months On the flip side  Cardiovascular Systems faces cut throat competition in the niche space Zacks Rank   Key PicksCardiovascular Systems has a Zacks Rank  5  Strong Sell   A few better ranked stocks in the broader medical space  which reported solid earnings this season  are Intuitive Surgical   NASDAQ ISRG    Stryker Corporation   NYSE SYK   and Merit Medical Systems  Inc    NASDAQ MMSI    All the stocks carry a Zacks Rank  2  Buy   You can see  Intuitive Surgical reported third quarter 2018 adjusted earnings per share of  2 83  which beat the Zacks Consensus Estimate of  2 65  Revenues totaled  920 9 million  also surpassing the consensus estimate of  918 6 million Stryker posted third quarter 2018 adjusted earnings per share of  1 69  steering past the Zacks Consensus Estimate of  1 68  Operating margin was 17 8   up 30 bps Merit Medical reported third quarter 2018 adjusted earnings per share of 47 cents  which trumped the Zacks Consensus Estimate of 42 cents  Revenues of  221 6 million edged past the consensus estimate of  218 million 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ",2018-10-30,Zacks Investment Research,https://www.investing.com/analysis/cardiovascular-systems-csii-q1-loss-wider-than-expected-200352492,200352492
30169,251684,CSII,Cardiovascular Systems Treats First Patient With Teleport,opinion,Following the receipt of the FDA 510 k  clearance for the OrbusNeich Teleport Microcatheter  Teleport   Cardiovascular Systems  Inc    NASDAQ CSII   recently announced treating first patient in the United States with the same Headquartered in Hong Kong with operations in Shenzhen  China  OrbusNeich is a balloon technologies company  particularly catering to the fields of percutaneous coronary intervention  PCI  and percutaneous transluminal angioplasty  PTA  Cardiovascular Systems had extended its partnership with OrbusNeich in July 2018 by signing an exclusive international distribution agreement to sell its coronary and peripheral Orbital Atherectomy System  OAS  outside the United States and Japan  OrbusNeich is focused on distributing Cardiovascular Systems  OAS across Europe and Southeast Asia in 2018 Notably  Cardiovascular Systems is the exclusive distributor of OrbusNeich s balloon products in the United States since January 2018 Market ProspectsCardiovascular Systems firmly stands to gain as a distributor of coronary balloons from several favorable trends existing in the peripheral arterial disease  PAD  and coronary arterial disease market spaces  According to estimates delivered by American Heart Association  as many as 8 12 million Americans suffer from PAD  Moreover  an aging population coupled with the increasing incidence of diabetes and obesity is likely to propel the prevalence of PAD further  This  in turn  also offers a huge scope to the unique PAD Orbital Atherectomy System of Cardiovascular Systems  Per Transparency Market Research  the global market for coronary heart diseases is expected to witness a surge in demand due to the rising instance of chronic diseases  Going by Technavio data  this market is likely to witness a CAGR of more than 5  by 2021 Portfolio Expansion to Widen ReachCardiovascular Systems is pursuing product improvements and evaluating new technologies to strengthen and broaden its portfolio of powerful micro invasive tools  During the fiscal first quarter  the company continued to gain from increased adoption of its new Diamondback 360 extended length or radial device and the Diamondback 360 with the new GlideAssist feature  The company has also been seeing solid uptake of Sapphire II coronary balloon  OrbusNeich coronary balloons and ZILIENT guidewires In November  the company announced treating first patient in Germany with its Stealth 360 Peripheral OAS  Again in the same month  Cardiovascular Systems announced the treatment of first patient with its Diamondback 360 Coronary OAS in Hong Kong Management also informed about submitting its 510 k  application to the FDA for the exchangeable peripheral platform  which is planned for launch in late fiscal 2019 Cardiovascular Systems also plans to expand its business by launching internally developed products and expanding into new geographies outside the United States  In this regard  the company plans to commercialize the radio product or peripheral lesions in calendar year 2018 Share Price MovementOver the past year  Cardiovascular Systems has outperformed its   The stock has gained 18 7   against the 5 3  decline of the industry  Launches and partnerships are likely to drive the stock further  Zacks Rank   Key PicksCardiovascular Systems carries a Zacks Rank  3  Hold  Some better ranked stocks in the broader medical space are Veeva Systems   NYSE VEEV    Integer Holdings Corporation   NYSE ITGR   and Surmodics  Inc    NASDAQ SRDX   Veeva Systems  long term earnings growth rate is estimated at 19 5   The stock flaunts a Zacks Rank  1  Strong Buy   at present  You can see  Integer Holdings  with a Zacks Rank  1  has earnings growth rate of 50 8  for the first quarter of 2019 Surmodics  long term earnings growth rate is projected at 10   The stock carries a Zacks Rank of 2  Buy   currently Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-12-30,Zacks Investment Research,https://www.investing.com/analysis/cardiovascular-systems-treats-first-patient-with-teleport-200371912,200371912
30173,251688,CSII,Cardiovascular Systems  CSII  Q2 Earnings Top  Revenues Lag,opinion,Cardiovascular Systems  Inc    NASDAQ CSII   reported adjusted loss per share of a penny in second quarter fiscal 2018  against the year ago quarter s adjusted earnings of 3 cents The figure was narrower than the earlier guided range of loss per share of 6 3 cents  The figure also compared favorably with the Zacks Consensus Estimate of a loss of 4 cents Net SalesCardiovascular Systems recorded revenues of  52 6 million in the fiscal second quarter  marking a year over year increase of 5 1   Also  the figure was within the guided range of  52 5  54 million  However  revenues missed the Zacks Consensus Estimate of  53 3 million Cardiovascular Systems  Inc  Price  Consensus and EPS Surprise     Segment DetailsCoronary device revenues increased 3 5  year over year to  13 4 million  To date  Cardiovascular Systems has sold over 3 56 000 devices to leading institutions in the United StatesMeanwhile  peripheral device revenues rose 5 8  to  39 2 million on a year over year basis  The company added 29 new peripheral accounts and 30 coronary accounts in the fiscal second quarter MarginGross margin in the reported quarter was 81 9   up 20 basis points  bps  year over year Meanwhile  selling and administrative  SG A  expenses contracted 8 9  to  37 million and research and development  R D  expenses were up 10 2  to  6 4 million  Resultantly  adjusted operating expenses were up 9 1  to  43 4 million Per management  operating expenses were lower than the earlier provided guidance due to reduced incentive compensation and payroll expenses  Operating loss was around  0 3 million  against operating income of  1 1 million in the year ago quarter Financial positionThe company exited the second quarter of fiscal 2018 with cash and cash equivalents of  107 3 million  compared with  104 7 million at the end of preceding quarter  The company has no long term debt OutlookCardiovascular Systems updated its fiscal 2018 revenue guidance to the range of  215  219 million  down from  226  233 million  The current Zacks Consensus Estimate for fiscal 2018 revenues is pegged at  225 3 million  below the company s guided range The company expects revenues in the range of  55  56 5 million for third quarter fiscal 2018  The current Zacks Consensus Estimate is pegged at  59 5 million  above the company s guided range Moreover  the company expects gross profit to account for 81  of revenues  while operating expenses are estimated at around  45 5 million for third quarter fiscal 2018 The company expects to incur net loss of  0 9 million to  0 0 million  Adjusted earnings per share is expected to be between negative 3 cents and breakeven  The current Zacks Consensus Estimate is pegged earnings at 3 cents  above the company s guided range Our TakeCardiovascular Systems exited second quarter fiscal 2018 on a solid notewith year over year increase in both Coronary device and peripheral device segment  Overall revenues increased on a year over year basis on strength in both the company segments  Also  the expansion is gross margin buoys optimism  The company is putting efforts in product innovation through R D investments  On the flipside  Cardiovascular Systems faces cutthroat competition in the niche space  Cardio Vascular incurred net loss in the recently reported second quarter  In fact  the company has a long history of net losses since inception Zacks Rank   Key ReleasesCardiovascular Systems has a Zacks Rank  3  Hold  A few better ranked stocks that reported solid results this earnings season are PetMed Express   NASDAQ PETS    PerkinElmer   NYSE PKI   and Becton  Dickinson and Company   NYSE BDX    While PetMed sports a Zacks Rank  1  Strong Buy   PerkinElmer and Becton  Dickinson carry a Zacks Rank  2  Buy   You can see PetMed recently reported third quarter fiscal 2018 results  Adjusted earnings per share were 44 cents  up 88 3  from the prior year quarter  Revenues rose 13 7  on a year over year basis to  60 1 million PerkinElmer reported fourth quarter 2017 adjusted earnings per share of 97 cents  Adjusted revenues were approximately  641 6 million  up from  567 million in the year ago quarter Becton  Dickinson reported first quarter 2018 adjusted earnings per share of  2 48  up 3 9  at constant currency  Revenues totaled  3 08 billion  up 3 7  at constant currency Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-02-07,Zacks Investment Research,https://www.investing.com/analysis/cardiovascular-systems-csii-q2-earnings-top-revenues-lag-200288393,200288393
30177,251692,CSII,Cardiovascular Systems Rides On Innovation Amid Several Woes,opinion,On Aug 4  we issued an updated research report on St  Paul  MN based Cardiovascular Systems  Inc    NASDAQ CSII    The company is a medical device manufacturer that develops and commercializes innovative solutions to treat patients suffering from peripheral and coronary arterial diseases  including those with arterial calcium For the majority of the last six months  Cardiovascular Systems has outperformed the with respect to price  Currently  the stock is up 15 4   better than the 12 1  gain of the broader industry Cardiovascular Systems delivered remarkable fourth quarter 2017 results  with earnings and revenues beating the Zacks Consensus Estimate  The company s lower operating expenses drove the year over year improvement in earnings Strong revenue performance also contributed to the upside in earnings  Moreover  the improvement in margins is encouraging  Overall  the company s fiscal 2017 performance has been impressive  The company s fiscal 2018 guidance also instils confidence in investors Among the recent developments  Cardiovascular Systems has received FDA approval for radial access Diamondback 360 Peripheral Orbital Atherectomy Device  Also  the one year results from the LIBERTY 360 study is to be presented at the 2017 Amputation Prevention Symposium  AMP  On the flip side  the company operates in the competitive medical device industry  which gets significantly affected by product introductions  Failure to expand business overseas might hamper growth  Also  on the profitability front  Cardiovascular bears a long history of net losses since its inception in 1989 with no immediate recovery in sight  In fiscal 2017  the company incurred a net loss of  1 8 million  Management still expects to incur net loss of  2 8  2 2 million in the first quarter of fiscal 2018 Zacks Rank   Key PicksCardiovascular Systems has a Zacks Rank  3  Hold   A few better ranked medical stocks are Edwards Lifesciences Corporation   NYSE EW    INSYS Therapeutics  Inc    NASDAQ INSY   and Align Technology  Inc    NASDAQ ALGN    Notably  Edwards Lifesciences  INSYS Therapeutics and Align Technology sport a Zacks Rank  1  Strong Buy   You can see INSYS Therapeutics has a long term expected earnings growth rate of 20   The stock posted a stellar four quarter average earnings surprise of 60 7  Align Technology has an expected long term adjusted earnings growth of almost 26 6   The stock has added roughly 23 6  over the last three months Edwards Lifesciences has a long term expected earnings growth rate of 15 2   The stock has gained around 5 7  over the last three months 5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-08-07,Zacks Investment Research,https://www.investing.com/analysis/cardiovascular-systems-rides-on-innovation-amid-several-woes-200205742,200205742
30178,251693,CSII,Cardiovascular Systems Unveils Favorable LIBERTY 360 Data,opinion,Medical device manufacturer Cardiovascular Systems  Inc    NASDAQ CSII   recently released one year data from its LIBERTY 360  clinical study in a late breaking presentation at the 2017 Amputation Prevention Symposium  AMP  in Chicago  LIBERTY 360  is a prospective  observational  multi center post market study  The study was based on more than 1 200 patients at 51 sites across the U S   including 501 patients with claudication  603 patients with critical limb ischemia  CLI  and 100 patients with the most severe form of CLI The study examined the acute and long term clinical and economic outcomes of peripheral vascular interventions  PVI  in peripheral artery disease  PAD  patients  LIBERTY 360  included all FDA approved endovascular devices to treat PAD The 12 month data from this study demonstrated that peripheral endovascular intervention marked improvement across all Ruthetford Classes along with high freedom from major adverse events  To be precise  LIBERTY 360 showed that PVI can help prevent amputation for patients with PAD  specifically CLI As per the company s press release  around 18 million Americans suffer from PAD  which is caused by the accumulation of plaque in peripheral arteries reducing blood flow  We believe that the company is adopting appropriate strategic moves to capture the niche market In this regard to note  the company recently received FDA approval for radial access Diamondback 360 Peripheral Orbital Atherectomy Device to treat PAD  The commercial availability is expected in the beginning of calendar year 2018 Some notable stocks in the broader  are Haemonetics Corporation   NYSE HAE    Stryker Corporation   NYSE SYK   and Lantheus Holdings  Inc    NASDAQ LNTH   Zacks  10 Minute Stock Picking SecretSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ,2017-08-14,Zacks Investment Research,https://www.investing.com/analysis/cardiovascular-systems-unveils-favorable-liberty-360-data-200207325,200207325
30179,251694,CSII,Cardiovascular Systems  CSII  Down 3 5  Since Earnings Report  Can It Rebound ,opinion,"It has been more than a month since the last earnings report for Cardiovascular Systems  Inc    NASDAQ CSII    Shares have lost about 3 5  in that time frame  underperforming the market 
Will the recent negative trend continue leading up to the stock s next earnings release  or is it due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts 
Recent EarningsCardiovascular Systems reported adjusted earnings per share of  0 2 in fourth quarter fiscal 2017  reflecting massive improvement from the year ago quarter s adjusted loss of  0 15 a share  The quarter s number compared favorably with the Zacks Consensus Estimate of a loss of  0 5 The year over year improvement was primarily backed by revenue growth and lower operating expenses on account of the company s cost realignment actions Full year adjusted earnings came in at a loss of  0 6 per share  narrower than the year ago loss of  1 72  Also  the loss figure was 53 8  narrower than the Zacks Consensus Estimate of a loss of  0 13  The Numbers in DetailsCardiovascular Systems posted revenues of  52 9 million in the fiscal fourth quarter  marking a year over year increase of 9 2   The figure also surpassed the Zacks Consensus Estimate of  52 million Fiscal 2017 registered revenues of  204 91 million  up 14 9  from the year ago number  Also  revenues outpaced the Zacks Consensus Estimate of  204 03 million Per management  the company received approvals for the new orbital atherectomy devices that give physicians more tools to effectively and routinely treat patients suffering from coronary and peripheral artery disease  Also  the approval of Diamondback 360 Coronary Orbital Atherectomy System Micro Crown in Japan marks the company s first international expansion  beginning in calendar year 2018 To date  Cardiovascular Systems sold over 324 000 devices to leading institutions across the U S  The company added 43 new peripheral accounts and 39 coronary accounts in the fiscal fourth quarter  Coronary device revenues improved 15 3  year over year to  13 2 million and peripheral device revenues rose 7 3  to  39 8 million MarginGross margin in the reported quarter was 81 7   up 206 basis points  bps  year over year  primarily on account of a 9 2  rise in revenues Meanwhile  selling and administrative  SG A  expenses contracted 4 4  to  35 9 million and research and development  R D  expenses were up 4 9  to  6 3 million  The resultant adjusted operating expenses decreased 3 1  to  42 2 million  primarily exhibiting management s cost realignment initiatives  Consequently  operating profit was around  1 0 million  improving from a loss of  4 9 million a year ago Financial positionThe company exited the fourth quarter of fiscal 2017 with cash and cash equivalents of  107 9 million  compared with  103 1 million at the end of third quarter fiscal 2017 OutlookCardiovascular Systems issued its first quarter fiscal 2018 and fiscal 2018 guidance  The company expects revenues in the range of  226  233 million in fiscal 2018  The current Zacks Consensus Estimate for fiscal 2018 revenues is pegged at  231 40 million  which is within the company s guidance The company also expects revenues in the range of  52 6  53 6 million for the first quarter of fiscal 2018  The current Zacks Consensus Estimate is pegged at  54 11 million  slightly above the company s guided range Moreover  the company expects gross profit to account for 81  of revenues  while operating expenses are estimated at around  45 million for first quarter fiscal 2018 The company expects to incur net loss of  2 8  2 2 million or loss per share of  0 9  0 7 in the first quarter fiscal 2018  The current Zacks Consensus Estimate is pegged at a breakeven  above the company s guided range 
How Have Estimates Been Moving Since Then  
Analysts were quiet during the past month as none of them issued any earnings estimate revisions Cardiovascular Systems  Inc  Price and Consensus
    VGM Scores
At this time  Cardiovascular Systems  stock has a great Growth Score of A  though it is lagging a lot on the momentum front with an C  Charting a somewhat similar path  the stock was allocated a grade of D on the value side  putting it in the bottom 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
The company s stock is more suitable  for growth than momentum based on our styles scores 
Outlook
The stock has a Zacks Rank  3  Hold   We are expecting an inline return from the stock in the next few months ",2017-09-08,Zacks Investment Research,https://www.investing.com/analysis/cardiovascular-systems-csii-down-35-since-earnings-report-can-it-rebound-200212165,200212165
30180,251695,CSII,Cardiovascular Systems  CSII  Q1 Earnings Top  Revenues Lag,opinion,Cardiovascular Systems  Inc    NASDAQ CSII   reported adjusted loss per share of 6 cents in first quarter fiscal 2018  flat with the year ago quarter s adjusted loss of 6 cents  The figure was narrower than the earlier provided guided range of loss per share of 9 7 cents  The figure compared favorably with the Zacks Consensus Estimate of a loss of 7 cents Results in DetailsCardiovascular Systems posted revenues of  49 7 million in the fiscal first quarter  marking a year over year decline of 0 2   Also  the figure was lower than the guided range of  52 6  53 6 million for the first quarter of fiscal 2018  The figure also missed the Zacks Consensus Estimate of  51 million Per management  procedure volumes in first quarter fiscal 2018 were impacted by hurricanes  Moreover  the saline infusion pump recall during the quarter resulted in lower than estimated usage of the coronary device  These factors played significant roles which resulted in the revenue miss in the quarter  Cardiovascular Systems  Inc  Price  Consensus and EPS Surprise     To date  Cardiovascular Systems has sold over 340 000 devices to leading institutions in the United States  The company added 36 new peripheral accounts and 29 coronary accounts in the fiscal first quarter  Coronary device revenues declined 0 6  year over year to  11 5 million and peripheral device revenues inched down 0 2  to  38 2 million MarginGross margin in the reported quarter was 81 5   up 48 basis points  bps  year over year Meanwhile  selling and administrative  SG A  expenses contracted 2 6  to  35 9 million and research and development  R D  expenses were up 18 2  to  6 3 million  Resultantly  adjusted operating expenses inched up 0 1  to  42 2 million  Per management  operating expenses were lower than the earlier provided guidance due to lower incentive compensation as a result of deterioration in financial performance  Operating loss was around  1 8 million  compared to the loss of  1 9 million in the year ago quarter Financial positionThe company exited the first quarter of fiscal 2018 with cash and cash equivalents of  104 7 million  compared with  107 9 million at the end of fiscal 2017 OutlookCardiovascular Systems reaffirmed its fiscal 2018 revenue guidance at the range of  226  233 million  The current Zacks Consensus Estimate for fiscal 2018 revenues is pegged at  228 25 million  which is within the company s guided range The company expects revenues in the range of  52 5  54 million for second quarter fiscal 2018 The current Zacks Consensus Estimate is pegged at  55 79 million  above the company s guided range Moreover  the company expects gross profit to account for 81  of revenues  while operating expenses are estimated at around  44 5 million for second quarter fiscal 2018 The company expects to incur net loss of  1 9  1 million or loss per share of 6 3 cents in the second quarter of fiscal 2018 The current Zacks Consensus Estimate is pegged at a loss of a penny  above the company s guided range Our TakeCardiovascular Systems exited the first quarter fiscal 2018 on a mixed note  The decline in year over year revenues at Coronary device and peripheral device was disappointing  Fiscal first quarter revenues declined on a year over year basis owing to the impact of hurricanes On a positive note  the reported loss in the quarter was narrower than the guided range of the company  Also  the expansion is gross margin was impressive  The company s reaffirmed revenue guidance for fiscal 2018 buoys optimism  Moreover  the company is putting efforts in product innovation through R D investments  During the quarter  the company released one year data from its LIBERTY 360  clinical study in a late breaking presentation at the 2017 Amputation Prevention Symposium  AMP  in Chicago  LIBERTY 360  showed that peripheral endovascular intervention can help prevent amputation for patients with peripheral artery disease Zacks Rank   Key PicksCurrently  Cardiovascular Systems has a Zacks Rank  4  Sell  A few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Abbott   NYSE ABT   and Intuitive Surgical  Inc    NASDAQ ISRG    Notably  PetMed sports a Zacks Rank  1  Strong Buy   while Abbott and Intuitive Surgical carry a Zacks Rank  2  Buy   You can see PetMed reported EPS of 43 cents for the second quarter of fiscal 2018  up 79 2  from the year ago quarter s 24 cents  Also  gross margin expanded 548 bps year over year to 35 2  in the reported quarter Abbott reported third quarter 2017 adjusted earnings from continuing operations of 66 cents per share  up 11 9  year over year  Also  third quarter worldwide sales came in at  6 83 billion  up 28 8  year over year  Intuitive Surgical posted adjusted earnings of  2 77 per share in the third quarter of 2017  up 34 5  on a year over year basis  Also  revenues increased 18  year over year to  806 1 million Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-10-25,Zacks Investment Research,https://www.investing.com/analysis/cardiovascular-systems-csii-q1-earnings-top-revenues-lag-200221261,200221261
30181,251696,CSII,Cardiovascular Systems Innovation On Track  Competition Rife,opinion,On Jun 6  we issued an updated research report on St  Paul  MN based Cardiovascular Systems  Inc    NASDAQ CSII    The company is a medical device manufacturer that develops and commercializes innovative solutions to treat patients suffering from peripheral and coronary arterial diseases  including those with arterial calcium Cardiovascular Systems has been trading above the Zacks classified broader  industry in most of last three months  An impressive third quarter 2017 result  with earnings and sales ahead of the Zacks Consensus Estimate  has further boosted the share price Over this period  the stock has gained 16 5   way higher than broader industry s 6 8   We are also encouraged by the company s improving operating expense scenario  driving a year over year rise in the earnings  Per management  the company delivered an enhanced revenue growth  moving toward positive cash flow and profitability Notably  Cardiovascular Systems has been conducting multiple clinical trials with an aim to display the efficacy of its technology  This has allowed physicians to select the company s products to offer best treatment options to their patients Recently  the company released 1 year results from its Coronary Orbital Atherectomy System Study  COAST  in a late breaking presentation  It also presented a six month data from its LIBERTY 360  post market study  The trial evaluated some acute and long term clinical and economic outcomes of peripheral vascular interventions  PVI  in treating patients with symptomatic lower extremity peripheral artery disease  PAD  On the flip side  Cardiovascular Systems operates in competitive medical device industry  which gets significantly affected by new product introductions  Thus failure to expand business overseas might hamper growth Currently its revenues are derived from domestic operations  However  the company plans to start selling internationally in future and has already commenced the process of seeking approval for commercial sales in both Europe and Japan  Nevertheless  uncertainty with regard to regulatory approvals and sales potential has been impacting operations in international markets Zacks Rank   Better Key PicksCardiovascular Systems currently carries a Zacks Rank  3  Hold   Few better ranked medical stocks are Align Technology  Inc    NASDAQ ALGN    Inogen  Inc    NASDAQ INGN   and Accelerate Diagnostics  Inc    NASDAQ AXDX    Notably  Align Technologyand Inogen sport a Zacks Rank  1  Strong Buy   while Accelerate Diagnostics carries a Zacks Rank  2  Buy   You can see Align Technologyhas an expected long term adjusted earnings growth of almost 22 8   The stock has roughly added 44 3  over last three months Inogen has a long term expected earnings growth rate of 17 5   The stock has a solid one year return of around 78 3  Accelerate Diagnostics has an expected long term adjusted earnings growth of 30   The stock has added roughly 13 7  over last three months 3 Stocks to Ride a 588  Revenue Explosion At Zacks  we re mostly focused on short term profit cycles  but the hottest of all technology mega trends is starting to take hold   By last year  it was already generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for those who make the right trades early ,2017-06-06,Zacks Investment Research,"https://www.investing.com/analysis/cardiovascular-systems-innovation-on-track,-competition-rife-200193815",200193815
30182,251697,CSII,Cardiovascular Systems  CSII  Hits 52 Week High On Solid Q3,opinion,Headquartered in St  Paul  MN  share price of Cardiovascular Systems  Inc    NASDAQ CSII   scaled a new 52 week high of  32 68 on Jun 9  eventually closing a bit lower at  30 93  The company has gained 20 3  over the past six months  ahead of the S P 500 s 7 3  gain  The stock has a market cap of over  1 billion Comparison with Broader IndustryOver the last three months  the company s share price has outperformed the Zacks categorized sub industry  The stock has rallied 14 9  over this period  outshining the sub industry s 6 1  Earnings SurpriseThis Zacks Rank  3  Hold  company posted a positive earnings surprise of 175  in the last quarter  The four quarter average earnings beat is 104 17  Cardiovascular Systems  Inc  Price and Consensus    CatalystsThe stock price rallied higher on better than expected results in third quarter 2017  Revenues increased a solid 17  year over year on the back of the strong contribution from the company s coronary and peripheral businesses Also  FDA s recent premarket approval application  PMA  supplement for the company s redesigned saline pump  used as part of the company s Diamondback 360 Orbital Atherectomy Systems  has bolstered market confidence in the stock Further  Cardiovascular Systems received FDA approval for the Diamondback 360 Coronary OAS Micro Crown system to facilitate stent delivery in patients with coronary artery disease Of late  Japan s Ministry of Health  Labor and Welfare  MHLW  approved the Diamondback 360 Coronary OAS Micro Crown as a frontline treatment for severe calcified lesions and to facilitate access to arteries for percutaneous coronary interventions  PCI  All these factors played a pivotal role in driving the company s share price to a 52 week high Key PicksA few better ranked medical stocks are Align Technology  Inc    NASDAQ ALGN    Inogen  Inc    NASDAQ INGN   and Accelerate Diagnostics  Inc    NASDAQ AXDX    Notably  Align Technologyand Inogen sport a Zacks Rank  1  Strong Buy   while Accelerate Diagnostics carries a Zacks Rank  2  Buy   You can see Align Technology has an expected long term adjusted earnings growth of almost 24 1   The stock added roughly 37 9  over the last three months Inogen has a long term expected earnings growth rate of 17 5   The stock has a solid one year return of around 84 7  Accelerate Diagnostics has an expected long term adjusted earnings growth of 30   The stock added roughly 15 9  over the last three months More Stock News  This Is Bigger than the iPhone  It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 ,2017-06-11,Zacks Investment Research,https://www.investing.com/analysis/cardiovascular-systems-(csii)-hits-52-week-high-on-solid-q3-200194556,200194556
30194,251709,CSII,Positive Market Trends Aid Cardiovascular Systems Amid Woes,opinion,On Jan 16  we issued an updated research report on Cardiovascular Systems  Inc    NASDAQ CSII    The company is a medical device manufacturer developing and commercializing innovative solutions to treat patients suffering from peripheral and coronary arterial diseases including those with arterial calcium Shares of Cardiovascular Systems have outperformed the broader in the past 30 days  The stock is up 10 2   better than the broader industry s 2 9  gain  Cardiovascular Systems  Inc  Price    A strong revenue performance has been consistently contributing to the upside in earnings of late  Also  an improved gross margin is encouraging  Additionally  the company s fiscal 2018 guidance instills confidence in investors Cardiovascular Systems firmly stands to gain from several favorable trends existing in the peripheral artery disease  PAD  as well as coronary artery disease  CAD  market spaces  Per estimates delivered by the American Heart Association  as many as 8 12 million Americans suffer from PAD  Moreover  an aging population coupled with increasing incidence of diabetes and obesity  is further likely to propel the prevalence of PAD  This offers a huge scope for the unique PAD Orbital Atherectomy System  OAS  of Cardiovascular Systems Per management  another major concern is underdiagnosis with patients failing to show symptoms and or physicians misinterpreting the same  So we believe  the PAD market space is still underpenetrated at large  providing Cardiovascular Systems with significant opportunities to expand in the market place Among the recent developments  this St  Paul  MN based Cardiovascular Systems has received an FDA approval for Radial Access Diamondback 360 Peripheral Orbital Atherectomy Device  Besides  the company has been conferred with a grant from Japan s Ministry of Health  Labor and Welfare for the Diamondback 360 Coronary OAS Micro Crown On the flip side  the company operates in the competitive medical device industry  significantly affected by product introductions  Failure to expand business overseas might hamper growth  Also  on the profitability front  Cardiovascular Systems has a long history of net losses since its inception in 1989 with no immediate recovery in sight  Management still expects to incur net loss of  1  1 9 million or loss per share of 3 6 cents in the second quarter of fiscal 2018 Zacks Ranks   Key PicksCardiovascular Systems carries a Zacks Rank  3  Hold   Some better ranked stocks in the broader medical space are Bio Rad Laboratories Inc    NYSE BIO    Neogen Corporation   NASDAQ NEOG   and Humana Inc    NYSE HUM    each sporting a Zacks Rank  1  Strong Buy   You can see  Bio Rad has a massive projected growth rate of 141 46  for the first quarter of 2018  The stock has outperformed the broader industry  gaining 14 2  in the last three months Neogen has a long term projected growth rate of 15   In the last six months  the stock has rallied 21 6   surpassing the industry s gain Humana has an expected growth rate of 15 6  in the first quarter of 2018  Over a month  the stock has gained 9 7  above the industry s return Zacks Top 10 Stocks for 2018In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2018 Last year s 2017 Zacks Top 10 Stocks portfolio produced double digit winners  including FMC Corp  NYSE FMC   and VMware which racked up stellar gains of  67 9  and  61   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ,2018-01-17,Zacks Investment Research,https://www.investing.com/analysis/positive-market-trends-aid-cardiovascular-systems-amid-woes-200281448,200281448
30197,251712,CSII,Cardiovascular Systems  Micro Crown Now Available In Japan ,opinion,Cardiovascular Systems  Inc    NASDAQ CSII   recently announced the commercial launch of Diamondback 360 Coronary OAS Micro Crown  Micro Crown  in Japan  following the country s Pharmaceuticals and Medical Devices Agency   PMDA   approval in March 2017 The device has been approved for frontline treatment of severe calcified lesions and for facilitating access to arteries for percutaneous coronary interventions  PCI  thereafter  Interestingly  the approval was given following presentation of favorable 1 year data from its Coronary Orbital Atherectomy System Study  COAST  The company noted that  with over 280 000 PCIs per year  of which 10 20  are projected to be extremely calcified  the Japan market for coronary interventions holds huge potential  Moreover  Micro Crown has received reimbursement approval  which will be implemented fully this month Cardiovascular Systems expects to successfully complete an initial Micro Crown stocking order in the third quarter of fiscal 2018 with Medikit Co   Ltd  as the exclusive distribution partner in Japan Recent DevelopmentsIn a bid to expand the peripheral and coronary interventions product portfolio  by adding supporting complementary products  Cardiovascular Systems signed two partnerships in January 2018  First  the company signed an exclusive U S  distributor agreement with OrbusNeich for its OrbusNeich balloon products in the United States  The company also entered into an original equipment manufacturer  OEM  agreement with Integer Holdings   NYSE ITGR    Per the agreement  Cardiovascular Systems will manufacture self branded ZILIENT guidewires to facilitate tip resilience and crossability in difficult arterial lesions Cardiovascular Systems has been pursuing product improvements and evaluating new technologies to strengthen and broaden its portfolio of powerful micro invasive tools  In 2017  the company received FDA approval for the Micro Crown system to facilitate stent delivery in patients with coronary artery disease  CAD  Market PotentialThe global market for coronary heart diseases is expected to see huge demand on the back of growing cases of chronic diseases  Moreover  going by a report published by Technavio  the global market for coronary heart diseases is expected to see a CAGR of more than 5  between 2017 and 2021  Considering the company s efforts  we believe it is well positioned to gain from the favorable trend in the CAD space Share Price MovementCardiovascular Systems has been outperforming the broader  over the past month  The stock has gained 2 6  compared with the industry s 1 3  rise Zacks Rank   Key PicksCardiovascular Systems carries a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are PerkinElmer   NYSE PKI   and Bio Rad Laboratories   NYSE BIO   Bio Rad Laboratories has a Zacks Rank  2  Buy   The company has a long term expected earnings growth rate of 25   You can see PerkinElmer has a long term expected earnings growth rate of 12 3   The stock carries a Zacks Rank  2 Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-02-04,Zacks Investment Research,https://www.investing.com/analysis/cardiovascular-systems-micro-crown-now-available-in-japan-200287138,200287138
30245,251760,CSII,Cardiovascular Systems  CSII  Swings To Earnings In Q3,opinion,Cardiovascular Systems  Inc    NASDAQ CSII   reported adjusted earnings per share of 3 cents in third quarter fiscal 2017  reflecting a massive improvement from the year ago quarter s adjusted loss of 47 cents  The quarter s number compared favorably with the Zacks Consensus Estimate of a loss of 4 cents The year over year improvement was primarily backed by revenue growth and lower operating expenses on account of the company s cost realignment actions Quarter in DetailsCardiovascular Systems posted revenues of  52 1 million in the fiscal third quarter  marking a year over year increase of 17 3   The figure surpassed the Zacks Consensus Estimate of  51 million Cardiovascular Systems  Inc  Price  Consensus and EPS Surprise    Per management  the strong top line performance exhibited the company s efforts to stabilize and support its field sales representatives During the reported quarter  Cardiovascular Systems sold over 15 700 devices  which generated 92  of revenues  The company added 37 new peripheral accounts and 35 coronary accounts Coronary device revenues improved 28  year over year to  13 5 million and peripheral device revenues rose 14  to  38 7 million MarginGross margin in the reported quarter was 78 6   down 174 basis points  bps  year over year  primarily on account of a 27 6  rise in cost of goods sold Meanwhile  selling and administrative  SG A  expenses contracted 11 8  to  37 3 million and research and development  R D  expenses fell 5 5  to  5 4 million  The resultant adjusted operating expenses declined 11 1  to  42 7 million  primarily exhibiting management s cost realignment initiatives and timing of studies and projects  Consequently  operating loss narrowed to a loss of  1 7 million from a loss of  12 3 million a year ago Financial positionThe company exited the third quarter of fiscal 2017 with cash and cash equivalents of  103 1 million  compared with  79 2 million at the end of second quarter 2017 OutlookCardiovascular Systems issued its fourth quarter fiscal 2017 guidance  The company expects revenues in the range of  51 5  52 5 million  The current Zacks Consensus Estimate for fourth quarter fiscal 2017 revenues is pegged at  52 8 million  slightly above the company s guidance Moreover  the company expects gross profit to account for 81  of revenues  while operating expenses are estimated at around  43 5 million The company expects to incur net loss of  2 0  1 4 million or loss per share of 6 4 cents in the fourth quarter  The current Zacks Consensus Estimate is pegged at a loss of 2 cents  narrower than the company s guided range Our TakeCardiovascular Systems delivered impressive third quarter 2017 results  Additionally  the company s lower operating expenses drove the year over year improvement in the earnings figure  Strong revenue performance also contributed to the upside in earnings  Per management  the company delivered improved results demonstrating significant progress in revenue growth  while moving toward positive cash flow and profitability Moreover  the company achieved several milestones during the quarter  Its Diamondback 360 coronary micro crown orbital atherectomy system was approved for the treatment of severely calcified coronary artery lesions by the Ministry of Health  Labor and Welfare in Japan and by the U S  FDA  The six month favorable data from the LIBERTY 360  trial were also presented at the International Symposium on Endovascular Therapy Zacks Rank   Key PicksCardiovascular Systems currently has a Zacks Rank  3  Hold   Better ranked medical stocks include Hologic  Inc    NASDAQ HOLX    Baxter International Inc    NYSE BAX   and Progenics Pharmaceuticals  Inc    NASDAQ PGNX    Hologic and Progenics Pharmaceuticals sport a Zacks Rank 1  Strong Buy   while Baxter International carries a Zacks Rank  2  Buy   You can see Hologic gained 33 6  in the last one year  in comparison to the S P 500 s 16 6   The company has a stellar four quarter average earnings surprise of over 4 16  Baxter International rose around 23 4  in the last one year  in comparison to the S P 500  It has a four quarter average earnings surprise of 17 14  Progenics Pharmaceuticals gained 56 6  in the past one year  better than the S P 500 mark  It has a four quarter average earnings surprise of 8 45  Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-05-04,Zacks Investment Research,https://www.investing.com/analysis/cardiovascular-systems-(csii)-swings-to-earnings-in-q3-200187101,200187101
30298,251813,CSII,DENTSPLY  XRAY  Beats On Earnings In Q3  Misses Revenue,opinion,DENTSPLY SIRONA Inc    NASDAQ XRAY   reported adjusted earnings per share  EPS  of 66 cents in the third quarter of 2016  beating the Zacks Consensus Estimate by 3 cents  Earnings were flat on a year over year basis Notably  DENTSPLY repurchased an additional  100 million of shares and paid  18 million in dividends during the third quarter Quarter DetailsNet sales increased to  954 2 million from  648 9 million in the year ago period  However  the figure came below the Zacks Consensus Estimate of  960 0 million  Sales  excluding precious metals  of the combined businesses grew 49 2  at constant currency  cc  exchange rates  Net sales  excluding precious metal content  were positively impacted by approximately 40 basis points due to the weakening of the U S  dollar over the prior year period Sales  excluding precious metals  of the combined businesses grew 49 2  at constant currency  cc  exchange rates In the quarter  U S  sales surged 33 9  to  334 2 million  while net sales in Europe increased 41 3  to  348 3 million  Sales  excluding precious metals  of the combined business fell 3 1  at cc in the U S   while European sales rose 1 6  Net sales in Rest of World increased 92 6  to  256 7 million  Sales  excluding precious metals  in Rest of World of the combined businesses improved 3 8  at cc Segment DetailsPost completion of the DENTSPLY SIRONA merger  the business has been organized into two reporting segments  Dental   Healthcare Consumables and Technologies  Dental   Healthcare Consumables comprises preventive  restorative  instruments  endodontic and laboratory dental products  as well as consumable medical device products  Sales increased 7  to  497 2 million  At cc  sales of the combined entity were flat year over year in the quarter Technologies consist of dental implants  CAD CAM systems  imaging systems  treatment centers and orthodontic products  Net sales increased 168 5  to  442 million  At cc  sales of the combined business climbed 0 9  in the quarter  Internal sales growth of the combined business was 0 2   DENTSPLY SIRONA Price  Consensus and EPS Surprise   GuidanceFor full year 2016  the company raised the bottom end of its previous EPS guidance range of  2 70 to  2 80 and now anticipates adjusted EPS in the range of  2 75 to  2 80 Zacks Rank   Key PicksCurrently  DENTSPLY carries a Zacks Rank  4  Sell  Better ranked stocks in the broader medical space include Cardiovascular Systems Inc    NASDAQ CSII    Exelixis  Inc    NASDAQ EXEL   and IDEXX Laboratories  Inc    NASDAQ IDXX    Notably  all the companies sport a Zacks Rank  1  Strong Buy   You can see  Cardiovascular Systems represents a stellar one year return of 55 1   Notably  the company has an expected long term growth rate of 22 5  Exelis has a stupendous one year return of 66 1   In the last reported quarter  the company registered an impressive earnings surprise of 40 74  IDEXX Laboratories represents a promising one year return of 48 6   The company has a long term expected growth rate of almost 14 8  Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-11-03,Zacks Investment Research,"https://www.investing.com/analysis/dentsply-(xray)-beats-on-earnings-in-q3,-misses-revenue-200162931",200162931
30299,251814,CSII,Masimo  MASI  Beats On Q3 Earnings  Revenues  Guides Up ,opinion,Masimo Corp    NASDAQ MASI   reported earnings of 47 cents per share in the third quarter of 2016  which increased from 36 cents in the year ago quarter  The figure also came above the Zacks Consensus Estimate of 42 cents Revenues improved almost 9 9  year over year to  167 6 million  well ahead of the Zacks Consensus Estimate of  166 million  We note that product revenues increased 10 8  to  160 3 million in the quarter  Quarter DetailsWorldwide direct product revenues  85 7  of product revenues  increased 14 3  to  137 4 million  OEM sales  14 3  of product revenues  fell 6 1  to  22 9 million from the year earlier quarter  Revenue from sales of Masimo rainbow products rose 5 0  year over year to  18 0 million During the reported quarter  the company shipped approximately 45 800 SET Pulse Oximeters and rainbow SET Pulse CO Oximeters  excluding handheld units  Per company estimation  its worldwide installed base as of Oct 1  2016 was 1 482 000 units  up 6 6  from 1 390 000 units as of Oct 3  2015 Financial ConditionAs of Oct 1  2016  total cash and cash investments were  126 0 million compared with  132 3 million as of Jan 2  2016  During the nine month period ending Oct 1  2016  the company generated  87 8 million in cash from operations and received  26 1 million in proceeds from stock option exercises  During the same nine month period  the company repurchased 1 5 million shares at a total cost of  63 4 million and made  77 5 million in repayments on the company s line of credit GuidanceFor 2016  Masimo raised the total revenue guidance to approximately  692 million from  689 million expected previously Product revenues are expected at around  661 million  up from the previous guidance of  658 million  Meanwhile  Royalty revenue projection was raised to  31 million from the previous  30 million Masimo now projects earnings of  2 13 per share  up from the earlier projected figure of  2 01  MASIMO CORP Price  Consensus and EPS Surprise   Zacks Rank and Other Key PicksCurrently  Masimo carries a Zacks Rank  3  Hold  Better ranked stocks in the broader medical space include Cardiovascular Systems Inc    NASDAQ CSII    Exelixis  Inc    NASDAQ EXEL   and IDEXX Laboratories  Inc    NASDAQ IDXX    Notably  Exelis and Cardiovascular systems sport a Zacks Rank  2  Buy   However  IDEXX has a Zacks Rank  1  Strong Buy   You can see  Cardiovascular Systems represents a stellar one year return of 52 8   Notably  the company has an expected long term growth rate of 22 5  Exelis has a stupendous one year return of almost 94   In the last reported quarter  the company registered an impressive earnings surprise of 40 74  IDEXX Laboratories represents a promising one year return of 50 23   The company has a long term expected growth rate of almost 14 8  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-11-06,Zacks Investment Research,"https://www.investing.com/analysis/masimo-(masi)-beats-on-q3-earnings,-revenues;-guides-up-200163206",200163206
30308,251823,CSII,Pacific Biosciences  PACB  Q3 Loss Narrower Than Expected,opinion,"Headquartered in Menlo Park  CA  Pacific Biosciences of California Inc    NASDAQ PACB    a pioneer in the field of single molecule long resequencing  reported a loss of 19 cents per share in the third quarter of 2016  a penny narrower than the Zacks Consensus Estimate Notably  the figure was also narrower than the loss of 27 cents reported in the year ago quarter Revenues of  25 1 million surpassed the Zacks Consensus Estimate of  24 million and crushed the year ago figure by 78 6   Product revenues were up 138 4  to almost  18 million  Service revenues grew 26 2  from the year ago quarter to  3 4 million Quarter HighlightsPacific Biosciences witnessed lower than expected orders in the third quarter and announced unrestricted  Single Molecule  Real Time  SMRT  Sequencing  Cell shipments In August  the company inked a multi year partnership with HistoGenetics  an international leader in HLA typing  Notably  per the contract  HistoGenetics will perform HLA typing using PacBio sequencing which is likely to boost demand in the days ahead Meanwhile  Pacific Biosciences got featured in over 1800 publications in the third quarter  courtesy of its smart sequencing platform  Of all the publications  two papers based their research on describing  de novo assembly of the genomes of individuals from Korea and China   In this regard  de novo assembly methods are used in the process of sequencing genomes  set of genes in living bodies  Also  Pacific Biosciences received orders for 20 PacBio instruments during the third quarter  At the end of the quarter  the company s backlog was over 40 systems Pacific Biosciences and Roche plans for a Sequel based product launch which is expected to take place by early to mid 2017 Revenue DetailsInstrument revenues surged more than 400  year over year to  11 5 million driven by growing Sequel instrument shipments  Notably  the company shipped and installed more than 30 Sequel instruments in the quarter  Currently  the company has a solid base of 75 installed sequel systems Consumable revenues totaled  6 5 million  up 22  on a year over year basis  Consumable comprises proprietary single molecule  real time  SMRT  Cells and reagent kits  which are required to be used in combination with the PacBio RS II instrument to attain the desired results Margin DetailsGross profit came in at  12 6 million  gross margin was 50 3   as compared with  6 5 million in the year ago quarter  The rise in gross profit and margin was supported by higher margin sales of the SequelTM System  which was introduced in the fourth quarter of 2015 Research   development  R D  expenses increased 8 1  year over year to  17 4 million  while selling  general   administrative  SG A  expenses were up 9 9  to  11 8 million  The increased can be attributed to compensation  non cash stock compensation  and chip development expenses Balance SheetCash and investments at the end of third quarter was  87 3 million  compared with  82 3 million as of Dec 31  2015 GuidancePacific Biosciences registered lower instrument bookings in the third quarter  resulting in a decline in backlog at the end of the quarter  For the above mentioned reasons  management is apprehensive that it might fail to achieve its revenue target of  93 million in full year 2016  Currently  total revenue for the year is projected in the band of  86 million to  90 million PACIFIC BIOSCI Price  Consensus and EPS Surprise
    The company forecasts product and service revenue growth between 55  and 65  for the year  compared to the previous forecast of a 70  increase  However  for the fourth quarter  the company expects its contractual revenues to decrease by  23 5 million on a year over year basis For the full year  management expects average gross margin percentage to be less than 50   In fact  operating expense is forecasted to grow in the band of 10  to 12  in the full year Zacks Rank   Key PicksCurrently  Pacific Biosciences has a Zacks Rank  3  Hold  Better ranked stocks in the broader medical space include Cardiovascular Systems Inc    NASDAQ CSII    Exelixis  Inc    NASDAQ EXEL   and IDEXX Laboratories  Inc    NASDAQ IDXX    Notably  Cardiovascular Systems and Exelixis carry a Zacks Rank  2  Buy  while IDEXX Laboratories sports a Zacks Rank  1  Strong Buy   You can see  Cardiovascular Systems represents a stellar one year return of 52 8   Notably  the company has an expected long term growth rate of 22 5  Exelixis has a stupendous one year return of almost 94   In the last reported quarter  the company registered an impressive earnings surprise of 40 74  IDEXX Laboratories represents a promising one year return of 50 23   The company has a long term expected growth rate of almost 14 8  Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-11-06,Zacks Investment Research,https://www.investing.com/analysis/pacific-biosciences-(pacb)-q3-loss-narrower-than-expected-200163189,200163189
30309,251824,CSII,Why Cardiovascular Systems  CSII  Could Be A Potential Winner,opinion,It can be very difficult to find companies that are both flying under the radar  and still might have potential for gains  Many times  stocks are off investors  radar screens for a reason  though there are some hidden gems that could be worth uncovering by those with a high risk tolerance   One way to find these underappreciated stocks is by looking at companies that haven t seen their share prices move higher lately  but have observed analysts raising earnings estimates for their stock  This trend could signal that investors haven t quite embraced the rising estimate story yet  but that the potential for a big move higher is definitely there One such company that looks well positioned for a solid gain  but has been overlooked by investors lately  is Cardiovascular Systems Inc    NASDAQ CSII    This Medical Products industry stock has actually seen estimates rise over the past month for the current fiscal year by about 71 4   But that is not yet reflected in its price  as the stock lost 4 8  over the same time frame CARDIOVASCLR SY Price and Consensus   You should not be concerned about the price remaining muted going forward  This year s expected earnings growth over the prior year is 90 6   which should ultimately translate into price appreciation And if this isn t enough  CSII currently carries a Zacks Rank  2  Buy  which further underscores the potential for its outperformance  See the performance of Zacks  portfolios and strategies here    You can see  So if you are looking for a stock flying under the radar that is well equipped to bounce down the road  make sure to consider Cardiovascular Systems  Solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for CSII and that now might be an interesting buying opportunity Confidential from ZacksBeyond this Tale of the Tape  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-11-06,Zacks Investment Research,https://www.investing.com/analysis/why-cardiovascular-systems-(csii)-could-be-a-potential-winner-200163151,200163151
30310,251825,CSII,Wright Medical  WMGI  Q3 Loss Narrower Than Expected,opinion,"Wright Medical Group N V    NASDAQ WMGI   reported adjusted loss of 19 cents per share  way narrower than the loss of 51 cents reported in the year ago quarter and the Zacks Consensus Estimate of a loss of 20 cents Net sales increased 96 3  year over year to  157 3 million but missed the consensus estimate of  158 million Quarter HighlightsThe company s newly introduced products   SIMPLICITI and ASCEND FLEX shoulder systems   raked in considerable growth and also hold promise going forward  Notably  the INFINITY total ankle replacement system  AUGMENT Bone Graft and SALVATION limb salvage system boosted Wright Medical s trajectory in the third quarter  The U S  biologics business was again the fastest growing segment  which grew 45  in the third quarter Coming to mergers and integrations  Wright Medical has completed over 80  of its  300 integration milestone  by the end of the third quarter  In fact  management has already completed the integration of the company s sales forces globally The integration of the U S  lower extremities sales force was done in the last quarter  and this quarter  Wright Medical closed the acquisition of the U S  upper extremities sales  ahead of the stipulated schedule Quarter in DetailWright Medical currently reports revenues under one segment   Total Extremities   Biologics  Consolidated sales at the segment in the U S  increased 95 5  from the year ago quarter to almost  118 million Internationally  sales in the extremities and biologics business were up 9  year over year to  39 2 million  driven by strong growth in the Canadian and Australian markets Total Extremities   Biologics include four sub segments  namely  Lower Extremities  Upper Extremities  Biologics and Sports Med   Other  The U S  lower extremities business sales increased 4  in the third quarter  However  the U S  lower extremities business was affected by revenue dis synergies in the range of 5  to 6  in the quarter Margin DetailsSelling  general and administrative expenses accounted for 78 5  of total revenues in the third quarter  totaling  129 8 million  a contraction of 420 basis points  bps  from the year ago quarter  This can be attributed to reduced cost structure and other cost synergies  Notably  expenses on Research and Development  R D  grew 30 4  year over year WRIGHT MED GRP Price  Consensus and EPS Surprise
    Wright Medical recorded adjusted EBITDA of  5 7 million from continuing operations at the end of the third quarter  As a percentage of revenues  adjusted gross margins from continuing operations was a stellar 78 2   Notably  this reflected the strength of the company s market position GuidanceFor the full year  Wright Medical narrowed the guidance for net sales to the range of  677 million to  683 million from the previous  675 million to  685 million  Wright Medical expects dis synergies for revenues of around  15 million for 2016  The company expects adjusted EBITDA from continuing operations in the band of  43 million to  48 million versus the previous range of  40 million to  45 million  Wright Medical forecasts adjusted loss from continuing operations  including share based compensation  in the range of 52 cents to 47 cents Zacks Rank   Key PicksCurrently  Wright Medical carries a Zacks Rank  3  Hold  Better ranked stocks in the broader medical space include Cardiovascular Systems Inc    NASDAQ CSII    Exelixis  Inc    NASDAQ EXEL   and IDEXX Laboratories  Inc    NASDAQ IDXX   Notably  Cardiovascular Systems and Exelixis carry a Zacks Rank  2  Buy  while IDEXX Laboratories sports a Zacks Rank  1  Strong Buy   You can see  Cardiovascular Systems represents a stellar one year return of 55 3   Notably  the company has an expected long term growth rate of 22 5  Exelixis has a stupendous one year return of almost 102 6   In the last reported quarter  the company registered an impressive earnings surprise of 40 74  IDEXX Laboratories represents a promising one year return of 50 6   The company has a long term expected growth rate of almost 14 8  Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-11-07,Zacks Investment Research,https://www.investing.com/analysis/wright-medical-(wmgi)-q3-loss-narrower-than-expected-200163421,200163421
30311,251826,CSII,PerkinElmer  PKI  Beats On Earnings  Misses Revenue In Q3,opinion,"Waltham  MA based PerkinElmer Inc   NYSE PKI    a worldwide provider of products  services and solutions to the diagnostics  research  and laboratory services markets  reported third quarter 2016 earnings of 68 cents per share  which beat the Zacks Consensus Estimate by 2 cents Additionally  the figure surpassed management s guided range of 65 cents to 67 cents  Earnings also improved 3  year over year However  adjusted revenues fell 2 7  on a year over year basis to  548 2 million  which lagged the Zacks Consensus Estimate of  572 million In fact  revenues were below management s guided range of  570  575 million  owing to cutthroat competition in the radiochemicals and other capital intensive business segments  Quarter HighlightsYear to date  PerkinElmer witnessed 2  organic revenue growth to  5 million  by the end of the third quarter The company reorganized the Diagnostics business segment and formed an applied genomics group under the platform to better serve the fast growing genomics market  Per management  this will fortify PerkinElmer s market position as an integrated provider offering preclinical and clinical applications PerkinElmer has gained considerable prominence in the markets in the third quarter with its series of innovative product launches  Per management  new product introductions will generate an incremental  40 million in revenue for the full year Taking the end markets into consideration  the company witnessed strong growth in the Diagnostics  healthy pharma and biotech segments in the quarter Lower than estimated growth in academic and government sales  experiencing low single digit organic revenue declines  and flat industrial revenues were major drags  Additionally  growth in the Medical Imaging segment declined in double digits in the quarter under review Region wise  solid organic revenue growth from China and India was noticed  demonstrating a year over year growth of growth of greater than 20  and 10  respectively in the third quarter Quarter in DetailsHuman Health  61 7  of total revenues  revenues deteriorated 1 6  year over year to  338 4 million  while Environmental health  38 3  of total revenues  revenues decreased 4 5  year over year to  209 8 million in the quarter  due to softer capital equipment end markets  Environmental Health organic revenues declined 5   while Human health remained flat year over year  On the Environmental front  the company introduced products in China  a standout region for PerkinElmer in terms of analytical equipment demand  However  lower sales in the U S  and Europe caused a drag on Environmental sales Coming to the Diagnostics Business segment  the company witnessed high single digit organic revenue growth in the third quarter  Life Science Solutions organic revenues declined in low single digits in the quarter Margin DetailsAdjusted gross margin was 48 9   up 170 basis points  bps  year over year  driven by successful cost cutting  Lean  initiatives  volume leverage and favorable product mix PERKINELMER INC Price  Consensus and EPS Surprise
    Adjusted selling  general   administrative  SG A  expenses  as a percentage of revenues  were 24   down 5 9  from the year ago quarter  Research and Development  R D  expenses  as a percentage of revenues  expanded 50 bps in the quarter to  33 1 million  thanks to incremental investments in product development  primarily under reproductive health  Adjusted operating margin expanded approximately 140 bps in the reported quarter GuidanceManagement at PerkinElmer intends to focus on continued operational improvement to counter the sluggish growth in the environment business going ahead Diagnostic Business is expected to prove accretive in the fourth quarter  However  lower than estimated demand in the academic and government segments and sluggishness in the developed markets are likely to mar opportunities for PerkinElmer For the fourth quarter of 2016  revenues are likely to represent low single digit organic growth and are forecasted in the range of  610 million to  620 million  Adjusted earnings are projected in the range of 85 cents to 87 cents per share Adjusted earnings per share for the full year are projected in the band of  2 75 to  2 77  compared to the previous range of  2 75 to  2 85 Zacks Rank   Stocks to ConsiderCurrently  PerkinElmer has a Zacks Rank  4  Sell  Better ranked stocks in the broader medical space include Cardiovascular Systems Inc    NASDAQ CSII    Exelixis  Inc    NASDAQ EXEL   and IDEXX Laboratories  Inc    NASDAQ IDXX   Notably  Cardiovascular Systems and Exelixis carry a Zacks Rank  2  Buy  while IDEXX Laboratories sports a Zacks Rank  1  Strong Buy   You can see  Cardiovascular Systems represents a stellar one year return of 55 3   Notably  the company has an expected long term growth rate of 22 5  Exelixis has a stupendous one year return of almost 102 6   In the last reported quarter  the company registered an impressive earnings surprise of 40 74  IDEXX Laboratories represents a promising one year return of 50 6   The company has a long term expected growth rate of almost 14 8  Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-11-07,Zacks Investment Research,"https://www.investing.com/analysis/perkinelmer-(pki)-beats-on-earnings,-misses-revenue-in-q3-200163493",200163493
30312,251827,CSII,Allscripts  MDRX  Beats On Earnings In Q3  Revenues Miss,opinion,"Allscripts Healthcare Solutions  Inc    NASDAQ MDRX   reported third quarter 2016 earnings of 11 cents per share  a penny above the Zacks Consensus Estimate  The figure also improved from 10 cents in the year ago quarter Revenues increased from  355 million in the year ago period to  404 million  However this came below the Zacks Consensus Estimate of  415 million Quarter DetailsSoftware delivery revenues in the quarter totaled  253 million on a GAAP basis and  262 million on a non GAAP basis  reflecting an increase of 10  and 14   respectively  year over year At the Client services segment  revenue totaled  140 million on a GAAP basis and  142 million on a non GAAP basis  up 13  and 15   respectively  year over year Gross margin was 42 3  on a GAAP basis and 47 6  on a non GAAP basis compared with 43 3  and 46 4   respectively  in the third quarter of 2015 Total operating expenses  consisting of selling  general and administrative and research and development expenses  were  144 million  reflecting a 4  increase year over year  The increase in operating expense was due to higher expenses from the consolidation of Netsmart Financial ConditionAs of Sep 30  2016  total cash and cash investments were  77 3 million compared with  116 9 million as of Dec 31  2015  During the nine month period ended Sep 30  2016  the company generated  185 million in cash from operations  marking a 44  increase year over year  ALLSCRIPTS HLTH Price  Consensus and EPS Surprise
    GuidanceAllscripts provided financial guidance for the fourth quarter of 2016  The projections include non GAAP revenue between  420 million and  435 million  based on sequential quarterly improvement for Standalone Allscripts and Netsmart   adjusted net EBITDA between  70 million and  80 million  and non GAAP earnings per share between 14 cents and 16 cents per diluted share           Zacks Rank   Key PicksCurrently  Allscripts has a Zacks Rank  3  Hold  Better ranked stocks in the broader medical space include Cardiovascular Systems Inc    NASDAQ CSII    Exelixis  Inc    NASDAQ EXEL   and IDEXX Laboratories  Inc    NASDAQ IDXX    Notably  IDEXX sports a Zacks Rank  1  Strong Buy  and Exelis and Cardiovascular Systems carry a Zacks Rank  2  Buy   You can see  Cardiovascular Systems represents a stellar one year return of 68 2   Notably  the company has an expected long term growth rate of 22 5  Exelis has a stupendous one year return of almost 152 9   In the last reported quarter  the company registered an impressive earnings surprise of 40 74  IDEXX Laboratories represents a promising one year return of 54 2   The company has a long term expected growth rate of almost 14 8  Zacks  Top Investment Ideas for Long Term ProfitHow would you like to see our best recommendations to help you find today s most promising long term stocks  Starting now  you can look inside our portfolios featuring stocks under  10  income stocks  value investments and more  These picks  which have double and triple digit profit potential  are rarely available to the public  But you can see them now ",2016-11-10,Zacks Investment Research,"https://www.investing.com/analysis/allscripts-(mdrx)-beats-on-earnings-in-q3,-revenues-miss-200164138",200164138
30313,251828,CSII,Cardiovascular Systems At 52 Week High On Huge Prospects,opinion,"Share price of St Paul  MN based Cardiovascular Systems Inc    NASDAQ CSII   reached a new 52 week high of  26 45 on Nov 15  eventually closing a tad lower at  26 34  The company gained 84 32  over the past year  much better than the S P 500 s 6 34  over the same period  It has added roughly 74 21  year to date compared to the S P 500 s 6 68  
Meanwhile  we note that Cardiovascular Systems carries a Zacks Rank  2  Buy   The stock has a market cap of  870 88 million 
The company is an attractive growth stock with an impressive one year projected earnings growth rate of 90 60  as compared to the industry s average of 7 80  CARDIOVASCLR SY Price and Consensus

   Estimate revision trend for the company also looks pretty favorable at the moment  In the past 60 days  four estimates have gone up with no downward revision  The trend has been quite favorable with estimates improving from a loss of 15 cents a share to a loss of 6 cents in the past 60 days 
The company s current year figures also hold promise  with five estimates moving higher over the past two months with no downward revision  The consensus estimate trend has also been encouraging over the same time period  narrowing from a loss of 56 cents per share to a loss of 16 cents over the last 60 days 
We note that in the last reported first quarter 2017  Cardiovascular Systems reported a loss of 6 cents per share  narrower than the Zacks Consensus Estimate of a loss of 18 cents  The four quarter average earning surprise is a positive 31 81  
The company also has an impressive Growth Style Score of A  Our Growth  highlights all the vital metrics of the company s financials to obtain a true picture of the quality and sustainability of its growth  Our research shows that stocks with Style Scores of  A  or  B  when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  offer the best investment opportunities 
Growth Catalysts
Cardiovascular Systems continues to grow strongly on the back of providing medical evidence to the physician community  Recently  it presented the 30 day favorable results from its LIBERTY 360  study in a late breaking presentation at the 2016 Amputation Prevention Symposium  AMP  in Chicago 
The results demonstrated high rates of procedural lesion treatment success and freedom from MAE  as well as quality of life improvements  across all Rutherford classes  Also  Cardiovascular Systems initiates largest randomized trial to study Coronary Atherectomy for calcified coronary lesions at Transcatheter Cardiovascular Therapeutics Conference  All these can be considered to be important milestones delivered by the company 
The market is also upbeat since the company s release of impressive first quarter 2017 results  Revenues rose 14  to  49 8 million from the prior year quarter  also coming in above the company s guided range  The upside in revenues can also be attributed to the strength in the coronary and peripheral segments The quarterly net loss of  1 9 million was also better than estimated  driven by strong revenue  improved gross margin and lower operating expenses  As per management  the results marked the third consecutive quarter of financial improvement  demonstrating significant progress toward its goal of driving revenues 
Zacks Rank   Key Picks
Cardiovascular Systems currently carries a Zacks Rank  2  Buy   Better ranked medical stocks are Nxstage Medical Inc    NASDAQ NXTM    Baxter International Inc    NYSE BAX   and Bovie Medical Corp    NYSE BVX    Nxstage Medical and Baxter sport a Zacks Rank  1  Strong Buy  while Bovie Medical carries a Zacks Rank  2  Buy   You can see 
Nxstage Medical surged 35 4  over one year compared to the S P 500 s 6 3  over the same period  The company has a four quarter average positive earnings surprise of 50 00  
Baxter International rallied 21 9  in the past one year  comparing favorably with the S P 500 s 6 3   It has a trailing four quarter average positive earnings surprise of 27  
Bovie Medical recorded a 124 2  gain in the past one year  way better than the S P 500 s 6 3   The company has a trailing four quarter average positive earnings surprise of 28 7  
The Best Place to Start Your Stock Search
Today  you are invited to download the full list of 220 Zacks Rank  1  Strong Buy  stocks   absolutely free of charge  Since 1988  Zacks Rank  1 stocks have nearly tripled the market  with average gains of  26  per year  Plus  you can access the list of portfolio killing Zacks Rank  5  Strong Sells  and other private research ",2016-11-16,Zacks Investment Research,https://www.investing.com/analysis/cardiovascular-systems-at-52-week-high-on-huge-prospects-200165083,200165083
30314,251829,CSII,Surging Earnings Estimates Signal Good News For Cardiovascular Systems  CSII  ,opinion,Cardiovascular Systems  Inc    NASDAQ CSII   is a medical device company that could be an interesting play for investors  That is because  not only does the stock have decent short term momentum  but it is seeing solid activity on the earnings estimate revision front as well These positive earnings estimate revisions suggest that analysts are becoming more optimistic on CSII s earnings for the coming quarter and year  In fact  consensus estimates have moved sharply higher for both of these time frames over the past four weeks  suggesting that Cardiovascular Systems could be a solid choice for investors Current Quarter Estimates for CSIIIn the past 30 days  4 estimates have gone higher for Cardiovascular Systems while none have gone lower in the same time period  The trend has been pretty favorable too  with estimates with estimates narrowing from a loss of 15 cents a share 30 days ago  to a loss of 6 cents today  a move of 60  Current Year Estimates for CSIIMeanwhile  Cardiovascular Systems  current year figures are also looking quite promising  with 5 estimates moving higher in the past month  compared to none lower  The consensus estimate trend has also seen a boost for this time frame  narrowing from a loss of 56 cents per share 30 days ago to a loss of 16 cents per share today  an increase of 71 4  CARDIOVASCLR SY Price and Consensus   Bottom LineThe stock has also started to move higher lately  adding 13  over the past four weeks  suggesting that investors are starting to take note of this impressive story  So investors may definitely want to consider this Zacks Rank  2  Buy  stock to profit in the near future  You can see  The Best Place to Start Your Stock SearchToday  you are invited to download the full  up to the minute list of 220 Zacks Rank  1   Strong Buy   stocks   absolutely free of charge  Since 1988  Zacks Rank  1 stocks have nearly tripled the market  with average gains of  26  per year  Plus  you can access the list of portfolio killing Zacks Rank  5   Strong Sells   and other private research ,2016-11-21,Zacks Investment Research,https://www.investing.com/analysis/surging-earnings-estimates-signal-good-news-for-cardiovascular-systems-(csii)-200166125,200166125
30332,251847,CSII,4 Stocks To Watch  IPHI  OI  CSII  JWN,opinion,"Morning Notes
US Futures are slightly lower this morning and European stocks are higher by nearly  1  as the market awaits the results of the Fed s 2 day policy meeting beginning tomorrow  Crude oil slid nearly  2  overnight  pulling energy producers lower  Asian stocks closed higher as the Nikkei closed  1 75  
Technicals

The SPDR S P 500  NYSE SPY  surged higher in yesterday s session  closing on highs and back above the 200 day SMA at  202 81  Support will lie at the 200 day SMA at  202 11  followed by  200   199 52  and the critical pivot zone of  197 60    197 40  Resistance will lie at the high of Friday s range at  202 81  followed by  203 87 and  205 89 
Small Cap Watch List
 Please refer to the momentum scanners displayed live in the chat room for potential plays at the market open  
  Others On Watch  
GW Pharmaceuticals  NASDAQ GWPH 
Economic Calendar
11 00 USDA weekly grain export inspections
Notable Earnings Before Open
NYSE DDD  3D Systems   EPS Est    09  Rev Est   166 38M
Notable Earnings After Close
NONE
March 14th Watch List
Inphi Corporation  NYSE IPHI    A strong move up off 22 support in a short time  This is holding the EMAs and trading under a big top  Looking good here for a move back to 29 50  Long entry will be over 27 75  add spot over 28 07  Stop initially will be 27 30 
Owens Illinois  NYSE OI    A nice liquid reversal setup  After a big curl off the bottom under 14  momentum says we could test the highs here and potentially get back to 17  First stop will be 15 50s  Long entry is over 14 81  add over 15  Stop will be 14 50 to start 
Cardiovascular Systems  NASDAQ CSII    A previous watch lister with a great gap to fill  Looking for a move toward that gap as this thing keeps legging up with higher highs lows  Long entry is over 10 25  stop 10 00  Add spot 10 71  Target will be somewhere on the way to 12 
Nordstrom  NYSE JWN    My favorite place to shop for clothes  but definitely ready for a short first  After a 30  move up in 2016  it could be time for breather  Looking for a short under 56  Room here is down to 54 70 and then 53 15  Alternatives to this with options Apr 16 57 5p debit 3 50 or less  Also  can do a bear call spread for maximum probability  but capped reward or a bear put spread for a debit for something in between ",2016-03-15,Warrior Trading,https://www.investing.com/analysis/economic-calendar---watch-lists-200121617,200121617
30333,251848,CSII,Economic Calendar And Watch Lists  CSII  VIPS  LRCX  UPS,opinion,"US Futures are slightly lower this morning and European stocks are trading lower by   6  after terrorist attacks in Brussels  airport and subway station killed at least 25  Transportation stocks are leading the overall market lower in pre market trading  Asian markets closed mixed 
Technicals

The SPY  NYSE SPY  put in a double bottom at a pivot low in yesterday s session at  203 80  Support will lie at the low of this pivot at  203 80  followed by  202 77 and the 9 EMA at  202 72  Resistance will lie at the high of yesterday s range at  204 94  followed by  205 23 and  205 89 
Small Cap Watch List
Sarepta Therapeutics Inc  NASDAQ SRPT 
Carnival PLC  NYSE CCL 
Economic Calendar
9 00 Jan FHFA house price index expected  0 5 
9 45 Markit preliminary March U S  manufacturing PMI expected  0 6 to 51 9
10 00 March Richmond Fed manufacturing index expected  4 to 0
12 30 Chicago Fed President Charles Evans speaks
Notable Earnings Before Open
NONE
Notable Earnings After Close
NKE  Nike  NYSE NKE    EPS Est    48  Rev Est   8 2B
RHT  Red Hat  NYSE RHT    EPS Est    48  Rev Est   537 20M
SUNE  Sunedison  NYSE SUNE    EPS Est    84  Rev Est   747 34M
March 22nd Watch List
Cardiovascular Systems  NASDAQ CSII    On watch for the third time in the past month  Maybe this will be the time it goes  Long entry over 10 30 10 40  add spot over 10 70  Stop is at 10  Room here is up to 11 85 if we get into the gap 
Vipshop Holdings Limited  NYSE VIPS    After seeing the 20 and 50 EMAs pinch  we can tell it was time to step up or break down  Well  VIPS chose up and is in the beginning of a bull trend  Long over 12 92 13 00  stop 12 50  Room to 13 50 and then 14 60 
Lam Research Corp  NASDAQ LRCX    On reversal watch as this big mover has put up over 25  in a month  I see room here back down to 76  as this has bumped and failed 80 now  Looking for an entry under the lows  78 95  If this moves higher  even better  I will watch to start a short as close to 80 as possible  RSI is in overbought land now 
United Parcel Service  NYSE UPS    A sympathy mover to FDX  this overbought high flier is testing big resistance with an extended daily chart  Looking for a short back down to 103 102 50  Entry will be near 106 or under 105  add spot under 104 ",2016-03-22,Warrior Trading,https://www.investing.com/analysis/economic-calendar---watch-lists-3-22-2016-200122503,200122503
30341,251856,CSII,Haemonetics  HAE  Lags Q4 Earnings  Sales  Margins Drop,opinion,Haemonetics Corporation   NYSE HAE   reported adjusted earnings per share  EPS  of 37 cents in the fourth quarter of fiscal 2016  missing the Zacks Consensus Estimate by 19 6   Moreover  adjusted EPS dropped 21  from the year ago quarter On a reported basis  Haemonetics posted net loss of  8 8 million or 17 cents per share  substantially wider than the year ago quarter s net loss of  2 9 million or 6 cents per share Fiscal 2016 adjusted EPS came in at  1 63  down 11 9  from the comparable year ago period  Total RevenueRevenues grew 7  year over year  up 10  at constant exchange rate or CER benefiting 6 8  from the inclusion of a 53rd week  to  243 2 million in the reported quarter  but missed the Zacks Consensus Estimate of  245 million  According to management  the year over year improvement was primarily driven by strong performance of the company s growth franchises of Plasma and Hemostasis Management  or TEG  These two business franchises delivered  17 million of revenue growth in the fourth quarter Full year revenues came in at  910 million  flat year over year  up 3  at CER  Revenues by Product CategoriesIn the Disposables product category  86 3  of revenues   which comprises Plasma  Blood center and Hospital Disposables  Haemonetics reported revenues of  209 7 million  up 7 7  year over year  This improvement is primarily attributable to the strong performance of Plasma disposables  up 19 7    which outweighed the sluggish performances in Blood center disposables  up 0 2   and Hospital disposables  down 0 7   Software Solutions revenues were up 8 6  at  19 7 million  up 10  at CER  Equipment and Other revenues increased 1 5   up 2  at CER  year over year to  13 9 million MarginsHaemonetics  fourth quarter adjusted gross margin was 41 1   a 760 basis point contraction  The quarter witnessed huge margin deterioration primarily due to currency headwinds  Italian rebate and inventory related charges that impacted gross margin negatively by 490 basis points  The balance of the decline is attributable to the donor inventory valuation reserves Adjusted operating income was  26 million in the fourth quarter  down  9 million  including a  4 million headwind attributable to currency  Adjusted operating margin was 10 6  in the quarter  a contraction of 490 basis points Financial PositionHaemonetics exited fiscal 2016 with cash and cash equivalents of  115 1 million  compared with  160 7 million at the end of fiscal 2015  Capital expenditure was  102 4 million for the fiscal year  down from  122 2 million in the comparable year ago period Haemonetics generated operating cash flow of  121 9 million at the end of fiscal 2016  compared to the year ago figure of  127 2 million  At the end of fiscal 2016  Haemonetics reported free cash flow  before transformation  restructuring costs and VCC capital expenditures  of  58 million  compared to  97 1 million in the comparable year ago period  In the fiscal fourth quarter  management bought back shares worth  61 million in the open market Fiscal 2017 GuidanceHaemonetics expects to provide its fiscal 2017 guidance in its annual Investor Day event on May 10  2016 Our TakeHaemonetics delivered a dismal fourth quarter fiscal 2016 performance with both EPS and revenues failing to meet the mark  The year over year decline in earnings also adds to our disappointment  Unfavorable foreign currency fluctuations primarily played spoilsport  However  on a brighter note  Haemonetics witnessed positive top line improvement across all geographies at CER  except in Europe Product category wise  while the Plasma disposables business retained its strong growth during the reported quarter  a continued challenging blood center disposable market added to our concerns  Going forward  in fiscal 2017  management still expects currency to be a significant dampener for growth  while the Plasma and TEG business are expected to deliver significant growth  Alongside  the company should continue generating strong balance sheet and free cash flow figures  Zacks RankHaemonetics currently carries a Zacks Rank  4  Sell   Some better ranked medical stocks are Baxter International Inc    NYSE BAX    Cardiovascular Systems Inc    NASDAQ CSII   and NuVasive  Inc    NASDAQ NUVA    All the three stocks hold a Zacks Ranks  2  Buy  ,2016-05-03,Zacks Investment Research,"https://www.investing.com/analysis/haemonetics-(hae)-lags-q4-earnings,-sales;-margins-drop-200127541",200127541
30342,251857,CSII,Cardiovascular  CSII  Narrows Loss In Q3  Revenues Beat ,opinion,"Cardiovascular Systems Inc    NASDAQ CSII   reported third quarter fiscal 2016 adjusted net loss per share of 31 cents  narrower than the year ago loss of 34 cents and the company s guidance range of 42 45 cents per share  The adjusted number excludes the impact of certain one time costs of  12 4 million  The Zacks Consensus Estimate of a loss of 44 cents remained way below the company s adjusted number Without these adjustments  Cardiovascular Systems reported loss of 69 cents  compared to loss of 34 cents per share in the year ago quarter According to the company  the improvement in operating loss in the quarter reflects its strategy to align its cost structure with revenue expectations  and is indicative of the disciplined management practices implemented to attain positive cash flow and profitability   
Quarter in DetailsRevenues dipped 1  year over year to  44 5 million  excluding Asahi Guide wire sales last year   but remained ahead of the company s guidance range of  40 5  42 million  The top line also exceeded the Zacks Consensus Estimate of  42 million During the third quarter  Cardiovascular sold over 13 000 devices  representing 92  of revenues  Coronary product revenues improved 31  to  10 5 million  Peripheral revenue demonstrated a 3  sequential increase  led by growth below the knee  In the quarter  the company added 44 new peripheral accounts and 53 coronary accounts MarginGross margin in the reported quarter was 80 4   ahead of the company s target   up 254 basis points year over year  primarily due to unit cost reductions Meanwhile  selling and administrative expenses increased 7 3  to  42 3 million  while research and development expenses decreased 26 1  to  5 7 million  The resultant adjusted operating expenses rose 1 8  to  48 1 million  Consequently  operating loss deteriorated 16  to  12 1 million Financial PositionThe company s cash and cash equivalents were  62 1 million in the fiscal third quarter  compared to  65 3 million at the end of the fiscal second quarter OutlookCardiovascular has provided its fourth quarter fiscal 2016 guidance  The company expects revenues in the range of  45  46 5 million  Moreover  the company anticipates gross margin of 80  in the fourth quarter On the bottom line front  the company expects to deliver net loss in the range of  5 9  6 9 million or loss per share of 18 21 cents  assuming 32 7 million average shares outstanding Our TakeCardiovascular Systems ended the third quarter of fiscal 2016 on a promising note  Loss incurred was narrower than expected and below our projection  Also  the year over year improvement was encouraging  Moreover  after a dismal second quarter  the improving top line performance was a positive  We are encouraged to find the improved stability in the company s territories combined with continued focus and increased success determining high volume of comps translated into better sales productivity Moreover  management is optimistic about engineering enhancements and higher production volumes  which may continue to reduce unit cost for the company in the quarters ahead  We believe this will result in higher gross margin realization for Cardiovascular Systems Zacks RankCardiovascular currently has a Zacks Rank  3  Hold   Some better ranked medical products stocks are Baxter International Inc    NYSE BAX    Capricor Therapeutics  Inc    NASDAQ CAPR   and Cardica Inc    NASDAQ CRDC    All the three stocks hold a Zacks Rank  2  Buy  ",2016-05-04,Zacks Investment Research,"https://www.investing.com/analysis/cardiovascular-(csii)-narrows-loss-in-q3,-revenues-beat-200128328",200128328
30343,251858,CSII,Cardiovascular Systems Seeks Device Approval In Japan ,opinion,Medical device manufacturer Cardiovascular Systems  Inc    NASDAQ CSII   recently announced the submission of its Diamondback 360 Coronary Orbital Atherectomy System  OAS  Micro Crown for marketing approval at the Japan s Pharmaceuticals and Medical Devices Agency  PMDA   The company expects to commence the marketing of this product in Japan from 2018 and is presently looking for a distribution partner there Notably  this device  used to treat severely calcified coronary artery disease for easy stent placement   serves as an enhancement to the company s existing first generation Diamondback 360 coronary OAS Classic Crown  The earlier version is already available in the U S   since its approval in 2013 This second generation OAS integrates a diamond coated tip for immediate engagement in tight lesions  Moreover  the increased mass of the sanding crown permits lower rotational speed compared to the first generation OAS  The unique orbital mechanism of action for both the first and second generation OAS enables continuous flow of blood during treatment The Orbital technology  supported by a large and growing body of medical evidence  has already been used in over 250 000 cases to date  We believe the enhancement of this product will expand Cardiovascular Systems  Coronary Artery Disease  CAD  product portfolio and thereby boost its revenues in Japan for now CAD is a common and life threatening condition that currently is the second most common cause of death in Japan  Percutaneous Coronary Intervention  PCI  is a common non surgical procedure used to pace a stent in CAD patients having plaque in their arteries  According to estimates  significant arterial calcium is present in nearly 40  of patients undergoing a PCI and absence of advanced treatment may lead to major adverse cardiac events  MACE  or even death It is worth noting in this context that as per the company s recently released data from the COAST clinical study  Cardiovascular System s next generation OAS has effectively treated 100 CAD patients  in the U S  and Japan  Evidently the trial results confirmed a 30 day freedom from MACE rate of 85  and a successful stent delivery rate of 99   Surely this outcome paved the way for the aforementioned submission On receiving the approval  Japan will become the first international market to offer a product of Cardiovascular Systems  marking a significant footstep on the company s part to capture substantial shares in the overseas Key Picks in the SectorAt present  Cardiovascular Systems carries a Zacks Rank  3  Hold   Better ranked stocks in the medical sector are NuVasive  Inc    NASDAQ NUVA    Hutchison China MediTech Ltd    NASDAQ HCM   and GW Pharmaceuticals plc   NASDAQ GWPH    While NuVasive and GW Pharmaceuticals sport a Zacks Rank  1  Strong Buy   Hutchison China MediTech carries a Zacks Rank  2  Buy  ,2016-07-07,Zacks Investment Research,https://www.investing.com/analysis/cardiovascular-systems-seeks-device-approval-in-japan-200140574,200140574
30344,251859,CSII,4 Stocks To Watch  EBIO  EXEL  NKTR  PBYI,opinion,"It was a really weird  volatile  up and down day all day on Monday  A kind of consolidation  wedge type day with no resolution  and a mixed close  A lot of stocks we follow had an interesting day  Some of them may be breaking back out  We might just have to wait and see  In the meantime  let s take a look at some of them and see what s going on and what to expect next 
Eleven Biotherapeutics  Inc   NASDAQ EBIO  has a phenomenal chart  They recently signed an exclusive licensing deal with Roche  and keep on climbing  It s a strong rising chart  great OBV  terrific Money Stream   Balance of Power  and great technicals  In the recent action  after spiking and pulling back for three days  it looks like it popped on Monday  up 31 cents to 5 09  or 6 5   on 1 6 million shares  That s a little bit of an increase in volume  I want to see this stock take out the 6 00 range  run up to 8 8 1 4  and then a lot higher down the road  but for now  let s watch that 
Exelixis  Inc   NASDAQ EXEL  has had a fantastic move  having gone from 3 1 2 to 11  and change  formed a wedge  broke back out  and on Monday  it was up 44 cents to 11 44  or 4   on 7 4 million shares  That s the best volume on an up day in a couple weeks  It looks like that if it could get through the spike high at 11 66  we may be looking at 12 3 4 13 short term 
Nektar Therapeutics  NASDAQ NKTR  advanced 57 cents to 17 83  or 3 3   on 785 097 shares traded on Monday  That was the best volume in two weeks  I m convinced that when this one does go  it s going to spike up to 20  and then maybe get to 22 1 2 23  the near term targets  Look for it to break out of the 18 range  and watch it from there 
Puma Biotechnology  Inc   NYSE PBYI  had a nice day on Monday  up 4 56 to 54 65  or 9   on 1 2 million shares  It appears this stock is at key resistance at the 55 1 2 56 range  Monday s high was 55 43  so it s right there  A punch through here is likely to get it up toward 68  which is the next target 
Stocks on the long side included Advaxis  Inc   NASDAQ ADXS   Alder Biopharmaceuticals Inc   NASDAQ ALDR   Arrowhead Research Corp   NASDAQ ARWR   A10 Networks  Inc   NYSE ATEN   ProShares Ultra Nasdaq Biotechnology  NASDAQ BIB   Direxion Daily S P Biotech Bull 3X ETF  NYSE LABU   Cardiovascular Systems Inc   NASDAQ CSII   Eleven Biotherapeutics  Inc   EBIO   Exelixis  Inc   EXEL   Novatel Wireless Inc   NASDAQ MIFI   Momo Inc   NASDAQ MOMO   Nektar Therapeutics  NKTR   Puma Biotechnology  Inc   PBYI   Progenics Pharmaceuticals  Inc   NASDAQ PGNX   Resolute Energy Corporation  NYSE REN   Rovi Corporation  NASDAQ ROVI   Twilio  Inc   NYSE TWLO   and Valeant Pharmaceuticals  NYSE VRX  ",2016-08-23,Harry Boxer,"https://www.investing.com/analysis/ebio,-exel,-nktr,-pbyi-200149422",200149422
30345,251860,CSII,Henry Schein Well Poised On Strategic Buyouts  Pricing Hurts,opinion,On Oct 5  we issued an updated research report on Melville  NY based Henry Schein  Inc    NASDAQ HSIC    a leading distributor of health care products and services across the globe  The company currently carries a Zacks Rank  3  Hold  Henry Schein stands to gain from several trends in its end markets  one of them being customer demographics  According to a recent estimation  between 2015 and 2025  the population aged 45 and older will likely grow approximately 12   This demographic trend is expected to boost the utilization of dental and medical products distributed by the company Of late  Henry Schein has been focused on making prudent acquisitions as part of its expansion strategies  The company has virtually been on an acquisition spree over the last couple of years  In this regard  the latest development is the company s decision to buy an 80  ownership position in Marrodent  one of Poland s largest full service dental distributors Earlier this year  the company acquired an 80 1  interest in Vetstreet  a leading provider of marketing solutions and health information analytics  Another important acquisition has been a 90  ownership stake in Dental Trey  an Italy based distributor of dental consumable merchandise and equipment Henry Schein also boasts a strong cash balance position  which allows it to indulge in high value acquisitions as well as share repurchase activities On the flip side  the recent emergence of group purchasing organizations  GPOs  and the consequent pricing pressure that they are exerting on single healthcare providers  like Henry Schein  might hamper the latter s business efficacy Moreover  Henry Schein operates in the highly competitive U S  healthcare products and service distribution industry  wherein the presence of other large players puts the company in a tight spot  Fluctuating currency rates and macroeconomic weaknesses are other threats to the stock Stocks to ConsiderSome better ranked stocks in the broader medical sector are Abiomed Inc    NASDAQ ABMD    Cardio Vascular Systems Inc    NASDAQ CSII   and Cepheid Inc    NASDAQ CPHD    All the companies sport a Zacks Rank  1  Strong Buy    Abiomed posted positive earnings surprise in the last four quarters  the average being approximately 35   The company represents an impressive year to date return of 42 3  Cardio Vascular Systems projects impressive long term earnings growth of 22 5   The company also represents a solid year to date return of 59 4  Cepheid posted positive earnings surprise in the last four quarters  the average being approximately 38 5   The company posted a solid year to date return of 44 1  Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-07,Zacks Investment Research,"https://www.investing.com/analysis/henry-schein-well-poised-on-strategic-buyouts,-pricing-hurts-200157678",200157678
30346,251861,CSII,Cardiovascular Systems  CSII  Q1 Loss Lower Than Expected,opinion,Cardiovascular Systems Inc    NASDAQ CSII   reported loss per share of 6 cents in first quarter fiscal 2017  reflecting a massive improvement from the year ago quarter s loss of 41 cents  Also  the loss reported was significantly narrower than the Zacks Consensus Estimate of a loss of 18 cents Per management  the year over year improvement in the loss figure was primarily backed by revenue growth  better gross margin and lower operating expenses on account of the company s cost realignment actions Quarter in DetailsCardiovascular Systems delivered better than expected revenues of  49 8 million in the fiscal first quarter  marking a year over year increase of 14   Revenues were almost in line with the Zacks Consensus Estimate of  50 million Per management  the strong top line performance exhibited the company s efforts to stabilize and support its field sales representatives CARDIOVASCLR SY Price  Consensus and EPS Surprise   During the reported quarter  Cardiovascular sold over 14 700 devices generating 92  of revenues  The company added 40 new peripheral accounts and 52 coronary accounts Coronary device revenues improved 33  year over year to  11 6 million  while peripheral device revenues rose 9  to  38 2 million  Other product revenues increased 20 1  year over year to  3 9 million  Customer reorder revenues were strong at 98  of total revenue MarginGross margin in the reported quarter was 80 9   up 99 basis points year over year  primarily on account of unit cost reductions and slightly higher device ASPs Meanwhile  selling and administrative  SG A  expenses dropped 10 9  to  36 9 million  while research and development  R D  expenses fell 23 1  to  5 3 million  The resultant adjusted operating expenses declined 12 7  to  42 2 million  primarily exhibiting management s cost realignment initiatives and timing of studies and projects  Consequently  operating loss narrowed to  1 9 million from a loss of  13 2 million a year ago Financial positionThe company s cash and cash equivalents were  58 2 million at the end of first quarter fiscal 2017  compared with  60 6 million at the end of fiscal 2016 OutlookCardiovascular Systems has provided its second quarter fiscal 2017 guidance  The company expects revenues in the range of  49  50 million  The current Zacks Consensus Estimate for second quarter fiscal 2017 revenues stands at  50 9 million  ahead of the upper end of the company s guidance Moreover  the company expects gross margin of 81  in the fiscal second quarter  flat sequentially The company expects to incur a net loss in the range of  1 7  2 3 million or loss per share of 5 7 cents  assuming 33 million average shares outstanding  The current Zacks Consensus Estimate is at a loss of 15 cents  wider than the guidance range Our TakeCardiovascular Systems kick started fiscal 2017 on a promising note  While the company s fiscal first quarter net loss was narrower than the Zacks Consensus Estimate  the top line met the mark  Additionally  the company s lower operating expense was the vital factor that drove the year over year improvement in the loss figure  Strong revenue performance also contributed to the improved loss outcome  According to the company  this result marked the third consecutive quarter of financial improvement  demonstrating significant progress toward its goal of driving attractive revenue growth  while moving toward positive cash flow and profitability Moreover  Cardiovascular Systems delivered an important milestone  Recently  it has presented the 30 day favorable results from its LIBERTY 360  study in a late breaking presentation at the 2016 Amputation Prevention Symposium  AMP  in Chicago  The results demonstrated high rates of procedural lesion treatment success and freedom from MAE  as well as quality of life improvements  across all Rutherford classes including challenging Rutherford 6 patients Zacks Rank   Key PicksCardiovascular Systems currently has a Zacks Rank  3  Hold  Some top ranked stocks in the broader medical space include GW Pharmaceuticals plc   NASDAQ GWPH    Quidel Corp    NASDAQ QDEL   and Baxter International Inc    NYSE BAX    GW Pharmaceuticals sports a Zacks Rank  1  Strong Buy   while Quidel and Baxter carry a Zacks Rank  2  Buy   You can see GW Pharmaceuticals surged 69 6  year to date compared to the S P 500 s 4 67  over the same period  The company s four quarter average earnings surprise is 41 7  Quidel rallied 23 5  in the past one year  higher than the S P 500 s 2 35   Over the next five years  the stock is estimated to record an earnings growth rate of 20   higher than the industry average of 15 1  Baxter s shares soared 24 4  year to date  Over the next five years  the stock is expected to see 12 3  earnings growth  It has a trailing four quarter average earnings surprise of 27  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-27,Zacks Investment Research,https://www.investing.com/analysis/cardiovascular-systems-(csii)-q1-loss-lower-than-expected-200161059,200161059
30383,251898,CSII,Acadia Healthcare  ACHC  Misses Q3 Earnings  Cuts View,opinion,"Acadia Healthcare Company Inc  NASDAQ ACHC   reported third quarter 2016 adjusted earnings of 58 cents per share  which missed the Zacks Consensus Estimate by a penny Further  earnings deteriorated 6 5  on a year over year basis  thanks to lower than expected same facility revenues from U K  operations In fact  current market sentiments have been unfavorable for Acadia Healthcare  as the company represents a negative one year return of roughly 49 6   much wider than the S P 500 s  0 54  over the same time frame   However  the company registered notable 53 1  growth in revenues in the quarter  totaling approximately  735 million  However  revenues failed to impress as it missed the estimate mark by  6 million The year over year upside in revenues may be attributed to the addition of beds at Acadia s facilities Quarter HighlightsAcadia Healthcare has been chosen as a provider of behavioral health and addiction treatment services to the FBINAA  FBI National Academy Associates   the second largest association in law enforcement in the quarter Acadia Healthcare formed a partnership with Ochsner Health System to establish an 82 bed acute psychiatric hospital  serving the greater New Orleans metropolitan area Quarter DetailsSame facility revenues increased 6 2  on a year over year basis  mainly owing to a 6 3  rise in patient days  Notably  revenue per patient day remained flat on a year over year basis The U S  same facility revenues were up 6 5  from the year ago quarter  There was also a 6 2  increase in patient days from a year ago The U K  same facility revenues increased 5 1  on a year over year basis to  87 1 million  Number of patient days rose 6 3  from the year ago quarter We note that revenues per patient day inched up 0 3  in the U S  but declined 1 1  in the U K ACADIA HEALTHCR Price  Consensus and EPS Surprise
    Same facility adjusted EBITDA margin was 26 9  compared to 27 4  in the year ago quarter  However  addition of new beds has driven organic growth at the company GuidanceAcadia Healthcare revised its full year guidance For full year 2016  Acadia Healthcare slashed its earnings guidance to the range of  2 41 to  2 42  from the previous  2 63  2 65  The guidance cut is primarily because of foreign exchange volatility and delayed CMA approval in our view For the fourth quarter  adjusted EPS is forecasted in the band of 55 cents to 56 cents Zacks Rank   Key PicksCurrently  Acadia Healthcare carries a Zacks Rank  5  Strong Sell  Better ranked stocks in the broader medical space include Cardiovascular Systems Inc    NASDAQ CSII    Exelixis  Inc    NASDAQ EXEL   and IDEXX Laboratories  Inc    NASDAQ IDXX    Notably  all the companies sport a Zacks Rank  1  Strong Buy   You can see Cardiovascular Systems represents a stellar one year return of 55 1   Notably  the company has an expected long term growth of 22 5  Exelis has a stupendous one year return of 66 1   In the last reported quarter  the company registered an impressive earnings surprise of 40 74  IDEXX Laboratories represents a promising one year return of 48 6   The company has a long term expected growth rate of almost 14 8  Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-11-03,Zacks Investment Research,"https://www.investing.com/analysis/acadia-healthcare-(achc)-misses-q3-earnings,-cuts-view-200162870",200162870
30389,251904,CSII,Vivus Proxy Battle Continues  Stock Weakens,opinion,Vivus  VVUS  is a pharmaceutical company that received FDA approval for their drug Qsymia  phentermine topiramate ER  in July 2012  Although there are long term cardiovascular risk and birth defect concerns associated with prolonged use of Qsymia  clinical trial data suggest that this is the most efficacious FDA approved weight loss drug ever made  Despite this  sales have been far below expectations up to this point  Part of this can be attributed to the initially restrictive REMS that Qsymia was approved under  Recall that after a September 2012 launch  Qsymia was a much less attractive option  since the drug had be largely  untested  outside of clinical trials  and had to be delivered through mail orders  This has changed  although Qsymia sales have only continued their old rate of growth in recent weeks  Also worth noting is the launch of competing weight loss drug Belviq  which is being marketed by Arena Pharmaceuticals   ARNA  partner Eisai  As many Vivus shareholders may already know  there has been a concentrated effort by shareholder activist groups led by 10  VVUS stakeholder First Manhattan Co   FMC    led by Sam Colin  to take control of the company due to claims that current management is incompetent  overcompensated  and unable to successfully launch Qsymia to maximize the value of this asset  The  itself  which was issued recently and released through Business Wire  explained that the 2013 Vivus Annual Meeting was fast approaching and that shareholders ought to support FMC in their efforts to replace company management  The grievances against current management were quite extensive  and included particularly notable points about the execution of the Qsymia launch   Vivus  Board and management damaged shareholders with a failed launch of Qsymia  No small company has ever successfully addressed the primary care physician market because such a huge challenge requires the vast resources of a large pharma partner  Vivus  two obesity therapy competitors got this fundamental decision right by partnering with larger companies in 2010  Vivus  management and Board got it wrong  In the absence of the required human and capital resources provided by a large pharma partner  Vivus shareholders are footing a massive bill for operating expenses over  2 20 per share annualized while generating insignificant revenue  You are paying dearly for the unforced errors of the sitting Vivus Board  The primary determinant of drug use is the out of pocket cost to the patient  Due to the lack of adequate market research on this most basic metric consumer price sensitivity  the launch failed  Vivus fails to grasp why the patients continue on Qsymia for only three months when medically they should continue for much longer  Inexplicably  Vivus  CEO recently proclaimed on a conference call that three months of persistence is a great accomplishment that will underpin Qsymia becoming a blockbuster  In reality  the low persistence on Qsymia is a sign of trouble ahead for Vivus shareholders   Vivus stock has seen slightly better performance since it became public knowledge the FMC was interested in turning the company around  although short interest seems to be rising along with VVUS  Possibly dangerous to these bears is increased involvement of  2  shareholder Sarissa Capital Management   led by Carl Icahn s former head of healthcare investments Alex Denner  Making the story more complicated  and far more interesting  was  to FMC s proxy letter  which can be found on the company s website Vivus did not directly address claims regarding the execution of Qsymia s launch as mentioned above  although the track record of CEO Leland Wilson was discussed   FMC s Incorrect Claim  Leland Wilson  VIVUS s CEO    has zero experience in launching blockbuster drugs into the US market   The truth is  Leland Wilson has extensive experience in new drug commercialization  including  Top ranked Sales Director in the U S  for Naprosyn   Syntex Laboratories  Inc    which was one of the largest selling drugs in the U S  at the time  Director of Marketing at Lifescan  when OneTouch  became one of the largest selling blood glucose monitors in the U S   and CEO of VIVUS during the launch of MUSE  in 1997  which was then considered to be one of the most successful drug launches in the U S  achieving  130M in first year sales   Update  I ve included a graph prepared by FMR  demonstrating the financial deterioration of VVUS since Q1 2011,2013-06-26,Myriad Equity,"https://www.investing.com/analysis/vivus-proxy-battle-continues,-stock-weakens-172854",172854
30391,251906,CSII,GlaxoSmithKline For The Dividend Yield Passive Income Portfolio ,opinion,The British drug manufacturer GlaxoSmithKline is the next stock purchase for my Dividend Yield Passive Income Portfolio  DYPI   I bought 30 shares at  52 16  the ADR version of the British stock  The total purchase amount was  1 569 80 and represents roughly 1 5 percent of the full portfolio value GlaxoSmithKline discovers  develops  manufactures  and markets pharmaceutical products  over the counter medicines  and health related consumer products worldwide  It offers pharmaceutical products in various therapeutic areas comprising respiratory  anti virals  central nervous system  cardiovascular and urogenital  metabolic  antibacterials  oncology and emesis  dermatology  rare diseases  immuno inflammation  vaccines  and HIV  The company provides prescription medicines to treat a range of conditions  including infections  depression  skin conditions  asthma  heart and circulatory disease  and cancer GSK is one of the world s leading drug manufactures with a solid non pharmaceutical division  It sells also oral care products and is the second biggest global player behind Colgate  The current dividend yield is above the 5 percent mark at 5 29 percent and the price to earnings ratio amounts to 18 90  The stock started to gain more momentum which resulted in a year to date gain of 21 81 percent The new GSK stake gives me  70 35 dividend income  The full portfolio dividend income is now estimated at  1 405 61  I plan to increase the total number of stocks by the end of the year to 50 70  As a result  the dividend income should grew to  3 000 to 4 000 All I need to do is to hunt further for stocks with a yield over 3 percent  As of now  the acquisition process was successful done with a yield on cost of 3 26  The DYPI Portfolio was funded virtual on October 04  2012 with 100k  Each week  I try to put one stock into the portfolio with a solid dividend growth history as well as an attractive yield  It s a slow buying process but in line with my strategy to show you how long term dividend investing works Not all stocks will deliver a great performance over the time but I believe that the huge amount of stockholdings should result in an adequate annual return of at least 8 percent of which 3 percent are dividends Because of the slow purchase process and the high cash amount  the full portfolio performance is up 4 percent since the date of funding  A deeper look at the stockholdings shows that the core performance is at 8 46 percent  a value better than the Dow Jones  Nasdaq and S P 500 ,2013-04-29,Dividend Yield,https://www.investing.com/analysis/glaxosmithkline-for-the-dividend-yield-passive-income-portfolio-164823,164823
30392,251907,CSII,Amarin Reports Solid Vascepa TRx Growth  Stock Holds Its Ground,opinion,Last week was quite decent for Amarin Corporation  AMRN  investors  who saw a 6  rally last Friday in reaction to the company s Q1 2013 financial results  Of particular interest was the continued growth in Vascepa  icosapent ethyl  capsules  which were approved for hypertriglyceridemia patients with 500  mg dL concentration in mid 2012  The launch at the end of January 2013 went surprisingly well  although it seems that Wall Street is still underwhelmed by the numbers that have been posted up to this point   In the first quarter of 2012  or the quarter ended March 31st  2013  Amarin reported  2 34 million in product revenues  although the company mentioned  2 9 million of deferred product revenue that will contribute to revenues in Q2 2012 results which are due in August 2013  The company s total prescriptions have been growing consecutively each month The finalized figures from Amarin are in line with analyst expectations and third party prescription data  and represent a slow but steady grind upwards for Amarin Vascepa  Additional analyst estimates suggest that Amarin will operate at total losses of  220 M for the fiscal year of 2013  and similar figures in 2014 given that the company will prepare for and execute Vascepa s launch into the ANCHOR indication in early 2014   Vascepa is on track to meet analyst expectations of   80M in total revenues for 2013  although we may see some surprises with the drug s overall trajectory after copayments are reduced by Vascepa s move into Tier 2 coverage  Since it is designed to be a long term primary care drug that is meant to improve cardiovascular function over more drawn out periods of time  cost related issues are expected to play a very important role in this drug s eventual success or failure  Lovaza  which generally costs between  280 520 per month  depending on the insurance   should also have problems justifying its price premium   The ANCHOR indication  which is a nickname for the hypertriglyceridemia indication for patients with triglyceride levels between 200 500 mg dL  is far larger than the MARINE indication  500  mg dL  which Vascepa current markets into  The sNDA that was submitted for Vascepa in the ANCHOR indication was confirmed with a PDUFA goal date of December 20th 2013   It s generally agreed that Amarin would have an extremely difficult time targeting a patient population that is about ten times to size of its current  4 million target population  which is why there are renewed expectations of a big pharma buyout or partnership with Amarin in the near future  Having said this  many analysts expect Vascepa sales to jump significantly in 2014 due to indication expansion for a drug that should be well established at that point  This implies that Amarin should be able to reduce SG A expenses and realize profits in 2015  or even the end of 2014 depending   The relatively neutral Q1 results may have caused some disinterest amongst the short sellers  who have already made large profits since Q4 2012 when the company initially announced its intentions to market Vascepa in the MARINE indication without a partner   Despite the potential of Vascepa   particularly after an indication expansion  the expectation is that Amarin s  202M in cash and cash equivalents will not carry the company quite far enough to realize a profit before a forced financing  even assuming that Vascepa continues to grow with consistency  Although the company was able to raise money last December in a non dilutive financing  a public offering may hold more appeal for Amarin later on   depending on the situation  Another likely option is an offering of convertible notes   Without any known catalysts before the PDUFA goal date for the ANCHOR indication  other than the FDA s NCE designation  which has yet to happen  investors should find a way to gauge Vascepa sales as we wait for Q2 2013 results  which will finalize the impact that Vascepa s shift to tier 2 coverage will have on TRx ,2013-05-13,Myriad Equity,https://www.investing.com/analysis/amarin-reports-solid-vascepa-trx-growth;-stock-holds-its-ground-166728,166728
30459,251974,CSII,Amarin Stays Rangebound  Prescriptions Stagnate,opinion,Amarin Corporation  AMRN  has been struggling a lot lately as retail channel prescription data for its EPA capsule Vascepa imply that the drug is starting to slow down its momentum in the MARINE indication  hypertriglyceridemia patients with  500 mg dL   While the company has seen significant progress since the launch of the drug in January  it is still not causing any excitement in an investor base that wanted to see a big pharma buyout of the company ever since the company reported successful Phase III results  Despite the incredible strength of the broader market and the biotech sector in particular this year  AMRN is down 14  YTD as of the time of writing  Since the company released Q1 2013 financial results  as discussed in a recent note   the company rallied all the way to  8 00 share before continuous selling brought shares back to the  7 00 per share level  We also have yet to see the FDA make a decision regarding the NCE  New Chemical Entity  status of Vascepa  which will have a profound positive negative impact on the value of Vascepa as a product and possibly on the chances for Amarin to receive an attractive partnership or buyout offer from a larger pharmaceutical company  CEO Joe Z s commentary seems to suggest that a partnership is needed prior to the prospective launch of Amarin into the ANCHOR indication due to the sheer number of sales reps that the company would need to market into such a huge primary care indication  although details are scare for the time being  Additionally  the market seems disinterested in more recent news which would normally generate some buying interest despite the mediocre market performance of Vascepa in its current disease indication  For instance  the market seemed to gloss over the recently released new data from the MARINE ANCHOR Phase III trials that shows statistically significant reductions in Apolipoprotein C III  Apo C III   which is a lipoprotein that serves as a biomarker for poor cardiovascular health  This bodes well for the REDUCE IT Phase III trial  which will transition Vascepa into a hypertriglyceridemia therapy into a preventative cardiovascular risk therapy that can be combined with standard statin regimens  But in general  we haven t seen anything new with Amarin or Vascepa that should change one s opinion on the stock quite yet  The market seems much more preoccupied with oncology drug developers who will be presenting at ASCO 2013   the American Society of Clinical Oncology meeting that will be held Chicago between May 31st and June 4th  2013  This generally explains why AMRN has been more of a trader s stock than an investor s stock  making exaggerated movements in reaction to news that has little implications on the long term health of Amarin  Despite the volatility  Amarin seems to favor trading ranges which is why the company may be a good candidate for options trades that favor sideways trading within a predetermined ranged  As mentioned in other notes  Amarin has a PDUFA goal date of December 20th 2013 for the sNDA that will significant expand the size and scope of Vascepa s target indication  If Vascepa sales move in line with analyst expectations  which should ultimately approach   80M in sales revenues for FY 2013  we may see continued sideways trading in the stock as the market waits for further developments  One particular strategy that takes advantage of neutral sentiment is the  Iron Butterfly  strategy  where one writes an at the money call and an at the money put while buying an out of the money call and an out of the money put  This could be very profitable  although the trade would likely go sour in the event that the FDA issues a decision on Vascepa s NCE status in one of its Orange Book updates  The same would also be true if the company announced any kind of partnership or acquisition offer  although a complete lack of any official information on this topic has pushed away would be M A speculators  Amarin  on the whole  seems to have fallen out of favor in the biotech investment community  This may change as we head closer to December 20th  or after an unexpected announcement   but without a tangible piece of news that can positively affect Vascepa s sales figures or its financial valuation don t expect much more than a continuation of what we ve seen this year ,2013-05-24,Myriad Equity,"https://www.investing.com/analysis/amarin-stays-rangebound,-prescriptions-stagnate-168261",168261
30460,251975,CSII,Two Companies Worth An Investor s Look,opinion,There are many different types of investment strategies and opportunities in the market if you are willing to take time and search for them  When I look through companies I look for two types  A large company with good growth potential  To define this  I look at revenue and EPS growth and I want to see at least 5 years of growth  For smaller companies I look for technology that has the potential to help a company grow and then I want to see if it has a good growth plan in place to increase its revenue As I scan through the medical industry  I have discovered two companies that are very diverse that I believe warrant and investor s time and effort to delve deeper into  PLC Systems  PLCSF OTC US  is one  and the other is ResMed  RMD   Let s take a look at these two companies and what type of opportunities they present to an investor PLC SystemsPLCSF  OTC USMarket Cap  7 04 millionPrice  0 11Who is PLC Systems PLC Systems  Inc  is a medical technology company specializing in innovative technologies for the cardiac and vascular sectors  It develops and manufactures medical devices and related products for the treatment of severe coronary artery diseases in a surgical laser procedure Main Product to WatchRenalGuardThis product was designed to eliminate contrast dyes that may be toxic to the kidneys when patients undergoing cardiac and imaging procedures may be  at risk   This damage can lead to Contrast Induced Nephropathy  CIN   a form of acute kidney injury CIN is a form of acute renal failure caused by exposure to high contrast media during image guided cardiology and radiology procedures  This has posed a problem for patients that are at risk because of renal insufficiency where the kidneys don t work properly The iodine based radio contrast media  or dye  used to facilitate the capture and display of x ray images  post a challenge to the kidneys which are responsible for filtering and removing waste from the body  Patients who have a pre existing or impaired kidney function are more susceptible to the toxic effects of the dye The procedure is based on something called the PRINCE study  which is a study that supports the theory that creating and maintaining a high urine output through the kidneys allows the body to quickly eliminate contrasts which naturally reduces toxic effects RenalGuard uses a  loop diuretic  that s prescribed by a doctor which induces a high urine output  Urine output is then measured and replaced with an equal volume of sterile saline  The results here are two eliminate the risk of under dehydration which can lead to increased risks MarketsArtech  the distributor for the company in Italy  accounts for about 50  of its sales presently ACIST Medical Systems has been brought on as an exclusive distributor for France and Germany which are the largest markets in Europe  This company is a subsidiary of worldwide leader in diagnostic imaging and contrast agents   the Bracco GroupIn March 2012 PLC announced they received approval to sell RenalGuard in Brazil and  through their Brazilian distributor  DISCOMEDAlso in March 2012 PLC received approval for sale of RenalGuard in IsraelJapan could be the next major international market but not until at least late 2013 or sometime in 2014  following completion of the proposed 60 patient study and regulatory approval in that country As you can see  the company continues to expand internationally  In the United States it is still going through clinical trials with the FDA Revenue ProjectionsThe projected revenue numbersfor this company look good in the next few years  While most sales come from consoles  consumables that service the installed base should continue to grow as the console base grows Revenue in 2013 is projected to be  1 6 millionRevenue in 2014 is rejected be  3 millionRevenue in 2015 is projected to be at  5 7 million which includes a midyear entrance into the United States market Why Be Interested in this Stock Not only does this company have a good product that is a necessity in renal care for a large number of patients  but timing is everything  The product is well received and the company is just branching out into other global regions A small ticket stock of this nature has the ability to grow as it continues to move into new regions and investors have the opportunity to grow right along with it  If the revenue projections hold  this is a good  ground floor  growth stock to move with ResMedMarket Cap   6 73 billionPrice   47 22Who is ResMed RMD develops  manufactures  and markets medical products that manage respiratory disorders associated with sleep disorder breathing  Their products are distributed through 70 countries around the world Main Product to Watch  The Quattro Full Air Mask  This mask will be the lightest full air mask coming out on the market weighing in at just 3 3 ounces  This makes it 45  lighter than the leading selling mask today  the Mirage Quattro mask  This mask will be very popular because it s also simple and has four pieces washing clean  For things like sleep apnea  positive airway pressure treatment is highly effective and has been chosen as the  treatment of choice   This type of treatment involves wearing a mask connected to a small airflow generator that delivers air at positive pressure Providing different treatments and products for sleeping disorders is a huge market  It has been estimated that 20  of all adults have some sort of sleeping disorder which would put it on par with diabetes and asthma as one of the most widespread disorders on the planet  Of this 20   a number of different sleeping orders have been identified SDB  sleep disorder breathing  is identified the simple things like snoring and  sleep suffocation  experiences OSA  obstructive sleep apnea  is more prevalent and is described as a collapse of the upper airway despite ongoing effort CSA  Central sleep apnea  is considered a lack of breathing and lack of effort as well as other forms of mixed apnea Why Be Interested in this Stock 73 consecutive quarters of revenue growthGross margin is at 62 4 Sustained EPS Growth 5 yr CAGR of 20 5 yr Net Income Growth of 19  CAGRAs I have stated earlier  the core market is another reason to consider investing in this company  With 20  of the population dealing with sleep disorders  13  mildly and 7  severely   there is a large resource that has yet to be tapped into  Among the conditions in society that lead to the sleeping disorders are things like drug resistant hypertension 83   obesity 77   congestive heart failure 76   and type II diabetes 72   just to name a few  This market will continue to grow and not go away  It has been proven that treatment saves money  At Waste Management  WM  when employees were treated under occupational health and safety for sleeping conditions  they experienced a 37  reduction in medical costs for those who are treated the first year  With results like this the industry is not going away and ResMed is well ingrained in the occupational health and safety arena  as well as CPOD in cardiovascular issues related to sleep problems This company has a track record of consistent earning metrics  and I believe that is a core conviction that investors should take a look at  The whole  sleep disorder breathing  market that this company has been pioneering may just be coming out of its infancy stage  There is much more opportunity for growth for the company and the market In SummaryBoth these companies  PLC Systems and ResMed  look like companies with good opportunities for investors  The companies are different sizes and the opportunities look good for different reasons  PLC Systems is a small company that investors who are interested in getting in on  ground floor opportunities  and growing with the business need to look at  It is opening up new markets  and just moving into the United States with its RenalGuard product soon and revenue is expected to triple in the next 2 to 4 years  ResMed is a larger established company with a track record of solid earnings growth that could make a good investment for an income investor Both companies are worth your time and effort to do further research  and if you are one of the types of investors that I have described here  I would encourage you to look deeper into these companies Disclosure  I have no positions in any stocks mentioned  and no plans to initiate any positions within the next 72 hours  I wrote this article myself  and it expresses my own opinions  I am not receiving compensation for it  other than from Seeking Alpha   I have no business relationship with any company whose stock is mentioned in this article ,2013-06-06,John Mylant,https://www.investing.com/analysis/two-companies-worth-an-investor's-look-170356,170356
30461,251976,CSII,U S  Stocks Post Triple Digit Losses,opinion,Stocks tumbled Wednesday  with small mid day losses accelerating despite the Federal Reserve promising to maintain its current stimulus policies as long as necessary  Equities had been drifting slightly underwater through most of the morning following two days of solid gains only to turn south after the Federal Open Market Committee statement at 2 p m  and remarks by Fed Chairman Ben Bernanke the central bank could start cutting back on its bond buying program late this year if conditions continue to improve  All 10 sectors in the S P 500 ended lower  with the steepest slides for shares of utility and consumer staples companies  Ben SpeakBernanke said on Wednesday the central bank expects to slow the pace of its bond purchases later this year  if the subsequent data remain broadly aligned with our current expectations for the economy   and bringing the program to an end by mid 2014  While those remarks are little different from current expectations for Fed policy  a clear statement of what conditions would trigger the central bank pulling the punchbowl still left traders in a sour mood  JobsIn other remarks  Bernanke said the Fed expects moderate growth to lead to continuing healing in the job market as headwinds facing the economy ease  He also said policymakers expect inflation to move back up toward their long term two percent goal  The FOMC statement also was slightly more upbeat than its recent statements   The committee sees the downside risks to the outlook for the economy and the labor market as having diminished since the fall   it said  Commodities were mixed  July crude oil fell 21 cents to  98 25 per barrel while July natural gas rose 6 cents to  3 96 per 1 mln BTU  August gold rose  7 73 to  1373 80 per ounce while July silver fell 7 cents to  21 61 per ounce  July copper fell a penny to  3 14 per pound  Here s Where The U S  Markets Stood At Day s EndDow Jones Industrial Average down 206 04   1 35   to 15 112 19S P 500 down 22 88   1 39   to 1 628 93Nasdaq Composite Index down 38 98   1 12   to 3 443 20GLOBAL SENTIMENTHang Seng Index down 1 13 Shanghai China Composite Index down 0 73 FTSE 100 Index down 0 40 UPSDIE MOVERS    NKTR  Drug maker says it is close to developing an opioid analgesic molecule that alleviates pain but does not lead to substance abuse of the drug     MNOV  Presents positive data for a prospective treatment for methamphetamine addition  The company also said preliminary results indicate its MN 166 drug candidate does not cause significant changes in cardiovascular functioning     AVHI  Private equity firm TPG pays  14 65 a share   or 37 5 mln overall   to acquire 2 6 mln shares of the homebuilder s common stock along with another  97 5 to purchase 700 000 newly created Series A convertible preferred shares  TPG will gain a 41 9  stake from the  135 mln transaction and have two of the eight seats on the AVHI board DOWNSIDE MOVERS    BIOD  Announces plans to sell a yet to be determined number of shares of common stock  subject to market conditions and other factors     POOL  Reduces FY13 EPS guidance by  0 10 to new range of  2 03 to  2 13 per share  trailing the Street view by at least  0 08 per share     TTEK  Revises Q3 outlook to reflect rising restructuring costs  now projecting a net loss of  0 30 to  0 50 per share compared with the  0 38 per share profit analysts are expecting  Also cuts revenue forecast by about 15  to  440 mln to  490 mln  The Street is at  551 mln  It also authorizes a  100 mln stock buyback program After Hours Stock News From  Copyright   2013 MT Newswires  a Division of MidnightTrader  Inc ,2013-06-19,Midnight Trader,https://www.investing.com/analysis/u.s.-stocks-post-triple-digit-losses-172042,172042
30462,251977,CSII,2 Big Name Biopharma Catalysts For 2013,opinion,Vascepa s ANCHOR Catalyst s   Yesterday  the FDA announced the scheduling of an Advisory Committee date for the sNDA submitted by Amarin Corporation  AMRN  for the omega 3 derived drug Vascepa  As AMRN investors may already know  this is the application that would expand Vascepa s hypertriglyceridemia indication into the 200 500 mg dL range  with the addition of  mixed dyslipidemia  on the label   AKA the  ANCHOR  indication  While this is not as expansive as the REDUCE IT  cardiovascular risk  indication  it is a huge step forward for the drug and allows the company to market to  40 M patients in the United States as opposed to the current  4 M   AMRN stock  which has been very weak this year  is expected to recover at least some of its losses upon a successful FDA approval of the ANCHOR sNDA although shareholder frustration is continually perpetuated by the lack of an NCE decision  AMRN has also been a wild ride to the downside for many shareholders who were expecting an acquisition of the company last year  following the FDA approval of Vascepa   The post approval M A speculation  which was perpetuated by both individual investors and analysts alike  brought AMRN as high as  15 96 and made the  crash  in December 2012 all the more painful for investors who established positions around this time   After licking their wounds  AMRN investors are looking for a serious rebound as we get closer to the October 16th Advisory Committee meeting and the PDUFA goal date of December 20th  Whether or not a rally will materialize before the AdCom meeting may depend on the speed of Vascepa s sales growth in its current  MARINE  indication  Since launch  the drug has performed roughly in line with analyst expectations   Early Results of the BELVIQ Launch in Q2 Earnings About a year after FDA approval for its obesity drug Belviq  lorcaserin   Arena Pharmaceuticals  ARNA  launched the drug in the United States with partner Eisai  The drug is expected to have a smoother and overall  better  launch than Qsymia had in September 2012  although Qsymia has been making fair progress   After yesterday s news that the American Medical Association  AMA  had officially deemed obesity a disease  we are seeing some renewed attention in the obesity space from the market  Although obesity had already been well defined with BMI parameters for years  this move in the medical community establishes some legitimacy for obesity drugs and adds distance between prescription obesity pills and OTC marketed weight loss products  This should help expand the size of the prescription obesity drug market   The catalyst that would offer appreciable upside potential for ARNA is the upcoming Q2 2013 earnings release in early August  which should provide detailed commentary of the first two months of Belviq s launch  June 6th  ,2013-06-21,Myriad Equity,https://www.investing.com/analysis/2-big-name-biopharma-catalysts-for-2013-172266,172266
30463,251978,CSII,ISIS Rally Continues On Phase II Data,opinion,ISIS Pharmaceuticals  ISIS  saw significant attention after the FDA approved the apo B inhibitor Kynamro  mipomersen   despite some hesitance from the FDA Advisory Committee meeting that was held in October 2012  The concerns were primarily related to lesions that were discovered in patients undergoing clinical testing of the drug and the toxicity of the drug  which is why the drug seems to be incapable of European approval  Also problematic for the homozygous familial hypercholesterolemia  HoFH  indication is the sheer success of Aegerion s  AEGR  Juxtapid  lomitapide   which is significantly more expensive at  295k versus  176k but has better efficacy data   Although Kynamro is a strong asset that constitutes a large chunk of ISIS  valuation  at least 40 50  if based on analyst revenue estimates for the next few years   investors are also seeing a lot of potential in the company s platform technology  RNA inhibiting antisense molecules are difficult to use on patients due to their size and instability  which makes ISIS  success with Kynamro all the more impressive  Going forward we are hoping to see similar results in the rest of ISIS  huge pipeline  which includes over a dozen partnered compounds   Despite a strong selloff in the broader markets this morning  which hit high volatility biotechnology stocks particularly hard   ISIS is up 16 5  at the time of writing and climbing on detailed data released from a Phase II study of ISIS APOCIIIRx in patients with high triglycerides  TG between 200 and 500 mg dL  and type 2 diabetes  What was particularly impressive was the 88  reduction in Apoc III and the 72  reduction of triglycerides  plus a 40  increase in high density lipoprotein cholesterol with no rise in low density lipoprotein cholesterol  which adds more data to confirm not only that this particular drug is extremely potent but that ISIS  platform is working as intended   ISIS APOCIII is being developed as treatment for patients that are at  very  high risk of cardiovascular disease development and pancreatitis  For patients with extremely high triglyceride levels   500 mg dL  there are very limited treatment options at this point  which allows ISIS APOCIII to target a niche market that is comparable to the HoFH market that is being fought over by Kynamro and Juxtapid  A lack of alternative treatment options may also allow ISIS to market this currently unpartnered drug at a very high price  which may allow the company to swing into EPS positive territory by 2017  These data may also entice another big pharma partnership  which means royalty payments and reduced R D expense   Going into the last five months of 2013 we are also looking for data from the CRP inhibitor ISIS CRP Rx  which is in Phase II trials for rheumatoid arthritis  This compound is in another highly lucrative indication  and also remains unpartnered up to this point  This adds more upside potential to ISIS  although investors should note that ISIS has had a tremendous run throughout the last 7 8 months and has a much less favorable risk reward as the company prepares to take the aforementioned compounds into Phase III development ,2013-06-25,Myriad Equity,https://www.investing.com/analysis/isis-rally-continues-on-phase-ii-data-172674,172674
30487,252002,CSII,Late Bid Higher Stalls  U S  Stocks End Down,opinion,A late rally for stocks fizzled  with shares unable to overcome the drags presented by the apparent lack of progress on fiscal legislation in the U S  Congress and a disappointing measure of holiday sales  Most industrial sectors in the S P 500 finished lower although mining and material stocks posted moderate gains  rising nearly 0 7   as a group with broad based advances for commodities  Consumer stocks were the worst performers today after MasterCard  MA  Advisors SpendingPulse reported a 0 7  rise in holiday spending over year ago levels  trailing a 2  rise last year and lagging estimates heading into the current season forecasting as much as a 3 5  rise in holiday sales  Shares of MasterCard rival Visa Corp  V  also fell today  President Obama is returning to Washington  D C   overnight  to still uncertain prospects for a positive outcome in efforts to avert scheduled tax hikes and spending cuts taking effect at the start of the new year  Senate members also are returning tomorrow and reportedly were discussing possible remedies but there are still no immediate plans for the House to reconvene  Home prices rose at an annual rate of 4 3  in October  according to the S P Case Shiller home price index  marking the biggest rise in home prices in more than two years and topping analysts  expectations  February gold rose  1 00 to  1660 50 per ounce  March silver rose 13 cents to  30 03 per ounce  March copper rose 5 cents to  3 60 per pound  Crude oil for February delivery settled  2 37 higher at  90 98 per barrel  January natural gas was up 4 6 cents at  3 392 per 1 million BTU  Here s Where The Markets Stood At Day s EndDow Jones Industrial Average down 24 49   0 19   to 13 114 59S P 500 down 6 83   0 48   to 1 419 83Nasdaq Composite Index down 22 44   0 74   to 2 990 16GLOBAL SENTIMENTHang Seng Index up 0 16 Shanghai China Composite Index up 0 25 FTSE 100 Index up 0 24 UPSIDE MOVERS    NVMI  Receives over  15 million in orders from  leading  foundries  as part of their production ramp up and development efforts for future technology nodes     RIMM  Reaches patent licensing agreement with Nokia Corp   NOK  terminating all patent related lawsuits between the firms  RIMM will exercise a onetime payment option although specific financial terms of the deal were not revealed     DQ  Appoints Arthur Wong as an independent director of the company     GOL  Said it is continuing to explore spinoff alternatives for its Smiles frequent flyer operation  including a possible initial public offering of stock DOWNSIDE MOVERS    AMPL  Tel Aviv District Court in Israel appoints a receiver for Gadot Chemical Tankers and Terminals shares     MED  Acting chief financial officer Edward Powers resigns his post     COV  Agrees to acquire CV Ingenuity  a privately held company specializing in cardiovascular drugs  Financial terms of the transaction were not disclosed   2012 MidnightTrader  Inc  All rights reserved ,2012-12-26,Midnight Trader,"https://www.investing.com/analysis/late-bid-higher-stalls,-u.s.-stocks-end-down-148867",148867
30488,252003,CSII,Evolva Asset Acquisition ,opinion,Rejuvenation Ahead Of Key TimeEvolva has expanded its pipeline with the acquisition of a yeast based resveratrol programme from the distressed Danish company Fluxome  The purchase is opportunistic and should become cash flow enhancing in 2014  However  Evolva s other assets are still the main value drivers  This may be highlighted in H113 by the potential partnering of the stevia and vanilla programmes  which could generate significant revenues and validate Evolva s strategy  We have increased our valuation by CHF54m to CHF269m  CHF1 52 per share Opportunistic Acquisition Of Resveratrol From FluxomeEvolva has acquired a yeast based resveratrol programme from Fluxome for CHF0 25m in cash and 1 077m Evolva shares  up to CHF0 8m in cash shares over the next year and single digit royalties until cumulative sales of c CHF65m have been achieved  Fluxome is a private Danish company that was already selling high purity resveratrol  but high production costs and slower than expected market uptake resulted in the company getting into financial difficulties Potentially A Major Dietary SupplementResveratrol is found in red wine and various plants and is claimed to have various beneficial cardiovascular  metabolism and ageing effects  The market is currently estimated to be worth c  60m and has double digit growth  which could accelerate significantly if greater evidence of its benefits are shown  Evolva needs to improve the production yields from the current yeast strain  but this should not pose a problem given its knowledge of the phenylpropanoid pathway from its vanilla programme Potential Partnering Deals Are ImminentDespite the potential of resveratrol  Evolva s key assets are still stevia  saffron and EV 077 and the strength of its yeast discovery platform  Its stevia and vanilla programmes could both be partnered in H113  Deals with these products would provide important validation of Evolva s business model and potentially generate significant near  and long term revenues Valuation  DCF Valuation Of CHF1 52 Per ShareWe have raised our valuation by CHF54m to CHF269m  primarily because of the inclusion of resveratrol  Evolva should still be able to operate to the end of FY13 with its current financing  as it will not make further investments in the EV 077 and Pomecin programmes  Its cash runway could be extended further by the planned equity raise of CHF10 20m in Q113 and the partnering of vanilla and stevia To Read the Entire Report Please Click on the pdf File Below ,2013-01-02,Edison,https://www.investing.com/analysis/evolva-asset-acquisition-149317,149317
30494,252009,CSII,The Market Awaits Financial Results From Nanosphere s Gram Positive Test,opinion,The biotech company Nanosphere  NSPH   which develops and markets their proprietary Verigene System  doubled in value throughout the last twelve months due to a bunch of positive developments  Especially great for the company s long term prospects was the FDA approval of their Gram Positive Blood Culture Nucleic Acid Test  BC GP   which allows very fast detection of bacteria that can cause fatal infections in patients One of the exciting traits about this new diagnostic test is that it can detect markets that indicate that the bacteria in a patient s bloodstream are resistant to methicillin oxacillin and vancomycin  Hospitals have had an especially hard time dealing with these  Methicillin resistant Staphylococcus aureus  MRSA  is one particularly prominent bacteria that has proven to be extreme dangerous  and is one of the many microbes that can be detected and identified with the Verigene System The FDA approval of the microbe diagnostic led to substantial appreciation in Nanosphere stock after the initial press release on June 27  2012  NSPH rallied from  1 91 share to  3 41 share by July 9th  While the stock has not been able to consistently hold on to all of its gains at this point  there is no question that the market sees major potential in rapid diagnostic tests to prevent dangerous microbial infections The Verigene system is also used for a host of other diagnostic purposes  The company has a strong presence in cardiovascular risk factor identification   especially through the detection of genes that are associated with thrombosis  or blood clot formation   For instance  the company sells Verisign detectors that can quickly find traces of the F5  F2  and MTHFR genes which are all linked to higher incidence of thrombosis They also sell detection for the CYP2C19 gene  which produces an enzyme that metabolizes a whopping 15  of prescription medications and has important physiological applications for patients on anti consultants  proton pump inhibitors  anti platelet drugs  and even anti depressants  Since these are all very common  Nanosphere should have no shortage of target patients for their CYP2C19 gene detecting Verigene systems The financial prospects for the company could also become quite outstanding in 2013  Nanosphere already has triple digit sales growth  and is expected by analysts to nearly triple its total revenue for fiscal year 2013  This is based on the roughly  5 5 million in sales revenue it will have for FY 2012  and the possible  20 8 million it will have next year  This enthusiasm seems to be largely based on Verigene s prospects in microbial gene detection While the company is already being pumped by the analysts  it seems that the market is hesitating on a few factors  Perhaps the most obvious concern is related to the ability for Nanosphere to breach  20 million in revenue in 2013 At this point  the company hasn t released any actual data on gram positive sales  which puts virtually everyone in the dark about the figures from Verigene s most exciting target market  While Nanosphere has potential to expand Verigene s indications in coming years to include more microbes and other human genes that could benefit from rapid identification  NSPH could have trouble if the gram positive market does not meet our expectations  It s also worth noting that short interest has declined significantly in recent months  which introduces the possibility of a milder bear raid on any piece of bad news  On the bright side  NSPH will be trading significantly higher if the analysts are right  I would expect the stock to be north of  4 share if it gets on track for  20 million in sales revenue from fiscal year 2013 The next quarterly earnings release is in early February  so there is still a bit of a wait left ,2013-01-06,Myriad Equity,https://www.investing.com/analysis/the-market-awaits-financial-results-from-nanospheres-gram-positive-test-149748,149748
30495,252010,CSII,Arca Biopharma Rallies On New Plans For A Phase III Trial,opinion,Arca Biopharma  ABIO  was a very boring ticker in 2013 until the company provided an update on a proposed clinical trial for a trial fibrillation for the company s flagship drug Gencaro  bucindolol hydrochloride  after the closing bell on January 29th   The market s response was overwhelmingly positive  which was shown as ABIO closed over 73  higher the next day  Yet another day later  the stock almost broke  1 share  although it seems that a good number of investors brought the price of ABIO back down to earn with profit taking pressures  Why is this phase III trial so exciting   Well  for one thing  Gencaro is just about the only thing that ABIO shareholders could get excited about since it s the only compound in the company s pipeline  Secondly  it targets a large number of patients with its intended indication  atrial fibrillation  which makes its market capitalization of   10 million quite cheap at first glance   The proposed phase III adaptive design trial  which is now called the GENETIC AF trial  will have 620 patients  The intention is to compare Gencaro to metoprolol CR XL for the prevention of atrial fibrillation for patients that already have cardiovascular conditions  in this case  heart failure and left ventricular dysfunction  HFRF    What I think is particular interesting is the genetic component of the trial  Patients that are tested to be homozygous  having 2 copies of 1 gene  for the beta 1 adrenergic receptor gene make up the entirety of the trial s population  They did this because it was shown in another clinical trial  the  BEST  trial  that these patients in particular had the best responses to Gencaro in the prevention of atrial fibrillation  Luckily for Arca  about 50  of the US population has this genotype  which means that Gencaro could target a truly enormous patient population if it managed to reach the drug market   There are about 2 3 million adults in the United States with atrial fibrillation  with a heavy skew towards the elderly population   Arca Biopharma estimates 2 7 million  This means that Gencaro  at its very best  could target about 1 4 million adults if its indication were restricted for use in patients that are homozygous for the beta 1 adrenergic receptor  On top of this  the prevalence of atrial fibrillation as a whole is expected to increase dramatically throughout the next few years due to an aging population  This is an enormous patient population for a company worth  10 million   If you look at the volume and price action in ABIO throughout the last few sessions  one can infer that there is major interest in the stock from a large number of buyers who seem to be chasing the  catalyst potential  of Gencaro s new phase III trial  You can also see that this rally was marred by substantial profit taking on Friday  February 1st   although this seems to be a temporary stall in a larger trend  ABIO looks like it wants to break  1 share  although there are also quite a few things to worry about going forward   For one  investors should take into consideration Arca s intention to secure financing for this phase III  which means that they will have to either form a partnership with another pharmaceutical company or perform an equity financing  This means that shareholders might see their ABIO get diluted in the near future   never a pleasant process for those who are involved  Also  while the formation of a partnership between Arca and another company may be good for the short run  t could cut into the market potential for the drug drastically depending on the terms dictated in any contracts that are signed   Overall  I think ABIO is your typical run up play  The company s valuation is extremely low right now  which reduces the downside risk dramatically in the long run  The catch is that the company may be quite cash strapped as it attempts to finance a 620 patient phase III trial  so financing in the near future is something that must be done  I think there is a high chance that ABIO will do an equity financing  which means that the stock is almost guaranteed to drop after the announcement  Investors may want to wait for this event prior to buying into ABIO ,2013-02-06,Myriad Equity,https://www.investing.com/analysis/arca-biopharma-rallies-on-new-plans-for-a-phase-iii-trial-154158,154158
30496,252011,CSII,Orphan Drug Mania  Amicus Migalastat HCl ,opinion,Orphan Drug Mania  Amicus Migalastat HCl I m going to be taking a look at orphan drugs and their underlying companies all throughout the month of February  which will result in a number of write ups with one specific theme  orphan drug investing  In the US  Orphan drugs are drugs that target diseases that affect less than 200 000 people  Europeans use an incidence rate threshold  which is 5 10 000  Orphan drugs are given certain benefits to encourage their production  including extended exclusivity periods on the drug market  7 in the US and 10 in Europe   These can be attractive investments due to their pricing power  extended market exclusivity  and their generally easier approval process  A Brief Overview Of Amicus   Fabry Disease The last time I took a look at the orphan drug specialist Amicus Therapeutics  FOLD   we were all waiting on the phase III results for their flagship drug Migalastat HCL  which was formerly known as AT1001 and or Amigal   This is a treatment for a very rare disease known as  Fabry Disease   and also makes the drug an orphan drug  Fabry disease is one of the many progressive genetic diseases is caused by a mutation which causes a deficiency in a vital protein   in this case in an enzyme that are used to metabolize lipids  Fabry disease is also known as  alpha galactosidase A deficiency   which names the specific enzyme that is missing due to the genetic mutation in these patients  Since Fabry patients have a mutated form of this enzyme  they are basically unable to process lipids as they are meant to  which leads to severe problems  Excessively high levels of lipids are extreme dangerous to many of the body s systems  but this is particularly true of the cardiovascular system  Ultra high lipid levels due to a deficiency of alpha galactosidase A causes symptoms in patients from an early age  with worsening conditions going into adulthood  Patients at the ages of 30 45 generally begin to see worsening function of the kidneys or the heart  which can lead to strokes and organ failure  Fabrazyme  agalsidase beta  Patients who have the disease do have a treatment option   an alpha galactosidase replacement therapy called Fabrazyme which is being marketed by Genzyme   a subsidiary of Sanofi  SNY   Fabrazyme drew recent attention due to its recent rise in sales volume after years are subpar performance  An article from 2012 on FiercePharma outlined just how well Fabrazyme has been performing  In Q3 2012  Genzyme reported an impressive total  87 million  which is  118 million using the very latest EUR USD rate   The United States made more than half of this revenue  which isn t surprising because of how lucrative the US market is with our health insurance system  Amicus Analysis  the fun part  FOLD  with a market capitalization of about  190 million after its drop in December 2012  is discounting the potential of a successful Fabry disease treatment by a decent amount  especially when you add in the value of the remainder of its pipeline   Why has it gotten cheaper  Again  we go back to points outlined in my previous article on FOLD  FOLD was trading in a predictable trading range for most of 2012 until phase III results for migalastat HCl were released  At the end of the last article  I mentioned the following   Top line results for Study 011 are due before the end of this year  which means that we could see the press release any day now   Because of the huge reaction that Wall Street had to other clinical trial data releases for orphan drugs this year  there is expectation that positive top line results from Study 011 could cause a massive rally based on the notion that orphan drugs with successful phase II III results have extremely high chances of approval   I was right about the  huge reaction  to the phase III data that was ultimately release for migalastat  although I was expecting better results than what we got  Because of that phase III trial  FOLD dropped from  5 77 share on December 19th all the way to  3 06 share the next day  This is a 47  drop that occurred in a single trading session  which is quite a traumatizing thing to see  This   which details the top line results from migalastat s phase III trial   Study 011  explains how the primary endpoint was specified as a 50  or greater reduction in kidney insterstitial capillary GL 3 after the 6 month treatment period for migalastat  GL 3 is the name of the glycolipid that is accumulated within blood vessels in patients with Fabry disease  and its buildup in the kidneys looks a bit like this   A  Baseline biopsy  pre treatment  GL 3 is present near endothelial nuclei and around the perimeter of the capillaries   B  Post treatment biopsy  Capillaries are clear of GL 3  magnification of A and B  100 objective      41  of the migalastat arm was able to demonstrated over 50  reduction in GL 3 in the kidneys versus 28  of the placebo arm  although this was not statistically significant  p  3  because of the large number of patients who were not evaluable  The overall percentage change in GL 3 in the migalastat arm  after 6 months  was 41  while the placebo arm s was 6   This shows that migalastat seems to work  although it wasn t proven with statistical significance with current data  I think that this can be fixed if the company lowers the bar for migalastat s 6 month performance and makes the trial bigger  Also  since migalastat is not a simple hormone replacement  and works through a different mechanism   I think that the FDA might have some lenience on the drug  The FDA has also indicated that it will consider 12 month results for a potential FDA approval  which indicates that this trial may add more to a migalastat NDA submission than the market originally thought  This should be further discussed in a presentation that Amicus will be making at the Lysosomal Disease Network WORLD Symposium  LDN WORLD  event in Orlando  Florida between February 12 15  Since further analysis on patient renal function will be addressed  I think we could see some interesting news  Conclusion There s no doubt that FOLD has been a terrible investment in the last few months  but migalastat might recoup the losses  and then some  if the clinical trial situation can be turned around  This is hinged around the success of the secondary endpoints in Study 011  which should be further analyzed very soon  At the same time  there are risks involved  Clearly there is some question about the efficacy profile of migalastat  which should naturally keep FOLD away from inflated price for quite some time  There is also the fact that Amicus has partnered with GlaxoSmithKline  GSK  for the development of migalastat  which means that the company is limited to the drug s market potential within the United States alone  This means that they will only be able to target about 3 000 patients  Still  this can be a surprisingly big market if you consider how much pricing power Amicus has with a necessary Fabry treatment ,2013-02-06,Myriad Equity,https://www.investing.com/analysis/orphan-drug-mania:-amicus-migalastat-hcl-154160,154160
30497,252012,CSII,Nektar Therapeutics  Outcomes Study Still Required ,opinion,Investment summary  Fear of the unknownNektar s  NKTR  pipeline features several late stage assets  Naloxegol for opioid induced constipation  OIC  currently gets the most attention  Positive Phase III data are already in hand  but long term cardiovascular  CV  safety concerns persist  Given recent FDA precedence  a long term CV outcomes study may be required  which by itself should make investors cautious on the stock at these levels Encouraging Phase III efficacy data   Naloxegol is an oral  mu opioid antagonist for OIC in non cancer pain  a significant issue affecting 40 50  of those taking opioids  The 12 week Phase III efficacy studies  KODIAC 4 and KODIAC 5  showed encouraging but somewhat mixed results in producing statistically significant improvements in spontaneous bowel movements  SBM  compared to placebo  AstraZeneca holds WW rights to naloxegol    but potential long term CV liability cannot be ruled out yetMu opioid antagonist drugs are associated with potential CV toxicity   Cubist s Entereg has a block box warning  while the FDA has concerns about a potential CV risk with the chronic use of mu opioid antagonists and has requested Salix to conduct a CV outcomes study for Relistor  In KODIAC 4 and KODIAC 5  and KODIAC 7  a 12 week safety extension of KODIAC 4   there were no clinically relevant imbalances in serious adverse events  but these were relatively small studies  KODIAC 8  a longer term 52 week safety study with data expected in Q113  is therefore key to providing a better barometer of naloxegol s safety profile Pipeline buffer optionsIf naloxegol hits a CV safety barrier with the FDA  Nektar has six further clinical stage pipeline candidates to turn to  some already partnered with Bayer and Baxter  Nektar s key unpartnered assets are NKTR 181 for chronic pain  a novel  abuse resistant opioid undergoing a 200 patient Phase II  results H213   and NKTR 102  etirinotecanin  in an 840 patient Phase III for breast cancer  results H115  and a recently complete 169 patient Phase II in ovarian cancer  FDA EMA review Q213  Valuation   835m EVNektar has an EV of c  835m   125m debt   300m cash   driven primarily by expectations for naloxegol  An NDA filing is expected in Q313  but if FDA requires another CV study  the stock could suffer  Upside could come from positive KODIAC 8 data and progress with other pipeline candidates To Read the Entire Report Please Click on the pdf File Below ,2013-02-10,Edison,https://www.investing.com/analysis/nektar-therapeutics:-outcomes-study-still-required-154675,154675
30498,252013,CSII,Pozen  An Undervalued Investment And Catalyst Trade Opportunity,opinion,It s not too often I come across a small cap biopharma that I think might make a nice longer term investment  Most small cap biopharmas burn a ton of cash on development treatments for such ailments as cancers  Hepatitis  and rare diseases  In this article  I would like to talk about the company Pozen  POZN   which I feel is a good longer term speculative investment  and a good trade with near term catalysts coming up  Pozen reminds me of another company I came across in 2011  Antares Pharma  NASDAQ  ATRS  which I made a substantial investment in  but have since sold for an 80  gain in 14 months  Antares is not a typical biotech that develops drugs to treat rare diseases such as the ones mentioned above  Rather  the company aims to take existing treatments and make them better via subcutaneous self injections  When I first bought Antares  the price was around  2 20 a share  Within one year  the stock nearly tripled  hitting a 52 week high of  5 58  before settling back to where it trades today  in the high  3 range  Antares looks to have a bright future ahead of it  Like Antares  Pozen takes existing drugs and seeks to make them safer and better   more tolerable  Today  I will look at the management  pipeline  upcoming catalysts  partnership potential  and noteworthy financial items for Pozen  ManagementOne reason Pozen reminds me of Antares is because of the strong management with strong backgrounds     is President  Chief Executive Officer  and Chairman of the Board of Directors of Pozen  Prior to founding the company in 1996  Dr  Plachetka has held many high level positions in the pharmaceutical industry  Most notably  he had a nine year career at Glaxo Inc  where Dr  Plachetka held various executive positions including Director of Cardiovascular Clinical Research and led the U S  development program for Imitrex   Trandate   and a thromboxane antagonist  Mr  Plachetka is the firm s biggest shareholder holding   He is also responsible for bringing Liz Cermak on as the firm s Executive Vice President and Chief Commercial Officer  A former Worldwide Vice President for Johnson   Johnson  Liz has served in a variety of senior leadership roles across the pharmaceutical  consumer products  and health management businesses  She has over 25 years  experience in the healthcare industry  The CEO s heavy ownership stake is one of the reasons why I believe the management team is extra focused with added incentives to perform well for its investors  The scenario arguably communicates a direct sense of personal accountability towards building shareholder value for investors in the company  The more that CEO is able to create shareholder value  the more he will ensure his own compensation and benefits  The value of the management s approach has been proven with its success in gaining FDA approval of two self invented products  One of these products is Treximet  developed with pharmaceutical giant GlaxoSmithKline  GSK  in June 2003 for the acute treatment of migraine attacks in adults  In what I feel is a very smart move  Pozen  and milestone payments covering Treximet sales in the United States to a financial investor for  75 million in November  2011  On the surface  this may not mean much  However  once I looked deeper  I noticed how the company is piggybacking the product by retaining exclusive U S  rights to develop and market a lower dose sumatriptan and naproxen combination  MT400   This is the same combination used in Treximet  Effectively  the company raised  75 million while potentially having virtually the same product in development  A pipeline chart later in this article will show the MT 400 drug in Phase III development  As a result of the Treximet decision  it is over one year later and the company has remained shareholder friendly by achieving a strong cash position while avoiding dilution  As of the end of Q3  2012  Pozen had approximately  92 million in cash and short term investments  The dilution alternative to raise cash was one annoyance I had with an otherwise strong Antares management team as they did a cash raise last year that I felt was unnecessary at the time  but might ultimately be the best course of action for them moving forward  Upcoming CatalystPozen plans on filing an NDA  for its first PA product PA32540  which is a combination of 325 mg aspirin and 40 mg time released omeprazole  better known as Prilosec  originally created by AstraZeneca  NYSE  AZN   From the company s website     Pozen s active PA product portfolio is focused on designing cost effective  integrated aspirin therapies that enable the full power of aspirin by reducing its potential gastrointestinal  GI  damage  The PA product portfolio has the potential to benefit millions of Americans who use daily aspirin to treat cardiovascular disease  osteoarthritis  and other diseases   PA32540 is designed to be a GI safer form of aspirin to be administered orally once a day  at a   PA32540 prevents secondary cardiovascular disease in patients at risk for aspirin associated gastric ulcers  Last week  the company  the combined results of two Phase III studies of PA32540   According to the studies  in the post hoc analysis of subjects with a history of transient ischemic attack  TIA  or stroke  long term  6 months  treatment with PA32540  compared to EC ASA  325 mg   was associated with a significantly reduced rate of endoscopic gastroduodenal ulcers  2 0  vs  12 4  respectively  p 0 005   and study discontinuation due to adverse pre specified upper GI events  0  vs  8 0  respectively  p 0 006   The incidence of adjudicated major adverse cardiac events was similar for PA32540  2 9   and EC ASA  325 mg   4 4     Mark J  Alberts  MD  UT Southwestern Medical Center  Dallas  Texas remarked   Discontinuation of aspirin therapy is often due to the adverse GI effects of aspirin  In these pivotal studies  PA32540 was associated with a significantly lower rate of treatment discontinuation than aspirin alone  Patient adherence to aspirin therapy saves lives  as aspirin discontinuation increases the likelihood of potential adverse cardiovascular and cerebrovascular events   In an  written by analyst Jason Napodano for Propthink  he writes   Amazon com sells a 500 tablet bottle of 325 mg aspirin for  11 00  or 2 2 cents per day  One can also buy 42 20 mg tablets of OTC Prilosec  omeprazole  for  23 95  or around 57 cents per pill  To re create Pozen s PA 325 40  a patient would spend approximately  1 16 per day  taking two Prilosec pills plus an aspirin    The above clearly demonstrates why it would be beneficial to choose Pozen s drug over taking aspirin and Prilosec separately   it would cost less at 1 dollar a day for a patient to buy PA32540 verses buying both drugs separately for  1 16  Additionally  PA32540 is time released and contains a dose specific solution in one pill where patients need not to worry about mixing both medications to get the desired result  Partnership PotentialThe above referenced article goes on further to note that the PA platform might be worth as much as  400M in sales per year globally  with the company receiving at least a  30M upfront payment from any potential partner  With an NDA filing expected in April the company s  before the filing  I expect Pozen s stock price to increase significantly in the short term  A partnership can spark a stock price depending on the details of the transaction  Generally  it shows that the development of a drug will be expedited and the potential is going to be greater because of more power and resources behind it  Last year  Sunesis Pharmaceuticals  SNSS  gained 15  on a day when it  a partnership with Royalty Pharma  Royalty Pharma agreed to pay Sunesis  25 million if the company is successful developing its lead product candidate Vosaroxin  which is an anticancer quinolone derivative class of compounds that have never used to attempt to treat cancer  In the time since  Sunesis has seen a stock price increase of well over 100  from  2 87 to  6 18  Pozen is already partnered with such pharma giants as GlaxoSmithKline  Johnson   Johnson  JNJ   and AstraZeneca  which shows Pozen s management has experience with gaining partnership deals with large pharmas  PipelineThe graphic below shows the rest of Pozen s marketed and pipelined solutions  It is worth noting that the company has other solutions that will also see NDA filings within the next year FinancialsPozen was profitable for the first two quarters of 2012  before showing a loss in the last two quarters of the same year  This was in part due to less than expected sales from Vimovo  which is partnered with AstraZeneca  AstraZenca may have priced Vimovo too high at  4 a day  causing the drug to lose market acceptance  However as Jason Napodano reported in his article  AstraZenca may become more aggressive in its price point for the drug  Furthermore  AstraZeneca has filed Vimovo in 80 countries  receiving approval in 60 countries  and is currently launched in 40 countries  This leaves about 40 countries left for approval and roll out of the drug  which will equate to more revenue for Pozen moving forward   The stock price and volume have been increasing steadily over the last two weeks or so  With nearly 6 4  of the float held short  Pozen makes for a decent short squeeze candidate  Institutional ownership is high  especially for a stock selling in the high  5 range like Pozen  With a market cap of  173 06M  I believe that Pozen is undervalued by about  100M when considering the market opportunity for its PA platform  40 more countries to roll out Vimovo  and the likeliness of a partnership for PAPA32540 which as already mentioned  should net at least a  30M upfront payment   From the chart above  the stock looks to be finally reversing the extended down trend it has been in since May of last year  It appears to me that catalyst traders and investors are accumulating the stock  With the NDA filing for PA32540 expected in April  and the likeliness of the company gaining a significant partnership with the drug before then  a short term price appreciation to the  6 50 range looks to be in short order  Price target opinions   6 50 to  6 75 in the short term as a catalyst trade  and a one year target price of  10  Pozen just might be a very good stock to buy and hold for the long term  which is a rare thing for small cap biopharmas  Disclosure  I am long POZN  Additional disclosure  Disclaimer  This article is intended for informational and entertainment use only  and should not be construed as professional investment advice  They are my opinions only  Trading stocks is risky    always be sure to know and understand your risk tolerance  You can incur substantial financial losses in any trade or investment  Always do your own due diligence before buying and selling any stock  and or consult with a licensed financial adviser ,2013-02-11,Scott Matusow,https://www.investing.com/analysis/pozen:-an-undervalued-investment-and-catalyst-trade-opportunity-154770,154770
30499,252014,CSII,Amarin Stagnates Despite New Attention From The Market,opinion,It seems that the market s attention is once again turning to Amarin Corporation  AMRN   which has recently launched the much anticipated prescription omega 3 hypertriglyceridemia drug Vascepa into the United States  Sales revenue is expected to become grow impressively over time because of the improved safety profile that Vascepa offers when compared to the current leader of the market  Lovaza   marketed by GlaxoSmithKline  GSK   Lovaza is an extremely successful drug  which boasts annual revenues of over  1 billion in the US alone  and over  400 million abroad   Given its current valuation of   1 3 B  the market is generally saying that Amarin won t even be able to match Lovaza s sales  Despite the big potential of the drug  it seems that the market still can t get over the fact that Amarin has not been acquired  Recall that in 2012  the AMRN investment community was utterly obsessed with the notion that there were buyers lined up to partner with  or buy the company outright  There were very big rumors about Teva Pharmaceuticals TEVA  and AstraZeneca  AZN  in particular  which were rumored to be some of Amarin s most interested potential acquirers  It was due to this intense M A speculation that I decided to purchase some AMRN for myself  with the intent to reap options premiums from the call options buyers who were expecting a buyout of AMRN north of  20 share in the near future  This was driving call options premiums through the room  and it ended up being a gold mine for those who expected AMRN to be acquired at a later date  like myself   Unfortunately  all good things come to an end  This was the case for the M A speculation over Amarin  especially after the company s  on December 6th 2012  which unveiled the company s plans to raise  100 million to basically prepare for the launch of Vascepa  Amarin also finalized their plans to hire a few hundred people for their Vascepa sales force for the marketing of Vascepa under the MARINE indication  What exactly does that mean  Well  let s just put these indications for Vascepa in an easy to understand format  MARINE Indication  Treatment of hypertriglyceridemia  high triglyceride levels  for patients over 500 mg dL ANCHOR Indication  Treatment of hypertriglyceridemia for patients over 200 mg dL REDUCE IT Indication  Treatment for  cardiovascular risk  In 2012  Vascepa was FDA approved for the MARINE indication  which means that it can be prescribed for adult patients with excessively high triglyceride levels  Excluding off label usage  this means that doctors use it only for patients with extremely high triglycerides  Only a small fraction  about 10  of the 40 million hypertriglyceridemia patients or so  reach that particular threshold  This also means that MARINE indication matches the indication that was given to GlaxoSmithKline s Lovaza  Things get more exciting for Amarin in the future because of the potential approval for the ANCHOR indication  which is scheduled to have its sNDA submission before the end of this month  This means that AMRN investors will have a PDUFA action date look forward to in December 2013 or early 2014 that could expand Vascepa s target market to about 40 million adult patients  far exceeding the reach of Lovaza   If Amarin receives this FDA approval  I think AMRN could move substantially higher although it will certainly be less than 900  upside   I d say 200  at best   Down the road  we also have the REDUCE IT trial which can expand Vascepa s potential into the overall  reduction of cardiovascular risk  area  This means that many of the patients that are on statin therapy for cholesterol  hyperlipidemia  might be taking Vascepa as well as a preventative medicine  Overall  while AMRN investors wait for the establishment of the PDUFA date for the FDA s decision on the ANCHOR indication there are other factors which could move the stock significantly this year  AMRN seems to have dropped 30  permanently following the equity financing press release mentioned earlier  which is ultimately a result of the mentioned  fizzling out  of M A speculation over AMRN and the big skepticism that the market is placing on Amarin over its ability to launch a drug into a huge and competitive market by itself  I think that Vascepa sales could help mitigate some of this skepticism given that they have a fast enough growth rate  I also want to mention that the lack of an NCE decision over Vascepa is another lingering topic from 2012 that has yet to be addressed  An NCE means the difference between 3 and 5 years of exclusivity for Amarin s Vascepa  although it s also worth mentioning that the extensive patent protection that Amarin has layered over Vascepa could make the NCE decision a moot point  these patents last until 2030   I would encourage anyone looking for a long term holding in the pharmaceutical industry to at least consider Amarin  although it s important to be aware of the risks surrounding this stock as well  As we ve seen with Vivus   NASDAQ  VVUS  launch of Qsymia last year  healthcare reimbursement issues can be crippling to a drug s sales figures  It s also true that large pharmaceutical companies are simply more efficient at drug launches  which puts Amarin at a disadvantage in many ways  Nonetheless  I think AMRN has significant downside protection due to the fact that M A speculation for the stock is somewhat dead  and investors are pricing Vascepa to be worth only a fraction of what Lovaza is  I don t think that Amarin has become a less attractive acquisition target either  in fact  I d say the opposite   and I think that an NCE decision could definitely result in an unexpected  sudden acquisition from a larger pharmaceutical company sometime this year  We ll have to see  Disclosure  I am long AMRN  and continue to sell covered calls against the position  I d also encourage investors who are looking to perform heavy due diligence on Amarin to consider points brought up against Vascepa by competitors  See an interview with Omthera Pharmaceuticals  CEO  Jerry Wisler on November 14th  ,2013-02-13,Myriad Equity,https://www.investing.com/analysis/amarin-stagnates-despite-new-attention-from-the-market-155104,155104
30500,252015,CSII,Did We Overshoot Expectations In the Obesity Drug Space ,opinion,After seeing relative underperformance of the two most prominent plays on the obesity drug space   Arena  ARNA  and Vivus  VVUS  throughout the first quarter of 2013  there has been talk about a potential  overshooting of expectations  for this new drug indication  While Wall Street was more comfortable with its optimistic valuation of ARNA and VVUS last year after we saw semi unexpected FDA approvals for Belviq  lorcaserin  and Qsymia  phentermine and topiramate ER   a dismal US launch of Vivus  Qsymia is leading many to believe that this drug market is much smaller than we thought Initially  many analysts made their sales projections based on the sheer number of Americans who are classified as  obese   which is technically defined through the BMI scale which simply divides someone s weight by their squared height  This was combined with arbitrarily defined penetration rates for the drug  which presumed that a certain percentage rate of physicians would prescribe a given obesity drug to their patients With something like 1 3 American adults being considered obese by the BMI scale  and with hundreds of thousands of deaths per annum being attributed to obesity by the most prominent government and physician organizations  it seemed like a no brainer to imagine that the obesity drug space would also be enormous  Since Qsymia would be the first available prescription obesity drug available since the 1990 s  wouldn t it be expected to become an instant blockbuster with multibillion dollar sales potential each year The bullish thesis makes sense from a common sense perspective  but Qsymia s performance since its launch in September 2012 has really shaken the faith that investors once had in this emerging drug indication  In addition  the European Medicines Agency seems hesitant to introduce obesity drugs to its population In its Q4 2012 earnings release  which can be found here   Vivus reported only  1 97 million in revenues for the quarter ended December 31  2012  This was offset by the company s  50 3 million budget for SG A  selling  general   administration  expenses and ultimately brought Vivus  losses to  56 3 million It s not fair to make a final judgment call on Qsymia  but the initial results are far from impressive and favor the argument that the obesity drug space might be significantly smaller or more elusive than we expected  Qsymia s  1 97 worth of quarterly revenue needs to expand drastically to justify the current valuation of the company at   1 2 billion  Even after a recent rally  VVUS has been brought down an additional 12 2  since the start of 2013 on the modest performance of its flagship drug  and its dismal chances at European approval Having said that  there are other factors that could turn the obesity drug space around after the introduction of Arena s Belviq  While Qsymia s efficacy profile is considered top notch in this space  it introduces cardiovascular risk factors on its label  Since obese patients are much more exposed to cardiovascular risk factors than most  I find it very possible that Qsymia sales are being thwarted by physician concerns on patient safety Due to this  I think Belviq  which is seeing a delayed launch due to some temporary government related factors  will give us a better read on the market potential of the obesity indication due to its relative safety  I also believe that the differential between the market value of Arena and Vivus are directly attributable to the respective  physician friendliness  of the Belviq and Qsymia alone So did we overshoot our expectations in the obesity drug space The answer seems to be yes based on what we know so far  although Belviq has a chance to disprove this conclusion given that it has a well orchestrated launch ,2013-03-18,Myriad Equity,https://www.investing.com/analysis/did-we-overshoot-expectations-in-the-obesity-drug-space-159273,159273
30526,252041,CSII,QuickView  Mesoblast  ,opinion,Mesoblast s  MSB AX  current valuation assumes a high probability of success for its stem cell technology  but it does hold the leadership position in this field  A proposed large Phase III study of Revascor in congestive heart failure  CHF   which is to be fully funded by co development partner Teva  holds promise of both validating the company s mesenchymal precursor cell  MPC  platform and moving stem cell therapeutics closer to commercial reality in the US  However  an EV of A 1 59bn  when compared to peers  belies the risk of any clinical trial setbacks and potential competition from rival approaches to indications being targeted Revascor to enter Phase III in congestive heart failureA planned Phase III trial of lead product Revascor in 1 700 patients with CHF should start in 2013  with co development partner Teva bearing all costs  Early data is positive but limited  A 60 patient Phase II trial examining the safety and efficacy of three doses of Revascor showed patients treated with a single intra cardiac injection of the highest dose had no hospitalisation events for decompensated heart failure or cardiac related deaths  over a mean follow up period approaching three years Stem cell therapy   promising but riskyDespite the potential of engineered stem cell therapies to address major unmet needs  the technology is unproven and there remains considerable clinical and regulatory risk  The FDA is yet to approve such a treatment Multiple clinical programmes   single technology platformThe recent A 170m capital raising extends the cash runway for funding of multiple clinical programmes  six Phase II  five preclinical  through to 2016  based on its current US 65m pa burn rate  during which time clinical data should be reported  In addition to cardiovascular indications  clinical trials are also targeting degenerative disc disease  type 2 diabetes and wet age related macular degeneration  AMD   Although this portfolio approach provides multiple shots at goal  clinical risk inherent in each trial is compounded overall by the use of a single technology platform Valuation  Assumes high probability of clinical successAn EV of A 1 59bn  based on net cash of A 332m  March 2013  including A 170m raising   assumes a high probability of success across a development pipeline built on a single technology platform with limited clinical efficacy data to date  By comparison  Osiris  which has the  albeit niche  allogenic stem cell therapy Prochymal  remestemcel L  approved in Canada in 2012  has an EV of US 338m To Read the Entire Report Please Click on the pdf File Below ,2013-03-24,Edison,https://www.investing.com/analysis/quickview:-mesoblast-160250,160250
30547,252062,CSII,Amarin  Waiting For The FDA ,opinion,Investment summary  Waiting for the FDAAmarin s  AMRN  potential blockbuster Vascepa  icosapent ethyl  is ostensibly due to be launched into the large US cardiovascular market in Q113  although how this will be achieved remains unresolved  Uncertainty over Vascepa s market exclusivity and commercial strategy has weighed on the shares   30   since FDA approval in July 2012  Amarin is considering a trade sale  securing a partner or going it alone as the commercial option for Vascepa  The imminent FDA decision  expected in Dec 12  on Vascepa s NCE status is a major potential catalyst and could set the shares on a new trajectory  although multiple FDA delays to this verdict do not bode well Vascepa could be a game changerVascepa  is an omega 3 fatty acid approved in the US as an adjunct therapy to reduce triglycerides  TG  in patients with very high TG levels  Launch is expected in Q113 and will compete against GSK s omega 3 product Lovaza  with FY12 sales run rate c  1bn  Vascepa also reduces LDL while Lovaza raises it  Based on this favourable profile  Vascepa could ultimately generate   1bn in sales Vascepa patents are positive  but NCE status is the focusAmarin has nine issued and allowed patents   30 pending  for Vascepa that extend its US patent protection out to 2030  However  as the market is unsure whether these patents would be upheld if challenged  Vascepa s new chemical entity  NCE  status has taken on new importance  If the FDA grants NCE status  Amarin would get at least five years of market exclusivity  only three years if not   The FDA previously delayed its NCE decision  which is now expected in December Multiple commercialisation optionsAmarin s options include launching Vascepa itself  with some third party support   through a partnership with a larger pharma company  which would likely drive greater utilisation  or it may sell itself to another company  The outcome of the FDA s NCE decision for Vascepa will largely determine how Amarin moves forward Valuation  Several near term catalysts lie aheadAmarin has an EV of c  1 5bn  reflective of the market s high expectations for Vascepa  Near term upside could come from a positive FDA NCE decision and subsequent partnering acquisition  Downside would come from negative NCE news and or Amarin launching on its own  putting pressure on its  215m cash reserves To Read the Entire Report Please Click on the pdf File Below ,2012-11-22,Edison,https://www.investing.com/analysis/amarin:-waiting-for-the-fda-144693,144693
30548,252063,CSII,3 Small Cap Biopharmas With Upcoming Catalyst Events,opinion,Alexza Pharma  ALXA  Alexza engages in the research  development  and commercialization of novel proprietary products for the acute treatment of central nervous system conditions worldwide  Its product candidates are based on a proprietary technology  the Staccato system  which vaporizes an excipient free drug to form a condensation aerosol that  when inhaled  allows for rapid systemic drug delivery  The company s lead product candidate includes Adasuve  Staccato loxapine  for the acute treatment of agitation in adults with schizophrenia or bipolar disorder  The first catalyst event for Alexza is a decision on its Marketing Authorization Application  MAA  submitted to the European Medicines Agency  EMA  for Adasuve  This decision is scheduled for the middle of December  2012  The second catalyst event for the company is Adasuve  s Prescription Drug User Fee Act  PDUFA  date of 12 21 12  which is the bigger catalyst driver  In May of this year  Alexza  a Complete Response Letter  CRL  from the FDA regarding its New Drug Application  NDA  for Adasuve inhalation powder    5 mg and 10 mg  In the CRL  the FDA   During a recent inspection of the Mountain View  CA manufacturing facility for this application  our field investigator conveyed deficiencies to the representative of the facility  Satisfactory resolution of these deficiencies is required before this application may be approved  The CRL went on to state that discussions can continue on the proposed Risk Evaluation and Mitigation Strategy  REMS  after the response to the action letter has been submitted  The CRL also contained comments on Alexza s draft product labeling  The company now believes there is a substantial agreement with the FDA on the REMS and product labeling  Senior Vice President of R D Jim Cassella   The issue that the FDA noted was an inspectional issue  so that was the only thing really in the letter  We addressed the issues with the CDRH reviewers who had raised the issue and then we responded to their questions  We resubmitted the NDA  which is basically a labeling resubmission  so there is not a lot of work left to do  We believe that we have addressed the inspectional issues and we have resubmitted an advanced draft of the label and we have probably a little bit of work left to do on some of the REMS documents  Since there was no clinical or safety issues identified  and no other deficiencies outlined in the CRL  Adasuve has a good chance at approval this go around in my opinion  Manufacturing  labeling  and REMS can be dealt with    efficacy and serious safety concerns cannot  Alexza has a very small float of which over 17  of it is held short  An FDA approval for Adasuve would likely cause a short squeeze  It s a good bet the smarter shorts will be covering their positions as we draw close to both catalyst event dates  Again  if safety and efficacy issues were the main concern here  then I could understand shorts holding their positions  However  this is not the case  Recently  we saw a 200  jump in Acadia Pharma s  ACAD  stock price when its drug Pimavanserin showed positive Phase III clinical results  Pimavanserin is designed for the treatment of Parkinson s disease psychosis  Adasuve is similar to Pimavanserin in that both are designed to treat  disorders  and both drugs saw initial failures  Also  Acadia still needs to engage in another clinical study for Pimavanserin  so there still remains considerable uncertainty in Acadia  On a related note  I feel Acadia is overvalued at its current price level and there remains too much downside risk at this time for me to consider it a good long trade investment  I would not be surprised to see a double of the company s stock on FDA approval  However  there is considerable risk for traders and investors holding through the PDUFA date  If the FDA rejects Adasuve again  it s likely Alexza as a company will not survive because they will simply run out of cash  At the very least  the company would have to engage in dilutive financing to survive  While I believe this will not occur  it s wise to consider this possibility  Alexza was beaten down after its last CRL  but since then it has begun to reverse leading into the December PDUFA date  The stock is wedged between two trend lines and poised to break out as sentiment remains strong  There is a psychological support level at  5 00 and the stock could break out to test the  6 00 level it touched earlier this year or perhaps even higher  With a market cap of around  80M  I strongly feel Alexza is undervalued at this time  My price target opinion before the PDFUA date is  6  If approval is confirmed   12 share is my expectation  Amicus Therapeutics  Inc   FOLD  focuses on the discovery  development  and commercialization of orally administered  small molecule drugs for the treatment of lysosomal storage disorders and diseases of neurodegeneration  Its drugs are known as pharmacological chaperones  which selectively bind to the target protein  enhance the stability of the protein  help it fold into the three dimensional shape  as well as allowing proper trafficking of the protein  This increases protein activity  enhances cellular function  and reduces cell stress  In its Fabry program  the company is investigating the use of AT1001 to bind to destabilized   galactosidase A enzyme    GAL  and thereby restore its intended biological function  A potentially big catalyst coming up for Amicus is the release of the phase III 011 six month results related to its medication for Fabry disease  This is a disorder caused by the deficiency of an enzyme called   galactosidase A    GAL   Reduced or absent levels of this enzyme s activity leads to the accumulation of a complex lipid in the affected tissues  including the central nervous system  heart  kidneys  and skin  This accumulation is believed to cause the various symptoms of Fabry disease including pain  kidney failure  and increased risk of heart attack and stroke  There has been historic difficulty in finding successful treatments for rare genetic diseases  If Amicus can show successful phase III data here  it could be quite a breakthrough in the treatment for Fabry s disease  On 9 6 12  Amicus issued a  to update the screening profiles related to the 011 study  which is one of two ongoing Phase III studies of migalastat HCl monotherapy being conducted by the company and GlaxoSmithKline  GSK   The updated screening profiles included the following  A total of 180 Fabry patients  60 males and 120 females  were screened for Study 011  Prior to screening  sites used genotype information when available to enrich Fabry patients with amenable mutations who were more likely to be interested in participating in the study Approximately 86   154 180  of patients screened had missense mutations  compared to a current estimate in the Fabry population of approximately 60   Approximately 88   136 154  of those patients  or 76  of patients screened  had alpha galactosidase A mutations amenable to migalastat HCl monotherapy  and were potentially eligible for enrollment Approximately 50   67 136  of those patients  or 37  of all patients screened  enrolled in Study 011 upon meeting all entry criteria  including  1  na ve to ERT or had not received ERT for at least 6 months prior to study entry  2  genetic mutations amenable to chaperone monotherapy and  3  for study purposes  urine globotriaosylceramide  GL 3  levels at least four times the upper limit of normal at baseline The primary endpoint in Study 011 is a change in interstitial capillary GL 3  as measured in a kidney biopsy at six months versus baseline  The six month primary treatment period in Study 011 was completed in the second quarter of 2012 and the six month follow up period is expected to complete in   Amicus and GSK will also un blind and analyze data from the primary six month treatment at this time  Currently  both companies remain blinded to all results  Also of significance  on November  8  2012  the company  additional preliminary results from an open label Phase 2 drug interaction study    to evaluate a single oral dose of migalastat HCl  150 mg or 450 mg  co administered with enzyme replacement therapy    in males with Fabry disease  In a poster at the   Dr  David G  Warnock  University of Alabama Birmingham  presented results from all 12 patients in the migalastat HCl 150 mg dose group  Based on the bullish move the stock has been making lately  I think it s possible the release of the expected December data comes before the middle of the month  If the results prove to be positive  I expect the stock to be at least double its current price for a couple of factors  GlaxoSmithKline owns 20  of Amicus  It s a good bet in my opinion that Glaxo will acquire the rest of Amicus if the clinical trial results prove to be positive  Fabry s is a rare disorder  and Amicus s Chaperone technology is cutting edge in my opinion  which if confirmed  would be worth a lot of money  Even if Glaxo does not acquire Amicus  with 20  interest in the company  Glaxo has a significant vested interest in seeing Amicus succeed Amicus has a small trading float of around 24 42M  with a market cap coming in at  290 76M  As mentioned prior  Acadia Pharma recently saw its stock price move up 200  on positive results from its Phase III drug study  Acadia s drug is nowhere near the worth of Amicus s in my opinion  yet Acadia has a current market cap of  304 05M with a larger trading float of around 40M shares In 2001  two  were released which attempt to replace the deficient enzyme by means of infusion  The drugs are expensive  with an annual cost of approximately  per patient  it s estimated about 10 000 people suffer from Fabry s disease globally  Insurance companies normally cover treatments for rare diseases such as Fabry s  so this is also a big positive for both Glaxo and Amicus  For a big pharma such as Glaxo  it always comes down to making big money   period  Glaxo would not be involved with Amicus and own 20  of the company for any other reason  Amicus also has other drugs in earlier clinical development  which adds further speculation value to the company in my strong opinion   Amicus recently bounced off of a support level at  4 25 with conviction  and since then the stock has gained significantly leading into its crucial Phase III data release  The stock needs to consolidate here at the 61 8  retrace point a bit but is setting up for the next leg higher to the  6 60 range  possibly even before the data is released in December  My price target opinion for Amicus  Over  10 a share on positive Phase III 011 data   12 to  14 on potential Glaxo acquisition  Arena Pharmaceuticals  ARNA  Arena engages in discovering  developing  and commercializing oral drugs that target G protein coupled receptors in the therapeutic areas of cardiovascular  central nervous system  inflammatory  and metabolic diseases  Since the  of its weight loss drug Belviq in June  the stock has fallen from a yearly high of  11 39 to  7 21  a fall of 37   I feel long term investors have excellent value here at its current price level of around  9 a share  The focus on Arena should now be on potential top line growth from its strong clinical pipeline  Because Arena will likely receive a large amount of cash from Belviq sales  I believe it is a strong speculative bet that management will re invest this cash into its pipeline  This would gain leverage for the company in any potential deal with a large pharma partner for any of its pipelined drugs which are  APD811  An orally available agonist of the prostacyclin receptor is intended for the treatment of pulmonary arterial hypertension  or PAH  In December 2010  Arena initiated a Phase 1 clinical trial to evaluate the safety  tolerability and pharmacokinetics of single ascending doses of APD811  The company believes the results of this early stage clinical trial suggest APD811 has the potential for once daily  oral dosing  APD334  A potential oral treatment for a number of conditions related to autoimmune diseases  including multiple sclerosis and rheumatoid arthritis  APD371  For the potential treatment of pain  The analgesic effects of CB receptor agonists are well established in the scientific literature  GPR119  A novel pharmaceutical target for discovering orally available small molecule agonists for the treatment of type 2 diabetes  Temanogrel  An inverse agonist of the serotonin 2A receptor intended for the treatment of arterial thrombosis and other related conditions has completed Phase 1a and Phase 1b clinical trials  In my opinion  if Arena can get the first weight loss drug approved since 1999  the company can get others approved in time as well  Also  if the company can manage its money correctly  it can become a large pharma within 3 to 5 years  similar to how Jazz Pharma  JAZZ  has grown in a little over 3 years from   to a current stock price of  53 58 a share  However  TheStreet com  as a sell with a ratings score of D   One area they are negative on is poor profit margins from the company  I find TheStreet s rating system to be insufficient at best concerning developmental small cap companies  Of course Arena is going to have poor profit margins    it does not have Belviq out on the market yet  The drug  to consumers through a doctor s prescription in early 2013  Arena also  to receive  65 million before the end of 2012 from its marketing partner Eisai following the Drug Enforcement Agency  DEA    which does not include any of the revenue under marketing agreement with Eisai such as product sales of the drug  Arena is more of a speculative long term investment than just a trade  so I will not engage in any chart analysis for the stock  My 3 to 5 year price target opinion for Arena  barring a market crash  is  25 to  45 a share  Disclosure  I am long ALXA  FOLD  I wrote this article myself  and it expresses my own opinions  I am not receiving compensation for it  I have no business relationship with any company whose stock is mentioned in this article  Disclaimer  This article is intended for informational and entertainment use only  and should not be construed as professional investment advice  They are my opinions only  Trading stocks is risky    always be sure to know and understand your risk tolerance  You can incur substantial financial losses in any trade or investment  Always do your own due diligence before buying and selling any stock  and or consult with a licensed financial adviser ,2012-12-02,Scott Matusow,https://www.investing.com/analysis/3-small-cap-biopharmas-with-upcoming-catalyst-events-145789,145789
30549,252064,CSII,Resverlogix  Pivot Trials And Partnerships Could Be Next ,opinion,Investment summary  A BET on ApoA IResverlogix  RVX TO  offers investors a potentially geared return based on the outcome   due in Q2 next year   of its ASSURE Phase IIb trial of RVX 208  This study is designed to show regression of atherosclerosis in high risk cardiovascular disease  CVD   a US 90bn global market  The study result represents a catalyst  magnified by the fact Resverlogix s valuation has recovered little since the steep fall in 2010 on the narrow miss on significance in the ASSERT Phase II trial for the same indication  Edison will take up formal coverage of Resverlogix in 2013 ASSURE to determine functional CVD risk measuresRecruitment has now completed in the 324 patient placebo controlled Phase IIb trial and data are due in Q213  The primary endpoint is change at 26 weeks in vascular plaque volume as measured by IVUS  ultrasound   This should be an effective surrogate for CVD risk  typically measured by MACE or major adverse cardiac events  and differs from the endpoint used in ASSERT  change in ApoA I levels at 12 weeks   The Phase III trial would use MACE as the primary endpoint Up regulation of nascent HDL could be key differentiatorRVX 208 acts via an epigenetic mechanism that leads to enhanced activity of the ApoA I gene resulting in increased production of the protein  ApoA I  This in turn produces new and unoccupied HDL particles that are potentially capable of removing atherosclerotic plaque  Its approach differs from recent failed HDL raising strategies  such as torcetrapib and dalcetrapib  that seek to delay HDL breakdown Pivotal trials and partnerships could be nextRVX 208 is unpartnered and Resverlogix will need to sign a deal for Phase III trials  This will potenitally focus on patients with high risk coronary artery disease  low baseline HDL and one or more risk factors  diabetes  smoking or high blood pressure   Resverlogix is also seeking to partner its epigenetics platform in autoimmune  oncology indications over the coming months Valuation  EV of  C 135m  still below pre ASSERT levelsGiven a recent C 25m loan  Resverlogix is currently funded beyond the ASSURE readout but with cash burn of C 28m year  it will still have to move fast to secure partnerships  Recently reported SUSTAIN Phase IIb results showing a significant increase in HDL C  p 0 001  and increases in levels of ApoA I  p 0 002  and large HDL particles  p 0 02  at 24 weeks bode well for the ASSURE trial  A positive result would  in our view  prompt a significant revaluation and allow the company to explore both financing and business development options To Read the Entire Report Please Click on the pdf File Below ,2012-12-12,Edison,https://www.investing.com/analysis/resverlogix:-pivot-trials-and-partnerships-could-be-next-147184,147184
30607,252122,CSII,44 Cash Rich Stocks Smart Money Investors Are Buying,opinion,Screen Criteria List of stocks with significant institutional buying  and a significant cash vs operating expense ratio Average Weekly Returns Average 1 Week Return of All Stocks Mentioned Below  0 15 Average 1 Month Return of All Stocks Mentioned Below  4 98 Analysis of List Alpha Number of Stocks in This List Generating Excess Return vs  SP500  Beta Adjusted Over Last Week   17 out of 44  38 64  Number of Stocks in This List Generating Excess Return vs  SP500  Beta Adjusted Over Last Month   24 out of 44  54 55  Chart  Distribution of 1 Week Returns For All Stocks Mentioned BelowChart  Distribution of 1 Month Returns For All Stocks Mentioned Below 1  Infinity Pharmaceuticals  Inc   INFI   Engages in the discovery and development of medicines for the treatment of cancer and other conditions in the United States  Net institutional shares bought during the most recent quarter at 8 7M shares  39 28  of float at 22 15M shares   Average quarterly operating expense over the last five quarters at  24 72M  vs  most recent cash and short term investments at  188 77M  implies a Cash   Avg  Operating Expense ratio at 7 64   2  Celldex Therapeutics  Inc   CLDX   Engages in the development  manufacture  and commercialization of targeted immunotherapies that prevent or treat specific forms of cancer  autoimmune disorders  and diseases caused by infectious organisms  Net institutional shares bought during the most recent quarter at 5 1M shares  8 26  of float at 61 75M shares   Average quarterly operating expense over the last five quarters at  15 55M  vs  most recent cash and short term investments at  77 61M  implies a Cash   Avg  Operating Expense ratio at 4 99    3  Idenix Pharmaceuticals Inc   IDIX   Engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases in the United States and Europe  Net institutional shares bought during the most recent quarter at 16 9M shares  23 76  of float at 71 12M shares   Average quarterly operating expense over the last five quarters at  22 45M  vs  most recent cash and short term investments at  251 87M  implies a Cash   Avg  Operating Expense ratio at 11 22    4  Medivation  Inc   MDVN   Focuses on the development of small molecule drugs for the treatment of castration resistant prostate cancer  Alzheimer s disease  and Huntington disease  Net institutional shares bought during the most recent quarter at 3 6M shares  5 41  of float at 66 60M shares   Average quarterly operating expense over the last five quarters at  39 47M  vs  most recent cash and short term investments at  340 41M  implies a Cash   Avg  Operating Expense ratio at 8 62    5  Corcept Therapeutics Incorporated  CORT   Engages in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders  Net institutional shares bought during the most recent quarter at 10 1M shares  15 71  of float at 64 31M shares   Average quarterly operating expense over the last five quarters at  8 92M  vs  most recent cash and short term investments at  101 63M  implies a Cash   Avg  Operating Expense ratio at 11 39    6  Orexigen Therapeutics  Inc   OREX   Focuses on the development of pharmaceutical product candidates for the treatment of obesity  Net institutional shares bought during the most recent quarter at 10 6M shares  14 30  of float at 74 13M shares   Average quarterly operating expense over the last five quarters at  14 19M  vs  most recent cash and short term investments at  108 28M  implies a Cash   Avg  Operating Expense ratio at 7 63    7  Synergy Resources Corporation  SYRG   Engages in the acquisition  exploitation  exploration  development  and production of oil and natural gas properties primarily located in the Wattenberg field in Denver Julesburg Basin in northeast Colorado  Net institutional shares bought during the most recent quarter at 3 2M shares  7 93  of float at 40 37M shares   Average quarterly operating expense over the last five quarters at  3 05M  vs  most recent cash and short term investments at  19 28M  implies a Cash   Avg  Operating Expense ratio at 6 32    8  Alnylam Pharmaceuticals  Inc   ALNY   Focuses on the discovery  development  and commercialization of novel therapeutics based on RNA interference  RNAi   Net institutional shares bought during the most recent quarter at 4 1M shares  9 44  of float at 43 42M shares   Average quarterly operating expense over the last five quarters at  33 32M  vs  most recent cash and short term investments at  228 34M  implies a Cash   Avg  Operating Expense ratio at 6 85    9  Arena Pharmaceuticals  Inc   ARNA   Focuses on discovering  developing  and commercializing oral drugs in the therapeutic areas of cardiovascular  central nervous system  inflammatory  and metabolic diseases  Net institutional shares bought during the most recent quarter at 29 5M shares  13 65  of float at 216 13M shares   Average quarterly operating expense over the last five quarters at  22 4M  vs  most recent cash and short term investments at  165 77M  implies a Cash   Avg  Operating Expense ratio at 7 4    10  Xenoport  Inc   XNPT   Focuses on developing and commercializing internally discovered product candidates that utilize the body s natural nutrient transport mechanisms to enhance the therapeutic benefits of drugs  Net institutional shares bought during the most recent quarter at 8 4M shares  21 53  of float at 39 02M shares   Average quarterly operating expense over the last five quarters at  19 34M  vs  most recent cash and short term investments at  112 86M  implies a Cash   Avg  Operating Expense ratio at 5 83    11  Immunogen Inc   IMGN   Engages in the research and development of antibody based anticancer therapeutics in the United States  Net institutional shares bought during the most recent quarter at 4 6M shares  5 48  of float at 83 90M shares   Average quarterly operating expense over the last five quarters at  23 79M  vs  most recent cash and short term investments at  233 61M  implies a Cash   Avg  Operating Expense ratio at 9 82    12  MAP Pharmaceuticals  Inc   MAPP   Focuses on the development and commercialization of inhalation therapies for patients suffering from migraine  Net institutional shares bought during the most recent quarter at 3 9M shares  13 12  of float at 29 72M shares   Average quarterly operating expense over the last five quarters at  14 76M  vs  most recent cash and short term investments at  114 22M  implies a Cash   Avg  Operating Expense ratio at 7 74    13  Sunesis Pharmaceuticals Inc   SNSS   Focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers  Net institutional shares bought during the most recent quarter at 10 2M shares  41 48  of float at 24 59M shares   Average quarterly operating expense over the last five quarters at  9 03M  vs  most recent cash and short term investments at  76 55M  implies a Cash   Avg  Operating Expense ratio at 8 48    14  Exact Sciences Corporation  EXAS   Focuses on developing a molecular diagnostic screening technology for the early detection and prevention of colorectal pre cancer and cancer  Net institutional shares bought during the most recent quarter at 5 8M shares  9 95  of float at 58 27M shares   Average quarterly operating expense over the last five quarters at  12 31M  vs  most recent cash and short term investments at  118 57M  implies a Cash   Avg  Operating Expense ratio at 9 63    15  Illumina Inc   ILMN   Develops  manufactures  and markets integrated systems for the analysis of genetic variation and biological function  Net institutional shares bought during the most recent quarter at 8 8M shares  7 24  of float at 121 61M shares   Average quarterly operating expense over the last five quarters at  223 87M  vs  most recent cash and short term investments at  1233 07M  implies a Cash   Avg  Operating Expense ratio at 5 51    16  Two Harbors Investment Corp   TWO   Operates as a real estate investment trust  REIT  that focuses on investing in  financing  and managing residential mortgage backed securities  RMBS  and related investments  Net institutional shares bought during the most recent quarter at 58 9M shares  20 04  of float at 293 85M shares   Average quarterly operating expense over the last five quarters at  55 76M  vs  most recent cash and short term investments at  833 61M  implies a Cash   Avg  Operating Expense ratio at 14 95    17  Repros Therapeutics Inc   RPRX   Net institutional shares bought during the most recent quarter at 2 6M shares  20 44  of float at 12 72M shares   Average quarterly operating expense over the last five quarters at  3 36M  vs  most recent cash and short term investments at  29 58M  implies a Cash   Avg  Operating Expense ratio at 8 8    18  VIVUS Inc   VVUS   Engages in the development and commercialization of therapeutic products for underserved markets in the United States  Net institutional shares bought during the most recent quarter at 5 8M shares  7 02  of float at 82 66M shares   Average quarterly operating expense over the last five quarters at  20 9M  vs  most recent cash and short term investments at  274 48M  implies a Cash   Avg  Operating Expense ratio at 13 13    19  Arlington Asset Investment Corp   AI   Arlington Asset Investment Corp   an investment firm  acquires mortgage related and other assets  Net institutional shares bought during the most recent quarter at 1 3M shares  15 01  of float at 8 66M shares   Average quarterly operating expense over the last five quarters at  4 99M  vs  most recent cash and short term investments at  85 74M  implies a Cash   Avg  Operating Expense ratio at 17 17    20  SolarWinds  Inc   SWI   Designs  develops  markets  sells  and supports enterprise information technology  IT  infrastructure management software to IT professionals  Net institutional shares bought during the most recent quarter at 3 2M shares  5 12  of float at 62 44M shares   Average quarterly operating expense over the last five quarters at  35 06M  vs  most recent cash and short term investments at  195 71M  implies a Cash   Avg  Operating Expense ratio at 5 58    21  Zillow  Inc   Z   Operates an online real estate information marketplace  Net institutional shares bought during the most recent quarter at 7 1M shares  40 73  of float at 17 43M shares   Average quarterly operating expense over the last five quarters at  23 18M  vs  most recent cash and short term investments at  228 88M  implies a Cash   Avg  Operating Expense ratio at 9 88    22  Maxygen  Inc   MAXY   Focuses on developing improved versions of protein drugs  Net institutional shares bought during the most recent quarter at 3 0M shares  12 25  of float at 24 48M shares   Average quarterly operating expense over the last five quarters at  2 63M  vs  most recent cash and short term investments at  83 48M  implies a Cash   Avg  Operating Expense ratio at 31 77    23  Threshold Pharmaceuticals Inc   THLD   Engages in the discovery and development of drugs targeting the microenvironment of solid tumors for patients living with cancer  Net institutional shares bought during the most recent quarter at 4 3M shares  9 52  of float at 45 18M shares   Average quarterly operating expense over the last five quarters at  6 76M  vs  most recent cash and short term investments at  65 83M  implies a Cash   Avg  Operating Expense ratio at 9 74    24  Resource Capital Corp   RSO   Operates as a specialty finance company that focuses primarily on commercial real estate and commercial finance in the United States  Net institutional shares bought during the most recent quarter at 6 1M shares  6 40  of float at 95 34M shares   Average quarterly operating expense over the last five quarters at  16 96M  vs  most recent cash and short term investments at  112 73M  implies a Cash   Avg  Operating Expense ratio at 6 65    25  SPS Commerce  Inc   SPSC   Provides on demand supply chain management solutions worldwide  Net institutional shares bought during the most recent quarter at 2 2M shares  15 10  of float at 14 57M shares   Average quarterly operating expense over the last five quarters at  16 8M  vs  most recent cash and short term investments at  69 72M  implies a Cash   Avg  Operating Expense ratio at 4 15    26  Nanosphere  Inc   NSPH   Develops  manufactures  and markets a molecular diagnostics platform  the Verigene System that enables genomic and protein testing on a single platform  Net institutional shares bought during the most recent quarter at 4 9M shares  19 41  of float at 25 25M shares   Average quarterly operating expense over the last five quarters at  9 66M  vs  most recent cash and short term investments at  41 92M  implies a Cash   Avg  Operating Expense ratio at 4 34    27  Ellington Financial LLC  EFC   Net institutional shares bought during the most recent quarter at 2 2M shares  14 22  of float at 15 47M shares   Average quarterly operating expense over the last five quarters at  7 14M  vs  most recent cash and short term investments at  69 22M  implies a Cash   Avg  Operating Expense ratio at 9 69    28  Aegerion Pharmaceuticals  Inc   AEGR   Engages in the development and commercialization of novel therapeutics to treat severe lipid disorders  Net institutional shares bought during the most recent quarter at 2 8M shares  17 48  of float at 16 02M shares   Average quarterly operating expense over the last five quarters at  12 64M  vs  most recent cash and short term investments at  95 46M  implies a Cash   Avg  Operating Expense ratio at 7 55    29  Ellie Mae  Inc  Common Stock  ELLI   Ellie Mae  Inc  and its subsidiaries host electronic mortgage origination network in the United States  Net institutional shares bought during the most recent quarter at 2 7M shares  13 47  of float at 20 05M shares   Average quarterly operating expense over the last five quarters at  17 48M  vs  most recent cash and short term investments at  93 86M  implies a Cash   Avg  Operating Expense ratio at 5 37    30  Kennedy Wilson Holdings  Inc   KW   Operates as a diversified real estate company that provides investment and real estate services in the United States and Japan  Net institutional shares bought during the most recent quarter at 7 4M shares  17 81  of float at 41 56M shares   Average quarterly operating expense over the last five quarters at  19 02M  vs  most recent cash and short term investments at  126 8M  implies a Cash   Avg  Operating Expense ratio at 6 67    31  THL Credit  Inc   TCRD   A private equity and mezzanine firm  Net institutional shares bought during the most recent quarter at 4 3M shares  20 53  of float at 20 95M shares   Average quarterly operating expense over the last five quarters at  4 98M  vs  most recent cash and short term investments at  25 95M  implies a Cash   Avg  Operating Expense ratio at 5 21    32  Newcastle Investment Corp   NCT   Operates as a real estate investment and finance company that invests in and manages a portfolio consisting primarily of real estate securities  Net institutional shares bought during the most recent quarter at 12 0M shares  6 96  of float at 172 50M shares   Average quarterly operating expense over the last five quarters at  43 56M  vs  most recent cash and short term investments at  229 04M  implies a Cash   Avg  Operating Expense ratio at 5 26    33  Insmed Incorporated  INSM   Focuses on the development of inhaled pharmaceuticals for the site specific treatment of serious lung diseases  Net institutional shares bought during the most recent quarter at 5 3M shares  33 44  of float at 15 85M shares   Average quarterly operating expense over the last five quarters at  14 45M  vs  most recent cash and short term investments at  89 75M  implies a Cash   Avg  Operating Expense ratio at 6 21    34  Evolution Petroleum Corp   EPM   Engages in the acquisition  exploitation  and development of properties for the production of crude oil and natural gas in Louisiana  Net institutional shares bought during the most recent quarter at 849 7K shares  5 47  of float at 15 52M shares   Average quarterly operating expense over the last five quarters at  2 3M  vs  most recent cash and short term investments at  13 38M  implies a Cash   Avg  Operating Expense ratio at 5 82    35  Kohlberg Kravis Roberts   Co   KKR   Kohlberg Kravis Roberts   Co  is a private equity and venture capital firm specializing in acquisitions  leveraged buyouts  management buyouts  and mezzanine investments in large cap companies  Net institutional shares bought during the most recent quarter at 22 7M shares  10 44  of float at 217 44M shares   Average quarterly operating expense over the last five quarters at  339 9M  vs  most recent cash and short term investments at  1603 44M  implies a Cash   Avg  Operating Expense ratio at 4 72    36  Exelixis  Inc   EXEL   Engages in the discovery  development  and commercialization of small molecule drugs for the treatment of cancer  metabolic  and cardiovascular disorders  Net institutional shares bought during the most recent quarter at 44 8M shares  26 51  of float at 169 00M shares   Average quarterly operating expense over the last five quarters at  42 08M  vs  most recent cash and short term investments at  484 59M  implies a Cash   Avg  Operating Expense ratio at 11 52    37  Fluidigm Corporation  FLDM   Engages in the development  manufacture  and marketing of microfluidic systems for growth markets in the life science and agricultural biotechnology  Ag Bio  industries  Net institutional shares bought during the most recent quarter at 5 2M shares  24 11  of float at 21 57M shares   Average quarterly operating expense over the last five quarters at  16 37M  vs  most recent cash and short term investments at  86 16M  implies a Cash   Avg  Operating Expense ratio at 5 26    38  NGP Capital Resources Company  NGPC   NGP Capital Resources Company is a business development company specializing in investments in small and mid size and middle market companies  Net institutional shares bought during the most recent quarter at 1 1M shares  5 37  of float at 20 49M shares   Average quarterly operating expense over the last five quarters at  2 8M  vs  most recent cash and short term investments at  31 86M  implies a Cash   Avg  Operating Expense ratio at 11 38    39  Agenus Inc   AGEN   Develops and commercializes immunotherapies for cancer and infectious diseases  Net institutional shares bought during the most recent quarter at 1 5M shares  6 82  of float at 22 01M shares   Average quarterly operating expense over the last five quarters at  5 61M  vs  most recent cash and short term investments at  25 46M  implies a Cash   Avg  Operating Expense ratio at 4 54    40  HomeAway  Inc   AWAY   Operates an online marketplace for the vacation rental industry  Net institutional shares bought during the most recent quarter at 5 6M shares  14 17  of float at 39 52M shares   Average quarterly operating expense over the last five quarters at  58 15M  vs  most recent cash and short term investments at  244 21M  implies a Cash   Avg  Operating Expense ratio at 4 2    41  Achillion Pharmaceuticals  Inc   ACHN   Engages in the discovery  development  and commercialization of treatments for infectious diseases  Net institutional shares bought during the most recent quarter at 10 2M shares  16 56  of float at 61 61M shares   Average quarterly operating expense over the last five quarters at  12 32M  vs  most recent cash and short term investments at  80 91M  implies a Cash   Avg  Operating Expense ratio at 6 57    42  Vista Gold Corp   VGZ   Engages in the evaluation  acquisition  exploration  and advancement of gold exploration and development projects in Australia  North America  and Indonesia  Net institutional shares bought during the most recent quarter at 6 4M shares  8 37  of float at 76 45M shares   Average quarterly operating expense over the last five quarters at  8 17M  vs  most recent cash and short term investments at  122 39M  implies a Cash   Avg  Operating Expense ratio at 14 97    43  Synthesis Energy Systems  Inc   SYMX   Operates as a global energy and gasification technology company that provides products and solutions to the energy and chemicals industries  Net institutional shares bought during the most recent quarter at 4 1M shares  12 14  of float at 33 76M shares   Average quarterly operating expense over the last five quarters at  5 06M  vs  most recent cash and short term investments at  22 73M  implies a Cash   Avg  Operating Expense ratio at 4 49    44  Tranzyme  Inc   TZYM   Focuses on discovering  developing  and commercializing small molecule therapeutics for the treatment of acute and chronic gastrointestinal  GI  motility disorders in the United States and internationally  Net institutional shares bought during the most recent quarter at 3 6M shares  29 24  of float at 12 31M shares   Average quarterly operating expense over the last five quarters at  8 27M  vs  most recent cash and short term investments at  40 77M  implies a Cash   Avg  Operating Expense ratio at 4 93 ,2012-12-12,Contextuall,https://www.investing.com/analysis/44-cash-rich-stocks-smart-money-investors-are-buying-147189,147189
30608,252123,CSII,10 Biotech Stocks Dragged Down By Short Selling,opinion,Screen Criteria All of these Biotech stocks have seen significant levels of short selling during the last month Ranking of This List Contextuall com tracks the performance of a wide variety of company characteristics  Based on performance data over the last month  the list below is currently ranked 5 out of 232 lists  In other words  the company characteristics described below have outperformed 97 84  of lists in Contextuall s coverage universe Average Weekly Returns Average 1 Week Return of All Stocks Mentioned Below  4 87 Average 1 Month Return of All Stocks Mentioned Below  17 14 Analysis of List Alpha Number of Stocks in This List Generating Excess Return vs  SP500  Beta Adjusted Over Last Week   6 out of 10  60 0  Number of Stocks in This List Generating Excess Return vs  SP500  Beta Adjusted Over Last Month   9 out of 10  90 0   List sorted by monthly performance  from best to worst 1  Infinity Pharmaceuticals  Inc   INFI   Engages in the discovery and development of medicines for the treatment of cancer and other conditions in the United States  Shares shorted currently at 2 74M vs  2 10M shares shorted in the previous month  an increase in short interest representing 2 89  of total float     2  Amicus Therapeutics  Inc   FOLD   Focuses on the discovery  development  and commercialization of orally administered  small molecule drugs for the treatment of various human genetic diseases  Shares shorted currently at 2 80M vs  2 18M shares shorted in the previous month  an increase in short interest representing 2 51  of total float     3  VIVUS Inc   VVUS   Engages in the development and commercialization of therapeutic products for underserved markets in the United States  Shares shorted currently at 20 13M vs  17 63M shares shorted in the previous month  an increase in short interest representing 3 02  of total float     4  Santarus  Inc   SNTS   Engages in acquiring  developing  and commercializing proprietary products that address the needs of patients treated by physician specialists  Shares shorted currently at 4 25M vs  2 62M shares shorted in the previous month  an increase in short interest representing 3 82  of total float     5  NuPathe  Inc   PATH   Focuses on the development and commercialization of branded therapeutics for diseases of the central nervous system  including neurological and psychiatric disorders  Shares shorted currently at 1 29M vs  1 17M shares shorted in the previous month  an increase in short interest representing 1 01  of total float     6  Arena Pharmaceuticals  Inc   ARNA   Focuses on discovering  developing  and commercializing oral drugs in the therapeutic areas of cardiovascular  central nervous system  inflammatory  and metabolic diseases  Shares shorted currently at 61 75M vs  50 95M shares shorted in the previous month  an increase in short interest representing 5 0  of total float     7  Savient Pharmaceuticals  Inc   SVNT   Focuses on developing KRYSTEXXA  a biologic PEGylated uricase in the United States  Shares shorted currently at 18 38M vs  17 05M shares shorted in the previous month  an increase in short interest representing 2 61  of total float   8  Idenix Pharmaceuticals Inc   IDIX   Engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases in the United States and Europe  Shares shorted currently at 13 06M vs  12 08M shares shorted in the previous month  an increase in short interest representing 1 38  of total float     9  PDL BioPharma  Inc   PDLI   Engages in the management of antibody humanization patents and royalty assets  which consist of Queen et al  Shares shorted currently at 21 94M vs  19 17M shares shorted in the previous month  an increase in short interest representing 2 17  of total float     10  Insmed Incorporated  INSM   Focuses on the development of inhaled pharmaceuticals for the site specific treatment of serious lung diseases  Shares shorted currently at 933 16K vs  564 46K shares shorted in the previous month  an increase in short interest representing 1 95  of total float  ,2012-12-18,Contextuall,https://www.investing.com/analysis/10-biotech-stocks-dragged-down-by-short-selling-147987,147987
30609,252124,CSII,Sucampo Pharmaceuticals ,opinion,Easing The Strain In 2013Sucampo is entering a pivotal year in 2013 on the commercial development  alone and through partnerships  of its prostone based products  Potential FDA approval of Amitiza  lubiprostone  in April 2013 for opioid induced constipation  OIC  is a significant opportunity  particularly in light of FDA concerns over the cardiovascular safety of mu opioid antagonists  the main competitive threat in OIC  Amitiza s established safety record is a key differentiating factor for the drug  boosted by the deletion of a pregnancy warning in its label  which also removes a barrier to use  Meanwhile Sucampo plans to commercialise glaucoma drug Rescula  unoprostone  itself in the US  to be launched in Q113 following recent FDA approval of its sNDA Priority Review In OIC  But Three Month DelayA recent submission of additional data analysis prompted a standard three month extension to Amitiza s PDUFA for its sNDA in OIC in patients with chronic  non cancer pain  The FDA granted a priority review in September 2012  FDA approval  with the decision now expected by the end of April 2013  would make Amitiza the only oral prescription therapy for the estimated two to three million OIC patients in the US Competitor SetbacksAs revealed by Salix and Progenics in November  the FDA has safety concerns over the chronic use of mu opioid antagonists for OIC in chronic  non cancer pain  linked to cardiovascular risks as a potential result of opioid withdrawal  Large cardiovascular outcomes trials may be required for these drugs  eg Salix s Relistor  to gain approval  potentially affecting a further six pipeline candidates  Amitiza s prostone based mechanism would appear to clear the drug of this specific concern  while the label update improves its overall safety profile Encouraging Q3 Sales GrowthAmitiza Q3 sales by US partner Takeda gained 24  to  71 5m  resulting in royalties of  13 9m to Sucampo  the best quarter since launch in 2006  This indicates a net sales run rate   265m for FY12  ahead of our prior estimate of  255m  Abbott has just launched Amitiza in Japan for chronic constipation  triggering a  15m milestone Valuation  Upgraded To  345m From  304mWe have upgraded our valuation to  345m  or  8 24 per share  based on a sum of the parts DCF valuation  This results mainly from an improved run rate in US sales  the inclusion of Amitiza s near term commercial milestones and FDA approval for Rescula  Further upside potential exists in Amitiza s commercial roll out in Europe and positive development of new pipeline candidates To Read the Entire Report Please Click on the pdf File Below ,2012-12-18,Edison,https://www.investing.com/analysis/sucampo-pharmaceuticals-148098,148098
30610,252125,CSII,Cardiome Shares Remain Low On Merck s Abandonment,opinion,Earlier in the year  specifically on March 19th 2012  shares of Vancouver based Cardiome Pharma Corp  CRME  dropped from  1 93 share or so to   88 share in reaction to a press release regarding their partnership with the pharmaceutical giant Merck   Merck was to officially discontinue development of the oral version of Cardiome s flagship drug vernakalant  which left the IV formulation  referred to as vernakalant IV in the release   Merck apparently made the decision based on the regulatory environment  and the projected development timeline of vernakalant oral   While there were some beneficial effects of this partnership termination  like significantly reduced development expenses and cash burn for Cardiome Pharma  investors did not like the fact that oral vernakalant was out of the picture   According to CEO Doug Janzen s statements  vernakalant oral also had a well established profile for both efficacy and safety  As a long term prevention treatment for atrial fibrillation  both Cardiome and the market seem to agree that an oral formulation would have been superior  Not only do oral formulations of drugs not have to deal with the invasiveness of IV formulations  but patients  and doctors  find them much easier and more convenient to administer  Whether or not Merck made the  right  decision is very debatable up to this point  For now  vernakalant oral is stuck in phase II development unless something can finance its progress later on   Vernakalant IV has already been approved in Europe and Latin America and is marketed under the name BRINAVESS  Merck held commercial rights to this drug until September 26th 2012  when global marketing and development rights were returned to Cardiome   presumably after Merck did a bit more of their own research on the cardiovascular drug market   While investors seemed to like the idea that Cardiome had regained the rights to its drug  the fact that Merck was so unimpressed by its prospects that it decided to basically dump the drug from its pipeline this year does bring up some concerns that should be considered by anyone that is considering an investment in this biotech stock   While the prospects of any drug are never completely black or white  it s important to realize that Merck must have seen something wrong  or at least lacking  with vernakalant  On the bright side for Cardiome  the patient population that could be using the drug as a long term treatment to prevent atrial fibrillation is enormous  Cardiome s research suggests that one out of every three patients admitted to hospitals for cardiac arrhythmia have atrial fibrillation    Going forward  vernakalant has two major obstacles towards achieving its true potential  First is its troubled attempt at approval in the United States  Recall that vernakalant was put on clinical hold as far back as October 2010 by the FDA in the middle of its Phase III ACT V trial  which should bring up some concern on the drug s safety and long term chances of US approval The second is the fact that small pharmaceutical companies have big trouble with the marketing of drugs   especially those that target enormous drug markets  While Cardiome could theoretically do well by selling vernakalant IV by itself  Merck s resources would have been extremely helpful   Another indirect consequence of the misfortune that Cardiome has seen this year is related to its actual stock price  NASDAQ listing qualifications indicate that its stocks have to be above  1 share to prevent delisting  Cardiome is only trading at   50 share as of yesterday s closing bell  even after a substantial rally caused by a settlement of its debt obligations to Merck that was caused by the return of commercialization rights to vernakalant   As dismal as the situation seems for Cardiome at this point  there is some hope of redemption for the stock  CRME would react quite well to news that the FDA removed its clinical hold on vernakalant IV  There is also a small chance that vernakalant could be scooped up cheaper by another pharmaceutical company that is willing to save Cardiome Still  the takeaway is that CRME seems very risky even though the stock has fallen so far  It s in danger of a reverse stock split in the near future too  which is generally bad for shareholders due to negative perceptions that develop about biotech stocks that have to perform those reverse splits to regain NASDAQ compliance ,2012-12-19,Myriad Equity,https://www.investing.com/analysis/cardiome-shares-remain-low-on-mercks-abandonment-148292,148292
30621,252136,CSII,Orexigen Therapeutics  Market Research Bodes Well For Contrave ,opinion,Investment summary  LIGHT aheadWith the screening completed of 13 192 patients for the cardiovascular outcome trial  CVOT   LIGHT  Orexigen  OREX  is on track to enroll c 10 400 and randomise c 9 000 patients by 1 January and 15 January 2013 respectively  An interim analysis of the trial could occur in between Q2 Q413  making the data available for FDA two to three months thereafter  We believe the LIGHT study has a high probability of generating positive outcome and ultimately leading to an approval in the US Market research data bodes well for ContraveAt the analyst day  management shared in depth market analysis of the US obesity market and how Contrave would fare in a three way competitive landscape  the other two drugs being Vivus  Qsymia and Arena s Belviq  These data are likely to guide the company and its partner  Takeda  to position Contrave to female patients  age 20 39  and with BMI of  30 and  40  a segment that is c 65  of the total market  Contrave s appeal to a wide patient segment also suggests that the company s partner choice of Takeda  a major player in the US PC market with potentially the largest sales force among the three drug s promoters  makes sense as heavy promotion and abundant resources is required to push a obesity drug across the blockbuster threshold LIGHT at the end of tunnelOrexigen was required by the FDA to conduct a COVT trial for Contrave s approval  hence  it was put at a disadvantage in terms of approval timeline compared to Vivus and Arena  However  the company has executed the LIGHT trial well  moving up the timeline several times in the last year and now expects to reach 87 required events for interim analysis in mid 2013 and then trigger a submission two to three months thereafter  Assuming the interim analysis does exclude a doubling of major adverse cardiac events  MACEs   Contrave could be approved by early 2014  This will make Contrave the third to market  but with potentially the strongest promotional backing and a balanced efficacy and safety product profile among the three obesity drugs Valuation  Cheapest  relatively  obesity companyOrexigen s EV of  272m  pales in comparison to Arena s  EV of  1 959m  and Vivus   EV of  1 096m   probably reflecting Contrave s later entry to market and some risks of the LIGHT study outcome  We believe the shares have upside potential going into LIGHT interim analysis  mid 2013  and Contrave approval  2013 14  To Read the Entire Report Please Click on the pdf File Below ,2012-12-23,Edison,https://www.investing.com/analysis/orexigen-therapeutics:-market-research-bodes-well-for-contrave-148720,148720
30629,252144,CSII,Three BioPharmas With Upside Potential,opinion,With some added confidence shown by investors yesterday  it s a good time to look at some  risk on  small cap bio pharma stocks that I feel offer good upside for both swing trades and longer term holds  However  with the looming  fiscal cliff  approaching and no clear agreement in Washington  the market might still see some additional selling pressure  BG Medicine  BGMD  BG Medicine engages in the discovery  development  and commercialization of novel cardiovascular diagnostics to address unmet medical needs  The company markets the BGM Galectin 3  a diagnostic test for measuring galectin 3 levels in blood plasma or serum for use in patients with heart failure  These are sold to hospitals and clinics in the United States  as well as through distributors in certain countries in Europe  It is also developing CardioSCORE  a cardiovascular diagnostic test designed to identify individuals at high risk for near term cardiovascular events  such as heart attack and stroke  and galectin 3 test for a second indication to identify individuals at risk for developing heart failure  such as patients who have suffered a heart attack  as well as patients suffering from hypertension or diabetes  It has strategic collaborations with Abbott Laboratories  ABT  to develop and commercialize galectin 3 assay kits and related control kits and calibrators  In the  dated November 13  2012  BG Medicine  Inc  announced financial results for the fiscal quarter ended September 30  2012 and provided a business update  Included in this business update  the company announced a new commercial strategy to speed the adoption of its cardiovascular diagnostic tests    the BGM Galectin 3 test and the CardioSCORE test  In the release  the company announced a strategic reorganization in its research and development department moving toward a more commercially oriented role in support of studies designed to further differentiate and support the BGM Galectin 3 and CardioSCORE tests in the marketplace  As a result of this strategic reorganization  eleven positions in early discovery research were eliminated on November 8  2012  As a result of the strategic reorganization  the company will record one time severance costs of approximately  150 000  which will be recorded in the fourth quarter of 2012  Further  the company estimates that it will generate savings of up to  1 2 million in 2013  After this strategic reorganization  the company will have 26 full time employees  President and CEO of BG Medicine Eric Bouvier remarked  We have taken a series of important steps over the past year to realign BG Medicine into a more commercially focused company  capable of playing a larger role in facilitating the market adoption of our innovative cardiovascular diagnostic tests  The steps outlined today represent the culmination of our efforts to transform BG Medicine  Taken together  these actions place us in a much stronger position to control our own destiny and drive our own commercial success  In July 2012  BD Medical  the filing of a 510 k  Pre market Notification with the U S  Food and Drug Administration  FDA  for regulatory clearance of the Abbott Architect galectin 3 assay  which is used with Abbott s fully automated Architect immunochemistry instrument platform  In August 2012  Abbott received a letter from the FDA regarding its 510 k  notification that requested additional information and Abbott is undertaking activities to respond to the FDA  In addition  BD Medical expects Abbott to begin marketing an automated version of the test in the EU under a CE Mark in late 2012 or early 2013  In May 2012  a 510 k  was submitted by the company to extend the labeling indication for the BGM Galectin 3 test to include individuals in the general adult population who are at risk for developing heart failure based on elevated levels of galectin 3  In July 2012  a letter from the FDA regarding the 510 k  notification requested additional information  including information regarding the clinical validation study and additional analytical study data  A response was submitted to the FDA in November 2012  If BD Medical obtains clearance in the United States for this additional indication  the company expects the potential market for the BGM Galectin 3 test to increase significantly  On November 15th  company officer Bancel Stephane purchased 100 000 shares for approximately  126 000  Obviously  this is a bullish sign when an insider buys a block this large with their own money  Tackling some of the cost issues the company has as BG is looking to do  is clearly a step forward  The chart above shows a very oversold condition  but the stock showed signs of turning around yesterday as the volume and stock price moved up  The RSI is finally starting to turn up along with the MACD  so it looks to me we have seen a bottom here  so I consider this a nice pinch chart bottom bounce trade    at the very least  With a current market cap of  23 58M  a strong partnership with Abott Labs  and speculative longer term value  BG Medicine seems ridiculously undervalued and oversold to me  My short target opinion  one day to three months  is between  1 45   1 55 a share  My long term target opinion here is not certain at this time    not until we see how the company executes its new business plan  Arena Pharmaceuticals  ARNA  Arena engages in discovering  developing  and commercializing oral drugs that target G protein coupled receptors in the therapeutic areas of cardiovascular  central nervous system  inflammatory  and metabolic diseases  Since the approval of its weight loss drug Belviq in June the stock has fallen from a yearly high of  11 39 to  7 21  a fall of 37   I feel long term investors have excellent value here at its current price level  The focus now on Arena should be the potential top line growth from its strong pre clinical pipeline  Because Arena will likely receive a large amount of cash from Belviq sales  I believe it is a strong speculation bet that management will re invest this cash into its pipeline  gaining leverage in any potential deal with a large pharma partner for any of its pre clinical pipelined drugs  Arena had some interesting things to say about its long term goals in its presentation at the Lazard Capital conference   We have a  significant market opportunity   for Belviq  worldwide it s 0 5 billion individuals that are classified as obese  So it s a significant market opportunity for us  We actually are very much ready for the launch  We ve delivered we announced in our last 10 Q launch supply to Eisai  So we delivered uh  11 6 million worth  It s a portion of the launch supply  So we ll be ready to launch as soon as we get DEA scheduling  So in terms of looking at further down the economics at  250 million in net sales  we ll get 31 5  of that  from its partner Eisai  which is about  80 million plus that threshold we achieved some purchase price adjustments as well as some milestones which another  55 million take on top of that when we get DEA scheduling is another  65 million  So if I do my math right that s an excess of  200 million on their first  250 million of sale  So it makes significant opportunity for us  In terms of other opportunities we just announced last week a nice collaboration with the South Korean company Ildong but we received a  5 million upfront payment great economic service as well first dollar on net sales is at 35  and that will ramps up to 45  on net sale  In terms of other areas that we are moving forward with the European strategy  We did file in the EU in March of this year  I can t believe it s for this year but and so we founded the 120 day questions and we are hopeful to get a decision on that in first half of 2013 probably behind that is actually Switzerland as well which is where our manufacturing facility is The chart above shows a nice symmetrical triangle setting up for Arena  The MACD and RSI indicate that this new leg up still has a lot of steam left to go higher  The catalyst trading is pretty much done in Arena  so the stock has been seeing a steady decline  hot money exiting  smart money accumulating  Although still speculative  Arena might just be a great long term investment if it manages its money correctly  Belviq sales could open the door for Arena to potentially become a full fledged pharma within the next three to five years  I believe the stock price could reach near  20 or so in the next two years    if again  managed correctly  My short term  one day to three months  target opinion for Arena is  10  My long term target opinion is  30 dollars    three years  Antares Pharma  ATRS  Antares engages in the development and marketing of self injection pharmaceutical products and technologies  and topical gel based products  It offers Vision Tjet reusable needle free injectors that deliver precise medication doses through high speed pressurized liquid penetration of the skin without a needle  The Vibex disposable pressure assisted auto injector devices that are used for the controlled pressure delivery of drugs into the body utilizing a spring power source  disposable pen injection systems  which are needle based devices designed to deliver multiple drugs by injection through needles from multi dose drug cartridges  Antares expects to file an NDA for Vibex MTX in February of 2013  but I believe the NDA filing to be as early as December of this year  based on the company s prior history of under promising and over delivering  The company recently announced positive results from an open label  randomized  crossover study comparing the systemic availability of MTX Medi Jet to oral methotrexate  MTX  in adult patients with rheumatoid arthritis  RA   This study was designed to compare the relative systemic availability of MTX following oral administration to subcutaneous  SC  self administered MTX using the Medi Jet device  Patients were assigned to one of four dose levels of MTX  10 mg  15 mg  20 mg  and 25 mg  Results showed that the systemic availability of methotrexate following oral dosing plateaus above 15 mg  Following administration of MTX with Medi Jet  the systemic availability increased proportionally at every dose  which will extend the range of exposure compared to patients receiving oral therapy  Historically  parenteral MTX use has been limited in clinical practice for several reasons including the inconvenience of weekly injections by a healthcare professional  and or the challenges associated with teaching patients with impaired hand function  safe and sterile self injection techniques  To address these issues  the easy to use  single use MTX Medi Jet auto injector was developed to optimize the clinical benefit of MTX  leading to cost effective treatment outcomes  VIBEX QS T For Testosterone Replacement TherapyQS T is potentially the first self injectable testosterone product for men suffering from symptomatic testosterone deficiency  Low T   Most of this market currently is made up of gel treatments  which most men really do not like  I am sure many of you have seen the commercials on TV advertising these testosterone gels  Rx s for current treatment options equal two thirds topical gel testosterone and one third intramuscular injections  and according to recent reports  U S  sales of testosterone replacement therapies exceeded  1 6 billion  in 2011  5 6 million Rx s  Studies have shown that gel patients do not achieve adequate absorption or therapeutic response  injection patients bear the cost and inconvenience of in office injections every two to four weeks Physicians surveyed believe self injection will improve patient compliance and deliver sufficient serum testosterone levels  according to the company The New VIBEX QS is particularly well suited for use with highly viscous drugs such as testosterone  Novel spring mechanism   up to a 1 ml capacity   highly compact device This combination drug device product is in pre clinical development  expected to go to market in 2015 2016 In early October  Antares engaged in a secondary offering at  4 00 to fund development of the above mentioned products    the company raised  47M in total  Antares now has an abundant reserve of over  70M in cash  so I would expect its Q4 2012 earnings call to show a profit from its royalty based revenue it primarily receives from Teva Pharma  TEVA  for Tev Tropin  Tjet  and reusable hGH    in which Antares receives strong margins on device sales  and mid to high single digit   royalty on overall product sales  Antares has two single shot disposable auto injectors  One is Epinephrine  N A  rights  and the other is an undisclosed product  U S rights  in which it receives margins on device sales along with mid to high single digit   royalty on overall product sales The chart above indicates that Antares has seen a double bottom bounce  The MACD and RSI are trending upwards  and with a little bit more volume  Antares could be seeing the  4 dollar range soon  In my opinion  investors and traders should look at both short and longer term fundamentals for Antares  especially the longer term ones for the company  My short term  one day to three months  target opinion for Antares is  4 before the end of the year  and near  5 by February of next year  My long term target opinion is  12 a share    three years  Disclosure  I am long BGMD  I wrote this article myself  and it expresses my own opinions  I am not receiving compensation for it  I have no business relationship with any company whose stock is mentioned in this article  Additional disclosure  Disclaimer  This article is intended for informational and entertainment use only  and should not be construed as professional investment advice  They are my opinions only  Trading stocks is risky    always be sure to know and understand your risk tolerance  You can incur substantial financial losses in any trade or investment  Always do your own due diligence before buying and selling any stock  and or consult with a licensed financial adviser ,2012-11-20,Scott Matusow,https://www.investing.com/analysis/three-biopharmas-with-upside-potential-144384,144384
30630,252145,CSII,Even As Impatience Grows  Amarin Likely To See NCE Designation,opinion,As one of the most watched names in the biotech sector  it s difficult for the market to ignore any news about Amarin Corporation  AMRN  and their ultra refined  fish oil  product Vascepa  Although it s been referenced as a  fish oil pill  by a large number of sources  there s a little more to it  Vascepa is a  96  eicosapentaenoic acid  EPA  pill  which is manufactured in a specific process that has been patent protected by Amarin  This isn t your ordinary over the counter fish oil pill  although the FDA has been unsure as to whether or not it is a unique enough derivative of fish oil to be considered a  New Chemical Entity   or NCE   The controversy over the NCE decision has been a big factor in recent Wall Street bearishness over Amarin  on top of a reduction in the intense M A speculation that has surrounded the stock all year  It s apparent that many analysts were expecting some sort of partnership between Amarin and a larger pharmaceutical company for the marketing of Vascepa right after  or soon after  the FDA approval for the drug  Vascepa was approved on July 26th 2012  which means that the company hasn t officially announced a deal of any kind after almost three months  Analysts like Wedbush claim that the likelihood of a partnership or acquisition is diminishing as time goes on  although many AMRN investors remain focused on the market potential for Vascepa and the possibility that Amarin is being very stubborn with its pricing during any talks that may occur behind closed doors  Although the speculation over Amarin  and Vascepa  deal activity is mostly based on just rumor  at this point   there are a few things we can observe about the situation  According to company statements  we know that Amarin would definitely prefer to initiate a strategic partnership for Vascepa  or an outright sale of the company itself in the near future rather than an lone entry into the triglyceride lowering drug market  Entering the market alone would require Amarin to hire a competent sales team that could cut into competing market share quickly enough to justify the company s valuation  The hypertriglyceridemia  high cholesterol  drug market is currently dominated by GlaxoSmithKline s Lovaza  which generates roughly  1 billion in annual revenue  Lovaza capsures are also derived from fish oil  specifically the omega 3 fatty acids   but the key difference with Amarin s Vascepa has to do with cholesterol  Lovaza lowers triglyceride levels  but actually raises  bad cholesterol   DHA   or Docosahexaenoic acid  levels in patients  since Lovaza itself contains DHA  This is essentially a trade off between one negative and another in the world of cardiovascular health  and makes Lovaza an easy target for a less dangerous drug that can match its performance with triglyceride level reduction  In clinical trials  Vascepa was found just as capable at lowering triglyceride levels while demonstrating the ability to actually lower DHA bad cholesterol levels in the bloodstream  This not only makes Vascepa a superior option for doctors that have patients with high triglyceride levels  but presents the opportunity for Vascepa to be marketed as a bad cholesterol lowering drug  Possibilities for Vascepa to become a cholesterol drug too are being explored in phase III trials  called  REDUCE IT   which some Amarin investors are extremely optimistic about   The triglyceride related takeaway is that Vascepa s domination of Lovaza s current market share  due to Lovaza s flaws  should be as easy as shooting fish in a barrel  no pun intended   Updates on Vascepa s NCE status  other than Amarin s announcement of indecision by the FDA  have been nonexistent until last week  Last Thursday  October 18th    Dr  Marvin Goldenberg published a  that claimed that the FDA considers Vascepa a New Chemical Entity based on the fact that its exact composition  96  EPA and no DHA  unlike Lovaza  was never submitted to the FDA for NCE consideration  This is not an official decision  but you can clearly see from last Thursday s  October 18th  trading that this was the green light confirmation that many investors needed to buy shares of Amarin  If you look at the chart  you can see that AMRN gave back all its gains on October 19th  but judging by the extremely bearish activity we saw in the broader market that day we can infer that AMRN selling was not reflecting news that the NCE status was in jeopardy again  At this point Vascepa looks much more likely to see NCE designation  which guarantees five  instead of three  years of exclusivity once it hits the market and increases the attractiveness of Amarin as a buyout target  Trade accordingly ,2012-10-28,Myriad Equity,"https://www.investing.com/analysis/even-as-impatience-grows,-amarin-likely-to-see-nce-designation-141445",141445
30631,252146,CSII,Did Shares Of ISIS Finally Bottom Out ,opinion,Shares of Isis Pharmaceuticals  ISIS  are finally bottoming out after last week s drop  which began on October 16th in reaction to documents that outlined the topics that would be discussed at the advisory committee meeting  on October 18th  regarding the NDA of Isis  flagship product  The market certainly didn t like the idea that FDA is worried that ISIS s cardiovascular drug KYNAMRO  mipomersen  could bring up concerns about its safety profile   especially since there s reason to believe that the drug may increase the risk of cancer in patients KYNAMRO is a first in class antisense drug that lowers cholesterol  which acts through a very unique mechanism that hasn t been targeted before within the cardiovascular drug space  According to company statements  KYNAMRO has met the primary  secondary  and tertiary endpoints in four clinical trials in the treatment of high cholesterol levels  and offers an alternative method for cardiologists to target the huge pool of high cholesterol patients  The problem is that KYNAMRO has a few intrinsic flaws that may prevent it from being able to compete with the major drugs that have already taken over the cholesterol treatment space  The biggest cholesterol lowering drugs are known as  statins   which include the record breaking and mega blockbuster Lipitor  atorvastatin  and Crestor  rosuvastatin  KYNAMRO  unlike its statin competitors  doesn t come in pill form and actually requires injections  The drug is waiting on an NDA that was submitted back in May  which set a PDUFA action date of January 29  2013  The advisory committee meeting that was held on October 18th came to a final vote of 9 to 6 in favor of approval  although it s important to note that this is actually a weak victory for Isis  Although the majority of the panel did in fact recommend the drug  and while headlines imply that the FDA is favoring approval for KYNAMRO  I would have a hard time trusting the narrow margin of victory There is a lot of reason for the FDA to send a complete response letter  CRL  instead of an acceptance letter to Isis on the PDUFA date in 2013  Perhaps the most important factor is the existence of a large number of highly effective and well tolerated cholesterol treatments already in the market  Since the demand for cholesterol reducing medication has been met by a big selection of statins  and other classes of drugs  the FDA can essentially conclude that there really isn t an unmet demand for KYNAMRO s prospective users  The FDA can afford to be very cautious regarding KYNAMRO  which means that there will be a lot of emphasis on the drug s potential to induce tumor growth when it comes time to evaluate the NDA Also note that while the world marketing rights for KYNAMRO were already sold to Genzyme Sanofi in 2008  Isis can still benefit significantly from milestone payments  Isis received a sum of  25 million just from its NDA submission  and is set to receive more on an FDA approval  ISIS shareholders are clearly looking for an FDA approval for KYNAMRO at this point The inherent risks brought about by KYNAMRO were already known to investors prior to October 16th  when the FDA brought up concerns again  but they weren t considered nearly as big of a threat until this point  We knew that KYNAMRO causes elevated levels of certain enzymes in patients  livers  but the severity of the risk is quite ambiguous due to some other factors brought up by the panel  This includes the scrutiny that was placed on the KYNAMRO arm in the latest phase III trials  specifically on patients  livers Still  the FDA generally leans towards the side of caution  If the FDA ends up being cautious with Isis Genzyme s NDA submission for KYNAMRO  they will reject it ask Isis to perform additional safety studies on KYNAMRO that can specifically address the concerns brought up about liver toxicity and tumor development  So  don t be too shocked if we see a rejection on January 29th  If KYNAMRO actually does get approved  however  the market would be shocked and ISIS would likely see immediate 30  gains  and then some  ,2012-10-28,Myriad Equity,https://www.investing.com/analysis/did-shares-of-isis-finally-bottom-out-141446,141446
30632,252147,CSII,Investigation Leaves ABIOMED Shareholders Uncertain And Vulnerable,opinion,A lot of uncertainty is currently priced into shares of the cardiovascular medical device company ABIOMED Inc   ABMD   which saw a 31 3  drop on November 1st in reaction to its second quarter earnings report  for fiscal year 2013  released on November 1st  2012  The company posted record earnings and double digit revenue growth relative to the numbers posted in Q2 2012  as well as some developments in its product portfolio  It wasn t disappointment in the financial data tor the operational hat caused the post earnings selloff though   it was the disclosure of an investigation by the US Attorney s Office for the District of Columbia regarding the marketing and labeling of their flagship Impella 2 5 device Investigations centered around pharmaceutical and medical device companies  flagship products are very frightening to investors  and it causes prolonged damage to share prices when considered serious enough  We saw something similar occur with Questcor  NASDAQ  QCOR  after an 8 K filing made on September 21st  which dropped shares an extra 20  after it had already suffered a massive selloff on Aetna s healthcare reimbursement policy  Their flagship product  H P  Acthar gel  was also being investigated for potentially illegal marketing and labeling practices which would artificially increase sales figures Impella has a medical device product line that falls into two major platforms   the Impella platform and the AB platform  Impella is a catheter based  percutaneous platform that includes the Impella 2 5 catheter introduced in June of 2008  which is small enough to reach the left ventricle of the heart through the femoral artery  The other Impella catheters  Impella 5 0 and Impella LD  were cleared in 2009 followed by an automated controller cleared in 2010  The AB platform is an artificial heart that allows for greater patient mobility  There is also the upcoming Symphony device which is intended to improve circulatory system function  although it has not been cleared by the FDA yet Impella platform revenue in the second quarter brought in a total of  32 8 million  representing a whopping 88  of the company s total sales revenue of  37 3 million  At a profit margin of 14 7   including tax expense   this brings total earnings to  5 5 million per quarter  The stock prices in a continuation of the double digit sales growth that Impella has been seeing since FDA clearance  although news of the investigation does make things more complicated for investors The seemingly permanent 30  drop in shares of ABIOMED equates to a rough discount of  230 million on the market capitalization of ABIOMED  which implies that the market is considering this to be a fair cost for the potential risks that ABIOMED faces with the litigation fees and possible lawsuits filed against them for improper marketing and labeling of Impella 2 5  Until the investigation is halted  or until it leads to additional action  I expect that the associated uncertainty will keep some pressure on ABIOMED due to the extreme sensitivity that the company s earnings and valuation have to Impella s performance in the medical device market ABIOMED is seeing general upward trend in short interest after a huge short covering rally that occurred in early February 2012 due to a stellar Q3 2012 earnings report  I would expect to see higher short interest in reaction to the Impella 2 5 investigation  which was disclosed after October 31st  the last time that NASDAQ released short interest   although it s not clear how long these positions will have to wait to hear more news about the district attorney s investigation  This is also true for investors and traders who are holding ABIOMED stock  Even if the company s financial data remains strong  the market will question the long term sales growth of the Impella system  the bulk of the company s valuation  so long as there is reason to believe that their marketing and labeling practices may have been illegal ,2012-11-15,Myriad Equity,https://www.investing.com/analysis/investigation-leaves-abiomed-shareholders-uncertain-and-vulnerable-143655,143655
30633,252148,CSII,GI Dynamics    QuickView ,opinion,Investment Summary  Barriers Coming DownGI Dynamics is making significant progress on multiple fronts with its key product EndoBarrier  a novel non surgical treatment for type 2 diabetes and obesity  It has received approval to start a US pivotal trial  which could lead to a US launch in 2016  A new study shows the device can be re implanted into patients  EndoBarrier is being approved more widely in Europe and there is an increased focus on gaining reimbursement in this region FDA Approves U S  Pivotal TrialGI Dynamics has received full approval from the FDA to start a pivotal 25 site clinical trial of EndoBarrier for the treatment of c 500 obese patients who have uncontrolled type 2 diabetes in the US  The primary endpoint is improved HbA1c  blood sugar measure  level and secondary measures include weight loss and various cardiovascular risk factors  Total US trials are estimated at US 35m with potential premarket application approval gained by 2016 New Study Data Supports Re implantationThe FDA approval follows recent positive safety data from a 24 patient long term clinical study of EndoBarrier shows the device may be re implanted safely one year after an initial 12 month course  In the trial  the mean body mass index fell from 43 8 to 33 5 and mean fasting blood glucose from 106 6 to 93 4  This raises the potential of the product being used in the long term treatment of diabetics Expanding Availability In Europe And AustraliaEndoBarrier has a CE mark and has been approved in some EU countries  Australia and Chile  It is commercially available in 20 key medical centres in seven countries  but only on a self pay basis  GI Dynamics is focused on approvals in more countries and gaining reimbursement for the product  the latter vital for EndoBarrier to be widely adopted Valuation  EV Of A 106m Belies Market PotentialGI Dynamics has cash of US 55m at 30 June  c A 53m   suggesting an EV of cA 106m  Clinical trials suggest that EndoBarrier is as effective in treating obese diabetics as various pharmaceutical blockbuster products  So  if physicians are persuaded routinely to treat obese diabetics using EndoBarrier  there is considerable upside To Read the Entire Report Please Click on the pdf File Below ,2012-11-15,Edison,https://www.investing.com/analysis/gi-dynamics----quickview-143736,143736
30634,252149,CSII,10 Nasdaq Short Seller Targets With Bullish Moving Averages,opinion,Recent Performance of the Stocks Mentioned Below   Average 1 Week Return  2 13  Average 1 Month Return   3 29  Average 1 Year Return  145 88    1  Arena Pharmaceuticals  Inc   ARNA   Focuses on discovering  developing  and commercializing oral drugs in the therapeutic areas of cardiovascular  central nervous system  inflammatory  and metabolic diseases  Short float at 23 62   SMA50 at  8 6 vs  SMA200 at  6 33    2  Celsion Corp   CLSN   Develops and commercializes targeted chemotherapeutic oncology drugs based on its proprietary heat activated liposomal technology  Short float at 16 78   SMA50 at  5 03 vs  SMA200 at  3 15    3  Expedia Inc   EXPE   Operates as an online travel company in the United States and internationally  Short float at 10 36   SMA50 at  56 01 vs  SMA200 at  45 27    4  Mellanox Technologies  Ltd   MLNX   Engages in the design  development  marketing  and sale of interconnect products primarily in North America  Israel  Europe  and Asia  Short float at 12   SMA50 at  94 98 vs  SMA200 at  71 73    5  PSS World Medical Inc   PSSI   Distributes medical products and equipment  pharmaceutical products  healthcare information technology  and billing services to alternate site healthcare providers in the United States  Short float at 11 36   SMA50 at  24 22 vs  SMA200 at  22 94    6  SBA Communications Corp   SBAC   Operates wireless communications towers primarily in the United States  Canada  Costa Rica  El Salvador  and Panama  Short float at 14 11   SMA50 at  63 88 vs  SMA200 at  55 87    7  Sarepta Therapeutics  Inc   SRPT   Short float at 15 35   SMA50 at  22 11 vs  SMA200 at  10 3    8  StemCells Inc   STEM   Short float at 13 82   SMA50 at  2 04 vs  SMA200 at  1 34    9  Smith   Wesson Holding Corporation  SWHC   Offers metal processing services and manufactures firearms and handcuffs as well as apparel and sportsmen s articles  Short float at 13 76   SMA50 at  10 17 vs  SMA200 at  8 16    10  Virgin Media  Inc   VMED   Provides of entertainment and communications services in the United Kingdom  Short float at 13 01   SMA50 at  30 97 vs  SMA200 at  26 19 ,2012-11-19,Contextuall,https://www.investing.com/analysis/10-nasdaq-short-seller-targets-with-bullish-moving-averages-144072,144072
30635,252150,CSII,14 NASDAQ Growth Stocks With Bullish Moving Averages ,opinion,Recent Performance of the Stocks Mentioned Below   Average 1 Week Return  0 67  Average 1 Month Return   4 55  Average 1 Year Return  126 2    1  Ariad Pharmaceuticals Inc   ARIA   Focuses on the discovery  development  and commercialization of small molecule drugs for the treatment of cancer  Earnings per share expected to grow by 25  over the next five years  SMA50 at  22 91 vs  SMA200 at  18 32    2  ARM Holdings plc  ARMH   ARM Holdings plc and its subsidiaries design microprocessors  physical IP  and related technology and software  as well as sells development tools to enhance the performance of high volume embedded applications  Earnings per share expected to grow by 18 1  over the next five years  SMA50 at  29 6 vs  SMA200 at  26 59    3  Arena Pharmaceuticals  Inc   ARNA   Focuses on discovering  developing  and commercializing oral drugs in the therapeutic areas of cardiovascular  central nervous system  inflammatory  and metabolic diseases  Earnings per share expected to grow by 25  over the next five years  SMA50 at  8 6 vs  SMA200 at  6 33    4  BioMarin Pharmaceutical Inc   BMRN   Develops and commercializes biopharmaceuticals for serious diseases and medical conditions  Earnings per share expected to grow by 36  over the next five years  SMA50 at  41 38 vs  SMA200 at  38 05    5  Avis Budget Group  Inc   CAR   Provides car and truck rentals  and ancillary services to businesses and consumers in the United States and internationally  Earnings per share expected to grow by 18 25  over the next five years  SMA50 at  16 6 vs  SMA200 at  14 97    6  Comcast Corporation  CMCSA   Provides entertainment  information  and communications products and services in the United States and internationally  Earnings per share expected to grow by 15 56  over the next five years  SMA50 at  35 91 vs  SMA200 at  31 65    7  Gilead Sciences Inc   GILD   Engages in the discovery  development  and commercialization of therapeutics for the treatment of life threatening diseases worldwide  Earnings per share expected to grow by 17  over the next five years  SMA50 at  66 64 vs  SMA200 at  54 89    8  LKQ Corp   LKQ   Earnings per share expected to grow by 20 1  over the next five years  SMA50 at  19 91 vs  SMA200 at  17 72    9  Mellanox Technologies  Ltd   MLNX   Engages in the design  development  marketing  and sale of interconnect products primarily in North America  Israel  Europe  and Asia  Earnings per share expected to grow by 69 33  over the next five years  SMA50 at  94 98 vs  SMA200 at  71 73    10  Onyx Pharmaceuticals  Inc   ONXX   Engages in developing therapies targeting the molecular mechanisms causing cancer in the United States and internationally  Earnings per share expected to grow by 37 38  over the next five years  SMA50 at  81 6 vs  SMA200 at  59 09    11  SIRIUS XM Radio Inc   SIRI   Provides satellite radio services in the United States and Canada  Earnings per share expected to grow by 27 87  over the next five years  SMA50 at  2 68 vs  SMA200 at  2 29    12  Sarepta Therapeutics  Inc   SRPT   Earnings per share expected to grow by 20  over the next five years  SMA50 at  22 11 vs  SMA200 at  10 3    13  Smith   Wesson Holding Corporation  SWHC   Offers metal processing services and manufactures firearms and handcuffs as well as apparel and sportsmen s articles  Earnings per share expected to grow by 22  over the next five years  SMA50 at  10 17 vs  SMA200 at  8 16    14  Urban Outfitters Inc   URBN   Operates lifestyle specialty retail stores under the Urban Outfitters  Anthropologie  Free People  Terrain  Leifsdottir  and BHLDN brands  Earnings per share expected to grow by 17 41  over the next five years  SMA50 at  37 39 vs  SMA200 at  31 21 ,2012-11-19,Contextuall,https://www.investing.com/analysis/14-nasdaq-growth-stocks-with-bullish-moving-averages-144080,144080
30638,252153,CSII,Trading The Triglyceride Players,opinion,After soaring about 120  higher since the start of the year  shares of the Irish pharmaceutical company Amarin Corporation  AMRN  are now trading in anticipation of the PDUFA action date of July 26  2012  That s the date the FDA will either approve or reject the drug AMR101 for the treatment of high triglycerides  Although it is arguable whether or not FDA approval has already been priced into AMRN shares  we do know that July 26 will be a major event for the stock  A rejection is not generally expected  although  15  of shares are short  indicating a significant amount of money betting on a surprise rejection Takeover SpeculationAdding to the enthusiasm over the company is Amarin s patent protection on its novel AMR101 compound  which was granted a few weeks ago by the USPTO  shares have tacked on  30  gains since   The patent is not set to expire until 2030  This has fueled a new round of takeover speculation from many analysts and continues to keep the stock in the limelight as the AMR101 NDA decision draws closer Despite the likelihood of a successful launch and the huge prospects of the massive triglyceride market  Amarin has become a rather expensive stock for what it is  Sitting at a market cap of about  2 1 billion    and with a significant fraction  or more  of AMR101 s value already priced into the stock    many would say that new buyers have missed the boat    even if we see FDA approval Other PlayersThis should lead investors to other high potential plays in the triglyceride drug market  One notable example that has recently emerged is Neptune Technologies   Bioressources  which is a more obscure pick capable of tapping the same demographic in the nutraceutical industry  This is a company that is developing NKO   Neptune Krill Oil   which is very similar to AMR101  it s 95  EPA without DHA refined from fish oil   NKO contains both of the Omega 3 fatty acids known as EPA and DHA  docosahexaenoic and eicosapentaenoic acid  Based on the company s claims  NKO has a few advantages against other similar compounds including its clinically proven effects on joint and brain function in addition to cardiovascular health and safety studies  Neptune has also released some good financial figures  In the last quarter of the company s fiscal 2012 year the company announced 15  year on year revenue growth and an astounding 136  improvement in net income  a total of  2 384 000 for the last four quarters  On top of NKO  Neptune owned pharmaceutical company Acasti is developing a compound known as CaPre for hypertriglyceridemia  which is in two phase 2 trials  The TRIFECTA study is the one to watch  since it was designed to focus exclusively on CaPre with regards to its effects in reducing triglycerides in blood plasma  For the most part  we are not worried about the safety data    it s about the efficacy and the supposed benefits it has on cholesterol levels So Called  Trifecta  DrugThe study was designed with three arms  two doses of CaPre versus a placebo  and has an estimated primary completion date of September 2012  What s most interesting to the market is that pre clinical studies implied that the drug induces lower LDL cholesterol levels  the bad cholesterol  and increases in HDL  the good one  on top of the intended reduction of triglycerides  No drug on the market has this  trifecta  of therapeutic benefit Time will tell whether or not CaPre can produce phase 2 studies that demonstrate the trifecta of therapeutic benefit  but until then we may see investors buying into Neptune simply due to its sales growth  It can also serve as a sort of substitute for Amarin s stock  which has become a bit expensive As of now  analysts are extremely bullish on Neptune  with some shooting as high as  10 30 share  a call by Roth Capital Partners   I expect the stock to rally until at least September 2012 based on its general undervaluation alone   6 share seems attainable if the broader market doesn t induce downward pressure in the biopharmaceutical sector When September does roll around  TRIFECTA data could induce significant rallying on CaPre related hype if the cholesterol side effect does show up again  This is one way that NEPT can reach the lofty price targets set by optimistic analysts  The other would be through more growth in the  nutraceutical  markets No matter how you slice it  NEPT looks like a strong buy and hold candidate that is extremely attractive on the meaningless dips  I m keeping the stock on my watchlist ,2012-07-12,Myriad Equity,https://www.investing.com/analysis/trading-the-triglyceride-players-129427,129427
30639,252154,CSII,LeMaitre Vascular  Multiple Growth Opportunites But M A Is Key ,opinion,Investment summary  Waiting for an inflectionLeMaitre Vascular  LMAT  is a leader in niche markets serving cardiovascular surgeons and has recovered well after a disastrous foray into non core areas several years ago  Underlying sales  ex stent grafts  have provided steady 8 9  revenue growth  but with the overall market for its products now growing 2 5   it is unclear whether the growth rate is sustainable  New bolt on acquisitions similar to the XenoSure biocompatible patch  c 60  sales growth a year  could help renew investor interest Analyst day highlights multiple growth opportunitiesAt its recent analyst meeting  LeMaitre outlined its strategy to achieve 8 9  organic revenue growth a year  Existing gold standard products  Valvulotomes and shunts already hold high market share  so growth could come from new product launches  LeMaitre has 12 pending approvals  including next gen versions of its Valvulotome and innovative UnBalloon product   or from greater productivity from the expanded direct sales force  both in the US and new international markets M A likely holds the keyLeMaitre s peripheral vascular disease products are projected to grow in low single digits  Investment in additional direct sales reps could boost sales and achieve penetration across new territories  but place pressure on near term margins  LeMaitre will continue to rely on acquisitions to drive growth  over 60  of sales are derived from acquisitions made since 1998   The company has  20m in cash or could use debt and equity to acquire compatible niche products Returning value to shareholdersIn 2009  LeMaitre began buying back shares and it continues today  Last year it also started paying a dividend  which now yields 1 6  a year Valuation  EV of  73m could be attractiveLeMaitre has an enterprise value of  73m  which generates a 1 3x EV sales multiple for FY12  given revenue guidance of  57m   The current valuation may be attractive for those confident in the company s ability to deliver on growth  An accretive deal could prove a more strategic use of cash than further share buy backs To Read the Entire Report Please Click on the pdf File Below ,2012-10-11,Edison,https://www.investing.com/analysis/lemaitre-vascular:-multiple-growth-opportunites-but-m-a-is-key-139496,139496
30695,252210,CSII,Bio Tech Vol Tops 2 Year High As FDA Decision Looms  Takeover Spec Heigh,opinion,Amarin Corporation plc  AMRM  is a late stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease  The Company s product candidate is AMR101  an ultra pure omega 3 fatty acid  It is developing AMR101 for the treatment of patients with high triglyceride levels  or hypertriglyceridemia This is a vol and stock note on a bio tech with  0 in revenue but a  2 billion market cap  The stock has been and continues to be the subject of takeover rumors and a huge FDA approval meeting  PDUFA  is due out July 26th  The vol is at a 2 year high  at least  I last wrote about AMRN on 4 25 2012  so  2 5 months ago   The stock was trading  10 05 and vol was spiking at 100 58   The Livevol  Pro Summary from that date is included below That blog post focused on the takeover rumors that were swirling and pushing vol up  Those rumors resurfaced on Friday and with the impending FDA decision  100  vol and a  10 stock are no longer the story    it s a  15 stock with 130  vol that we re lookin  at now  You can access the original post in April on AMRN here Moving on to yesterday s action  let s start with the news  First  the takeover spec  then the FDA ruling  Then we can look at how the vol reflects both of these phenomena in distinctly different ways  Very  very cool News7 5 2012Rumor activity resumed yesterday on a soft note   Chatter circulated that AstraZeneca  AZN  could be interested in Amarin  AMRN  While many rumors circulate during the day  and the validity of the source of these rumors can be questionable  the speculation may increase volatility in the near term     Source  Provided by Briefing com   7 9 2012Shares  of AMRN  have been trading between  5 99 and  15 60 during the past 52 weeks  and are poised to trade higher as the company draws closer to an FDA approval decision for its prescription fish oil AMR101 on July 26th  2012  which I believe the FDA will approve AMR101 is an investigational ultra pure omega 3 fatty acid in a capsule  comprising not less than 96  icosapent ethyl  ethyl EPA  in a capsule  Amarin is developing AMR101 for the potential treatment of patients with very high triglyceride levels and high triglyceride levels  or hypertriglyceridemia  Triglycerides are fats in the blood  Amarin s cardiovascular strategy leverages our extensive knowledge and experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids in cardiovascular disease     Source  Seeking Alpha via Yahoo  Finance     written by Scott Matusow So there you go    Let s turn to the Charts Tab  six months   below  The top portion is the stock price  the bottom is the vol  IV30    red vs HV20    blue vs HV180    pink  On the stock side  we can see how AMRN climbed abruptly in mid late Mar on takeover spec  That s what the first blog post focused on  At its peak  the stock popped  70  from that news  from   7 to   12   The stock came back down and settled at  10  ish   However  starting in late May  the stock has found legs to the upside again and is now trading above  15 On the vol side  we can see how the implied popped abruptly to triple digits in mid late Mar  see first blog for details  off of the takeover rumors  but then settled to the mid 70 s  But  since 6 20 2012  the IV30  has steadily but substantially increased from 63 98  to now over 133   That s a 108  rise in vol as the stock has risen 20  over the last three weeks  As I noted at the top of the article  the level of the implied now is well into new 2 year high territory  the prior high was 126   ish   Let s turn to the Skew Tab and we ll be able to see both the impact of the takeover rumors and the PDUFA date   decision We can see that Aug vol is well elevated to Sep  on all strikes  and Jul  for the ATM   In fact  the ATM vol in Jul is the lowest of the front three expiries  This elevated vol in Aug is a reflection of the risk inherent in the FDA decision  That vol will rise as we get closer tot he PDUFA date as long as  1  no news is broken early and  2  the PDUFA date remains in the Aug cycle  no delays  We can also see the incredible vol in the upside calls in Jul  In fact  the vol is at such a fevered pitch in the Jul OTM calls that they surpass the vol in Aug which has the PDUFA date  It s that reverse skew that reflects the risk of the takeover So  in English  what we see are two distinct vol phenomena    the risk of the FDA decision and the risk  potential  of the takeover  It s fascinating to watch the takeover spec given the fact that this firm has  0 in revenue yet is worth  2 billion in market cap  One might say that the FDA decision is a  big  one for AMRN   Finally  let s turn to the Options Tab  for completeness Across the top we can see the monthly vols are priced to 102 67   147 67  and 120 43  respectively for Jul  Aug and Sep  Keep in mind that Aug vol comprises of a month worth of days  or whatever   We re looking at a bunch of  normal  vol days  and one  huge  vol day  the PDUFA ruling   As we move through the  normal  days in Aug and approach the singular  huge  vol  the overall level of Aug vol will rise substantially  A very rough back of the envelope calculation shows me that the vol on the day of the FDA decision is priced at  500   that s assuming 100  vol is  normal    That doesn t mean Aug vol goes to 500   But you already knew that    right    Disclosure  This is trade analysis  not a recommendation,2012-07-10,Ophir Gottlieb,https://www.investing.com/analysis/bio-tech-vol-tops-2-year-high-as-fda-decision-looms;-takeover-spec-heigh-129075,129075
30698,252213,CSII,This Great Performing Stock Just Got A Lot Better,opinion,Not long after I wrote about this big health care firm   this stock began a nice hot streak  It s now up 31  in the past 12 months  compared with a 14  gain for the S P 500 during the same time  This is undoubtedly a great performing stock  But when I first suggested investing in this company  currently best known for its blockbuster rheumatoid arthritis drug Humira  I wasn t thinking much about what the stock might do in the next year or two  What I liked about it then  as I still do now  is how well it s likely to perform over a much longer time span    So even though the stock s already up 31   I think it has plenty more room to grow  In fact  I think it could easily rise another 50  during the next three to five years  I m talking about Abbott Laboratories  NYSE  ABT   I referred to Abbott Labs as a health care company instead of a pharmaceutical manufacturer  because it s more than just a drug maker    even though many investors probably only see it that way  Actually  Abbott Labs has so many irons in the fire that last November it announced it would split into two separate public companies  by the end of 2012  The plan is for the medical products segment to retain the Abbott Labs name  while the newly created research based pharmaceutical segment will be spun off to existing Abbott Labs shareholders  Both stocks will be publicly traded  Analysts project the medical products division to have  23 billion in sales  while the newly formed drug company should initially have  18 billion in annual sales  Abbott will be in charge of the company s medical devices  which include blood analyzers and other devices for use by diabetics  such as blood glucose meters  It will also make Abbott s line of nutritional products  such as PediaSure formula for children and Ensure nutritional drinks for older adults  It also has a new stent    a device that holds open blocked coronary blood vessels  The stent is already available in Europe and Japan and should soon be approved for use in the United States  The new pharmaceuticals company will own several patent protected blockbuster drugs    aside from Humira  which I mentioned earlier    including the HIV AIDS treatment Kaletra  and the cardiovascular medications Tricor and Trilipix  Together  these four medications currently account for roughly  11 billion in annual revenue  with Humira alone kicking in  8 billion   This accounts for almost 30  of the  39 billion in total revenue Abbott Labs generated in the past year  Splitting into two companies makes good strategic sense  While Abbott Labs has a very long history of success  it was founded in 1888   the two divisions that currently make up the company have evolved along very different lines  The pharmaceutical segment  while profitable  is more mature  domestically focused and noticeably slower growing  Indeed  management projects 3  4  annual growth in sales  at most  in the coming years  The medical device business  on the other hand  is poised for faster growth because of greater exposure to emerging markets like China and India  where demand for medical devices is growing 20  annually  compared with a only a 4  6  growth rate in the U S  and Europe  Once the split is complete  investors will have a choice   They can either own a dependable  slower growing drug stock that will likely pay a nice dividend  thanks to dependable cash flow  or a medical device health care stock with more prospects for growth  but a lower dividend  Risks to Consider  Though it has diversified  Abbott Labs still counts heavily on current blockbuster drugs for revenue  Keep in mind the danger of increased competition for Humira  but don t worry too much about it   Actemra  a newer drug developed by Roche  was recently shown in a study to be more effective for treating rheumatoid arthritis  It also goes off patent in the U S  in 2016 and Europe in 2018  The drug should still do well in the meantime  Besides  the new pharmaceuticals company could be bought out long before Humira loses patent protection  perhaps even right away The drug unit is adapting by developing new drugs with blockbuster potential  including several hepatitis C medications and a kidney disease drug  all of which have been performing well in clinical trials  Plus  new uses for Humira have been identified in the treatment of psoriasis and an intestinal condition called Crohn s disease  which should further propel global sales ,2012-03-22,StreetAuthority,https://www.investing.com/analysis/this-great-performing-stock-just-got-a-lot-better-117853,117853
30699,252214,CSII,Watch Achillion Pharmaceutical For Upcoming Phase IIa Data,opinion,Achillion Pharmaceuticals  ACHN  is a development stage pharmaceutical company developing treatments that combat the heptatitis C virus  which is estimated by the company s website to affect over 170 million worldwide If pharmas want to sell into emerging markets they will need a product list that includes HCV drugs  Behzad Aghazadeh of venBio told BioCentury this week  They have to sell into China with a full package   cardiovascular  diabetes  vaccine  hepatitis B and C   Aghazadeh said   If they don t have it that weakens the portfolio selling opportunity  that s how you sell into China as opposed to in the U S   where they are selling to individual doctors   Aghazadeh sees GlaxoSmithKline  GSK  plc and AstraZeneca plc  AZN  as among potential acquirers of HCV companies  According to the  2Q Financial Markets Preview  published for BioCentury subscribers  Idenix Pharmaceuticals Inc  and Achillion Pharmaceuticals Inc  are names several buy siders said they have a position in or are watching closely  Each will present at the European Association for the Study of the Liver  EASL  meeting in Barcelona on April 18 22  Abstracts will be available starting on April 4 Achillion s pipeline also includes one preclinical stage drug being developed for bacterial infections  although the bulk of the company s resources are being spent on HCV  hepatitis C virus   Achillion have five separate HCV drugs in various stages of development  most notable is ACH 1625 which is classified as a protease inhibitor The hepatitis C virus  in order to replicate  needs particular protease enzymes to construct new virions which allow the disease to continue to attack the body  ACH 1625 is an inhibitor of the HCV NS3 protease  which means this drug should prove effective if it can prevent this protein from functioning  The NS3 protein that is targeted by ACH 1625 has been studied extensively  and serves critical functions in the HCV infection process  All non structural proteins with regards to HCV are processed by NS2 and NS3  and due to their necessary interaction  inhibition of NS3 should hypothetically be a nearly insurmountable obstacle for HCV replication  As of now  ACH 1625 has passed Phase I trials which have validated its relative safety and lack of side effects  Phase II trials will give further insight into the efficacy of the drug against viral replication by HCV ACH 2684 is a broader protease inhibitor being developed to suppress the natural variants of the hepatitis C virus by the same mechanism  According to the company  the compound is also potent against standard genotypes of HCV which means it could be just as  if not more  effective than inhibition of just the NS3 protein  although the company claims that it has actually been tailored to affect the NS3 protease  The efficacy of this broader ranged protease inhibitor is difficult to determine at this stage  since it has only proven potency in the  low pico molar range   an incredibly small volume   but the fact that it might target mutant strands of HCV makes it worthwhile The third drug in the pipeline that has begun its clinical trials is ACH 2928  which acts through another mechanism by inhibiting HCV NS5A  This protein actively antagonizes a cell s response to a viral infection through RNA binding  and research is being done to investigate its suspected role in genome replication  The second generation version of this  ACH 3102  is being developed with enhanced abilities to fight off resilient strains of HCV that would be less susceptible to ACH 2928 ACH 1625 will be releasing results of its Phase IIa clinical trials on April 18 22  at the International Liver Conference being hosted in Barcelona  Shares have already rocketed up at the start of 2012  but there s reason to believe that some early confirmation of ACH 1625 s efficacy in a larger sample size could be immensely beneficial for the stock  News may be slow after this since many fresh studies are being started this year  but investors may jump the gun if the data on this generation of protease inhibitors gives hope on stopping HCV That being said  from a purely technical perspective  see chart    the market could be hinting that a move like we saw earlier in the year might occur when details of those results come ,2012-04-08,Myriad Equity,https://www.investing.com/analysis/watch-achillion-pharmaceutical-for-upcoming-phase-iia-data-119459,119459
30759,252274,CSII,Likely Approval Spurring Rise Of Forest Laboratories  Shares,opinion,Forest Laboratories  FRX  has been rising steadily during the past three months on rumors and speculation that larger pharmaceutical companies are considering a buyout of the company  despite the expiration of Lexapro  the company s old flagship SSRI Antidepressant drug  and other losses en route The company s valuation seems to be the main focus of the rally  as the most recent quarterly report  Q3 2012  released on January 17th 2012 recorded an overall 9 2  increase in revenue from Q3 2011 The major drawback in the consolidated financial data was in earnings  which came in at  1 04 EPS  below most estimates   The P E ratio of the stock is now about 8 7  which about half the industry average P E of 17 2  This makes Forest a compelling value play from this angle  but there are major issues that might arise in 2012 Lexapro  Forest s blockbuster product  was responsible for much of the company s recent success  Just under 50  of the company s revenue is tied up in this SSRI alone  The expiration that occurred this month is about to begin taking its toll though  since generic competition will arrive later in the year Forest is looking forward to a very likely NDA approval for aclidinium bromide  their treatment for COPD  Chronic Obstructive Pulmonary Disease   The FDA s Pulmonary Allergy Drugs Advisory Committee  in February 2012  voted 12 to 2 in favor of approving the currently submitted NDA which will have a decision on April 30th  2012  This  in addition to continued speculation over a takeover by a larger pharmaceutical company might be enough to continue to drive shares higher in the near term Forest Laboratories offers diverse range of prescription products such as Lexapro   Namenda   and Bystolic  that treats conditions like depression and anxiety  Alzheimer s disease  hypertension  and more  The company s other products include  Aerobid Aerobid M  flunisolide  Inhaler System  AeroChamber Plus Flow Vu Anti Static Valved Holding Chamber  Small Mask  Medium Mask   Bystolic  nebivolol  Tablets  Combunox  oxycodone HCl and ibuprofen  Tablets  Lexapro  escitalopram oxalate  Tablets Oral Solution  Monurol  fosfomycin tromethamine  Sachet  Savella  milnacipran HCl  Tablets  Tiazac  diltiazem hydrochloride  ER Capsules  etc  Its pipeline includes product candidates in all stages of development and across a wide range of therapeutic areas like  asthma  cardiovascular disease  Alzheimer s disease  depression  chronic obstructive pulmonary disease  gastrointestinal disease  and infectious disease The BioMedReports FDA Calendar shows more than ten upcoming catalysts for the stock  including previously mentioned review of the New Drug Application for linaclotide for the treatment of irritable bowel syndrome with constipation  IBS C  and chronic constipation  CC   With a standard 10 month review timeline  the FDA Prescription Drug User Fee Act target action date is expected to occur in June 2012 ,2012-04-08,Myriad Equity,https://www.investing.com/analysis/likely-approval-spurring-rise-of-forest-laboratories-shares-119460,119460
30760,252275,CSII,Amarin Corp  Rumors Break Vol  Risk Elevated    Skew Diverges,opinion,Amarin Corporation plc  AMRN  is a clinical stage biopharmaceutical company focused on developing improved treatments for cardiovascular disease  The Company s development programs capitalize in the field of lipid science and the therapeutic benefits of essential fatty acids in cardiovascular disease This is a vol note  obviously   as the wave of bio tech takeovers  and rumors  continues to build  Let s start with the news snippet that s pushing vol 10 48 EDT Rumor  Amarin moves up on renewed takeover chatterSource  Theflyonthewall com via Yahoo  Finance OK  that was kinda terse  but we get the idea  Let s start with the Charts Tab  six months   below  The top portion is the stock price  the bottom is the vol  IV30    red vs HV20    blue vs HV180    pink  On the stock side  we can see that within just a few months AMRN has gone from a  6 03 close on 12 15 2011 to now  10 05    that s a 66 7  rise  The 52 wk range in stock price is   5 99   19 87   so volatility kinda comes with the territory Looking to the vol  we can see both the meteoric rise today in the implied  and how  quiet  the underlying has been of late  As of right now  the HV20  is 55 64  while the IV30  is 100 58   Said differently  the last twenty trading days have seen the stock move at a 55  vol clip  annualized  while the options reflect for the next 30 calendar days   22 trading days  a vol almost twice that  So  the quiet period is over according to the options  The 52 wk range in IV30  is  61 50   128 78    putting the current level in the 57th percentile This vol story gets really interesting when looking to the skew I ve included four expiries for sake of comparison  We can see how dramatically different the risk profile looks through the options when examining the short  versus the long term  The two front expiries show reverse skew  where the OTM calls are the most expensive options  The back two expiries show the opposite    where OTM puts are most expensive I ve included the Skew Tab from one month ago  3 26 2012   below We can see a few differences from today s skew 1  A month ago  the Sep options were vastly more expensive than the front three expiries across all strikes 2  A month ago  there was a monotonic vol increase from the front to the back 3  The front three expiries showed a flattish skew  Apr had that one super bid OTM call  Without having done any research on this firm  it s apparent to me that as of a month ago the big  valuation changing  news was due out in Sep  As of today  that vol diff has essentially evaporated to the front  and the near term reflects substantially more upside risk  potential  than the back months  In English  the takeover rumors and actualizations in this industry have changed the risk profile for this firm quite substantially  and there s no easier way to see it than in the options Let s turn to the Options Tab for completeness Just looking at the top of the Tab where the monthly vols are displayed  102 45   97 82   110 33  and 103 31  for May  Jun  Sep and Dec  respectively  The greatest vol diff now lies in between Jun and Sep    an interesting but logical result  If there s gonna be a takeover  the  risk  is in the near term  If not  the risk goes back to the news   results   updates due out in the back months  Pretty cool   Disclosure  This is trade analysis  not a recommendation ,2012-04-26,Ophir Gottlieb,https://www.investing.com/analysis/amarin-corp:-rumors-break-vol;-risk-elevated----skew-diverges-121353,121353
30761,252276,CSII,Five Healthy Dividend Growth Stocks To Cure What Ails Your Portfolio ,opinion,These five above average growing opportunities in the healthcare sector provide dividend growth investors potential alternatives to the traditional large cap pharmaceuticals  This is a high quality group of healthcare companies that possess above average growth potential plus an above average dividend yield that is expected to grow at above average future rates  Consequently  we believe these candidates offer the total package  We believe that each of these nontraditional healthcare opportunities are attractively valued  provide an attractive dividend  and the opportunity for above average total return The following table summarizes Five Healthcare Dividend Growth Stocks that appear to be attractively valued  and lists them in order of Estimated Total Return  From left to right  the table shows the company s stock symbol and name  Next the company s historical EPS growth followed by the estimated EPS growth  Next you will find the current PE ratio followed by the historical normal PE ratio for perspective  Then the 5 year estimated annual total return  followed by dividend yield for each company  The final three columns show the company sector  debt  and its market cap A Closer Look at the Past and the Future Potential    Since a picture is worth 1 000 words  we ll take a closer look at the past performance and future potential of each of our five candidates through the lens of    Earnings Determine Market Price  The following earnings and price correlated historical graphs clearly illustrates the importance of earnings  The Earnings Growth Rate Line or True Worth  Line  orange line with white triangles  is correlated with the historical stock price line  On graph after graph the lines will move in tandem  If the stock price strays away from the earnings line  over or under   inevitably it will come back to earnings  The historical normal PE ratio line  dark blue line with   depicts a PE ratio that the market has historically applied    The orange True Worth  line and the blue normal PE ratio line provide perspectives on valuation  The orange line reflects the fair value of each company s earnings relative to its growth rate achievement  and the blue line reflects how the market has traditionally valued the company s stock relative to its fair value  The blue line represents a trimmed historical normal PE ratio  the highest and lowest PEs are trimmed   These lines should be viewed as barometers or aids for ascertaining sound buy  sell or hold decisions  Rather than seen as absolutes  they should be seen as guides to better thinking   Lincare  headquartered in Clearwater  Florida  is one of the nation s largest providers of respiratory therapy and other services to patients in the home  The Company provides services and equipment to more than 750 000 customers in 48 states through 1 071 local centers   The consensus of 10 leading analysts reporting to Capital IQ forecast Lincare Holdings Inc s long term earnings growth at 14   Lincare Holdings Inc has low long term debt at 22  of capital  Lincare Holdings Inc is currently trading at a P E of 11 7  which is below the value corridor  defined by the five orange lines  of a maximum P E of 18  If the earnings materialize as forecast  Lincare Holdings Inc s True Worth  valuation would be  59 86 at the end of 2017  which would be a 19 4  annual rate of return from the current price  Headquartered in Dublin  Ohio  Cardinal Health  Inc   NYSE  CAH  is a  103 billion health care services company that improves the cost effectiveness of health care  As the business behind health care  Cardinal Health helps pharmacies  hospitals  ambulatory surgery centers and physician offices focus on patient care while reducing costs  enhancing efficiency and improving quality  Cardinal Health is an essential link in the health care supply chain  providing pharmaceuticals and medical products to more than 60 000 locations each day  The company is also a leading manufacturer of medical and surgical products  including gloves  surgical apparel and fluid management products  In addition  the company supports the growing diagnostic industry by supplying medical products to clinical laboratories and operating the nation s largest network of radiopharmacies that dispense products to aid in the early diagnosis and treatment of disease  Ranked  19 on the Fortune 500  Cardinal Health employs more than 30 000 people worldwide   The consensus of 15 leading analysts reporting to Capital IQ forecast Cardinal Health Inc s long term earnings growth at 12 7   Cardinal Health Inc has medium long term debt at 27  of capital  Cardinal Health Inc is currently trading at a P E of 13 7  which is inside the value corridor  defined by the five orange lines  of a maximum P E of 18  If the earnings materialize as forecast  Cardinal Health Inc s True Worth  valuation would be  85 75 at the end of 2017  which would be a 16 4  annual rate of return from the current price  Kensey Nash is a medical device company primarily focused on regenerative medicine utilizing its proprietary collagen and synthetic polymer technology  Kensey Nash is recognized as a leader for innovative product development and unique technology in the field of resorbable biomaterials  Kensey Nash has an extensive range of products  which are sold through strategic partners in multiple medical markets  including the cardiology  orthopaedic  sports medicine  spine  trauma  craniomaxillofacial and general surgery markets   The consensus of 4 leading analysts reporting to Capital IQ forecast Kensey Nash Corp s long term earnings growth at 15   Kensey Nash Corp has low long term debt at 25  of capital  Kensey Nash Corp is currently trading at a P E of 18  which is inside the value corridor  defined by the five orange lines  of a maximum P E of 18  If the earnings materialize as forecast  Kensey Nash Corp s True Worth  valuation would be  52 47 at the end of 2017  which would be a 15 6  annual rate of return from the current price  St  Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac  neurological and chronic pain patients worldwide  The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient  St  Jude Medical is headquartered in St  Paul  Minn  and has four major focus areas that include  cardiac rhythm management  atrial fibrillation  cardiovascular and neuromodulation   The consensus of 29 leading analysts reporting to Capital IQ forecast St Jude Medical s long term earnings growth at 9 6   St Jude Medical has medium long term debt at 38  of capital  St Jude Medical is currently trading at a P E of 11 9  which is below the value corridor  defined by the five orange lines  of a maximum P E of 18  If the earnings materialize as forecast  St Jude Medical s True Worth  valuation would be  79 94 at the end of 2017  which would be a 15 3  annual rate of return from the current price  Amgen discovers  develops  manufactures and delivers innovative human therapeutics  A biotechnology pioneer since 1980  Amgen was one of the first companies to realize the new science s promise by bringing safe  effective medicines from lab to manufacturing plant to patient  Amgen therapeutics have changed the practice of medicine  helping millions of people around the world in the fight against cancer  kidney disease  rheumatoid arthritis  bone disease and other serious illnesses  With a deep and broad pipeline of potential new medicines  Amgen remains committed to advancing science to dramatically improve people s lives   The consensus of 28 leading analysts reporting to Capital IQ forecast Amgen Inc s long term earnings growth at 10   Amgen Inc has medium long term debt at 53  of capital  Amgen Inc is currently trading at a P E of 13 5  which is inside the value corridor  defined by the five orange lines  of a maximum P E of 18  If the earnings materialize as forecast  Amgen Inc s True Worth  valuation would be  147 80 at the end of 2017  which would be a 15 2  annual rate of return from the current price Summary and ConclusionsThe healthcare industry represents a significant opportunity for long term growth thanks to an aging population  However  there are also many challenges facing the industry due to high cost and regulatory scrutiny  Nevertheless  we believe the five candidates listed in this article are well positioned to be part of the healthcare solution rather than part of the problem  Although these are not your traditional healthcare companies  we do believe that they are well positioned to prosper during the forthcoming healthcare environment and challenges Therefore  we believe these companies possess the opportunity for above average long term growth of both capital and dividend income  As you review each company  note that several have just begun a dividend policy  Therefore  they do not possess long histories of dividend excellence that many dividend growth investors covet  On the other hand  due to their expected above average growth and above average market yields we believe that they do offer the potential for strong total returns  On the other hand  we believe their potential for an increase in dividend income stream is excellent as well  As always  we recommend you conduct your own thorough due diligence Disclosure   No positions at the time of writing Disclaimer  The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients  Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted  The information in this document is believed to be accurate  but under no circumstances should a person act upon the information contained within  We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation  A comprehensive due diligence effort is recommended ,2012-05-06,F.A.S.T. Graphs,https://www.investing.com/analysis/five-healthy-dividend-growth-stocks-to-cure-what-ails-your-portfolio-122334,122334
30762,252277,CSII,GNC  Health Products  Healthy Stock,opinion,The Overview   GNC Holdings Inc   NYSE    has seen its stock soar 37 3  YTD  significantly buoyed by its positive earnings for the first quarter of 2012  On April 25  GNC reported EPS of  0 60  beating estimates by  0 08  it also reported revenue of  624M  which beat analyst estimates by  38M and constituted a 23  increase YOY  Moreover  same store sales increased 15 8  in domestic company owned stores  representing the Company s 27th consecutive quarter of positive same store sales growth    However  GNC has not been without its share of negative developments  Recently  it has been adversely affected by the FDA s crackdown on supplements with the stimulant DMAA  which are bestsellers among fitness enthusiasts  DMAA is an ingredient which the FDA claims could lead to cardiovascular and blood pressure complications  GNC is currently facing a lawsuit concerning a DMAA based product and has recently seen the U S  military pull several DMAA based products from the GNC stores situated on military bases  Despite the controversy surrounding DMAA  GNC continues to sell DMAA based products     The Niche   GNC is a specialty retailer of health and wellness products that sells products made under its GNC proprietary brand as well as under third party brands  GNC products range from vitamins  minerals  and herbal supplement products to sports nutrition and diet products     One of the biggest appeals of GNC right now is its proprietary brand business  This business not only differentiates GNC from its competitors  but it also helps promote brand loyalty among customers who often cannot find the same products elsewhere in other vitamin health retailers  Moreover  GNC s proprietary brand business is extremely profitable  as GNC produces its own products and then sells them with much higher profit margins than simply selling third party brands  Thus  an extremely positive development in GNC s first quarter report was its announcement that sales from proprietary GNC brands accounted for nearly 60  of total sales  GNC President and CEO Joe Fortunato notes that the increase in proprietary sales  will increase our margins   One significant product driving this increase in proprietary sales is the Total Lean brand  which has found huge success in the weight management marketplace     Moreover  GNC has also distinguished itself from other competitors by also emphasizing the online experience  In its first quarter of 2012  GNC saw a 34 1  growth in sales from GNC com as the website remains a hit with a large segment of GNC s consumers  GNC is also aggressively cementing and expanding its presence online  on August 31  2011  GNC acquired LuckyVitamin com  a discount vitamin site  GNC s development of its online business is crucial because  as shown by the growth of such e commerce companies as Amazon com and eBay  more and more consumers depend on online transactions instead of visiting brick and mortar shops     GNC is broadening its presence through partnerships with other organizations and people as well  One of its most significant partnerships is with major drug store Rite Aid Corporation  NYSE     This strategic alliance  formed in 1999  has resulted in the creation of more than 2 125 GNC  store within a store  locations inside Rite Aid establishments as well as a line of vitamins and nutritional supplements called PharmAssure   More recently  in April 2012  GNC announced a partnership with Mark Wahlberg to develop  market  and sell a nutritional supplement line named MARKED  In May 2012  GNC became the presenting sponsor and exclusive sports nutrition provider to the 2012 ESPNHS Games  These partnerships and strategic alliances could prove to be extremely beneficial for GNC in the long run  not only increasing its presence in terms of store locations but also in terms of generating publicity    In terms of its niche in the stock market right now  GNC is currently positioned as a very favorable play on not only the health of the company  but the robustness of the vitamin sector  In fact  at its current PE of 23  GNC is more attractive than its competitor Vitamin Shoppe Inc   NYSE     which has a PE of 29 6  On May 17  Deutsche Bank actually downgraded Vitamin Shoppe to a Hold from Buy  one of the reasons was their belief that Vitamin Shoppe was trading at a premium multiple to GNC  a development which Deutsche Bank believed was unjustified    The Results   GNC is currently firing on all cylinders in terms of financial performance  Its EPS increased 82  YOY from the first quarter of 2011 to the first quarter of 2012  Moreover  in its last three quarters  GNC has reported an average EPS growth of 84   Estimate for the current quarter are strong and the consensus estimate is that GNC will report an EPS that constitutes a 33  YOY increase  From a broader perspective  GNC is expected to report an annual EPS increase of 38 41   which  if fulfilled  would mark the fifth consecutive year of annual EPS growth for GNC  In terms of profitability  GNC has a solid annual ROE of 20 1  and an annual Pre Tax Margin of 12 2   a bit on the low side     A not so stellar component of GNC s financials is its 3 Year Sales Growth Rate  which comes in at a paltry 9   However  sales seem to have picked up as of late  last quarter  GNC reported a 23  increase in sales YOY  Joe Fortunato has stated that sales from new products have exceeded historical rates  while cross selling has also increased  40  of customers that bought sports nutrition products also bought vitamins last quarter     The Verdict   Overall  GNC has a lot of positive factors going for it and its stock has significant upside potential  As for the recent DMAA controversy  JPMorgan analysts recently pointed out that DMAA only makes up only a mid single digit percentage of GNC sales and called the recent weakness in GNC stock a  buying opportunity   GNC has also experienced 3 consecutive quarters of increasing fund ownership and saw a 26  increase in fund ownership in its first quarter of 2012  I heavily recommend that prospective investors look more into GNC s operations and formulate their own decisions ,2012-05-26,George Liu,"https://www.investing.com/analysis/gnc:-health-products,-healthy-stock-124403",124403
30763,252278,CSII,Edwards Lifesciences  Vol Opportunity Now On Bio tech  Like  Event ,opinion,Edwards Lifesciences Corporation  EW  is engaged in the science of heart valves and hemodynamic monitoring  The products and technologies provided by Edwards Lifesciences to treat advanced cardiovascular disease or critically ill patients are categorized into four main areas  Heart Valve Therapy  Critical Care  Cardiac Surgery Systems  and Vascular The stock just came up on a real time custom scan  This one hunts for calendar spreads between the front two months  But there s a good reason for it  and we ll examine that below  First some details on the custom scan Custom Scan DetailsStock Price GTE  5Sigma1   Sigma2 GTE 8Average Option Volume GTE 1 000Industry isNot Bio techDays After Earnings GTE 5 LTE 70Sigma1  Sigma2 GTE 1The goal with this scan is to identify back months that are cheaper than the front by at least 8 vol points  I m also looking for a reasonable amount of liquidity in the options  thus the minimum average option volume   want to avoid bio techs  and their crazy vol  and make sure I m not selling elevated front month vol simply because earnings are approaching ANALYSISOddly  though I try to remove bio techs from scans  unless I m specifically scanning for bio techs   this one kinda has the bio tech flavor  Let s look to the Skew Tab  below   and then examine the news We can see how elevated the front expiry vol is to the back two months  Obviously there s a vol event expected to occur before next Friday s expiration  Here s a news snippet from Briefing that incorporates both the news and an opinion on direction 6 7 2012  Edwards Lifesciences target raised to  103 at Canaccord Genuity  87 79  1 45 Canaccord Genuity raises their EW tgt to  103 from  93  They think the two year Cohort A results of the PARTNER transcatheter heart valve trial convincingly demonstrated that transcatheter aortic valve implantation is non inferior to surgical aortic valve replacement in high risk patients with severe symptomatic aortic stenosis  They expect the June 13 FDA Panel to vote in favor of SAPIEN and believe final FDA approval could come by October  If approved  they see upside to 2012 and 2013 revenue expectations and significant EPS upside in 2013 due to high operating margins    Provided by Briefing com   They key there is the June 13th FDA panel  That s the vol event  So far nothing terribly interesting  but when I looked at the Charts Tab  six months  included below  my attention was grabbed On the stock side we can see that the price can gap on known volatility events  read  news   In the recent past that news has been earnings  The stock gapped down on 2 3 2012  earnings reported 2 2 2012 AMC  from  80 67 to  71 54  close to close  or down 11 3   A similar move  but in the opposite direction  occurred off of the earnings report on 4 24 2012 AMC  The one day move from the 24th to the 25th was from  73 33 to  81 84  close to close  or up 11 6  OK  so what  Well  with expiration fast approaching the IV30  is vastly weighted to the second month  Just look at that number in the overview section    35 94   That s it  The stock has a recent history of gapping  up and down  on earnings reports and this FDA panel thingy seems like it s similar to an earnings report but with a high likelihood of a definitive ish  result  So  I think of it as an earnings report where there is a greater than 50  chance of either a big earnings miss or earnings blowout  That s worthy of some vol    Look at Jun    ATM is  60  vol which would be an annual high in IV30      SUMMARY   Finally  let s look to the Options Tab  below  Across the top we can see the monthly vols are 57 74   34 70  and 34 84  for Jun  Jul and Aug  respectively  The HV180  is 37 77   I like to think of that as the long term actual vol  Given that HV180  is  38  and Jun vol is  60   isn t it odd that Jul is priced to 34 70   No  OK  how about this    Aug has an earnings cycle in it as well as this FDA panel thingy and is priced to just 34 84   I find these vol numbers quite interesting  if not perplexing      DISCLAIMER   This is trade analysis  not a recommendation ,2012-06-08,Ophir Gottlieb,"https://www.investing.com/analysis/edwards-lifesciences:-vol-opportunity-now-on-bio-tech-""like""-event-125905",125905
30764,252279,CSII,Osiris Therapeutics  Stock Up 133 ,opinion,Osiris Therapeutics  Inc   Osiris  is a stem cell therapeutic company  It focuses on developing and marketing products to treat serious medical conditions in the inflammatory  autoimmune  orthopedic and cardiovascular areas This is a vol note in a bio tech that has exploded over the last six weeks ish  from a  4 95 stock  to now just under  11     ANALYSIS    Let s start with the Charts Tab  six months   below  The top portion is the stock price  the bottom is the vol  IV30    red vs HV20    blue vs HV180    pink  On the stock side  we can see first a nice pop in late May  and then the recent abrupt climb  The current level is essentially a 2 year high  I ve posted some news snippets from 5 30 2012 and more recently  but suffice it to say  the first pop was on a medicare reimbursement decision  and the second was on a drug ruling in New Zealand 5 30 2012NEW YORK  AP     Shares of Osiris Therapeutics Inc  rose Wednesday after the stem cell product developer said Medicare is assigning reimbursement codes to its Grafix skin therapy The Columbia  Md   company said the transitional code will take effect July 1  Medicare plans to create a permanent reimbursement code for Grafix  and if it does so  that code would take effect in January  The code makes easier for physicians who use Grafix on a Medicare patient to get reimbursement from the Medicare program  and that encourages greater use of the product Source  AP via Yahoo  Finance  And then some more recent news   6 14 20012Osiris Therapeutics  Inc  has received approval for its stem cell therapy drug in New Zealand  the second country to approve the drug for treatment of a rare disease Columbia based Osiris  NASDAQ  OSIR  said Thursday that the company s Prochymal drug is expected to be available for commercial sale there later this year Canada approved the drug in May  making Osiris the first company to receive approval for a stem cell therapy Source  Baltimore Business Journal via yahoo  Finance    written by Sarah Gantz That news flow has pushed OSIR up from a close of  4 71 on 5 7 2012  to now  10 96    that s a 133  gain in about six weeks On the vol side  we can see how the implied has been rising steadily over the last week  ish   IV30  has risen from 74 2  on 6 12 2012 to now 98 51  or a 33  increase  The 52 wk range in IV30  is  55 36   92 97    obviously making today s value a new annual high by a fairly substantial amount  OSIR has been making new annual highs in vol consistently over the last few sessions  but the action today is quite large The interesting reality here is that as the news has been coming out  the vol has been increasing  This is unusual in that normally as news comes out  risk  unknown stuff  lessens  The option market clearly reflects heightened risk in this name even after the recent discoveries  How elevated     The highest it s been in nearly two years Let s turn to the Skew Tab to examine the monthly vols We can see a monotonic increase in vol from the back to the front  while the skew shape is pretty consistent across the term structure  In English  the option market reflects heightened risk in the near term relative to the mid term     SUMMARY   Finally  let s turn to the Options Tab  for completeness We can see the monthly vols are priced to 98 51   94 13  and 83 43  for Jul  Aug and Nov  respectively  With the risk elevated and the stock surging  the question is    What now        DISCLAIMER   This is trade analysis  not a recommendation ,2012-06-21,Ophir Gottlieb,https://www.investing.com/analysis/osiris-therapeutics:-stock-up-133-127291,127291
30765,252280,CSII,Closer Look  Furiex s Big Bounce,opinion,After a total nose dive following the FDA s rejection of the alogliptin and fixed dose combination therapy alogliptin pioglitazone NDA that was filed by partner Takeda Pharmaceuticals  Furiex Pharmaceuticals  FURX  has recovered almost all its lost ground  I last covered Furiex mid April  and pointed out the importance of the FDA decision on alogliptin  The rejection came as a surprise to me due to the drugs  success in Japan It was probably a shocking event to Takeda and Furiex shareholders too  since the alogliptin products are currently being marketed successfully in Japan under the trade names NESINA  and LIOVEL   This rejection came despite a significant amount of data supporting the drug s safety like the recently acquired interim data of a cardiovascular outcomes trial  Still  Furiex and Takeda believe that alogliptin will not have any major problems being brought to the US drug market according to the company s statements While the complete response letter from the FDA regarding alogliptin and the fixed dose combination alogliptin and pioglitazone was disappointing  the alogliptin program remains on track in the other global markets  and we remain optimistic Takeda will be able to address the agency s requests    Fred Eshelman in the company s Q1 2012 press releaseIt s also worth noting that Mr  Eshelman has been a massive buyer of FURX stock  with over 1 4th of total shares  which are now worth almost  60 million  Alogliptin is a DPP 4 inhibitor that will be marketed as a type 2 diabetes treatment alongside standard recommendations of improved diet and exercise  Since the prevalence of diabetes in the United States is so extreme  with roughly 25 8 million  or 8 3  of the population according to CDC estimates   it is absolutely essential that Takeda and Furiex market their drug in the United States to realize the full sales potential of alogliptin The market realizes this too  which is why price action of FURX has been so focused on recent press releases  Even with the quickly expanding royalty income that Furiex is receiving from Takeda s marketing in Japan  the company is at an operating loss of roughly  9 5 million per quarter  A continuation of this trend would wipe out the remainder of the company s cash and short term investments  although the company has recently taken measures to bolster their balance sheet A big reason why investors have been able to shake off the alogliptin rejection in April is due to Furiex s newly acquired rights to the premature ejaculation drug Priligy  On May 14th it was announced that Eli Lilly subsidiary Janssen  LLY  as well as Johnson   Johnson s ALZA  JNJ  transferred worldwide commercialization rights to Furiex  In an effort to raise money immediately  Furiex turned around and sold commercialization rights to most lucrative territory outside of the United States for  15 million and  60 million in other potential milestone payments  Although Priligy is the only oral   on demand  premature ejaculation drug on the market now  the market seems to think that Furiex made a smart move given the financial stress induced by alogliptin s slow progress with the FDA But ultimately  it seems that Takeda will not fail to receive an NDA submission to the FDA  even if it takes multiple tries   This is another reason why investors have been able to shake off the NDA rejection in April  On top of fresh data developments in its clinical studies  Takeda will now be able to point to the acceptance of alogliptin s MAA  marketing authorization application  by the EMA  European Medicines Agency  as well as alogliptin combined with pioglitazone and metformin On a side note  the acceptance of alogliptin by the EMA triggered a  10 million milestone payment from Takeda to Furiex  which should provide a larger cushion as Furiex waits for a substantial source of revenue  Unfortunately  all of the easy money was already made following alogliptin s FDA rejection in April  and we need an FDA approval before we can expect real revenue for Furiex  especially since the company sold the rights to a lot of the territory that Priligy could have sold in   Furiex is worth buying on the big dips due to the raw prospects of alogliptin  although it might be a painful wait for actual sales revenue ,2012-07-10,Myriad Equity,https://www.investing.com/analysis/closer-look:-furiexs-big-bounce-129047,129047
